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  The inflammatory bowel diseases (IBDs) are a group of chronic conditions affecting the 
gastrointestinal tract, often presenting with non-specific clinical features such as abdominal 
pain, weight loss and diarrhoea. Approximately 25% of patients are diagnosed with IBD in 
childhood. 
 
  For epidemiological studies, previously collected (1990-1995) and original (2003-2008) 
Scottish incidence data were used to determine national trends in newly diagnosed 
paediatric IBD (PIBD). A smaller, geographically defined, prospective 14-year cohort (1997-
2011) in South-East Scotland (SES) was used to assess regional trends in incidence, point 
prevalence, disease extent, medication use and PIBD surgery rates in 326 children. For the 
detailed analysis of the role of ICOSLG and CRP in Scottish children with PIBD, haplotype-
tagging of both genes in 448 children (and their parents) registered on the Paediatric 
Inflammatory bowel disease Cohort and Treatment Study (PICTS) database was performed. 
Further clinical information from this database and previously gathered adult mRNA 
microarray data were also used to inform the analysis. For the faecal calprotectin (FC) case-
control study, all PIBD patients diagnosed in SES between 01.01.05 and 31.12.10 (aged 1-
17yrs) with a FC performed during initial workup were identified; controls were matched non-
IBD patients who had similarly undergone endoscopy with a referral FC level available. The 
systematic review and meta-analysis of FC case-control studies was performed with 
keywords relating to IBD and calprotectin in electronic resources from 1946 to May 2012. 
Inclusion criteria were studies that reported FC levels prior to the endoscopic investigation of 
IBD in children less than 18 years old. Laboratory work used newly derived HEK293 and 
HCT116 cell lines stably expressing wild-type NOD2 and the CD-associated NOD2 
frameshift mutant, as well as utilising previously derived HEK293 and HCT116 cells stably 
expressing green fluorescent-labelled protein LC3 during the assessment of autophagy. 
Western blot, immunofluorescent microscopy and flow cytometry were used for analysis. 
 
  There was a significant rise in PIBD incidence in Scotland since the early 1990s, with 260 
new cases between 1990-1995 (4.45/100,000/year) and 436 in the 2003-2008 epoch 
(7.82/100,000/year) (p<0.001). A five-fold increase in Crohn's disease (CD) in the last 40 
years was also demonstrated. SES was shown to have the highest recorded PIBD incidence 
rate in the UK for the six-year epoch from 2006-2011 (9.50/100,000/year) with a significant 
rise in ulcerative colitis (UC) to 2.67/100,000/year (p=0.010). Point prevalence rates for PIBD 
in SES had also risen significantly to 41.2/100,000 between the 2000-2005 and 2006-2011 
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epochs (p=0.016). With a follow up of 1577 patient years, the severe phenotype in children 
with PIBD was confirmed; 34% of children with CD presented with pan-enteric disease (44% 
at follow up), and 76% of children with UC had pancolonic disease at diagnosis (81% at 
follow up). 26% of patients required methotrexate and 18% were exposed to 
infliximab/adalimumab, with the time to first exposure of both significantly lower in children 
diagnosed between 2006-2011 (p=0.001 and p<0.001 respectively). A total of 70% of 
children were exposed to azathioprine and 20% underwent IBD-related surgery. 
 
  Using a haplotype-tagging approach and transmission disequilibrium testing (TDT) in 230 
PIBD case-parent trios there was significant overtransmission of the rs8126734-A single 
nucleotide polymorphism (SNP) in ICOSLG following correction (p=0.0467). In the CD TDT 
analysis the same SNP was overtransmitted (p=0.0084). The strongest susceptibility signal 
was evident across the two marker haplotype rs762421-A / rs8126734-G (p=0.0072), 
suggesting that the 3-prime untranslated region in ICOSLG may be targeted for deep 
sequencing. mRNA microarray data from adult patients showed downregulation of ICOSLG 
expression in the ascending colon (p=0.023) and upregulation in the descending colon 
(p=0.0351) in uninflamed biopsies from CD patients and non-IBD controls; no difference in 
gene expression was shown in UC patients. Using a similar approach, the A allele of two 
SNPs tagging CRP showed significant over-transmission to affected IBD patients after 
correction (rs1417938, p=0.006; rs1130864, p=0.015). The six-marker haplotype (ACACAC) 
showed significant distortion of transmission to affected individuals (p=8x10-4). CD and UC 
patients demonstrated differences in rs1205 genotype (p=0.0085) and CRP haplotype 
(p=0.0024), with the influence of the rs1205 SNP on response to anti-tumour necrosis factor-
alpha therapy also shown (p=0.021). 
 
  During the FC case-control study significantly elevated FC levels at diagnosis were 
demonstrated compared to controls (1265 µg/g vs 65 µg/g; p<0.001). FC also outperformed 
commonly used blood parameters (e.g. CRP, ESR, platelets), with an area under the curve 
of 0.93 (95% CI 0.89-0.97) and good sensitivity (0.93 [95% CI 0.86-0.98]) and specificity 
(0.74 [95% CI 0.64-0.82]) when values above 200μg/g were used. FC levels were not 
influenced by disease location in CD or UC. The systematic review and meta-analysis 
highlighted the often poor methodological quality of previous studies and concluded that 
across all studies FC had a pooled sensitivity of 0.98 (95% CI 0.95-1.00) and pooled 
specificity of 0.68 (95% CI 0.50-0.86) for PIBD at diagnosis. 
  
  Characterisation of cells stably-expressing wild-type NOD2 or the CD-associated NOD2 
frameshift mutation demonstrated increased cell proliferation compared to empty vector, and 
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an accentuated apoptotic response to serum starvation. The NOD2 frameshift protein had a 
shorter half-life (at 11 hours) than the wild-type protein, with degradation of the NOD2 
protein shown to be mediated through a proteasome-dependent pathway, possibly through 
lysine residues on the CARD domain. Following the establishment of a robust method of 
assessing autophagy in a cell culture system, experimental work showed that muramyl 
dipeptide-induced autophagy is unlikely to signal through the mammalian target of 
rapamycin, with the intermediate filament vimentin shown to be intimately involved in this 
pathway; the vimentin gene (Vim) was also shown to be a candidate susceptibility gene for 
CD. Using a panel of PIBD drugs azathioprine was shown to induce autophagy in a dose-
dependent manner through an mTOR-dependent, ERK-independent pathway. 
 
  It can be seen that with the increasing incidence and prevalence of PIBD in Scotland that a 
greater understanding of epidemiological trends, the role of genetic susceptibility, the optimal 
use of biomarkers and translational functional biology are all needed to understand further 
the aetiopathogenesis of PIBD. This future work will undoubtedly help to inform service 
design and the clinical care pathways utilised to provide the best care for children in addition 
to targeting pathways for potential drug development, with these measures helping to 
















































1.  The pathogenesis and clinical phenotype of paediatric 
inflammatory bowel disease 
 
1.1  Introduction 
 
  The inflammatory bowel diseases (IBDs) are a group of chronic conditions affecting the 
gastrointestinal (GI) tract, often presenting with non-specific clinical features such as 
abdominal pain, weight loss and diarrhoea. To date the precise pathogenic mechanisms 
underlying IBD remain unclear, however it is likely that dysbiosis of the intestinal microbiota 
and other environmental influences contribute to disease in those with genetic 
susceptibility.[1] The IBDs are divided into three disease types: Crohn’s disease (CD), 
ulcerative colitis (UC) and colonic inflammatory bowel disease, type unclassified (IBDU).[2] 
CD is typically characterised by transmural, granulomatous inflammation affecting any part 
of the GI tract from mouth to anus, often discontinuously. In contrast, UC is limited to the 
colon and consists of superficial ulceration of the bowel mucosa. The third type, IBDU, 
describes patients with chronic colitis within the spectrum of IBD but in the absence of 
distinguishing features of either CD or UC.[2]  
 
1.2  Inflammatory bowel disease genetics 
 
  One of the first indications that a significant genetic component was important in IBD 
pathogenesis was the observation of increased twin concordance in the late 1980s.[3] It has 
since been shown that the risk of CD in monozygotic twins is 36% and for UC 16%, in 
contrast to 4% for both diseases in dizygotic twins.[4] Furthermore, the risk of IBD has also 
been shown to be increased in first-degree relatives (more than a 1 in 10 lifetime risk of 
developing disease[5,6]) and also in certain ethnic groups[7,8]. In addition, several IBD genetic 
risk loci have been identified in other inflammatory disorders.[9] For example single 
nucleotide polymorphisms (SNPs) associated with the gene encoding interleukin-23 receptor 
(IL23R) have been shown to be involved in psoriasis[10] and ankylosing spondylitis[11] as well 
as IBD[12,13].  
  Following the strong evidence for heritability in IBD in the 1990s the search began to 
uncover the genetic variations that led to this increased disease susceptibility. Using non-
parametric linkage analysis, a number of genome-wide searches were conducted between 
1996-2006 in order to identify genetic regions involved in IBD (Figure 1.1).[14] This method of 
gene identification has come under scrutiny in recent years, mainly due to newer techniques 
26 
 
failing to replicate findings in these early analyses. However, these studies uncovered a 
large number of both putative and confirmed linkage regions including the identification of 
NOD2/CARD15 which remains the strongest individual signal using more modern genome-




Figure 1.1.  Timeline of epidemiological and genetic discoveries in inflammatory bowel 
disease. GWAS, genome-wide association scan; IBD, inflammatory bowel disease; CD, Crohn’s 
disease; UC, ulcerative colitis; ER, endoplasmic reticulum. 
 
 
  The discovery of NOD2 in 1996 was a major breakthrough in not only IBD genetics but 
complex polygenic disease overall. Discovered by the French paediatric gastroenterologist 
JP Hugot following fine mapping of the IBD1 locus,[16] Hugot’s group later identified variants 
in the leucine-rich repeat region (LRR) of the gene as conferring susceptibility to IBD,[17] 
something which has been widely replicated in both adult and paediatric disease[13,18]. The 
gene encoded by NOD2 is intimately involved in the innate immune response and has gut 
expression limited to anti-microbial Paneth cells, with the LRR domain recognising muramyl 
dipeptide (MDP), a product of bacterial cell wall degradation.[19,20] Since these initial studies 
further work has demonstrated a diverse range of functions for this pattern recognition 
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receptor including the regulation of commensal bacteria,[21] the control of certain immune cell 
populations[22] and viral recognition[23]. 
  The process of autophagy (i.e. the delivery of portions of the cytoplasm to the lysosome for 
degradation) is now receiving increasing attention, with three loci containing autophagy-
related genes (ATG16L1, IRGM and LRRK2) reaching genome-wide significance in the 
recent CD GWAS meta-analysis[13] and two (ATG16L1 and IRGM) in UC[24]. Recent work in 
this area has shown that, in the ileal epithelium, ATG16L1 is crucial for Paneth cell biology[25] 
with CD patients homozygous for the risk allele displaying Paneth cell granule 
abnormalities[26]. IRGM, a member of the GTPase family, has similarly been shown to have 
key roles in the protection against adherent-invasive E.coli,[27] the protection of effector 
CD4+ cells against interferon-gamma (IFN-γ)-induced autophagic cell death[28] and 
macrophage motility[29]. It should also be noted that a link between innate immune 
recognition molecules (NOD1 and NOD2) and autophagy has now been established, [30,31] 
with alterations in the ubiquitin-proteasome system (which accounts for the remaining 80% 
of intracellular component degradation) also demonstrated in IBD[32].   
  A number of genetic susceptibility loci containing genes involved in T cell biology have also 
been identified by recent analyses. Following innate immune system signalling, a 
coordinated T helper (Th) cell response by the adaptive immune system leads to tissue-
specific inflammation.[33] One of these recently described subsets are the Th17 effector cells, 
classified on the basis of intracellular transcription factors such as signal transducer and 
activator of transcription 3 (STAT3), RAR-related orphan receptor gamma T (RORT) and 
RAR-related orphan receptor alpha (RORα).[34] The association with CD of a germline 
variation of the IL23R gene in 2006 provided the initial stimulus to look more closely at the 
Th17 subset.[12] Specifically the Arg381Gln variant in IL23R has been shown to be protective 
for the development of IBD although other signals within the gene also confer disease 
susceptibility independently of this SNP.[35] IL23R is expressed on T cells with IL-23 
promoting the stabilisation of the Th17 subset after differentiation through various 
intracellular transcription factors such as STAT3. Furthermore, germline variations in the 
genes encoding STAT3, the tyrosine kinase Janus kinase 2 (JAK2) and the G protein-
coupled chemokine receptor C-C chemokine receptor type 6 (CCR6) (all intimately involved 
in Th17 biology) have also been implicated in CD pathogenesis.[13] Similarly, Barrett et al. 
demonstrated that a SNP at chromosome 21q22.3 conferred susceptibility to CD, with the 
recent paediatric GWAS showing significance in both CD and UC.[18] The gene encoding 
inducible T cell co-stimulator ligand (ICOSLG) was suggested as the candidate susceptibility 
gene at this locus, although no replication or expression data has yet confirmed this 
association.[13] Early in the differentiation of the Th17 subset ICOSLG binds with its T cell 
ligand (ICOS) leading to T cell activation.[36] The interaction of ICOSLG with its ligand ICOS 
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is not only essential in the early differentiation of naive T cells but is likely to be important in 
the careful balance of IL-10-producing regulatory cells and the Th17 population.[37] An 




Figure 1.2.  Broad overview of the genetic architecture of inflammatory bowel disease 
giving examples of confirmed and candidate genes implicated in each pathway. Treg, 
regulatory T cell.  
 
 
1.3  The intestinal epithelium - barrier function, immune regulation 
and the microbiota 
 
  The intestinal mucosa is constantly exposed to a milieu of both commensal bacteria and 
dietary antigen. The gut is therefore uniquely characterised by a state of 
hyporesponsiveness through carefully balanced local responses.[38] This active process not 
only maintains mucosal integrity but also prevents the induction of an overwhelming immune 
response leading to intestinal inflammation. At the heart of this complex interface is a single 
monolayer of intestinal epithelium acting as a physical barrier to foreign antigen. However, in 
addition to this barrier function, the intestinal epithelial cell (IEC) also recognises, processes 
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and presents antigen, produces a myriad of signalling molecules and directly affects immune 
cell proliferation and differentiation; IBD is characterised by inflammation at this mucosal 
surface. It is now becoming apparent that abnormalities within the epithelial layer, such as 
increased permeability and abnormalities in IEC-immune cell interactions, play a key role in 
the disease process.[39,40]  
  The proximal and distal sections of the human intestinal tract (i.e. the oral cavity, 
oesophagus and anus) are lined with stratified squamous epithelium and are commonly 
affected in CD patients. The epithelium lining the remainder of the gut is composed of non-
ciliated, columnar epithelium. This rapidly self-renewing tissue is primarily involved in the 
absorption of water and nutrients, but also has a vital role in acting as a barrier to luminal 
pathogens. The epithelial monolayer is carefully folded, producing crypts [of Lieberkühn] and 
villous protrusions. The crypts are an important site of IEC differentiation and it is here that 
the four IEC types are derived from pluripotent stem cells.[41] Three of the cell types (goblet, 
enteroendocrine and absorptive) migrate to the tip of the villus where they undergo 
spontaneous apoptosis several days after terminal differentiation.[42] On the contrary, Paneth 
cells remain within the crypt after differentiation and have a considerable role in antibacterial 
defence.[43] The secretory lineages (Paneth, goblet and enteroendocrine cells) are small in 
number within the epithelial layer with the absorptive lineage (the enterocyte) accounting for 
over 80% of the epithelial cells.[44] These enterocytes are highly polarised, with an apical 
brush border that is in constant contact with the luminal contents and a basolateral 
component adjacent to the stroma.  
  Interspersed between the single epithelial cells lining the intestine are intraepithelial 
lymphocytes (IELs). These cells, which express αβ T-cell receptors (TCRs) or TCRs, 
monitor for stressed or damaged IECs.[45] Several pathways involving IELs are of particular 
interest in IBD, particularly the so-called natural killer T (NKT) IELs,[46] the key chemokine 
receptor C-C chemokine receptor 9 (CCR9)[47] and IEL-expressed α4β7 integrin[48]. 
Additionally, individual epithelial cells effectively compartmentalise the underlying stroma 
through intercellular junctions, contributing to the epithelium’s overall barrier function. These 
proteins help maintain cellular polarity by regulating the flux of water, electrolytes, lipids and 
proteins across the epithelium, in addition to providing a physical barrier to both commensal 
and pathogenic bacteria. Defects in these intercellular junctions have been shown to lead to 
increased epithelial permeability which has been reported in those suffering from IBD and 
their first–degree relatives.[49-52] Disordered intestinal permeability has also been shown to 
predict and possibly cause relapse[53,54] and is increased in those at high risk of CD at 
baseline[55]. Defects in E-cadherin have been of particular interest in IBD research with 
upregulation in areas of active inflammation[56] and downregulation by pathogens implicated 
in the development of colitis such as adherent-invasive E.coli[57]. Similarly, the tight junction 
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protein junctional adhesion molecule-A (JAM-A), occludin expression,[58] claudin 
dysregulation[59] and altered cytokine production[60,61] have also been implicated in the overall 
barrier disruption in IBD, however the mechanisms involved remain unclear and often 
controversial[62]. An overview of the intercellular junctions within the intestine is shown in 




Figure 1.3.  The intestinal epithelial junctional complexes. Each enterocyte is connected at the 
tight junction (TJ), adherens junction (AJ) and desmosomes (DMs) from the luminal to lamina propria 
side respectively. (A) The TJs are localised to the apical-lateral membrane junction and consist of 
three integral transmembrane proteins (claudins, occludin and JAMs) with the proteins connected to 
the actin cytoskeleton through PDZ-domain-containing proteins via the zonulins (ZO-1,2 & 3) or PAR 
adaptor proteins. (B) E-cadherin is the main transmembrane protein at the AJ and associates with 
the alpha and beta catenins, this complex is further maintained through interaction with the 
serine/threonine phosphatase PP2A. (C) The DMs lie at the basal end of the enterocyte and are in 
contrast to the TJ and AJ in that they associate with the keratin filament cytoskeleton of the cell. 
JAMs, junctional adhesional molecules; PAR-3, partitioning defective-3; ZO, zonulin; Keratin IF, 
keratin intermediate filament. 
 
 
  Recently a renewed interest in the role of mucosal dendritic cells (DCs) in IBD 
pathogenesis has occurred.[63,64] This has mainly been as a result of work demonstrating that 
DCs are primed locally to undertake tissue-specific roles within the intestine.[65] Some of 
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these local functions include driving the differentiation of certain T cell populations,[66,67] the 
development of IgA-producing B cells[68] and the selective imprinting of gut-homing T cells[69]. 
There is considerable cross-talk between the IEC and lamina propria DCs, with IECs 
presenting antigen to DCs,[70] in addition to DCs playing an important role in IEC 
homeostasis[71]. The observation that DCs could express tight junction proteins and sample 
luminal antigens by intercalating their dendrites between IECs[72] has led to further work 
demonstrating the ability of the IEC to promote the differentiation of tolerogenic DCs, a 
capacity lost in CD[73]. 
  In both murine and human models the ability of the IEC to alter T cell proliferation has been 
demonstrated, although many of the mechanisms involved remain unclear.[74-77] IECs do not 
express classical co-stimulatory molecules (such as CD80 and CD86) which are needed to 
interact with local T cells. However, they do express other co-stimulatory molecule ligands 
such as ICOSLG,[78] suggesting that co-stimulation may also be involved in IBD 
pathogenesis.[18,79] The area of T cell differentiation and its role in inflammatory diseases is 
also expanding rapidly, with multiple T cell lineages now recognised.[80] The aberrant 
differentiation of this immune cell population has been postulated to be involved in the 
pathogenesis of several chronic inflammatory conditions including IBD.[81] Researchers have 
demonstrated that T cell co-culture of IECs from IBD patients and normal controls produce 
significantly different T cell populations.[40,78,82] Similarly, it has been recognised that T 
regulatory (Treg) cells play a key role in oral tolerance,
[83] and that defects in the Treg response 
may be important in IBD pathogenesis[84]. Although the precise role of Tregs in human IBD is 
not fully understood, patients do show a reduced number of Tregs in the blood and colon with 
the remaining cells functional in vitro.[85] Other regulatory cells are currently under 
investigation, most notably the CD28-CD101+CD103+ subset of CD8+ T-cells, with these 
having been shown to expand following interaction with healthy IECs and reduced in IBD.[86] 
  The gut microbiota is a complex anaerobic environment, with approximately 1014 bacteria 
composed of four major phyla: Firmicutes, Bacteriodetes, Actinomycetes and 
Proteobacteria.[87] Around 70-80% of intestinal bacteria have yet to be cultured, therefore 
bacterial diversity in both health and disease has only really been evaluated by culture-
independent techniques.[88] These techniques have demonstrated that the gut microbiome 
contains hundreds of species,[89] which are stable over long periods of time[90] and are 
person-specific[91]. Much of this work has been based on 16S rDNA sequencing of faecal 
material, however the debate on the usefulness of this method over more specific 16S rRNA 
sequencing (i.e. metabolically active gut microbial diversity) or the use of mucosal samples 
is still ongoing.[92] Additionally, large scale metagenomic analyses of the intestinal microflora 
are now underway which will undoubtedly begin to tease out the complexities of microbial 
diversity, especially in relation to IBD.[93] 
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  Since the first description of CD in the early 20th Century[94,95] there have been several lines 
of evidence implicating bacteria in the pathogenesis of IBD. Firstly, faecal stream diversion 
(via a diverting ileostomy) after ileal resection and ileocolonic anastamosis prevented 
microscopic recurrence of CD in a small group of adult patients, suggesting that faecal 
material, carrying a high bacterial load, may be involved.[96] Further work by the same group 
demonstrated that deliberate infusion of intestinal luminal contents in three patients following 
resection led to mononuclear infiltration and lymphocyte recruitment in the lamina propria.[97] 
Secondly, in several murine models of IBD (such as interleukin-10-deficient[98] and 
interleukin-2-deficient[99] mice) housing of animals a pathogen-free environment limited the 
development of chronic enterocolitis, with antibiotic therapy also shown to prevent the 
development of disease and treat active inflammation in another model[100]. Thirdly, it has 
been shown that peptide extracts from biopsies of IBD patients have reduced antimicrobial 
activity compared to healthy controls,[101] supporting the work demonstrating abnormal 
Paneth cell biology in CD[102,103]. All of this work is greatly enhanced by the plethora of 
genetic susceptibility genes involved in the innate immune response, bacterial handling and 
adaptive immunity.[104] 
  Although a large volume of research has now been performed looking specifically at the 
role of the intestinal flora in IBD, no specific pathogen has yet been identified as a disease-
causing microorganism. However, a number of bacteria have been implicated including 
Mycobacterium avium paratuberculosis, Helicobacter species and E.coli.[105] Of particular 
interest are adherent-invasive E.coli strains (AIEC) that have been consistently isolated by 
independent investigators from CD patients with ileal disease, and shown capable of 
inducing epithelial injury and subsequent inflammation.[106] A direct role for AIEC in CD is 
supported by the relationship of colonisation density to mucosal inflammation,[107] their ability 
to exploit host defects in bacterial killing and autophagy conferred by CD-related  
polymorphisms in ATG16L1, IRGM and NOD2,[27,108] their binding of inflammation-induced 
proteins such as CEACAM6[109] and the ability to induce granulomas in vitro[110]. 
 
1.4  Environmental aspects of IBD pathogenesis 
 
  Although the genetic susceptibility of patients with IBD is now being dissected, the 
predisposing or triggering environmental events have yet to be firmly established. Over the 
decades there have been a multitude of factors suggested as possible influences on IBD 
pathogenesis. Several perinatal factors have been suggested to influence the risk of PIBD 
development, such as breast-feeding[111] and the protective effect of delivery by caesarean 
section (on a background of genetic predisposition[112]). However the studies drawing these 
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conclusions have often been small or of poor methodological quality and not adequately 
powered to determine effect size.  
  A paradoxical relationship has been demonstrated between smoking and IBD 
pathogenesis. A meta-analysis concluded that active smokers were less likely to develop UC 
compared to individuals who were never smokers or ex-smokers; in contrast, active 
smokers, followed by ex-smokers, were at an increased risk for acquiring CD.[113] However, it 
should be noted that the highest incidence of smoking is found in countries with the lowest 
incidence of IBD.[114] A similar relationship has also been proposed with passive smoke 
exposure, however, a meta-analysis did not demonstrate an association for childhood 
passive smoke exposure or prenatal smoke exposure.[115] Appendicectomy has been 
consistently shown to be negatively associated with UC, especially in children with 
appendicitis under the age of 10 years. This was confirmed by meta-analysis, although no 
causal mechanism has been suggested.[116] The relationship between appendicectomy and 
CD is less clear, with positive[117] and negative[118] associations published. However any 
attributable risk for CD is consistently strongest in the first year after appendicectomy[119] 
suggesting that this may be part of the clinical spectrum of disease, rather than a cause in 
itself.  
  The role of diet and the cold-chain/hygiene hypothesis have been put forward as 
aetiological factors in IBD, however results have often been inconclusive. With regard to diet, 
insulin resistance, butyrate and polyunsaturated fatty acids have all been implicated as well 
as high sugar intake and dietary fibre.[120] The hygiene hypothesis suggests that reduced 
exposure to microbial antigen in early life increases the risk of IBD in later life. Although this 
has been shown in well designed case-control studies,[121,122] these studies rely heavily on 
patient questionnaires and assumptions based on geographical location and social class. 
Conversely the cold-chain hypothesis suggests that bacteria such as Yersinia and Listeria, 
which can survive the refrigeration process, contribute to disease.[123] Although 
demonstrated in a small case-control study,[124] this hypothesis is now difficult to evaluate, as 
people living in the most research-active countries now almost universally consume 
refrigerated food. The use of antibiotics in the first year of life has also been postulated as a 
possible factor,[125] in addition to the risk attributable to episodes of gastroenteritis,[126,127] 
however these factors, like those above, have yet to be confirmed.  
 
1.5  Paediatric inflammatory bowel disease (PIBD) 
   
  Approximately 25-30% of patients are diagnosed with IBD in childhood, and in addition to 
the risk of morbidity and mortality from acute exacerbations of disease, the burden of chronic 
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illness can often lead to significant problems with linear growth,[128] education and future 
employment[129,130] as well as psychosocial effects[131]. Along with other complex immune 
diseases such as childhood asthma[132] and early-onset type 1 diabetes,[133] there has been 
consistent reporting of a rising incidence of paediatric IBD (PIBD) both in Scotland[134] and 
worldwide.[135,136] It is not yet clear if these observed rises are purely an essential increase 
prior to a plateau, or whether a sustained rise will be evident over time. A number of 
hypotheses have been put forward to explain this apparent rise, including westernisation of 
lifestyle,[137] the rising rates of obesity,[138] and the cold chain hypothesis[123] and the hygiene 
hypothesis as discussed above,[121] however to date none of these have been confirmed. 
Unlike incidence data, there has been a notable paucity in prevalence figures with regard to 
PIBD, with many data nested within larger adult cohorts.[139,140]  
 
1.5.1  PIBD Diagnosis and Classification 
  Although a uniform definition of PIBD has not yet been universally agreed, extensive 
intestinal involvement and rapid early progression,[141,142] differences in baseline mucosal 
responses,[143,144] and the early requirement for second-line immunomodulatory drugs[145,146] 
suggest that early-onset disease has a distinct clinical phenotype from adult-onset disease, 
although the precise reasons for these differences are still under investigation. Due to these 
important differences, in addition to variations in symptomatology, a working group of the 
European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
was formed to recommend criteria for the diagnostic work-up of children with suspected 
PIBD. This work culminated in the publication of the Porto criteria in 2005 which presented 
consensus-based guidelines with regard to history taking, physical examination, laboratory 
investigation, endoscopic and histological assessment and radiological evaluation.[147] These 
criteria suggested that clinical suspicion of PIBD should be raised in children with persistent 
(≥4 weeks) or recurrent (≥2 episodes in 6 months) symptoms such as abdominal pain, 
diarrhoea, rectal bleeding and weight loss. They highlighted the importance of growth failure 
and pubertal development, as well as extra-intestinal manifestations and anal inspection. 
Suggested laboratory investigations included C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), with stool cultures for common enteric pathogens, notably 
Clostridium difficile. However, it was the promotion of both upper and lower endoscopy with 
a determined effort to perform terminal intubation which set apart these paediatric-based 
criteria from adult practice, with distinct histological findings also helping to standardise 
diagnosis. 
  Since the mid-1970s efforts have been made to comprehensively classify CD to allow 
meaningful multi-centre research to be performed. Following the first endeavour by Farmer 
et al.,[148] several systems were adopted including the Rome classification in 1992[149,150]. The 
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Rome classification included location, behaviour, extent of disease and operative history 
therefore theoretically resulting in as many as 756 subgroups of CD. A working party was 
therefore established to simplify this classification, resulting in the publication of the Vienna 
classification in 2000.[151]  
 
Table 1.1.  Comparison of Montreal and Paris IBD classification systems 
 
 Montreal Paris 
Crohn's disease   
Age at diagnosis A1: below 17 years 
A2: 17 to 40 years 
A3: above 40 years 
A1a: 0 to <10 years 
A1b: 10 to <17 years 
A2: 17 to 40 years 
A3: above 40 years 




L4: isolated upper disease 




L4a: upper disease proximal to the 
ligament of Treitz 
L4b: upper disease distal to the 
ligament of Treitz and proximal to 
the distal 1/3 ileum   
Behaviour B1: non-stricturing, non-penetrating 
B2: stricturing 
B3: penetrating 
P: perianal disease modifier 
B1: non-stricturing, non-penetrating 
B2: stricturing 
B3: penetrating 
B2B3: both penetrating and 
stricturing disease, either 
concurrently or at different times 
P: perianal disease modifier 
Growth N/A G0: no evidence of growth delay 
G1: growth delay 
   
Ulcerative colitis   
Extent E1: ulcerative proctitis 
E2: left-sided UC (distal to splenic 
flexure) 
E3: extensive (proximal to splenic 
flexure) 
E1: ulcerative proctitis 
E2: left-sided UC (distal to splenic 
flexure) 
E3: extensive (hepatic flexure 
distally) 
E4: Pancolitis (proximal to hepatic 
flexure 
Severity S0: clinical remission 
S1: mild UC 
S2: moderate UC 
S3: severe UC 
S0: never severe* 
S1: ever severe* 




Subsequent to this, and in light of the growing volume of research being generated from 
genetic studies at the turn of the millennium, a further revision of the criteria were published 
to address the limitations in the Vienna system, notably the absence of UC and 
indeterminate colitis nomenclature; the Montreal classification was therefore published in 
2005.[2] With regard to indeterminate colitis, the Montreal classification suggested that this 
pathological diagnosis should be reserved for patients following colectomy, based on the 
original description by Price in 1978.[152] However with the introduction of endoscopy since 
Price's report it was recognised that biopsies with histological assessment was 
commonplace, therefore patients with chronic colitis within the clinical spectrum of IBD but in 
the absence of distinguishing features of either CD or UC were given the diagnosis of 
colonic IBD, type unclassified (IBDU). Although many patients with IBDU are later 
reassessed and reclassified as either CD or UC, there are those who remain in this sub-
group well into adult life.[153] 
  Following the eager adoption of the Montreal system paediatric gastroenterologists felt the 
need to further refine the system to account for the nuances of PIBD, especially with regard 
to disease extension, age at disease onset and linear growth parameters. Therefore in 
November 2010 a group of international experts published the Paris classification which 
introduced two subgroups of the Montreal CD A1 and L4 categories, the ability of stricturing 
and penetrating disease to co-exist (as B2B3 disease) as well as a growth parameter.[154] 
Other subtle adjustments were made to Montreal, especially with regard to UC extent; a 
comparison of the Montreal and Paris systems for CD and UC are outlined in Table 1.1.  
 
1.5.2  Diagnostic biomarkers 
  Due to the variable and often vague symptoms in children presenting with suspected PIBD, 
a number of both serum and faecal biomarkers have been evaluated to effectively 'screen' 
patients prior to undergoing upper and lower endoscopy (the diagnostic gold standard). Until 
relatively recently only four common blood parameters have been in routine clinical use, 
namely haemoglobin, platelet count, albumin and ESR. Although anecdotally felt to be useful 
during the diagnostic work-up, a comprehensive evaluation of these parameters was carried 
out by Mack et al. through prospective enrolment of 526 PIBD patients at diagnosis in the 
United States and Canada.[155] These data demonstrated that 21% of patients with mild CD 
and 54% of patients with mild UC had values in the normal range for all four tests. Although 
the number of abnormal tests rose with increasing disease severity (more so for UC), it was 
clear that these parameters were of limited use when used in isolation. Within the United 
Kingdom the use of CRP during the diagnosis of inflammatory or infectious conditions has 
become routine, and although there is some evidence that CRP is useful when assessing 
IBD severity in the paediatric population,[156] results have been inconclusive[157]. To date 
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there have been only a small number of studies evaluating CRP at PIBD diagnosis. One of 
these studies by Quail et al. assessed the role of faecal calprotectin (FC), a well-
characterised calcium-binding protein found in neutrophilic granulocytes,[158] in combination 
with the blood parameters outlined above, including CRP[159]. Although unable to provide 
sensitivity and specificity due to the lack of a control group, this study highlighted the 
previously reported poor performance of the isolated blood parameters. Furthermore, this 
study brought to light the role of FC, with 100% of the PIBD patients having at least one 
abnormal blood test and/or raised FC, and 96% of patients having a raised FC at diagnosis. 
The use of FC at PIBD diagnosis had been evaluated by a number of groups prior to this 
study, however many of these had small patient numbers or a non-representative PIBD 
cohort.[160,161] A recent meta-analysis looking at the role of FC during the diagnosis of both 
adult-onset and PIBD highlighted the poor methodological quality of the paediatric studies, 
and concluded that the discriminative power to safely exclude IBD was significantly better in 
adults than in children.[162]  
  As well as the routine blood tests available a number of serum antibodies specific to IBD 
have been investigated, although more often in the adult population. These markers have 
frequently been used within a research setting and include perinuclear anti-neutrophil 
antibody (pANCA), anti-Saccharomyces cerevisiae antibody (ASCA), and antibodies to 
E.coli outer membrane porin C (OmpC), anti-CD-related bacterial sequence I2 and CBir1 
flagellin.[163] Many of these biomarkers, such as the anti-glycan antibody ASCA, OmpC and 
I2 are prevalent in approximately 55-60% of CD patients, with others more prevalent in 
UC.[163] Approximately 85% of CD patients are positive for at least one antibody, although 
only 4% are positive for all four;[164] this does not account for often highly variable 
quantitative responses. A recent study comparing these serological markers with routine 
blood investigations demonstrated that a combination of three abnormal blood indices had 
higher predictive values that a commercially available panel of seven antibodies, highlighting 
the difficulties in interpreting these biomarkers.[165] Other serum and faecal markers have 
been looked at with regard to IBD diagnosis, such as lactoferrin,[166] antilaminaribioside 
carbohydrate IgG (ALCA) and antichitobioside carbohydrate IgA (ACCA),[167] however these 
have only been assessed in the context of research and have yet to be fully investigated in 
routine clinical practice. 
 
1.5.3  PIBD treatment summary  
  Following a diagnosis of PIBD the aims of management are to induce and maintain 
remission, prevent relapse, normalised growth and development and provide each child with 
a good quality of life.[168] Due to the complexities of PIBD management, especially with 
regard to disease severity and growth, it is important that the multidisciplinary team involved 
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is led by a paediatric gastroenterologist with an interest in PIBD. This was highlighted by the 
inclusion of IBD as a special condition in the UK National Specialised Services definition 
set.[169] Within the multidisciplinary team patients should have access to a paediatric 
gastroenterologist, paediatric surgeon, IBD nurse specialist, dietician, pharmacist and 
psychologist, in addition to support from local IBD-related charities.[170]  
  To date, there have been very few therapeutic trials in PIBD, with guidelines often 
extrapolated from adult data. In a comprehensive review of the literature as recently as 2003 
only one placebo-controlled randomised controlled trial in PIBD was reported.[171] The IBD 
working group of the British Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(BSPGHAN) recently carried out a systematic review of the evidence base for medical 
treatment in PIBD.[168] They highlighted the paucity of trials of high methodological quality 
with regard to PIBD treatment. They concluded that the development of clinical guidelines for 
managing PIBD should be consensus based, and informed by the best-available evidence 
from the paediatric literature and high-quality data from the adult IBD literature, together with 
the clinical expertise and multidisciplinary experience of PIBD experts. At present a number 
of therapeutic modalities are used to induce and maintain remission, treat exacerbations of 
disease and 'rescue' those with severe disease. 
  
1.5.3.1  Exclusive Enteral Nutrition 
  A nutritional approach to managing gut inflammation, especially with regard to the induction 
of disease remission in paediatric CD, has been validated in recent years.[172,173] The main 
advantages of exclusive enteral nutrition (EEN) are the avoidance of drug side-effects (such 
as those encountered with corticosteroids) with the benefit of nutritional support and 
supplementation.[174] Although there is not yet universal consensus on the optimal regimen 
when introducing EEN, a typical course of therapy for a child newly diagnosed with 
paediatric CD would consist of 6-8 weeks of EEN using either an amino-acid based or whole 
protein (polymeric) formula;[175] it should be noted that EEN currently has no clear role in the 
treatment of UC. During this time adherence can be difficult and children may require naso-
gastric feeding, with a sizeable proportion of children not completing their full course and 
instead opting for corticosteroids.[176] Although remission rates of up to 88% have been 
reported in some case series,[177] a recent Cochrane review yielded a pooled odds ratio of 
0.33 (95% CI 0.21-0.53) favouring corticosteroid therapy during induction[178]. As well as 
induction of remission, EEN is often used during disease relapse and has been shown to 
result in mucosal healing,[179] improved linear growth[180] and better bone health[181]. The 
mechanism of action of EEN currently remains elusive and is almost certainly multifactorial, 
with potential effects on the bacterial microflora,[182] circulating antioxidants[183] and through 
direct anti-inflammatory pathways[184]. 
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1.5.3.2  Corticosteroids 
  Corticosteroids have long been the mainstay of treatment for IBD in both adults and 
children, and often the first-line treatment of choice in UC. Although the anti-inflammatory 
properties of corticosteroids have been demonstrated to induce remission in approximately 
85% of children with either CD or UC,[185] their potential side effects and detrimental effects 
on growth have led to their more cautious use in PIBD. Initial doses of approximately 1-
2mg/kg/day, weaning slowly over 8-10 weeks, may be used in both CD and UC following 
diagnosis, although the evidence for this dosing regimen is lacking.[168] The majority of 
studies evaluating corticosteroids in PIBD have used either prednisolone or methyl 
prednisolone,[168] with one small randomised controlled trial evaluating the different rectal 
formulations available.[186] Corticosteroids are commonly used during PIBD relapses and 
constitute the basis of pharmacological management of acute severe ulcerative colitis.[187] 
Steroid dependence is widespread with between 30-45% remaining on steroids at one 
year,[168] with steroid-related side effects such as increased ocular pressure,[188] cataracts,[189] 
intracranial hypertension[190] and osteoporosis[191] all reported in PIBD studies. 
 
1.5.3.3  5-aminosalicylate (5-ASA) 
  5-aminosalicylate (5-ASA) is a derivative of salicylic acid and is used as local therapy most 
often in the treatment of UC. In mild to moderate UC 5-ASA is commonly used to induce and 
maintain remission, however evidence is lacking with regard to both paediatric UC and 
CD.[168] 5-ASA rectal preparations are either administered as foam enemas or suppositories, 
with oral preparations releasing active 5-ASA in the distal small bowel and colon. To prevent 
absorption of the oral formulations, utilisation of different carrier molecules or pH- and time-
dependent mechanisms are employed. Side effects are seldom serious but include 
diarrhoea, skin rashes and neutropenia. Again several mechanisms of action are described 
including scavenging of reactive oxygen species,[192] inhibition of leukotrienes,[193] inhibition 
of platelet activation,[194] and activating the gamma form of the peroxisome proliferator-
activated receptors[195]. 
 
1.5.3.4  Azathioprine and 6-mercaptopurine (6-MP) 
  Azathioprine and 6-mercaptopurine (6-MP) are two commonly used immunosuppressive 
drugs used in the treatment of PIBD.[196] Although these drugs have a slow onset of action 
and are therefore seldom used to induce remission, their use in maintaining remission is 
commonplace. Azathioprine is a prodrug which is absorbed in the gut and converted to 6-MP 
via glutathione and similar compounds in the intestinal wall, liver and on red blood cells. It 
has been long thought that the incorporation of 6-thioguanine nucleotide metabolites of 6-
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MP into leucocyte DNA was the main mechanism of these drugs but recent data has 
suggested that interaction with the GTP-binding protein RAC1 leads to increased T cell 
apoptosis, through the co-stimulation of CD28.[197] Furthermore, the precise mechanism of 
action of these drugs in the context of PIBD is not yet clear, with other potential pathways 
possibly yet to be elucidated.  
  Although the addition of 6-MP may have a steroid-sparing effect during remission 
induction,[198] overall data is lacking, and concerns over the risk of developing lymphoma [199] 
may be outweighed by the benefits of thiopurine therapy[200]. The side effect profile can also 
be troublesome, with between 25-50% of children suffering from adverse effects such as 
raised aminotransferase levels, leucopenia, nausea, pancreatitis and recurrent infections, 
leading to dose reduction or drug cessation.[201,202] The genetically determined activity of 
thiopurine S-methyltransferase (TPMT), the primary inactivating enzyme for the thiopurines, 
are now routinely used in most centres to explain variations in drug metabolite levels. 
Although there does not seem to be a clear relationship between TPMT genotype and 
adverse effects,[203] the direct measurement of TPMT can help inform initial dosing and dose 
adjustment to improve outcome.[204]  
 
1.5.3.5  Methotrexate, Cyclosporin and Tacrolimus 
  Although there are published data regarding the use of methotrexate during induction of 
remission in CD (methotrexate has a shorter onset of action than the thiopurines),[202,205] 
methotrexate is often thought of as a second line therapy in PIBD[196]. Methotrexate is an 
antifolate drug that inhibits DNA and RNA synthesis in rapidly dividing cells and requires folic 
acid supplementation following administration. Taken orally or as a weekly subcutaneous 
preparation, nausea is a common side-effect, often requiring anti-emetics to aid 
toleration;[206] hepatotoxicity and bone marrow suppression can also occur during 
methotrexate treatment. 
  Both cyclosporin and tacrolimus work as calcineurin inhibitors, altering the transcription of  
interleukin-2 and leading to a reduction in T-cell activity.[207] Their use is mostly limited to 
second-line medication in the treatment of steroid-refractory acute severe ulcerative 
colitis,[208] or in children with fistulising CD[209]. Significant renal and neurological side-effects 
can occur with these drugs, therefore careful serum monitoring is required to ensure 
successful bridging to maintenance drugs such as azathioprine or biological agents.[185] 
 
1.5.3.6  Biological agents 
  In the last decade, the arrival of monoclonal antibodies (such as anti-tumour necrosis 
factor-alpha [TNF-α]) in clinical practice has led to dramatic changes in IBD treatment.[210] 
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Although the indications and treatment regimens for these drugs are still under debate,[211,212] 
several of these drug therapies have proven efficacy with newer biologicals showing 
promising results in early trials[213,214]. Even the most effective of these biologicals (infliximab) 
only induces remission in around fifty percent of adult Crohn’s patients,[215] although higher 
rates are reported in paediatric studies.[146,216] There are therefore renewed efforts to identify 
other cytokine pathways involved in IBD aetiopathogenesis with a myriad of cytokines likely 
to be involved in IBD, such as interleukin-21,[217] interleukin-22,[218] and interleukin-32[219]. 
Infliximab has been used to induce remission in those intolerant or refractory to EEN and 
steroids, and in those with frequent relapses 6-8 weekly infusions are becoming more 
common during maintenance therapy. The acute risks surrounding the use of biological 
therapies, such as infliximab and adalimumab, arise from infusion reactions and sepsis 
events,[220] with the long term risk of T-cell lymphoma of major concern[221]. Despite the 
known anti-inflammatory effects of these drugs, the exact mechanism of action within the 
gut, the variable response from patients with clinically similar disease severity and the 
optimal dosing regimens are still under debate. 
 
1.5.4  Conclusion 
  It can be seen that although the genetic susceptibility and pathogenic mechanisms of 
disease in PIBD are similar to those of adult-onset IBD, a distinct clinical phenotype and 
treatment strategies lacking a clear evidence base exist. Further work is required to 
elucidate the epidemiology of PIBD, including incidence, prevalence and therapeutic 
utilisation, further characterisation of the genetic architecture of disease, new robust 
biomarkers to help screen children presenting with suspected bowel inflammation and 










































2.  The rising incidence of paediatric inflammatory bowel 
disease in Scotland 
 
2.1  Background and aims  
 
2.1.1  Background 
  The identification of true rises in disease incidence, in conjunction with other population 
trends, have the potential to provide useful insights into disease pathogenesis, especially 
with regard to environmental influences. By contrast, trends in disease prevalence are 
invaluable for organising current health care provision, planning future service design and 
informing patients and the charities that support them.[222] 
  The incidence of paediatric inflammatory bowel disease (PIBD) has been shown to vary 
significantly worldwide.[223] Although a large body of evidence exists with regard to incidence 
figures, a significant proportion of these data lacks analyses of trends over time.[223] Within 
the United Kingdom (UK), Scotland has a long history of PIBD epidemiological research with 
incidence data spanning over 30 years showing an increase in PIBD.[134,224] Work from 
Wales has shown a modest rise, with an overall Welsh incidence of 2.6/100,000/year for 
PIBD (less than 17 years old) between 1995-1997[225] and a subsequent small prospective 
regional study in South Wales providing an incidence of 5.4/100,000/year (less than 16 
years old) during 1996-2003[226]. England with its large geographical area and extensive 
network of healthcare trusts has yet to produce robust population-wide incidence rate trends 
for PIBD, although a few studies have presented some adolescent data nested within adult 
data in smaller regions.[227,228] In the same way, single centres in Ireland had previously 
contributed to larger epidemiological studies,[229] with robust PIBD data only recently 
becoming available[230]. To date the only prospective UK- and Ireland-wide PIBD incidence 
data is the 13-month British Paediatric Surveillance Unit (BPSU) survey carried out between 
1998-1999, which demonstrated an overall PIBD incidence of 5.2/100,000/year across all 
regions (again in children diagnosed less than 16 years old); incidence rates ranged from 
3.6/100,000/year in Northern Ireland, through 4.4/100,000/year in the Republic of Ireland to 
6.5/100,000/year in Scotland.[231] 
  With regard to worldwide rates of PIBD incidence, a recent exhaustive systematic review 
presented data on 139 studies from 32 different countries, demonstrating a clear increase in 
worldwide trends.[223] Significant variation was apparent, with rates varying from 
0.24/100,000/year in Libya to 13.3/100,000/year in Ontario, Canada. This review highlighted 
the differing methodologies utilised during case ascertainment, the lack of robust and 
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appropriate statistical analysis to assess trends over time (only performed in 20% of studies) 
and the paucity of data from developing nations in Asia, Africa and South America. Since 
this review a number of studies have continued to present data demonstrating the rising 
incidence of PIBD worldwide.[230,232,233]  
  There is now a pressing need to provide an accurate indication of the incidence of PIBD in 
Scotland within the last decade, as any continued rise in conjunction with other population 
trends may provide further insights into susceptibility factors and the mechanisms underlying 
disease pathogenesis.  
 
2.1.2  Hypotheses and aim 
Hypotheses:  
1. The incidence of PIBD in Scotland has risen significantly between the periods 1990-
1995 and 2003-2008. 
2. The age at PIBD diagnosis has remained stable between the periods 1990-1995 and 
2003-2008.  
 
Aim: To compare the incidence of PIBD (diagnosed less than 16 years) in Scotland over a 
six year period (2003-2008), to incidence rates and other basic demographic data in an 
historical cohort (1990-1995). 
 
2.2  Methods 
 
2.2.1  Setting 
  Scotland covers an area of 30,500 square miles and has a population of just over 5 million 
people. The total population has risen steadily since 2002 and represents approximately 
8.4% of the population of the UK.[234,235] The paediatric gastroenterology service within 
Scotland is coordinated through three tertiary centres, with academic paediatric centres and 
their associated district general hospitals combining to form regional networks. These 
networks currently provide nationwide coverage for a total population of approximately 
915,000 children less than 16 years.[234]  
 
2.2.2  Data acquisition 
  
2.2.2.1  2003-2008 cohort 
  Prospective accrual of all new PIBD (diagnosed less than 16 years of age) cases in South 
East Scotland who were managed solely or in shared care with the PIBD team in Edinburgh 
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has been performed since 1997. This prospective database is held by Ms Pam Rogers (IBD 
Nurse Specialist) at the Royal Hospital for Sick Children, Edinburgh, and holds basic 
demographic information as well as details regarding diagnosis, therapies and surgery. A 
similar database, developed in Edinburgh for this project, was distributed to each of the two 
remaining regional networks (West of Scotland and North of Scotland) to allow the routine 
audit of their retrospective PIBD caseloads. Datasets of these retrospective cases were 
compiled through exhaustive examination of PIBD clinic lists, endoscopy lists, pathology 
reports and local team knowledge. As a result of this collaboration, the cohort of all new IBD 
diagnoses within the entire Scottish PIBD service between 1st July 2002 to 1st July 2009 was 
captured. Anonymised incidence datasets were then combined and examined in detail and 
to ensure the most robust recent cohort (hereafter referred to as cohort 2), the records of 
those patients diagnosed before their 16th birthday between 1st January 2003 and 31st 
December 2008 were retrieved. Of note, PIBD cases diagnosed in adult IBD services and 
who were not transferred to any of the Scottish PIBD centres were neither systematically 
sought nor enumerated. The combined database included demographic data and diagnosis, 
all recorded electronically using Microsoft Access 2007 (Microsoft Corporation, Redmond, 
WA, USA) following thorough case note review. Before database entry all case notes were 
reviewed at each centre by individuals trained specifically in PIBD phenotyping and all 
ambiguous cases discussed with senior clinicians (Dr Richard K Russell, Consultant 
Paediatric Gastroenterologist, Royal Hospital for Sick Children, Glasgow, and Prof. David C 
Wilson, Professor of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick 
Children, Edinburgh). The participating clinicians in the other regional networks were Dr 
Richard Hansen (NHS Grampian and the University of Aberdeen), Dr Fiona Cameron (NHS 
Greater Glasgow and formerly NHS Highland) and Dr Kostas Gerasimidis (NHS Greater 
Glasgow and University of Glasgow). Prof. David C Wilson, Dr Richard K Russell and Dr W 
Michael Bisset were the clinical leads for IBD in the South East, West of Scotland and North 
of Scotland regional networks respectively and oversaw local data collection. Diagnostic 
category was determined using standard clinical, histological and radiological findings in line 
with Lennard-Jones and Porto criteria.[147,236]  
   
2.2.2.2  1990-1995 cohort 
  For the earlier cohort (hereafter referred to as cohort 1), all raw data on incident cases 
between 1st January 1990 and 31st December 1995 used by Dr Emma Reynish (nee 
Armitage) in a previously published study[134] were re-examined. These cases were originally 
identified from national coding records and validated by studying the pathology reports and 
case notes of all IBD patients less than 18 years old (to ensure complete ascertainment of 
those less than 16 years) in all hospitals throughout Scotland, encompassing all adult and 
46 
 
paediatric gastroenterology centres. The raw data from this study have been held in hand-
written paper copy in the Gastrointestinal Unit based at the Institute of Genetics and 
Molecular Medicine, University of Edinburgh since the late 1990s. To allow for a more 
efficient analysis to be performed, over 1000 individual patient records were manually re-
entered onto a newly created Microsoft Access 2007 database, with any queries cross-
checked with the local hospital records or historical notes.  
  Within both the cohorts a small number of children originally diagnosed with UC or IBDU 
were subsequently re-classified as CD. Regardless of the timing of this diagnostic change 
only their most recent diagnosis was recorded to ensure a true representation of IBD 
distribution. All children who were not living in Scotland at the time of their diagnosis but 
subsequently moved to Scotland were excluded. 
 
2.2.2.3  Methodological differences in cohort ascertainment 
  It should be noted that some differences in the data collected between the two cohorts 
exists. Firstly, during initial data collection for cohort 1 (the earlier cohort), the classification 
of IBDU was not well established in the literature, and so children with IBD colitis but without 
features of CD were almost universally placed in the diagnostic category of UC. In fact, the 
previously published historical cohort (comprising incident IBD cases from 1981-1995[134]) 
only included two children with the classification of IBDU (both children were diagnosed prior 
to 1990). To compensate for this, and to provide a meaningful analysis, the UC and IBDU 
categories in cohort 2 were combined to create a ‘non-Crohn’s colitis’ (NCC) group. 
Secondly, within the entire historical cohort (1981-1995), the date of IBD symptom onset was 
used to generate the original incidence data, whereas our current database used to define 
cohort 2 uses the date of the diagnostic endoscopy. As children are generally admitted for 
their diagnostic procedures it was therefore felt that the date of the first IBD-coded admission 
(which was also recorded for the original historical cohort) was a more suitable proxy and 
more in line with current IBD epidemiological literature,[223] and this was therefore used to 
define the incident date in cohort 1. To further validate this, the median time from symptom 
onset to the date of first IBD-coded admission for cohort 1 was calculated and was 3 months 
(interquartile range [IQR] 1-8 months). This is comparable with the duration between 
symptom onset and diagnostic endoscopy previously reported in the literature.[237] The date 
of diagnostic endoscopy was used in cohort 2 because as a fixed point in time it was easily 
reproducible on a retrospective case note review. In addition, this made cohort 2 more 





2.2.3  At-risk population and statistics 
 
2.2.3.1  At-risk population 
  In Scotland the number of children under 16 years decreased from a mean of 1,025,360 
per year between 1990-1995 to 926,668 per year between 2003-2008.[234] To allow for these 
changes in population structure between and within the cohorts, incidence figures and sex 
ratios for each year were first calculated from known population figures (Table 2.1) and then 
standardised to the 2001 Scottish Census population to enable direct comparison.[234] Age 
groups were defined as pre-school (0-5 years), primary school (6-10 years) and secondary 
school (11-15 years). Age-sex standardised rates were calculated using the direct 
method[238] and 95% confidence intervals (CIs) determined using a method based on gamma 
distribution.[239] All rates are presented as per 100,000 of the at risk population, that is those 
less than 16 years of age.  
 
 
Table 2.1.  At-risk Scottish population (all children less than 16 years old) for each year 
during the 1990-1995 and 2003-2008 epochs. 
 
Year Male Female Total 
1990 522,036 498,252 1,020,288 
1991 522,389 498,560 1,020,949 
1992 522,413 499,775 1,022,188 
1993 524,641 503,034 1,027,675 
1994 527,337 505,166 1,032,503 
1995 525,087 503,468 1,028,555 
Total 3,143,903 3,008,255 6,152,158 
    
2003 482,952 460,288 943,240 
2004 478,706 456,750 935,456 
2005 475,538 453,456 928,994 
2006 471,729 450,104 921,833 
2007 469,295 447,656 916,951 
2008 467,572 445,962 913,534 
Total 2,845,792 2,714,216 5,560,008 
 
 
2.2.3.2  Statistics  
  p values for comparisons between time periods were obtained from Poisson regression 
models. Analysis was carried out using the epitools package in R version 2.9.2 (R 
Foundation for Statistical Computing, Vienna, Austria)[240] and Mann-Whitney tests using 
GraphPad Prism version 4.03 (GraphPad Software, CA, USA). R scripts outlining the 
methods used for age-sex adjustment and Poisson analysis are shown in Figure 2.1. 
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2.2.4  Ethics  
  Ethics approval was sought from the Lothian Research and Ethics Committee but was 
deemed unnecessary as this was an anonymous, observational study of patients already 
under the care of paediatric gastroenterology services and under the umbrella of the 




Figure 2.1.  R scripts to determine age-sex standardised incidence rates (a) and the Poisson 





2.3.1  The incidence of PIBD, CD and UC has risen in Scotland   
  In total, 260 children under 16 years were diagnosed in the period 1990-1995 (cohort 1), 
compared to 436 children between 2003-2008 (cohort 2). The crude numbers of patients 
diagnosed each year by disease category and sex is shown in Table 2.2. Following age-sex 
standardisation, the incidence rates of IBD were 4.45/100,000/yr (95% CI 3.91 to 5.03) and 
7.82/100,000/yr (95% CI 7.10 to 8.59) for cohorts 1 and 2 respectively revealing a 76% rise 
(p<0.001) in the adjusted number of cases in each period. The adjusted incidence of CD 
rose significantly from 2.86/100,000/yr [95% CI 2.45 to 3.33] to 4.75/100,000/yr [95% CI 4.19 
to 5.36]) (p<0.001) and in UC from 1.59/100,000/yr [95% CI 1.28 to 1.94] to 2.06/100,000/yr 





Table 2.2.  Crude number of PIBD cases diagnosed in Scotland during each six-year epoch by 





IBD CD UC IBDU NCC 
Male 
1990-1995 523,984 137 93 44 0 44 
2003-2008 474,299 251 157 63 31 94 
Female 
1990-1995 501,376 123 74 49 0 49 
2003-2008 452,369 185 108 52 25 77 
* = Mean number of persons at risk (i.e. less than 16 years old) for each year of the cohort. IBD, inflammatory 
bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IBDU, colonic inflammatory bowel disease, type 
unclassified; NCC, non-Crohn’s colitis (UC and IBDU combined). 
 
 
  In addition, comparing the NCC group in cohort 2 with the UC group in cohort 1, led to a 
more significant rise in non-Crohn’s colitis (1.59/100,000/yr [95% CI 1.28 to 1.94] to 
3.07/100,000/yr [95% CI 2.63 to 3.57]) (p<0.001). The percentage rise in each type of IBD 




Figure 2.2.  Graph showing percentage rise between the two six-year epochs for all 
inflammatory bowel disease and by inflammatory bowel disease type. IBD, inflammatory 
bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; NCC, non-Crohn’s colitis (comprising UC 
and IBDU).  
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2.3.2  The incidence of both males and females diagnosed with PIBD has increased 
  Analysing the incidence rates of all males under 16 years diagnosed with IBD, and the 
three IBD types (CD, UC and NCC) during the study periods, demonstrated a significant rise 
in the respective incidence rates within cohort 2 (Table 2.3). There was also a significant rise 
in females diagnosed with IBD, CD and NCC in cohort 2 (Table 2.3). Stratifying the results 
by age demonstrated that the adjusted incidence of IBD, CD, UC and NCC had risen 
significantly in males in the 6-10 year and 11-15 year age groups, most notably in the later 
group with an overall IBD incidence of 16.44/100,000/yr (Table 2.4). Although there were 
rising trends for all IBD types across all age-specific groups in females, only rises in total IBD 
and NCC in the 6-10 year age group reached statistical significance (Table 2.5). There was 
no significant change in those diagnosed less than 6 years in any IBD type in either sex. 
 
 
Table 2.3.  Age-adjusted incidence rates of PIBD in Scotland for all males and females by 
IBD type. 
 
Cohort 1990-1995 2003-2008 Difference between 
cohorts (P value) 
Male 
   IBD 4.60 (3.86-5.44) 8.78 (7.73-9.94) <0.0001 
   CD 3.14 (2.53-3.84) 5.48 (4.66-6.41) <0.0001 
   UC 1.46 (1.06-1.96) 2.20 (1.69-2.82) <0.01 
   NCC 1.46 (1.06-1.96) 3.30 (2.66-4.04) <0.0001 
Female 
   IBD 4.29 (3.56-5.12) 6.80 (5.85-7.86) <0.01 
   CD 2.58 (2.02-3.24) 3.97 (3.25-4.79) <0.05 
   UC 1.71 (1.27-2.26) 1.91 (1.43-2.51) 0.394 
   NCC 1.71 (1.27-2.26) 2.83 (2.23-3.54) <0.01 
Figures are adjusted rates per 100,000 at risk population per year [95% CIs]. IBD, inflammatory bowel disease; 




2.3.3  PIBD continues to affect more males with a reduction in age at diagnosis 
  These results demonstrate that a male preponderance continues in the Scottish paediatric 
population; most clearly evident for CD. (Table 2.2). The adjusted male to female incidence  
ratio for all IBD in cohort 2 was 1.29, rising from 1.07 in cohort 1. This was mainly driven by 
an increase in the male to female incidence ratio in CD (1.22 to 1.38). In addition, the age at 
diagnosis was reduced in cohort 2. For total IBD the age at diagnosis decreased from 12.7 
years to 11.9 years (p<0.01) driven by a decrease in the age at CD diagnosis (13.2 years to 




Table 2.4.  Age-adjusted incidence rates for males diagnosed with PIBD in Scotland by IBD 
type and age group. 
 
Cohort 1990-1995 2003-2008 Difference between 
cohorts (P value) 
0 – 5 years 
IBD 0.76 [0.35-1.44] 1.81 [1.07-2.86] 0.143 
CD 0.34 [0.09-0.86] 1.21 [0.62-2.11] 0.129 
UC 0.42 [0.14-0.98] 0.40 [0.11-1.03] 0.636 
NCC 0.42 [0.14-0.98] 0.60 [0.22-1.31] 0.772 
6 – 10 years 
IBD 3.44 [2.38-4.81] 8.37 [6.57-10.51] <0.001 
CD 2.12 [1.32-3.25] 4.75 [3.42-6.42] 0.011 
UC 1.32 [0.70-2.25] 2.04 [1.21-3.22] 0.037 
NCC 1.32 [0.70-2.25] 3.62 [2.46-5.11] <0.001 
11 – 15 years 
IBD 9.72 [7.86-11.90] 16.44 [14.00-19.20] <0.001 
CD 7.03 [5.46-8.92] 10.65 [8.69-12.92] 0.009 
UC 2.69 [1.76-3.94] 4.24 [3.04-5.75] 0.037 
NCC 2.69 [1.76-3.94] 5.79 [4.37-7.52] 0.003 
Figures are adjusted rates per 100,000 at risk population per year [95% CIs]. IBD, inflammatory bowel disease; 




Table 2.5.  Age-adjusted incidence rates for females diagnosed with PIBD in Scotland by IBD 
type and age group. 
 
Cohort 1990-1995 2003-2008 Difference between 
cohorts (P value) 
0 – 5 years 
IBD 0.88 [0.42-1.62] 1.48 [0.81-2.48] 0.292 
CD 0.62 [0.25-1.27] 0.63 [0.23-1.38] 0.952 
UC 0.26 [0.05-0.77] 0.53 [0.17-1.23] 0.434 
NCC 0.26 [0.05-0.77] 0.84 [0.36-1.66] 0.184 
6 – 10 years 
IBD 4.33 [3.11-5.88] 7.37 [4.65-9.44] 0.039 
CD 2.43 [1.54-3.65] 4.28 [3.00-5.92] 0.105 
UC 1.90 [1.13-3.01] 1.90 [1.09-3.09] 0.999 
NCC 1.90 [1.13-3.01] 3.09 [2.02-4.53] 0.039 
11 – 15 years 
IBD 7.78 [6.09-9.80] 11.80 [9.69-14.23] 0.052 
CD 4.76 [3.46-6.39] 7.14 [5.52-9.09] 0.099 
UC 3.03 [2.01-4.38] 3.36 [2.28-4.76] 0.701 
NCC 3.03 [2.01-4.38] 4.65 [3.37-6.27] 0.092 
Figures are adjusted rates per 100,000 at risk population per year [95% CIs]. IBD, inflammatory bowel disease; 





2.4.  Discussion 
 
  This study has shown a clear rise in the incidence of both paediatric CD and UC in 
Scotland, representing a minimum 76% increase in the adjusted cases of IBD between the 
periods 1990-1995 and 2003-2008. It highlights and extends data regarding the continued 
male preponderance in paediatric disease in contrast to adult onset disease,[141] and also 
demonstrates a significant reduction in the age at diagnosis between the two cohorts.  
  The strengths of this study stem from the fact that the regional networks in Scotland have 
for many years collaborated effectively in combined research studies.[141,241,242] Other studies 
providing epidemiological data on PIBD have often made broad assumptions about 
population figures, based on smaller cohorts within a region[223] and over short periods of 
time[243]. This study presents data with robust case note review as the only method of case 
confirmation. It should be emphasised however that although the historical cohort is 
absolutely robust for those less than 16 years, with cases obtained from paediatric and adult 
clinical services, the more recent cohort represents a dataset generated from tertiary 
paediatric practice only. This is due to the fact that no attempt was made to ascertain cases 
of IBD diagnosed less than 16 years of age in adult centres in cohort 2 which historically 
have seen a significant number of paediatric cases.[244] However, there is anecdotal 
evidence that this has happened much less in the last decade during which regional PIBD 
services have been strengthened considerably. The selection bias that exists within cohort 2 
therefore would be likely to produce an underestimate of that cohort’s incident caseload of 
IBD by reduced acquisition of cases diagnosed by adult physicians. However, despite this, 
there has been a significant increase in incidence, therefore only minimal rises in incidence 
of IBD, CD, UC and NCC are reported here. Furthermore, due to the shorter follow up of the 
most recent cohort, fewer patients with IBDU would have had the opportunity to be 
reclassified as either UC or CD and so possibly further underestimating their true rise, 
although this of course would not change total IBD incidence.    
  There is a historical body of evidence with regard to PIBD incidence in Scotland. The first 
report by Barton et al. showed the incidence of CD to be 0.7/100,000/yr and UC 
1.9/100,000/yr in 1968, demonstrating a rise in CD.[224] This study was however hampered 
by poor coding of hospital admissions in those under five years with UC, who were 
subsequently completely excluded. Armitage et al. later reported that between 1981-1995 
there was an overall incidence of 2.6/100,000/yr for CD and a marginal fall in UC to 
1.2/100,000/yr.[245] The current study has added significantly to this historical data and 
demonstrates the sharp rise, especially in CD, within the 2003-2008 cohort. This is clearly 
demonstrated in a summary graph (Figure 2.1.3) which has been constructed using the 
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adjusted rates of incident paediatric CD diagnosed in Scotland from previously published 
Scottish studies[134,224] in addition to the most recent cohort. (All raw data has been age-sex 
standardised to the 2001 Scottish population as described above). There has therefore been 
a 5-fold increase in incidence of paediatric CD over the last 34 years, representing a huge 
rise in this chronic childhood disease. 
  As mentioned above, another study from the UK which is of particular relevance is the 
prospective survey carried out by the BPSU which recorded all instances of new IBD 
diagnoses in those under 16 years over a 13 month period during 1998-1999.[231] This study 
showed that the overall incidence of PIBD UK-wide was 5.2/100,000/yr with Scotland 
producing the highest rate of 6.5/100,000/yr. This clearly shows an ‘intermediate’ incidence 
rate between the two epochs presented here (i.e. 4.45/100,000/yr and 7.82/100,000/yr), and 
further supports the current data. This current study has therefore provided the highest 
recorded incidence of PIBD in the UK to date, and is the first published from anywhere in the 
UK since 2003. However, it has yet to be seen if incidence rates in Scotland will continue to 
rise to the levels described in Canada[246] and Scandinavia[247] which have reported rates of 
13.3/100,000/yr and 10.6/100,000/yr respectively.  
 
 
Figure 2.3.  Summary graph showing age-sex adjusted incidence rates and 95% confidence 
intervals for paediatric Crohn’s disease from various Scottish cohorts between 1969-
2008.[134,224] All crude rates are age-sex adjusted to the 2001 Scottish Census data. In addition to the 
significance values pictured, significant increases in incidence rates exist between the 1986-1989 and 




  Also of interest is the recent study from Denmark which reported the incidence of UC as 
3.1/100,000/yr suggesting that Scotland may yet see further rises in the UC patient 
population.[232] It is also noteworthy that a recent study from Northern California has 
demonstrated a stable incidence of CD and a significant rise in UC during a similar study 
period (1996-2006) to the new Scottish data presented above.[136] However, it should be 
noted that although this study demonstrated a robust method of case identification, 
calculations were based on children registered with a private healthcare insurer and 
therefore only included 30% of the population. In addition there was poor diagnostic 
agreement between physicians during a pilot study and unlike the current study no 
correction was made for statistical overdispersion (i.e. the presence of greater variability 
[statistical dispersion] in a data set than would be expected based on a given simple 
statistical model[248]).  
  Studies showing an increasing incidence of PIBD are often criticised as being due to an 
increased accrual of milder cases of IBD than occurred in the past; this is felt to be 
particularly true for the milder phenotypic cases of CD. There are three reasons why this 
may not be the case in the Scottish PIBD population. Firstly, the Scottish PIBD population 
has previously been shown to not only have significantly more extensive involvement of the 
intestinal tract at diagnosis than the Scottish adult IBD population, but also to have 
significant extension of location within the first few years after diagnosis;[141] the majority of 
the 2003-2008 cohort were included in this previous phenotypic publication. Secondly, 
specifically in the paediatric population, once infection has been excluded, chronic 
symptoms of abdominal pain, rectal bleeding, diarrhoea and growth failure[249] due to IBD will 
almost invariably have led to appropriate assessment at any time in the last 40 years by 
adult and paediatric gastroenterologists or by colorectal surgeons. Additionally, although 
newer diagnostic tests, most notably faecal calprotectin and capsule endoscopy, have been 
in more widespread use in recent years these tests have not been shown to significantly 
influence the number of new PIBD diagnoses. Finally, none of the CD cases in the 2003-
2008 cohort were diagnosed by wireless capsule endoscopy alone, with this imaging 
modality having been suggested to potentially identify milder cases of CD.[250] 
  It is not clear from these studies which factors are contributing to this rise but several 
hypotheses have been suggested. The westernisation of lifestyle, such as the increased 
consumption of a low-fibre, high-sugar diet[137] and the rising rates of obesity have been 
suggested as a possible cause of the rising rates of IBD[138,251]. Other hypotheses regarding 
dysbiosis of the gut microbiota have been postulated and include the cold chain 
hypothesis,[123] the hygiene hypothesis[121] and the protective effect of breast-feeding.[111] 
However, it is not clear how significantly these factors have changed in recent decades in 
those populations with rising rates of PIBD. Interestingly one environmental aspect of 
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Scottish life which has demonstrated an increase in recent years is the number of families 
living outwith towns and cities.[252] This coupled with further Scottish work demonstrating that 
higher human density is protective for PIBD at diagnosis,[253] suggests that movement of 
urban populations back to more remote areas may contribute to the development of IBD. 
With regard to vitamin D and sunlight exposure (a topical subject in IBD pathogenesis [254]), 
although the recent PIBD epidemiology systematic review was unable to confirm a north-
south gradient in incidence,[223] studies showing that vitamin D deficiency may play a role in 
disease development or prevention, and that sunlight may exert vitamin D independent 
beneficial effects on inflammation through nitric oxide production are certainly of interest [255-
257]. 
  Although the selection bias outlined above will have underestimated the rise in PIBD 
incidence this may also have potentially produced a false positive with regard to the 
demonstrated earlier age at onset. As discussed, during the 2003-2008 epoch a significant 
number of adolescents will have been treated in adult units, without any input from paediatric 
gastroenterologists. This fact alone may have led to the reduced age at onset seen in the 
analysis. In contrast, a recent study has in fact demonstrated a rise in the age at PIBD 
diagnosis, however this was not a population-based study, and may have been influenced 
by tertiary referral bias.[258] With regard to gender differences, early-onset disease 
predominantly occurs in males[141,259,260] in contrast to an overall female preponderance in 
adult disease[261,262]. The full picture however is more complex with CD showing a male bias 
and UC demonstrating equal gender frequencies until puberty.[263] The reason for this sex 
difference is not clear, however both genetic (e.g. males with a certain interleukin-6 [IL-6] 
genotype are prone to develop CD at a younger age) and environmental influences (e.g. 
increased risk relating to oral contraceptive use) are among several possible aetiological 
factors.[264,265] In addition to these risk factors, there are data to suggest that the clinical 
presentation differs with gender in PIBD. Gupta et al. showed that in 989 consecutive 
paediatric CD patients girls were more likely to have aphthous mouth ulcers and low serum 
albumin levels at diagnosis.[266] Although disease location did not differ, boys were less likely 
to develop erythema nodosum and pyoderma gangrenosum but more likely to have growth 
failure. A follow-up study by the same group demonstrated that males with paediatric CD 
have lower insulin-like growth factor-1 (IGF-1), with inflammation (as determined by ESR, 
CRP and albumin) more likely to affect IGF-1 levels and bone age in males.[267] Although 
gender differences exist at presentation in PIBD, studies have highlighted the similarities in 
disease severity and medication use in childhood,[268] with possible differences in adult 





2.5.  Conclusion 
 
  This study has demonstrated a minimum 76% rise in PIBD in Scotland through the turn of 
the millennium, however the reasons for this rise have yet to be elucidated. Many avenues of 
research are continuing to unravel the possible gene-environment interactions which may be 
implicated in IBD pathogenesis, in particular at the gut epithelial-microbiota interface,[105] with 
a greater understanding of the basic mechanisms underlying gut inflammation already 
uncovering the new molecular pathways involved.[271] Furthermore, well constructed, 
longitudinal, prospective studies examining the incidence of PIBD across a sufficient time 
period, in addition to secondary epidemiological research, are required to clarify the 

























3.  The epidemiology and natural history of paediatric 
inflammatory bowel disease in South-East Scotland: a 
prospective 14-year study 
 
3.1  Introduction 
 
  In order to further understand the burden of disease on young people with paediatric 
inflammatory bowel disease (PIBD) several parameters should be closely examined: (1) a 
clearer appreciation of the prevalence of disease; (2) the location and behaviour of disease 
at diagnosis and its subsequent natural history; (3) the need for medical therapies (including 
biologicals) and (4) the requirement for surgery. To date, little data exists either in the United 
Kingdom (UK) or worldwide with regard to many of these aspects and with the provision of 
healthcare now high on the political agenda,[272] it is now more important than ever to fully 
determine the most likely future provision of services required and the potential morbidity 
faced by children with PIBD.  
 
3.2  Background 
 
  Unlike disease incidence, disease prevalence is more valuable in the context of informing 
service design, identifying emerging healthcare costs and evaluating clinical pressures.[139] 
Although in relatively stable populations such as Scotland the rates of incident and prevalent 
PIBD cases are likely to fluctuate in parallel,[273,274] it is particularly important to fully 
understand the service requirements of the prevalent population to provide efficient 
management strategies. This is especially important with regard to PIBD as it is clear that 
with the increasing incidence demonstrated both in Scotland (Chapter 2) and worldwide,[223] 
a subsequent increase in overall disease burden will undoubtedly emerge in the paediatric 
population.  
  To date there has been a paucity of robust data on the prevalence of PIBD. Although there 
are several large studies presenting data on adult cohorts,[275,276] these have rarely provided 
a detailed analysis of the paediatric data within their research. However, there have been 
some figures of PIBD prevalence presented in both Europe and further afield. One of the first 
of these studies was in fact from Scotland where in a retrospective cohort of children from 
1968-1989 a figure of 9.5/100,000 was provided for those under 16 years of age prevalent in 
1983.[224] A study from a similar time period performed in Scandinavia gave figures of 
between 17.6/100,000 to 18.2/100,000 children less than 16 years.[277] These studies were 
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however hampered by difficulties ascertaining clear diagnoses in younger patients with 
colitis,[224] and lack of clear endoscopic evidence of PIBD[277]. More recently, studies from the 
United States (US) have been predominant in the literature with most studies based on data 
retrieved from insurance databases, with selection bias likely confounding the results; [278,279] 
although population-based studies have also been reported[280,281]. There is some 
consistency to these data with Crohn's disease (CD) prevalence figures of 39/100,000 (<20 
years old; 2001),[280] 43/100,000 (<20 years old; 2003-2004)[279] and 57.8/100,000 (<20 years 
old; 2008-2009)[278] however it can be seen that two of these studies analysed the same 
database, with all studies using a relatively wide paediatric age range. The equivalent 
prevalence figures for UC in these studies were 42/100,000, 28/100,000 and 33.9/100,000 
respectively. One of the largest studies to date carried out in five Canadian provinces 
demonstrated the large variation in IBD prevalence within a single country.[281] They reported 
paediatric prevalence rates of between 30.5 - 71.1/100,000 for CD and 17.5 - 30.7/100,000 
for UC (less than 20 years of age), postulating that ethnicity and environmental risk factors 
played an important part in disease development and varying prevalence. Further data was 
published by Abramson et al. in which figures from Northern California collected from 1996-
2006 were analysed.[282] Although again using a large health-plan database (with potential 
selection bias), they demonstrated age-standardised point prevalence rates of 12.0/100,000 
for CD and 19.5/100,000 for UC, with the useful inclusion of rates of colonic IBD, type 
unclassified (IBDU) of 3.5/100,000 (less than 18 years of age). These figures were however 
low in contrast to the other US studies, possibly as a result of the much higher non-
Caucasian population investigated.  
  As discussed in Chapter 1 it has been clearly shown that PIBD presents with extensive 
anatomical involvement, with higher rates of pan-enteric CD[266,283] and pancolitis in UC[284,285] 
compared to adult disease[141,286]. Furthermore, heterogeneity within the paediatric 
population is evident, with those diagnosed before eight years of age showing significantly 
less ileal disease and more isolated colonic disease than patients with adult-onset 
disease.[141,287,288] Disease behaviour however has been shown to be similar to adult disease 
with progression from inflammatory disease to stricturing/penetrating complications,[141,289] 
with surgical intervention being more diverse. 
  With regard to PIBD phenotype at diagnosis and its natural history the most comprehensive 
data to date has come from Scotland and France. Van Limbergen and Russell et al. 
demonstrated that 31% of children with CD had pan-enteric disease (Montreal A1/L3+L4) at 
diagnosis with 44% after 2-years follow up.[141] With regard to CD behaviour, 24% of children 
developed stricturing or penetrating disease after 4 years from diagnosis in the same study. 
Similarly for UC, 75% had maximal colonic disease at diagnosis (Montreal A1/E3), with 82% 
having E3 disease at last follow up. This was in stark contrast to adult-onset disease 
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(Montreal A2/A3) were 3% of CD patients and 48% of UC patients had maximal disease 
location at last follow up. In France, the Registre des Maladies inflammatoires chroniques de 
l'Intestin du Nord Ouest de la France (EPIMAD), has provided data on an incident cohort of 
children diagnosed since 1988, allowing the publication of a large volume of research 
regarding the natural history of PIBD. Several overlapping studies involving children (less 
than 17 years old) newly diagnosed with PIBD from an at-risk population of 1.3 million have 
now been published, with the most recent study involving 309 CD patients with at least 5-
years follow up.[259,290-294] Interestingly, this group report similar rates of pan-enteric CD (27% 
at diagnosis, 48% at follow up) as the Scottish data,[291] however their rates of pancolitis in 
UC were lower at diagnosis (37%) but with a more comparable extension of disease at a 
median of 77 months follow up (60%).[290] Further data has now been presented by the 
EUROKIDS registry, an inception cohort of children (less than 18 years) newly diagnosed 
with PIBD since 2004, highlighting that terminal ileal disease and stricturing behaviour are 
uncommon in children under 10 years old,[295] and the high prevalence of pancolitis and 
atypical phenotypes in UC[296]. Of further note, a recent population-based Scandinavian data-
set (n=130; children <15 years old) possibly suggests a slightly milder phenotype at 
diagnosis for both CD and UC, although the data is unclear with regard to the total number 
of incident cases per centre, with no complete geographical case ascertainment.[232]  
  With the increasing use of biological agents such as infliximab and the growing impetus 
towards the use of exclusive enteral nutrition (EEN) in paediatric CD, there may have been 
significant changes in the use of immunomodulators and surgical rates in PIBD patients over 
recent years. Jakobsen et al. described the rate of immunomodulator use in a cohort of 65 
paediatric CD patients (less than 15 years of age) with a median of 1.6 years follow up 
between 2007-2009.[232] This study showed that 61.5% of patients required azathioprine 
(AZA) or 6-mercaptopurine (6-MP), with 3.1% requiring methotrexate (MTX) and 24.6% 
requiring any biological. Van Limbergen and Russell et al. described the combined use of 
any immunomodulator (AZA, 6-MP, MTX or biological) in a larger cohort of 408 Scottish 
PIBD patients with extended 10 year follow up data showing that 11.5%, 40.5% and 38.4% 
of CD, UC and IBDU patients respectively had remained free from immunomodulators. [141] 
One of the most recent studies to evaluate therapeutic usage in PIBD was a survey of 164 
children aged 8-17 years old attending a charity-run camp in the US.[297] This survey showed 
that after approximately 4 years of follow up 47.1% were on an immunomodulator with 
36.3% on a biological; interestingly 5% were being treated with a biological agent and an 
immunomodulator. Other studies have shown the variable use of immunomodulators in both 
UC[298] and CD[299] most likely reflecting the length of follow up, the population studied and 
the historical use of biologicals in the study centres. 
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  With regard to surgery in PIBD, Van Limbergen and Russell et al. demonstrated that after 5 
years follow up 20.2% and 20.0% of children with CD and UC respectively had undergone 
resectional surgery.[141] Schaefer et al. in a study of 854 children with CD demonstrated a 
similar 17.7% CD-related surgery rate at 5 years.[300] Gupta et al. also described the rates of 
surgery in 989 consecutive CD patients less than 17 years old from six centres in the US. [301] 
They showed that the cumulative risk of surgery was 17% at 5 years from diagnosis, with the 
addition of female gender, initial diagnosis of UC, poor growth, and fistulating or stricturing 
CD increasing the risk of surgery in a multivariate model. Extended data from the EPIMAD 
registry demonstrated that 32% of CD patients required bowel resection at a median of 13 
years of follow up with the probability of a second resection being 8%, 17% and 29% at 2, 5 
and 10 years respectively. 
  It is clear that in patients diagnosed with IBD in childhood the disease burden is high.[302] 
However, an accurate indication of the need for therapies in larger geographically defined 
cohorts are required to ascertain the true extent of healthcare service use and disease 
morbidity. 
 
3.3  Hypotheses and aims 
 
Hypotheses: 
1. The incidence and prevalence of PIBD in South-East Scotland are rising in-line with 
Scottish trends (Chapter 2). 
2. Children diagnosed with PIBD have a severe disease phenotype at diagnosis which 
continues to extend within a short time from diagnosis. 
3. PIBD medical therapies have been used more aggressively in recent years with the 
use of immunomodulators, especially biologicals, more commonplace. 
4. A large proportion of children with PIBD require surgery while still in paediatric 
services. 
 
Aims: To collate data from a prospective cohort of children diagnosed with PIBD in South-
East Scotland from August 1997 to December 2011 to ascertain the natural history of 
disease, including (1) incidence and prevalence; (2) disease location and behaviour; (3) 






3.4  Methods 
 
3.4.1  Setting 
  The Department of Paediatric Gastroenterology and Nutrition at the Royal Hospital for Sick 
Children, Edinburgh (RHSCE) was initially established in August 1997 following the 
appointment of Prof. (then Dr) David C Wilson as a Paediatric Consultant Gastroenterologist. 
The hospital currently acts as a secondary referral centre for City of Edinburgh, East Lothian 
and Mid-Lothian (all NHS Lothian) as well as the a tertiary referral centre for three district 
general hospitals (DGH) (Borders General Hospital, NHS Borders; Victoria Hospital, NHS 
Fife; St. John's Hospital, West Lothian, NHS Lothian) in South-East Scotland (SES). 
Historically, the Department has managed all PIBD in paediatric services in SES, and also 
cared for the majority of PIBD patients referred from Dumfries and Galloway Royal Infirmary 
(NHS Dumfries and Galloway) and a sizeable minority of PIBD patients referred from Forth 
Valley Hospital (NHS Forth Valley) until recent changes in health board restructuring 
gradually came into full effect (April 2010). The Department currently employs four 
experienced paediatric consultants, three nurse specialists and two senior dietitians, as well 
as junior medical staff and administrative assistants. Serving a population of approximately 
228,000 children less than 16 years,[303] RHSCE currently provides all the initial diagnostic 
evaluation, induction of remission and ongoing medical and surgical management of all 
children with PIBD. In 1998, Dr Wilson had contacted the paediatric services in all the DGHs 
and adult gastroenterology units in SES to confirm that RHSCE would manage all PIBD 
patients less than 16 years old in addition to any 16-18 year old teenagers still to complete 
puberty. This transition was aided by agreeing to provide endoscopy under general 
anaesthetic, outreach clinics in DGHs, and transition clinics in the main academic adult 
gastroenterology centre. All prevalent PIBD in RHSCE under the care of general 
paediatricians and paediatric surgeons were also transferred to the PIBD clinic. Therefore by 
1999, there is a high degree of confidence that all SES PIBD patients were in paediatric 
services in RHSCE, however a small number of patients less than 17 years old may have 
remained in adult services without any paediatric involvement. 
 
3.4.2  Patient cohort 
  Following the inception of the paediatric gastroenterology service in August 1997 all cases 
of incident and prevalent PIBD cared for at RHSCE were initially recorded retrospectively in 
paper copy. Ms Pam Rogers (Liver and IBD Nurse Specialist) was appointed in April 1998 
and until November 1999 all prevalent cases were retrospectively entered on an hand-held 
database until the current prospective database was introduced in December 1999; this is 
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currently a custom-made Microsoft Access 2003 database (Microsoft Corporation, 
Redmond, WA, USA) with previous versions of Microsoft Access used prior to this. Children 
are entered in the database if they are diagnosed within the study centre with either CD, UC 
or IBDU using standard clinical, histological and radiological findings in-line with the 
Lennard-Jones and Porto criteria.[147,236] For those children who have moved into the area 
with a known diagnosis of PIBD, as much information as possible is compiled from transfer 
letters, histology reports, imaging and direct contact with their previous physician to confirm 
the diagnosis prior to database inclusion, with re-evaluation undertaken in cases where the 
diagnosis is in any doubt. 
 
3.4.3  Data collection 
  Following a confirmed diagnosis of PIBD the basic demographics of each patient are 
entered into the departmental Access database (unique hospital number, surname, 
forename, date of birth, referral area and sex). Additionally, details of the patient's diagnosis 
(CD, UC or IBDU) and the date of diagnostic endoscopy are also entered. Following this 
initial entry, data regarding the commencement of AZA, 6-MP, MTX and biologicals are 
entered prospectively with the dates of initial prescription recorded. Evidence of perianal 
disease and details of surgery are also entered. The date of 
discharge/transfer/transition/death is also stipulated and the destination post-discharge (i.e. 
other hospital, adult services or moved out of area). Where there is any doubt as to an exact 
date the 15th day of the month is used as this would ensure the smallest margin of error 
when subsequent calculations are made. 
  To augment the current dataset several other sources of information were used to obtain as 
much clinical information on each patient as possible. Firstly, the incident cohort from 2003-
2008 (Chapter 2) was used to ensure the accuracy of diagnosis and the patient's sex, date 
of diagnosis and date of birth. An even greater degree of clinical information was also 
obtained from the current Paediatric Inflammatory Bowel Disease Cohort and Treatment 
Study (PICTS) database currently held by Mrs Hazel Drummond at the Gastrointestinal Unit, 
Institute of Genetics and Molecular Medicine, University of Edinburgh under the supervision 
of Prof DC Wilson, Dr RK Russell and Prof J Satsangi (co-investigators on PICTS). This 
comprehensive database holds a vast array of clinical data on over 800 children with PIBD 
(diagnosed less than 17 years old) cared for in Scotland, with diagnoses dating back as far 
as 1979. This database has been used in a number of previous studies,[141,241,304,305] with 
comprehensive case-note review providing detailed phenotyping of patients at diagnosis and 
at 2-yearly intervals. Data pertaining to medical therapies and surgical interventions is also 
collated on this database along with histology reports, environmental questionnaire results, 
genetic data and data regarding biomarkers and anthropometric data. With regard to 
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phenotypic classification, although the Paris classification (see Chapter 1) has now become 
the standard system for paediatric disease,[154] historically all data collected in Edinburgh has 
been recorded using the Montreal classification. There is currently an ongoing process to 
update these data to the Paris classification, however the current data-set presents only 
Montreal location and behaviour, which allows comparisons to cohorts derived over a similar 
period of time to be made. With regard to CD it should be noted that since commencing 
detailed phenotyping in Edinburgh, following the confirmation of histological granulomatous 
disease with macroscopic changes in any location, the presence of classical microscopic 




Table 3.1.  Definitions of microscopic and macroscopic disease used in Edinburgh to classify 
paediatric Crohn's disease location using the Montreal classification.  
 
Definite macroscopic CD Non-diagnostic macroscopic CD 
 Mucosal apthous ulcers 
 Linear or serpentine ulceration 
 Cobblestoning 
 Pseudopolyps 
 Stenosis/stricturing of bowel 
 Radiological or surgical – bowel wall 
thickening with luminal narrowing 
 Perianal CD – fistula(s), abscesses, anal 
stenosis, anal canal ulcers 






 Loss of vascular pattern 
 Single or very few isolated apthous 
ulcers 
 Perianal – fissures, skin tags 
Definite microscopic CD Non-diagnostic microscopic CD 
 Non-caseating granuloma(s) – must be 
remote from ruptured crypt 
 Classical features of IBD – mucosal 
ulceration/erosion, crypt architectural 
changes, colonic Paneth cell metaplasia, 
focal chronic inflammation, transmural 
inflammatory infiltrate, submucosal fibrosis 
 Granuloma adjacent to ruptured crypt 
 Non-specific inflammatory infiltrate in 
lamina propria 
 
CD, Crohn's disease; IBD, inflammatory bowel disease 
 
 
  Despite the well validated sources of data described above there were occasions were data 
was incomplete or uncertain and in all of these cases the case-notes and computerised 
laboratory pathology reports were re-examined were possible to clarify the information 
provided. Within the cohort a small number of children had been re-classified as CD, UC or 
IBDU. Regardless of the timing of this diagnostic change only their most recent diagnosis 
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(taken on the 1st October 2012) was recorded to ensure a true representation of IBD 
distribution. The date of last follow up was taken to be the last clinical episode with paediatric 
services in SES, and follow up duration was taken from the date of diagnosis regardless of 
whether the child was diagnosed in SES. 
 
3.4.4  At-risk population and statistics 
  In view of the differences in health board referral patterns and the fact that children over the 
age of 16 years old often continue to be managed in the PIBD service until transition in their 
late teenage years, there are in fact two separate cohorts evident within the current data. 
The first cohort is the complete prevalent case-load cared for since August 1997 and 
includes children from the core referral areas (i.e. NHS Borders, NHS Fife and NHS Lothian) 
as well as children from NHS Forth Valley, NHS Dumfries and Galloway and a small number 
of children from other areas such as NHS Highland and NHS Tayside (Figure 3.1); this 









  The second cohort is the robust, prospective prevalent cohort consisting of those in Cohort 
1 that were less than 16 years old and cared for in RHSCE between 1st January 2000 and 
31st December 2011, importantly residing in one of the three core referral areas at the time 
of diagnosis (Cohort 2). Additionally those who moved into the area from outwith SES were 
also removed from this cohort.  
  To allow for changes in population structure within Cohort 2, incidence and prevalence 
figures for each year were first calculated from known population figures and then 
standardised to the 2001 Scottish Census population to enable direct comparison. [234] 
Although the most recent Scottish census took place in 2011 the figures are not yet available 
publicly and therefore mid-year estimates from 2000-2011 were used (Table 3.2). To allow 
for differences in age structure within the cohort age groups were defined as pre-school (0-5 
years), primary school (6-10 years) and secondary school (11-15 years). Age-sex 
standardised rates were then calculated using the direct method[238] and 95% confidence 
intervals (CIs) determined using a method based on gamma distribution.[239] All rates are 
presented as per 100,000 of the at risk population, that is those less than 16 years of age. p 
values for comparisons between time periods were obtained from Poisson regression 
models. Analyses were carried out using the epitools package in R version 2.14.1 (R 
Foundation for Statistical Computing, Vienna, Austria)[240] and Mann-Whitney U, Chi-squared 
analysis using GraphPad Prism version 4.03 (GraphPad Software, CA, USA). A two-tailed p 
value of less than 0.05 was considered significant in all analyses.  
 
 
Table 3.2.  Numbers of children aged less than 16 years of age in the three NHS health 
boards that have consistently referred to the Royal Hospital for Sick Children, Edinburgh 
since 2000. 
 
Year NHS Borders NHS Fife NHS Lothian Total 
2000 20,765 71,145 145,007 236,917 
2001 20,185 68,516 143,896 232,597 
2002 20,165 67,612 142,081 229,858 
2003 20,233 66,949 140,347 227,529 
2004 20,271 66,524 139,625 226,420 
2005 20,310 66,041 138,890 225,241 
2006 20,131 65,478 139,013 224,622 
2007 20,107 65,104 138,937 224,148 
2008 20,126 65,028 139,314 224,468 
2009 19,947 64,882 140,444 225,273 
2010 19,880 64,833 141,376 226,089 
2011 19,763 64,988 142,984 227,735 





3.4.5  Ethics 
  Formal ethics approval was sought from the Lothian Research and Ethics Committee but 
was deemed unnecessary as this was an anonymous, observational study of patients 
already under the care of paediatric gastroenterology services and under the umbrella of the 
Paediatric-onset IBD Scottish Audit (PISA). For the children were data was obtained from 
the Medical Research Council-funded PICTS database, the patient and/or their parents 
provided full written consent which was approved by local ethics committees at all three 
participating Scottish clinical networks: South-East Scotland (LREC/2002/6/18), West of 
Scotland (YREC/P12/03) and North of Scotland (GREC/03/0273). 
 
3.5  Results 
 
3.5.1  Cohort characteristics 
  In total, 326 children with PIBD were cared for at RHSCE between 1st August 1997 and 
31st December 2011. Of this complete cohort (Cohort 1) the median age at diagnosis was 
11.7 years (range 0.5-13.4; interquartile range [IQR] 9.1-13.4), with approximately two thirds 
of children suffering from CD. In Cohort 2 the proportion of children with each PIBD type was 
similar and although there was a higher median age at diagnosis in this cohort this was not 
significantly different (p=0.376). There was a slight preponderance of males in both cohorts, 
driven by the (non-significant; p=0.169) higher proportion of males patients with CD. Details 
of the basic characteristics of both cohorts are shown in Table 3.3. Cohort 1 had a total 
follow up time of 1577 patient years, with a median of 4.4 years (IQR 2.7-6.3) per patient; the 
corresponding figures for Cohort 2 were 1075 patient years and 4.1 years (IQR 2.4-5.8) 
respectively. A total of 292 children (90%) were registered on the PICTS database in Cohort 
1 and 240 children (98%) in Cohort 2. Seven patients (four CD and three UC) in Cohort 2 
had been diagnosed outwith SES (three in the north of Scotland, two in mainland Europe 
and two in North America), with 26 discharged/transferred/transitioned to centres outside 
SES; 20 while still under 16 years old (therefore an overall negative net migration for Cohort 
2). There was one death in a 12-year old girl following surgery for UC, this was suspected to 








Table 3.3.  Basic characteristics of the two study cohorts of children diagnosed with 
paediatric inflammatory bowel disease in South-East Scotland. 
 
 IBD CD UC IBDU 
Cohort 1     
Total number 326 215 74 37 
Male sex (%) 178 (55) 127 (59) 35 (47) 16 (43) 
Median age at diagnosis 
(years [IQR]) 
11.7 (9.1-13.4) 11.6 (9.5-13.4) 12.0 (9.4-13.6) 11.5 (8.5-13.7) 
Age range (years) 1.5-17.7 2.5-16.8 1.5-17.7 3.3-17.0 
     
Cohort 2     
Total number 244 157 58 29 
Male sex (%) 136 (56) 95 (60) 29 (50) 12 (41) 
Median age at diagnosis 
(years [IQR]) 
12.2 (9.7-13.6) 12.1 (9.8-13.5) 12.4 (9.5-13.8) 11.8 (8.3-13.8) 
Age range (years) 1.5-15.9 2.5-15.7 1.5-15.9 3.3-15.7 
IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; IBDU, colonic IBD, type 
unclassified; IQR, interquartile range. 
 
 
3.5.2  South-East Scotland has the highest recorded incidence of paediatric 
inflammatory bowel disease in the UK and demonstrates a significant increase in 
ulcerative colitis  
  Although incidence figures for the entire Scottish population have been presented in 
Chapter 2 it is important to determine if this effect is evident in constituent regions. The 
details of all children in Cohort 2 were therefore examined to determine those who were 
diagnosed in SES following referral from the three core SES health boards, leaving 237 
incident cases of PIBD in SES over the 11-year period between 2000-2011. This incident 
cohort consisted of 153 CD, 55 UC and 29 IBDU patients of which 134 (57%) were male. 
 
 
Table 3.4.  Crude number of paediatric inflammatory bowel disease cases diagnosed in 
South-East Scotland during each six-year epoch by sex and IBD type. 
 
Epoch Persons at 
risk* 
IBD CD UC IBDU 
Male 
2000-2005 117,562 61 46 9 6 
2006-2011 115,182 73 48 19 6 
Female 
2000-2005 112,198 50 31 11 8 
2006-2011 110,206 53 28 16 9 
* = Mean number of persons at risk (i.e. less than 16 years old) across each epoch. IBD, inflammatory bowel 
disease; CD, Crohn’s disease; UC, ulcerative colitis; IBDU, colonic IBD, type unclassified. 
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  It can be seen in Table 3.4 that there was an increase in the number of diagnoses of PIBD 
between the two six-year epochs (2000-2005 and 2006-2011) from 111 to 126. Interestingly 
this seems to have been driven by an increase in the number of children (both males and 
females) diagnosed with UC during the study periods.  
  Following age-sex standardisation, the incidence rates of PIBD were 8.00/100,000/year 
(95% CI 6.58-9.64) and 9.50/100,000/year (95% CI 7.91-11.31) for the 2000-2005 epoch 
and the 2006-2011 epoch respectively (p=0.325). The adjusted incidence of CD rose 
marginally from 5.55/100,000/year (95% CI 4.38-6.94) to 5.70/100,000/year (95% CI 4.49-
7.14) (p=0.974) and significantly in UC from 1.44/100,000/year (95% CI 0.88-2.22) to 
2.67/100,000/year (95% CI 1.86-3.71) (p=0.010). There was no significant rise in the 
incidence of IBDU from 1.01/100,000/year (95% CI 0.55-1.70) to 1.13/100,000/year (95% CI 
0.63-1.87) across the two epochs respectively (p=0.827). Although there was a trend 
towards an increasing age-standardised incidence in both sexes across all PIBD types, none 
of these were significant (Table 3.5).  
 
 
Table 3.5.  Age-adjusted incidence rates of PIBD in South-East Scotland for all males and 
females by IBD type. 
 
Cohort 2000-2005 2006-2011 Difference between 
cohorts (p value) 
Males 
IBD 8.59 (6.57-11.04) 10.80 (8.46-13.58) 0.462 
CD 6.48 (4.75-8.65) 7.06 (5.20-9.37) 0.734 
UC 1.26 (0.58-2.40) 2.84 (1.71-4.45) 0.104 
IBDU 0.84 (0.31-1.84) 0.90 (0.33-1.97) 0.964 
Females 
IBD 7.39 (5.48-9.24) 8.14 (6.10-10.67) 0.731 
CD 4.59 (3.12-6.51) 4.29 (2.85-6.21) 0.766 
UC 1.62 (0.81-2.90) 2.48 (1.41-4.04) 0.337 
IBDU 1.18 (0.51-2.33) 1.37 (0.63-2.62) 0.831 
Figures are adjusted rates per 100,000 at risk population per year (95% CIs]). IBD, inflammatory bowel disease; 
CD, Crohn’s disease; UC, ulcerative colitis; IBDU, colonic IBD, type unclassified. Significance = p<0.05. 
 
 
3.5.3  The South-East of Scotland has seen a significant rise in the point 
prevalence of PIBD since 2000 
  In areas with high incidence rates of PIBD (as demonstrated in SES) it is important to fully 
understand the current trends in disease prevalence. To first ascertain the overall service 
case-load experienced at RHSCE the crude number of PIBD cases in Cohort 1 was 
calculated on 30th August annually. Figure 3.2 shows that the number of children with PIBD 
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under the care of the paediatric gastroenterology team has risen steadily, even accounting 
for the initial years of service establishment. In the last five years of the study (2007-2011) 




Figure 3.2.  Graph showing the crude number of paediatric inflammatory bowel disease 
patients cared for by the paediatric gastroenterology service in RHSCE on the 30th August 
annually between 1997 and 2011. PIBD, paediatric inflammatory bowel disease; RHSCE, Royal 
Hospital for Sick Children, Edinburgh. 
 
 
  To further define the true trends in the prevalence of PIBD, age-sex standardised point 
prevalence figures on the 30th August annually were calculated for Cohort 2. To further 
increase the accuracy of these data, children were removed from the prevalence figures 
after their 16th birthday to ensure that only prevalence rates for those less than 16 years old 
were included. To take full account of service establishment, only figures from 2000 onwards 
are presented. 
  Following age-sex standardisation, the point prevalence rates of PIBD were 29.5/100,000 
(95% CI 26.8-32.5) and 41.2/100,000 (95% CI 37.6-44.8) for the 2000-2005 epoch and the 
2006-2011 epoch respectively (p=0.016). The adjusted point prevalence of CD rose from 
21.1/100,000 (95% CI 18.7-23.6) to 27.5/100,000 (95% CI 24.8-30.5) (p=0.073) and 
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significantly in UC from 5.3/100,000 (95% CI 4.1-6.6) to 8.4/100,000 (95% CI 6.9-10.2) 
(p=0.004). There was also a significant rise in the point prevalence of IBDU from 
3.2/100,000 (95% CI 2.7-4.3) to 5.2/100,000 (95% CI 4.1-6.6) across the two epochs 
respectively (p=0.021). Table 3.6 presents the age-standardised point prevalence rates by 




Table 3.6.  Age-adjusted point prevalence rates of PIBD in Scotland by IBD type for males 
and females aged less than 16 years old.   
 
Cohort 2000-2005 2006-2011 Difference between 
cohorts (p value) 
Males 
IBD 31.1 (27.1-35.5) 48.7 (43.6-54.3) 0.001 
CD 24.9 (21.4-28.8) 34.9 (30.6-39.6) 0.043 
UC 3.5 (2.3-5.2) 9.3 (7.1-11.9) 0.003 
IBDU 2.7 (1.6-4.2) 4.6 (3.1-6.6) 0.013 
Females 
IBD 27.9 (24.1-32.2) 33.3 (29.0-38.0) 0.124 
CD 17.1 (14.1-20.5 19.9 (16.6-23.6) 0.316 
UC 7.1 (5.2-9.4) 7.6 (5.6-10.0) 0.813 
IBDU 3.8 (2.5-5.6) 5.8 (4.1-8.0) 0.087 
Figures are adjusted rates per 100,000 at risk population per year (95% CIs). IBD, inflammatory bowel disease; 
CD, Crohn’s disease; UC, ulcerative colitis; IBDU, colonic IBD, type unclassified. Significance = p<0.05. 
 
 
3.5.4  Children with inflammatory bowel disease present with a severe phenotype 
and progress quickly to extensive disease 
  Using the data available in the RHSCE departmental database, in addition to the 
comprehensive PICTS database (and review of clinical and histological reports were 
necessary), data regarding CD Montreal classification disease location and behaviour was 
available for 212/215 (98.6%) of all patients. CD patients were followed up for a median of 
4.9 years (range 0.5-15.4, IQR 3.0-6.9) before discontinuing their contact with paediatric 
services. It can be seen from Table 3.7 that, in line with previous studies, children with CD 
presented with a severe phenotype, with over one third of children having pan-enteric 
disease at diagnosis (Montreal L3+L4) and 43.9% of children having L3+L4 disease at last 
follow up. In addition, a significant proportion of children presented with only oral and/or 
perianal disease (4.7%) with a small number (1.4%) remaining with this phenotype at follow 
up. With respect to behaviour, the vast majority of children presented with an inflammatory 
phenotype (95%) with 14% of children demonstrating perianal disease at diagnosis, 
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increasing to 20% at last follow up. However for those with B1 behaviour at diagnosis (+/- 
perianal disease), 30% had extended to either B2 or B3 disease at follow up. There was no 
difference in males and females with regard to the presence of pan-enteric disease at 
diagnosis (p=0.931), in those diagnosed less than or greater than 10 years of age (p=0.816) 
or the presence of perianal disease (p=0.755). The presence of any ileal disease (Montreal 
L1 or L3 +/- L4) was rare in children aged less than 8 years and 10 years old (13% and 30% 
respectively). There was also a significantly higher number of children aged less than 10 




Table 3.7.  Montreal classification of Crohn's disease location and behaviour at diagnosis 





 (n [%]) 
At last  
follow up 




 (n [%]) 
At last  
follow up 
 (n [%]) 
L1 8 [3.8] 3 [1.4] B1 173 [81.6] 137 [64.6] 
L2 34 [16.0] 24 [11.3] B1p 29 [13.7] 35 [16.5] 
L3 38 [17.9] 44 [20.8] B2 5 [2.4] 20 [9.4] 
L4 2 [0.9] 0 [0.0] B2p 1 [0.5] 5 [2.4] 
L1+L4 5 [2.4] 4 [1.9] B3 4 [1.9] 12 [5.7] 
L2+L4 43 [20.3] 41 [19.3] B3p 0 [0.0] 3 [1.4] 
L3+L4 72 [34.0] 93 [43.9] 
Oral/perianal 
only 
10 [4.7] 3 [1.4] 
 
 
  With regard to cases of UC and IBDU, 107/111 (96.3%) had Montreal location data 
available at diagnosis and Montreal maximum extent at last follow up; the median follow up 
time for these patients was 3.9 years (range 0.1-11.3, IQR 2.1-5.4).  
 
 
Table 3.8.  Montreal classification location at diagnosis and maximal extent at last follow 
up for 107 patients with UC or IBDU cared for in South-East Scotland between 1997-2011. 
 
Montreal Classification At diagnosis (n [%]) Maximal Extent at  
follow up (n [%]) 
E1 16 [15.0] 11 [10.3] 
E2 10 [9.3] 9 [8.4] 





  Table 3.8 shows that three quarters of children with UC or IBDU presented with a 
pancolitis, with 81.3% having extensive disease at last follow up. Of the 26 children who 
presented with a more limited colitis (i.e. Montreal E1 or E2), eight (30.8%) had extended 
their disease at last follow up. 
 
3.5.5  Immunomodulators and biologicals are used earlier in the disease course in 
children diagnosed in the more recent 2006-2011 epoch 
  With regard to the use of immunomodulators and biologicals, data regarding 'any exposure' 
of AZA, 6-MP, MTX or biologicals, including the date of first prescription, was available for all 
patients.  
  AZA was prescribed to a total of 217 of patients (70.0%) in Cohort 1 with no difference in 
the numbers of males and females prescribed the drug (p=0.991). With respect to the time of 
commencing AZA in Cohort 2, 101 children diagnosed between 2000-2005 were started on 
AZA at a median of 202 days from diagnosis (IQR 92-550); the corresponding values for 
those diagnosed between 2006-2011 (n=76) was 182 days (IQR 67-375), this was not 
significantly different (p=0.295). Looking at patients diagnosed before their 10th birthday in 
Cohort 1 there was a significantly longer period to their first AZA prescription (403 days [IQR 
157-1164]) compared to those diagnosed greater than 10 years old (196 days [IQR 92-488]) 
(p=0.001). Additionally there was no difference in the proportion of younger (i.e. less than 10 
years old at diagnosis) or older (i.e. over 10 years old at diagnosis) children prescribed AZA 
across the whole study period (p=0.767). A total of 20 children were prescribed 6-MP (50% 
male) at a median of 21 months following diagnosis (IQR 13-36). All these had previously 
been exposed to AZA and were converted to 6-MP for AZA intolerance confirmed on 
reproducible symptoms (nausea, headache, fatigue) on two separate exposures. 
  MTX was prescribed to a total of 85 patients (26.1%) in Cohort 1, with a slighter greater 
proportion of males (p=0.123). In Cohort 2 51 patients diagnosed between 2000-2005 
commenced MTX at a median of 34 months (IQR 22-53) from diagnosis, which was 
significantly longer than those diagnosed more recently in the 2006-2011 epoch (22 months 
[IQR 15-27]) (p=0.001). Children diagnosed before 10 years of age were not more likely to 
receive MTX across the entire study period (p=0.604) and had a significantly longer time to 
first prescription (47 months [IQR 28-76]) than older children (25 months [IQR 16-35]) 
(p<0.001). 
  The use of biological therapy (such as infliximab and adalimumab) has increased in recent 
years, with preparations now licensed for both CD and UC. A total of 58 patients in the entire 
cohort received either infliximab, adalimumab or both during the study period (17.8%); 12 
(20.7%) of whom had a diagnosis of UC. Fifty-seven patients were administered infliximab 
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and 14 adalimumab (only one patient was given adalimumab without previously 
encountering infliximab; a child with known juvenille idiopathic arthritis diagnosed prior to 
confirmed luminal CD) of which 34 were male and 24 female (p=0.594). Twenty-seven 
children in Cohort 2 diagnosed between 2000-2005 were given a biological at a median time 
from diagnosis of 47 months (IQR 22-58), with the 26 children diagnosed between 2006-
2011 receiving their first dose of biological at a significantly shorter 20 months (IQR 4-37) 
(p<0.001). The same proportion of those diagnosed less than 10 years old were 
administered a biological as children diagnosed in later childhood (p=0.912); older children 
were more likely to receive a biological quicker (23 months [IQR 11-42]) than younger 
children (58 months [IQR 35-92]) (p=0.003). Overall, 67.4% (220/326) received any 
immunomodulator (including biologicals) during the study period. 
 
3.5.6  Surgery 
  A detailed account of the surgeries performed in this cohort of children is outwith the scope 
of this study, however crude data on surgery was available through the departmental 
database and the PICTS database. A total of 65 patients (19.9%) had 73 IBD-related 
surgeries carried out while under the care of paediatric services (35 male, 30 female). 
Figure 3.3 shows the total number of surgeries performed during the study period. It can be 
seen that the majority of children required a sub-total or total colectomy, with 15 requiring 
surgery for perianal disease. Eight children underwent perianal surgery prior to a confirmed 
diagnosis of IBD, with a further 11 undergoing surgery within one month of diagnosis. Of the 
remaining 44 children, the median time to first surgery was 3.3 years (IQR 1.8-4.6) and 






Figure 3.3.  Graph showing the number of each type of IBD-related surgery performed in the 
South-East Scotland cohort while in paediatric services. PIBD, paediatric inflammatory bowel 
disease; ileo, ileostomy; Restor.Procto, restorative proctocolectomy. 
 
 
3.6  Discussion 
 
  This study has demonstrated that SES has the highest recorded incidence rate of PIBD in 
the UK to date, with a significant increase in UC diagnoses since 2000 and rising prevalence 
rates in those under 16 years of age. It has also confirmed the severe disease phenotype 
both in CD and UC, and the high rates of immunomodulator use and surgery. 
  The data regarding the incidence and prevalence of PIBD in SES are certainly of interest. 
In the context of the figures presented in Chapter 2, the higher incidence rates of total PIBD 
of 8.00/100,000/year in the 2000-2005 cohort are higher than would have been expected, 































































































































































previous work from Canada showing varying incidence rates of between 5.4 to 12.0 per 
100,000 population per year for CD and between 3.2 and 4.7/100,000 for UC in five large 
regions.[281] The authors suggest several reasons for these differences including hospital 
coding[306] and changes in immigration and ethnic diversity. It is not clear however how these 
changes currently affect the Scottish population and certainly these regional variations may 
partly be explained by environmental factors.[253] It is also of interest that SES had higher 
incidence rates of CD and UC than the Scotland-wide data, evident between 2000-2005. 
This suggests that the incidence for both these IBD types has been higher for a greater 
length of time, again questioning the role of urban dwelling,[253] diet and standard of 
living,[307,308] migration patterns[273] and potential bacterial pathogens[309]. Specifically with 
relation to migration, publicly available data from the General Registrar Office shows that net 
migration of children 0-15 years old has remained stable but positive since 2001 Scotland-
wide, with a mean of 3,400 children per year. However, regional variation exists with a 
decline in net migration in the NHS Borders and NHS Fife health boards and a dramatic 
increase in positive net migration in NHS Lothian from 2001-2011. This is unlikely to have 
significantly influenced the currently robust prevalent cohort given that there was an overall 
negative net migration of patients during the study period. An alternative explanation of this 
higher incidence rate in SES is the greater accrual of older teenagers (14-15 years old) in 
this region, which anecdotally is the certainly the case. 
  Despite the evidence suggesting increasing incidence rates of PIBD in both the UK 
(Chapter 2) and Ireland,[230] these figures do not fully encompass the burden of disease 
encountered by these young people. In the first comprehensive study of PIBD prevalence in 
the UK, it has been shown here that children with this chronic disease create a significant 
workload for the centres providing their care.[310] Not only can the prevalence figures 
presented provide a sound basis for the provision of future services (as with other 
conditions[311]) but they can also better inform the charities that support these young 
people[312]. A greater understanding of the prevalence and disease burden of PIBD may also 
help inform allied health services such as psychology and dietetics,[313,314] as well as helping 
to underpin the drive for translational research in the field of IBD[315]. The infrastructure for 
PIBD services has been brought into focus over recent years in the UK by the IBD audit 
commissioned by the Healthcare Quality Improvement Partnership.[316,317] The recent round 
of the audit demonstrated that although there had been an increase in the PIBD service 
workforce nationwide (especially with regard to PIBD nurse specialists) there were still 
inadequacies in the shared care pathways with primary care, annual review of patients in 
outpatient services, real time patient management systems and research network trial 
participation.[317] With accurate prevalence data now available, a stronger business case 
regarding funding for many of these issues may be put forward.  
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  Besides the crude numbers of children living with PIBD, the disease severity evident even 
at diagnosis is notable. This current study has confirmed the work by Van Limbergen and 
Russell et al. (whose study included a large number of SES patients[141]), and others,[291] by 
demonstrating a high percentage of children with pan-enteric CD or pancolonic UC at 
diagnosis. It has also highlighted once again in CD the rarity of an ileal disease location in 
those less than 10 years old at diagnosis and the high prevalence of colonic disease in this 
age group.[318] In keeping with the differences between paediatric-onset and adult-onset 
disease outlined by the Scottish group, other groups have now shown similar results. 
Pigneur et al. evaluated 206 CD patients (aged less than 16 years) diagnosed at a median 
age of 13 years, comparing various parameters with 412 adult-onset CD patients. They 
reported that the paediatric-onset CD group consistently had a higher proportion of patients 
with active disease year-on-year, greater use of immunomodulators (including biologicals) 
and a trend towards a higher 25-year cumulative risk of permanent stoma, all resulting in 
lower mean adult final height in the early-onset group.[142] In a smaller Danish study by 
Jakobsen et al., they reported disease location in 49 PIBD and 173 adult-onset IBD 
cases.[319] Although the UC outcome data were consistent with previous observations (i.e. 
more severe disease within the first 2 years from diagnosis), there were concerns about the 
validity of the predominantly negative conclusions drawn from the small paediatric-onset CD 
cohort (n= 29).[320] Additionally Guariso et al. demonstrated that children (aged less than 18 
years old) have a higher risk of perianal disease and extra-intestinal manifestations following 
diagnosis.[321]  
  With regard to perianal involvement in CD, the figure of 14% at diagnosis in the current 
dataset (and previous Scottish data[141]) is higher than reported by the EPIMAD group 
(9%).[291] It is unclear if pure methodological variation is responsible for this difference, but 
with disease location and ethnicity having been shown to influence the presence of perianal 
disease,[322] other studies that present a figure of 9-10% for perianal disease at diagnosis 
suggest that geographical variation may certainly play a part[295,323]. In terms of behaviour, 
the reasons for the low proportion of children presenting with non-inflammatory disease (i.e. 
Montreal B2 or B3) in Scotland is of interest. One reason for this difference could be age at 
diagnosis,[295] with the EPIMAD group consistently reporting a median age of 14 years,[291-293] 
and national (Chapter 2) and regional Scottish data (above) demonstrating a median age of 
11.9 and 11.7 years respectively.  
  With respect to medication use, the overall combined use of immunomodulator and 
biological use is comparable to previous data showing that 68% of children diagnosed after 
1995 in France, when immunomodulator use became common practice, were prescribed 
one of these drugs.[291] Specifically the use of biologicals in the current cohort is similar to 
other reports with a similar follow up period.[324] The basic surgery data for PIBD presented 
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here are also similar to previous studies at approximately 20%,[300,301] however these were 
mainly concerned with resectional surgery. With perianal disease included in the above 
figures, however, it is likely that removal of these non-resectional cases and a longer follow 
up into adult services would bring together any discrepancies in the data. 
  The strengths of this study are mainly due to the prospective nature of the data collection. 
Although for a short period during 1998-1999 children were retrospectively entered into a 
paper record, the numbers of PIBD patients under the care of the paediatric 
gastroenterology department at that time were small, therefore robust inclusion was likely. 
Prospective accrual of cases since late 1999 in this setting was vital and has permitted the 
accurate calculation of incident cases since 2000 in a geographically defined population. 
Restriction of cases residing in the three core health-board referral areas has enhanced the 
data further. Also with regard to incidence and prevalence rates, the availability of health-
board specific population estimates, age-sex standardisation and correction for 
overdispersion increase the accuracy of the results. With the correct identification of all PIBD 
cases, the strict methods employed to ensure a correct IBD type is assigned, using case-
note review, histology reports, endoscopy reports and multidisciplinary team discussion 
ensure a true reflection of PIBD epidemiology is given. The inclusion of data from the PICTS 
database has also refined the results with 'free-text' comments often providing useful and 
insightful information. 
  There are also potential limitations to this study, mostly with regard to medication use and 
surgery. At present, the departmental database does not hold sufficient information to 
ascertain the precise length of medication course, reasons for discontinuation, drug side 
effects or the achievement of disease remission; however much of this data is available from 
other research sources and is currently under analysis. These are important aspects to 
consider for not only immunomodulators such as AZA, but also for the biological agents. It 
can be seen that these drugs have been used more aggressively in recent years in SES and 
data pertaining to their efficacy may influence future practice and provide a clearer safety 
profile for these drugs. With regard to surgery, the minimal data available here does not 
convey the specific indications for surgery, the medical and psychosocial morbidity of the 
patients and their families,[325] or the long-term sequelae which may only become apparent 
following transition to adult services. As highlighted and discussed in detail in Chapter 2.4, 
due to the inability to accrue all cases of PIBD diagnosed less than 17 years in adult centres 







3.7  Conclusion 
 
 In the first paediatric study of its kind in the UK, it has been shown that the incidence of 
PIBD may vary across Scottish regions with high rates of both CD and UC in the paediatric 
population. The prevalence of disease is also continuing to rise which will undoubtedly lead 
to changes in health provision and service development. With this increased prevalence 
comes additional morbidity in these young people, who have extensive disease at diagnosis 
with rapid progression. Further work is now required to determine the reasons behind this 





























4.  The genetics of paediatric inflammatory bowel disease 
 
4.1  Introduction 
 
  There is some evidence that in those with IBD, a disease course that starts earlier in life 
may have a stronger genetic influence[288,326-328] although clear similarities in the genetic 
susceptibility to adult disease are also apparent[18]. This chapter will focus on the newly 
implicated genes described in the two exclusively paediatric genome-wide association 
studies (GWAS) and the associated dysregulated immunological pathways implicated in IBD 
pathogenesis.  
  In recent years the introduction of the Human Genome Project and other international 
collaborations have allowed the detailed examination of the entire genetic code.[329] This 
information, coupled with the creation of high-throughput genotyping platforms, has led to 
the ability to analyse up to 500,000 single nucleotide polymorphisms (SNPs) using 
hypothesis-free GWAS. (Table 4.1) This has led to an explosion of multiple candidate genes 
implicated in IBD pathogenesis.  
 
 
Table 4.1.  Table comparing genome-wide linkage analysis and genome-wide association 
studies. 
 
Characteristic Linkage Analysis Association Study 
Methods Non-parametric linkage High-throughput genotyping using 
information from the HapMap Project 
and Human Genome Project 
SNPs analysed (n) 500-5000 300,000 – 500,000 
Population (n) Affected sibling pairs or small families 
(<500) 
Single cases and healthy controls 
(500 – 4000) 
Cost Expensive Relatively cheap 
Significance LOD score >3.6, 
or P-value <2.2 x 10-5 
p values less than 5 x 10-8 (after 
Bonferroni correction for multiple 
testing) 
Implicated genes  
per study (n) 
< 3 5-10 
SNP, single nucleotide polymorphism; LOD score, logarithm of the odds score 
 
 
  Before the first major CD meta-analysis published in 2008 by Barrett et al., only 16 loci had 
been identified,[330] with the meta-analysis confirming many of these and providing evidence 
for 21 additional SNPs[13]. There have now been over 15 GWAS performed in IBD 
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patients[331] with only two GWAS performed exclusively in early-onset disease. The most 
recent of these built on the first study by Kugathasan et al. in 2008[332] and involved 3,426 
affected individuals and 11,963 genetically matched controls[18] (Table 4.2). These two 
international collaborations involving countries throughout Europe and North America 
identified seven new regions associated with childhood IBD susceptibility (Table 4.3), in 
addition to nominally replicating 29 of 49 previously recognised loci implicated in both adult-
onset CD and UC.[13]  
 
 







Discovery Cohort Healthy 






















1636 724 53 6158 
CD, Crohn’s disease; UC, ulcerative colitis; IBDU, colonic IBD, type unclassified. 
 
Table 4.3.  Summary of new risk loci for IBD identified by the two early-onset genome-wide 





Best SNP PCombined OR Other Genes in Region 
2q37 CAPN10 rs4676410 3.64 x 10-8 1.41† GPR35, KIF1A, RNPEPL1 
10q22 ZMIZ1 rs1250550 5.63 x 10-9 0.86  
16p11 IL27 rs8049439 2.41 x 10-9 1.20 SULT1A1, SULT1A2, EIF3C, CLN3 
19q13  rs10500265 4.26 x 10-10 1.21  
20q13 TNFRSF6B rs2315008 
rs4809330 
8.85 x 10-15 
1.62 x 10-14 
0.84 
0.84 
STMN3, RTEL1, ARFRP1, ZGPAT, 
LIME1, SLC2A4RG, ZBTB46 
21q22 PSMG1 rs2836878 4.48 x 10-12 0.90  
22q12 MTMR3 rs2412973 1.55 x 10-9 1.18 HORMAD2, LIF 
*Underlined genes found to have altered expression in IBD patients vs controls. SNP, single nucleotide 
polymorphism; PCombined, Bonferroni corrected p-value for IBD combined; OR, odds ratio.




4.2  Is childhood-onset IBD genetically distinct?  
   
  It seems clear from recent GWAS that early-onset and adult disease share the majority of 
their risk loci. However, whether those developing IBD at an earlier age have an increased 
‘genetic risk’ is still in dispute, with variability in family history and certain risk genotypes 
fuelling the debate. Several studies have shown the increased prevalence of a family history 
in those diagnosed in early life. Polito et al. demonstrated that those diagnosed with CD 
under the age of 20 years were more likely to have a positive family history of CD compared 
to those diagnosed over 40 years (29.9% vs. 13.6%).[333] These high rates of family history 
have also been demonstrated in UC (26% vs. 11%).[287] With regard to variations in adult-
onset and early-onset genotype, inconsistencies still exist. One of the first indications of 
genotype variability came from a Canadian genome-wide scan which showed that a locus of 
genome-wide significance in the 5q31-q33 (IBD5) region contributed to CD susceptibility in 
families with early-onset disease.[334] Although this was not replicated in two independent UK 
studies,[335,336] IBD5 variants have been shown to be associated with growth indices in early-
onset disease[337] and a more severe overall phenotype[338]. Several studies have also been 
performed looking at the frequency of NOD2  mutations in early-onset disease. Although 
several of these have suggested differing allele frequencies, these studies have included 
small numbers and often lacked control cohorts.[17,339,340] One of these studies demonstrated 
that the 3020insC polymorphism in NOD2 occurred more often in early-onset (less than 19 
years old) than adult-onset CD.[328] Markers in the IBD1 locus have also been shown to be 
more common in early-onset disease in both Jewish[327] and non-Jewish[326] Caucasian 
populations. 
  Although some differences in the genetic susceptibility of childhood and adult-onset IBD 
exist, results from the recent early-onset GWAS have highlighted the overall similarities in 
these geenotypes with some notable exceptions. As mentioned above, 29 of the 49 known 
susceptibility loci where replicated including PTPN22, MST1 and IL-12B.[18] Overall, 72% of 
known adult CD loci and 47% of adult UC loci were replicated suggesting more 
heterogeneity in the ‘genetic risk’ in UC. Of interest, two SNPs, rs3024505 (in the region of 
IL10) and rs917997 (in the region of IL18R1, IL18RAP) showed genome-wide significance 
for CD in the early-onset population and not in adult disease.[18] In addition, SNPs near 
ORMDL3 and ICOSLG were shown to be significant for early-onset UC, having only 
previously been implicated in adult CD.[13] In addition to the known risk alleles common to 
both early-onset and adult-onset disease a recent study has also demonstrated no 
significant association between CD genetic risk score and age at onset.[341] This paper 
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illustrated that the genetic effect of established CD risk variants is similar in early and late-
onset disease.  
 
4.3  Dysregulated pathways implicated by the study of IBD genetics 
 
  The increasing success of genome-wide scans has led to the identification of large 
numbers of possible candidate genes with many involved in the same immunological 
pathways. These pathways broadly involve the control of intestinal barrier function, mucosal 
response to luminal bacteria and the secondary downstream immune response. Furthermore 
the analysis of the effect of multiple SNPs within these pathways has already been 
successful, most notably by the observed IL-12/IL-23 pathway-specific association signal in 
CD.[342]  
 
4.3.1  Innate pattern recognition receptors (NOD2, TLR4, CARD9) 
  The innate immune system is the body’s first-line, non-specific response to foreign antigen. 
Both transmembrane and intracellular pattern recognition receptors (PRRs) recognise 
conserved, microbe-specific molecules named pathogen-associated molecular patterns 
(PAMPs), leading to an appropriate immune response.[343] As mentioned above, the major 
breakthrough in IBD genetics came when fine mapping of the IBD1 locus on chromosome 16 
by the French paediatrician JP Hugot identified the leucine-rich repeat (LRR) variants of the 
NOD2 gene as conferring susceptibility to CD.[17] Since this discovery the NOD2mutations 
have been widely replicated in both adult- and early-onset disease.[13,332] This gene encodes 
for NOD2 which is an intracellular PRR which recognises muramyl dipeptide (MDP), a 
product of bacterial cell wall degradation. It has now been shown that NOD2 has expression 
limited to the Paneth cells[19] in the intestinal crypts and that the recognition of MDP is 
facilitated through the LRR domain of the protein[20]. Three main regulatory pathways have 
since been described for NOD2, namely through the activation of RIP2 and NF-B,[344] 
preferential expression of a truncated NOD2 isoform (NOD2-S)[345] and 5’ UTR splice forms 
linking NOD2 with the autophagy process[346]. Furthermore the important role of NOD2 in the 
regulation of commensal bacteria and viral recognition have also been demonstrated in 
recent studies, highlighting the complex role of this intracellular receptor.[21,23] 
  Besides NOD2, two further gene groups implicated in IBD and involving the innate immune 
response are the toll-like receptors (TLRs) and CARD9. TLRs are a family of  
transmembrane receptors which bind a myriad of ligands such as LPS, beta-defensins and 
heat shock proteins,[347] possibly through binding with specific hydrophobic portions of such 
molecules[348]. The TLR4 Asp299Gly polymorphism has generated most interest[349] with 
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other molecules involved in the complex TLR4 pathway also under investigation [350,351]. The 
locus at 9q34.3 containing the CARD9 gene (which contains the characteristic caspase-
associated recruitment domain) has also been shown to confer susceptibility to CD and is 
linked to several mechanisms including TLR-NOD2 signalling and Th17 cell differentiation.[15] 
Although mutations in TLR4 or CARD9 have yet to be confirmed as conferring disease 
susceptibility in the early-onset population, studies have shown that more TLR4 Asp299 Gly 
variants were found in early-onset disease[352] and that carriers of NOD2/TLR4 mutations 
present at an earlier age[353]. 
 
4.3.2  Th17 differentiation and IL-27 
  Following innate immune system signalling, a coordinated T helper (Th) cell response by 
the adaptive immune system leads to tissue-specific inflammation. The now outdated 
Th1/Th2 classification has been superseded by a multitude of T cell lineages including 
iTregs, Tr1 and TFH subsets.
[80] One of these recently described subsets are the Th17 
effector cells, classified on the basis of intracellular transcription factors such as STAT3, 
RORT and RORα and a cytokine profile including IL-17A, IL-21 and IL-22.[34] The 
association with CD of a germline variation of the IL23R (interleukin-23 receptor) gene in 
2006 provided the initial stimulus to look more closely at the Th17 subset.[12] This association 
has been replicated in both adult-onset CD and UC,[354-356] as well as trios with both CD and 
UC in the index study[12]. Replication studies in the paediatric population have mainly 
demonstrated significant association for CD patients only, however the recent early-onset 
GWAS showed significance for both CD and UC.[18,241,357,358] Specifically the Arg381Gln 
variant in the IL23R gene has been shown to be protective for the development of IBD 
although other signals within the gene also confer disease susceptibility independently of 
this SNP.[35] Taylor et al. genotyped multiple SNPs in IL23R and identified IL23R risk and 
protective haplotypes demonstrating a substantial increase in population-attributable risk 
compared to Arg381Gln alone.[359] Raelson et al. also reported multiple significantly 
associated SNPs within the IL23R gene itself or within linkage disequilibrium (LD) blocks 
extending from the gene into 3’ and 5’ intergenic regions.[360]  
  IL-23 is a soluble type I cytokine member of the IL-12 family and signals through a 
heterodimeric receptor consisting of the IL-12β1 and specific IL-23R chains.[81] This receptor 
is expressed on T cells with IL-23 promoting the stabilisation of the Th17 subset after 
differentiation through various intracellular transcription factors such as STAT3. Furthermore, 
germline variations in the genes encoding STAT3 and the tyrosine kinase JAK2, have also 
been implicated in the recent CD GWAS meta-analysis,[13] however only SNPs in the region 
of JAK2 gained genome-wide significance in the paediatric population[18]. Variations in the 
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gene encoding CCR6, which is involved in the recruitment of Th17 cells to the epithelium, 
has also been shown to predispose to CD[13], but again this has not been replicated in early-
onset disease, possibly due to lack of power.  
  Earlier in the differentiation of the Th17 subset the molecule inducible co-stimulator ligand 
(ICOSLG) binds with its T cell ligand (ICOS) leading to T cell activation.[36] The gene 
encoding ICOSLG was suggested as the candidate gene at 21q22.3, however no replication 
or expression data has yet confirmed this association.[13] Barrett et al. demonstrated that the 
SNP at this locus (rs762421) conferred susceptibility to CD, however the recent paediatric 
GWAS showed significance in both CD and UC.[18] The interaction of ICOSLG with its ligand 
ICOS is not only essential in the early differentiation of naϊve T cells but is likely to be 
important in the careful balance of IL-10 producing regulatory cells and the Th17 




Figure 4.1.  IBD susceptibility genes implicated in Th17 differentiation. (Molecules 
highlighted by *). Under the influence of IL-6, IL-21 and TGF-β Th17 cells differentiate from naϊve T 
cells. IL-23 is not required for this initial differentiation, but instead stabilises the Th17 lineage and 
enhances the production of various cytokines including IL-17 and IL-21. In addition to this ICOSLG 
expressed on antigen presenting cells (such as dendritic cells and intestinal epithelial cells) interacts 
with ICOS, enhancing the balance of pathogenic Th17 cells and IL-10 producing Tr1 cells.  
85 
 
  Functional assays in IBD patients show that IL-17 producing cells and the levels of the 
Th17-related cytokines IL-17 and IL-22 are increased in IBD patients.[361-363] It is also clear 
that Th17 cells are required during the inflammatory response with studies showing that 
mice with T cells lacking the gene encoding RORT (which is required for efficient Th17 
differentiation) are protected from chemically induced colitis in addition to experimental 
autoimmune encephalomyelitis.[364,365] Of further interest is work showing that priming of 
human dendritic cells by bacteria promotes IL-17 production through NOD2.[366] Coupled with 
evidence that signalling through the dectin-1-Syk-CARD9 pathway induces the maturation of 
dendritic cells capable of eliciting Th17 differentiation[367] and with dectin-1 levels elevated in 
IBD patients,[368] the interaction between known IBD susceptibility genes and the Th17 
subset is growing. 
  The SNP rs8049439 identified in the recent paediatric GWAS at 16p11.2 lies in LD with the 
gene encoding the p28 subunit of the IL-12 cytokine family member IL-27.[18] The SNP 
identified reached genome-wide significance (p<1 x 10-7) for both CD and IBD combined, 
however a surrogate SNP (rs4788084) did not attain genome-wide significance in the recent, 
majority adult-onset CD meta-analysis.[13] With regard to IL-27 mRNA expression, Imielinski 
et al. demonstrated a decrease of over 90% in lymphoblastoid cell lines from individuals 
homozygous for the risk allele and significantly reduced colonic expression in early-onset 
IBD patents compared to controls.[18] Other candidate genes in the region include SULT1A1, 
SULT1A2 and EIF3C (Box 4.1). 
  IL-27 is a type 1 cytokine composed of the p28 subunit in addition to the EBV-induced gene 
3 (EBI3)[369] and was first described by Pflanz et al. in 2002[370]. IL-27 mediates its effects 
through a heterodimeric receptor complex made up of the widely expressed gp130 and IL-
27-specific WSX-1(TCCR) subunit.[371] The role of IL-27 has been controversial mainly due 
to its perceived contradictory anti-inflammatory and pro-inflammatory roles.[372] It is now 
recognised that IL-27 is required for the initial phase of Th1 differentiation by inducing the IL-
12Rβ2 subunit which is then ligated by IL-12 which commits the naϊve T cell to the Th1 
lineage.[373] In this respect IL-27 has also been shown to upregulate the Th1 transcriptional 
factor TBET[374] and reduce the Th2 transcriptional factor GATA3[375] thus skewing the 
Th1/Th2 differential.  
  However it is the role of IL-27 in the careful balance of pathogenic Th17 cells and 
suppressive T cell subsets which is of most interest in the pathogenesis of IBD. [376] (Figure 
4.2) As discussed above, Th17 cells are essential in the propagation of intestinal 






Box 4.1. Other candidate genes at 16p11. 
 
SULT1A1 and SULT1A2 (sulfotransferase family, cytosolic, 1A, phenol preferring member 1/2) 
These cytosolic sulfotransferase 1A family members have various known actions including the 
metabolism of phenolic substances,[377] drugs, oestrogens and the activation of 
procarcinogens[378]. These proteins have already been implicated in bladder[379], breast[380] and 
colorectal cancer risk[381]. SULT1A1 is highly expressed in differentiated enterocytes throughout 
the gut[382] and culture of colonic cell lines with TNFα increases colonocyte SULT1A1 activity[383].  
EIF3C (eukaryotic translation initiation factor 3, subunit C)   
Encodes for the ubiquitous EIF3C subunit of the EIF3 complex, the largest of 12 eukaryotic 
initiation factors that interact with Met-tRNAi
Met, mRNA and ribosomal subunits during 
translation initiation.[384] Although there is evidence of an interaction between the EIF3 complex 
and the autophagy regulator the mammalian target of Rapamycin (mTOR),[385,386] there has been 
no direct evidence of EIF3 dysregulation altering the autophagy process.  
CCDC101 (coiled-coil domain containing 101)  
Comprises a subunit of STAGA, a complex involved in gene activation.[387] 
CLN3 (ceroid-lipofuscinosis, neuronal 3) 
Function in humans has yet to be delineated but is known to be mutated in Batten disease and 
may be involved in mechanisms within the Golgi complex[388] and the regulation of the 
transcription factor SBF[389].  
NUPR1 (nuclear protein, transcriptional regulator, 1) 
Encodes a stress-induced protein and has a variety of functions, some of which apparently 
contradictory, and has been implicated in a wide variety of cancers including pancreatic,[390] 
brain[391] and thyroid[392]. 
 
 
  In this respect IL-27 has been shown to directly influence the balance of these T cell 
subsets through direct actions on transcriptional factors such as STAT1 and RORT. IL-27 
has been shown to suppress the production of pro-inflammatory cytokines demonstrated by 
the fact that WSX-1 deficient mice (lacking the ability to ligate IL-27) over-produce pro-
inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and IL-6 from CD4+ T 
cells following Trypanosoma cruzi infection.[393] Of great interest was work carried out by 
Murugaiyan et al. which showed that, in the presence of IL-27, there was reduced IL-17 
production by T cells (in addition to reduced RORC expression), IL-23R and 
CCR6/CCL20.[376] With regard to IL-27 during intestinal inflammation Troy et al. used IL-27R 
deficient mice to show a significant reduction in Th1 IFN- producing cells and an increase in 
Th17 cells in gut-associated lymphoid tissue.[394] In addition the IL-27R deficient mice 
showed earlier-onset and increased clinical severity of DSS-induced colitis. Besides the 
effect of IL-27 on the Th17 cell lineage other anti-inflammatory properties of IL-27 have been 
demonstrated. These mostly comprise the production of the anti-inflammatory cytokine IL-10 
through mechanisms involving STAT3,[395] cMAF and ICOS,[396] although other pathways 
including the suppression of cFos,[371] B cell class switching[397] and enhanced TLR 




Figure 4.2.  The effect of Interleukin-27 (IL-27) on various T cell lineages. (A) IL-27 exerts its 
effects on IL-10-producing T regulatory cells in a STAT3-dependent manner. (B) In Th1 effector cells 
IL-27 induces the transcription of TBET via STAT1. (C) In Th17 effector cells IL-27 down-regulates IL-
17 production and IL-23R expression. (D) Through STAT1, IL-27 down-regulates GATA3 leading to a 
reduction in Th2 effector cell differentiation.  
 
 
4.3.3  Autophagy and MTMR3 
  Along with the degradation of unwanted organelles, autophagy is responsible for the 
elimination of pathogenic micro-organisms gaining entry to the cytoplasm through 
mechanisms involving TLRs[399] and NOD2 signalling[30,31]. SNPs in the region of three genes 
encoding proteins involved in the process of autophagy have been shown to confer 
susceptibility to CD, namely ATG16L1,[26] IRGM[400] and LRRK2[13]. The association with 
ATG16L1 and CD was first described by Hampe et al. and has since been widely replicated 
in both adult[13,401,402] and in most but not all paediatric populations[283,305,332,403]. ATG16L1 has 
been shown to be crucial for Paneth cell biology[25] with the associated CD coding variant 
driven by ileal disease[305,404]. A SNP in the region of LRRK2, which reached genome-wide 
significance for CD in both the majority adult GWAS meta-analysis[13] and the recent 
paediatric GWAS,[18] was implicated in the autophagy process through its association with 
another autophagy-mediated condition, Parkinson’s disease[405]. Although its role in CD 
pathogenesis has yet to be defined, a recent study has shown its involvement in negatively 
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regulating the autophagy process with silencing of LRRK2 increasing the cell’s autophagic 
activity.[406] SNPs in the region of IRGM, a member of the p47 immunity-related GTPase 
family, although replicated in adult association studies as conferring susceptibility to both CD 
and UC,[407,408] do not seem to confer as strong a risk in several paediatric studies[18,332,409].  
 
 
Box 4.2. Other candidate genes at 22q12.  
 
HORMAD2 (HORMA-domain protein 2)   
The SNP rs2412973 identified at the locus 22q12.2 lies within HORMAD2, an open reading frame 
with functions involved in the generation of haploid gametes. HORMA-domain proteins lead to 
efficient crossovers during meiosis with both HORMAD1 and HORMAD2 being implicated in 
double strand break (DSB) formation, the suppression of synaptonemal complex formation 
between non-homologous chromosomes and meiotic prophase checkpoint that monitors DSB 
repair.[410] 
LIF (leukaemia inhibitory factor)   
Encodes LIF which is a member of the IL-6 cytokine family. This cytokine was first identified in the 
late 1980s as a factor that induced the differentiation of murine myeloid leukaemic cell lines [411] 
and is now known to signal through a receptor which shares one of its subunits (gp130) with IL-6. 
Since its discovery the major focus on this molecule has been in the fields of reproductive 
medicine, [412] stem cell research[413] and cancer[414]. Although the most recent paediatric GWAS 
did not demonstrate altered expression in colonic biopsies from IBD patients it should be noted 
that LIF and IL-6 have been implicated in regulating the balance between the recently described 
Th17 CD4+ lineage and FOXP3+ regulatory cells.[415] Also due to the ubiquitous nature of this 
molecule, the known increase in serum IL-6 in Crohn’s disease patients[416,417] and the recent 
interest in IL-6-receptor monoclonal antibody for inflammatory disorders[418] the possibility of this 
molecule being dysregulated in IBD should not be discounted.   
 
 
Coding-sequence variation has been excluded as a source of this association with adult IBD 
in the IRGM region.[400] However, a common 20-kb deletion polymorphism upstream of 
IRGM which affects IRGM expression has been shown to be in perfect LD (r2=1.0) with the 
mostly strongly associated CD SNP.[408] In the recent paediatric GWAS the SNP at locus 
22q12.2 (rs2412973) showed genome-wide significance in the combined discovery IBD 
cohort but again, as with the SNP at 16p11, not in the adult CD meta-analysis.[13,18] The only 
gene in this region which was shown to differ in colonic expression was MTMR3. Other 
candidate genes at the 22q12 locus are summarised in Box 4.2. This gene showed 
significantly reduced expression in colonic biopsies in UC patients compared to controls. 
Further details of MTMR3 and the other genetic susceptibility genes implicating the 




4.3.4  The ubiquitin-proteasome system and PSMG1 (21q22)  
  The SNP rs2836878 identified in the paediatric GWAS by Kugathasan et al. resides at 
21q22 in a small region of linkage disequilibrium with no known genes.[332] However, in their 
studies of gene expression Kugathasan et al. did observe an increase in the closest gene 
PSMG1 in the colon of IBD cases compared to controls. PSMG1 (also known as PAC1 or 
c21-LRP) encodes the protein proteasome (prosome, macropain) assembly chaperone 1 
which is most closely associated with the clinical entity of Down syndrome (trisomy 21), 
where the gene is more commonly named Down syndrome critical region 2 (DSCR2). This 
gene was first described in 1998 and found to contain a potential open reading frame 
predicting a 288-amino acid protein[419] with functions relating to cell proliferation[420]. In 2005 
PSMG1 was found to directly act as a chaperone involved in the assembly of the four 
heteroheptameric rings of the 20S proteasome.[421] The ubiquitin-proteasome system (UPS) 
is responsible for the degradation of over 80% of intracellular components (autophagy 
accounting for the remaining 20%) with Ubiquitin used as the initial signal for protein-
targeting and the proteasome ensuring the efficient removal of denatured and misfolded 
proteins.[422] Proteasomes have become of particular interest to those studying inflammatory 
conditions mainly due to the observation that ubiquination and proteasomal degradation of 
IкB leads to NFкB activation and the subsequent upregulation of proinflammatory 
cytokines.[423] In addition, other immunoregulatory functions such as the generation of 
peptide antigen presented to MHC class I molecules[424] and the regulation of T-cell receptor 
and co-stimulatory molecule signalling[425] are controlled by the UPS system. These studies 
have prompted a growing interest in the therapeutic role of proteasomal-inhibitors in several 
conditions including pancreatitis[426] and rheumatoid arthritis[427]. It is also of note that certain 
subunits (beta1i and beta2i) of the 20S core particle have been shown to be up regulated in 
CD compared to UC patients[32] and that the probiotic and commensal bacteria Lactobacillus 
plantarum acts as a proteasomal inhibitor through the IкB-NFкB pathway[428].    
 
4.3.5  The secondary immune response and TNFRSF6B, ZMIZ1 and Smad3  
  Following the interaction between pathogenic material and the innate immune machinery, 
certain cells present these antigens leading to the production of soluble mediators, 
chemotactic elements and immune cell recruitment. Several genes involved in this complex 
mechanism have been implicated in adult-onset disease with varying degrees of replication 
in the paediatric population. The Human Leukocyte Antigen (HLA) region on chromosome 6p 
(IBD3) reached significance in the meta-analysis by van Heel et al. with several SNPs also 
reaching nominal significance in the GWAS meta-analysis by Barrett et al.[13,429] Although the 
SNPs previously identified were not replicated in the early-onset GWAS, a SNP in the region 
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of HLA-DRA (recently confirmed in adult-onset disease[430]) was shown to be significant in 
early-onset UC[18]. Furthermore, SNPs in other genes involved in the secondary immune 
response were replicated in the childhood-onset GWAS.[18] These included IL-12B, a gene 
encoding the p40 subunit shared by the cytokines IL-12 and IL-23, and MST1 which 
encodes macrophage-stimulating protein (MSP) that regulates the innate immune response 
to several bacterial ligands such as LPS.[15,431] Two SNPs shown to be only nominally 
significant in the recent CD GWAS meta-analysis showed significant association with early-
onset CD, namely the IL18R1-IL18RAP locus on 2q12 (rs917997) and the C-C motif 
chemokine (CCL) gene cluster on 17q12 (rs991804). IL-18 is of particular interest in CD 
pathogenesis with IL-18 expression increased in the mucosa of CD patients[432] and IL-18 
blockade demonstrated to ameliorate murine colitis[433].  
  The association between TNFSF15 (tumour necrosis factor superfamily member 15; also 
known as TL1A or VEGI) at 9q33 has been widely replicated in adult CD and encodes a 
TNF-like factor expressed in endothelial cells and professional antigen presenting cells.[13,434-
436] Interaction of this molecule with the IL-12/IL-18 pathway has been shown to induce the 
secretion of IFN-[437] and can promote the proliferation of Th17 cells[438]. Although SNPs in 
this region were not shown to be significant in either early-onset GWAS, another member of 
this receptor family (TNFRSF6B – tumour necrosis factor receptor superfamily 6B) gained 
genome-wide significance for IBD combined with levels of mRNA expression correlating with 
the degree of mucosal inflammation within the colon.[332]    
  The 20q13 signal suggested by the SNPs rs2315008 and rs4809330 lies in a complex 
telomeric region of LD, the central block of which contains multiple genes, most interestingly 
TNFRSF6B.[332] Other genes in the region are summarised in Box 4.3. After gaining 
genome-wide significance in the first early-onset GWAS it has since been replicated in an 
independent paediatric study.[439] As mentioned above, differing expression and its 
correlation with inflammation made it the most promising candidate gene at this locus. 
  The protein product of TNFRSF6B, decoy receptor 3 (Dcr3) has three known ligands, Fas 
ligand (FasL), LIGHT (also known as tumour necrosis factor [ligand] superfamily, member 14 
[TNFSF14]) and TL1A (see above).[440] Interaction with these ligands influences a number of 
mechanisms, mostly involving T cell expansion and apoptosis. Dcr3 has been shown to 
reduce FasL-induced[441] and TL1A-induced apoptosis of lymphocytes with the addition of 
reducing TL1A-induced lymphocyte proliferation[442]. The interaction between Dcr3 and 
LIGHT is more complex with soluble Dcr3 blocking[443] and solid Dcr3 enhancing[444,445] T cell 
costimulation. Kugathasan et al. showed that serum Dcr3 was significantly increased in 





Box 4.3. Other candidate genes at locus 20q13. 
 
STMN3 (stathmin-like 3) 
Also known as SCLIP, STMN3 is a member of the stathmin family of cytosolic phosphoproteins 
which is involved in microtubule dynamics.[447] It is known to colocalise with STMN2 in the Golgi 
apparatus[448] and is ubiquitously expressed throughout human tissues including the small 
intestine[449]. 
RTEL1 (regulator of telomere elongation helicase 1) 
A helicase which antagonises homologous recombination by promoting the disassembly of 
recombination intermediates which is required for genome stability and tumour avoidance.[450] It 
has been further shown to protect telomeres through the shelterin component TRF1[451] and has 
been implicated in the genetic susceptibility of gastrointestinal tumours[452] and gliomas[453,454]. 
ARFRP1 (ADP-ribosylation factor related protein 1) 
A membrane associated GTPase that regulates intracellular protein trafficking[455] and is essential 
for embryonic development by stabilising the egg cylinder during gastrulation[456]. ARFRP1 is 
involved in anterograde transport form the trans-Golgi network[457] and is colocalised with ARL1 
to the Golgi membrane[455]. Of specific interest, in the enterocytes of ARFRP1 -/- mice there is 
mistargeted E-cadherin expression to the intracellular as opposed to lateral membranes.[458] [The 
E-cadherin gene CDH1 has recently been shown to be linked to the genetic susceptibility of 
Crohn’s disease, in addition to those with the disease-risk haplotype showing increased E-
cadherin cytoplasmic accumulation[459]]  
ZGPAT (zinc finger, CCCH-type with G patch domain) 
The 5’-flanking region of ARFRP1 contains the first exon of ZGPAT on the opposite strand[460] 
which is a G patch domain-containing protein and has been shown to be involved in the 
repression of gene transcription[461]. 
LIME1 (Lck interacting transmembrane adaptor 1) 
A transmembrane adaptor protein primarily expressed in haematopoetic cells and the lung.[462] It 
has been shown to associate with phophatidylinositol 3-kinase thus activating ERK1/2 with 
overepxression shown to induce the transcriptional activation of the IL-2 promotor.[462] It has 
been found to be involved in T cell[463] and B cell[464] activation through the TcR and BcR 
respectively. 
SLC2A4RG (SLC2A4 regulator)  
A transcriptional regulator also known as GEP and HDBP1 which has been shown to regulate the 
transcription of the human GLUT4 promoter[465] and the Huntington disease (HD) gene[466].  
ZBTB46 (zinc finger and BTB domain containing 46) 
A CACC cis-regulatory zinc finger protein which regulates gastrin gene expression by interfering 
with the transactivation of the ubiquitous zinc finger protein Sp1.[467] 
 
 
Of note, elevated serum concentrations of Dcr3 have also been demonstrated in other 
inflammatory conditions such as rheumatoid arthritis[468] and systemic lupus 
erythematous[469]. Several studies have now demonstrated that both lamina propria T cells 
and intestinal epithelial cells in both UC and CD are resistant to apoptosis, with Dcr3 shown 
to be significantly over-expressed in the ileum of CD patients.[446,470,471] The hypothesis that 
IBD patients lack effective T cell apoptosis is further strengthened by the likely mechanism of 
action of newer biological therapies, most notably Infliximab.[472] Although the precise 
pharmacodynamics of anti-TNF alpha antagonists is not yet clearly understood, induction of 
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apoptosis is almost certainly involved. Three independent studies have now demonstrated 
an increase in apoptotic lamina propria T cells and peripheral blood monocytes of CD 
patients after Infliximab infusion, with the timing of apoptotic-induction ranging from four 
hours to four weeks.[473-475] It is clear that confirmation of mutations in TNFRSF6B conferring 
susceptibility to IBD would be critical in our understanding of IBD pathogenesis. Not only 
would it allow a deeper understanding of the mechanistic dysregulation at the protein level, 
but it would further enhance our understanding of the pharmacodynamics of current 
biological therapies. 
  The SNP rs1250550 lies at 10q22 within the gene ZMIZ1 and was associated with early-
onset CD and IBD combined in the recent early-onset GWAS.[18] ZMIZ1 was initially named 
hZIMP10 (human zinc finger-containing, Miz1, PIAS-like protein on chromosome 10) and 
was identified as a novel androgen receptor (AR)-interacting protein that augmented AR-
mediated, ligand-dependent transactivation in prostate cells.[476] This gene has since been 
shown to act as a transcriptional co-regulator, possibly through chromatin-remodelling,[477] 
and is known to play a role in vascular development[478] and the co-activation of the p53 
tumour suppressor[479]. However, it is the role of ZMIZ1 in the modulation of transforming 
growth factor-beta (TGF-β) through the transcriptional activity of Smad3 (mothers against 
decapentaplegic homolog 3) which is of most interest in the pathogenesis of IBD. Li et al. 
showed that the altered expression of ZMIZ1 affected Smad3-mediated transcription, in 
addition to using a Smad4-negative cell line to demonstrate that ZMIZ1 may mediate Smad3 
activity by interacting with the Smad3/Smad4 transcriptionally active complex.[480]  
  Importantly a SNP in the region of Smad3 at 15q22 was also found to confer susceptibility 
in the early-onset IBD discovery cohort providing further evidence of dysregulation in this 
pathway.[18] Following ligation of the heterodimeric TGF- receptor, phosphorylation of 
Smad2 and Smad3 occurs leading to a Smad2-Smad3-Smad4 complex which translocates 
to the nucleus where it participates in the transcriptional control of target genes.[481] Targeted 
disruption of Smad3 has been shown to result in diminished cell responsiveness to TGF- 
with Smad3 mutant mice demonstrating massive intestinal T cell infiltration and impaired 
mucosal healing.[482-484] Of possible therapeutic interest is the role of Smad7 which interferes 
with TGF- signalling by preventing the activation of the Smad2/Smad3 complex.[485] Smad7 
has been found to be increased in the lamina propria mononuclear cells (LPMC) of IBD 
patients with recent work demonstrating that IBD LPMCs were resistant to regulatory T cell 
suppression which could be reversed using Smad7 antisense treatment.[486] With ZMIZ1 
playing a role in Smad3 transcription and the importance of the TGF- pathway in immune 




4.3.6  Endoplasmic reticulum stress and CAPN10 
  The endoplasmic reticulum (ER) is contiguous with the nuclear envelope and contains a 
membranous network of tubules and sacs. Its main functions are the biosynthesis, folding 
and assembly of soluble proteins and it also operates as a dynamic calcium store. 
Endoplasmic reticulum stress occurs as a result of dysregulated homeostatic pathways in 
secretory cells (such as Paneth and goblet cells[488]) leading to the accumulation of misfolded 
or unfolded proteins.[489] The unfolded protein response (UPR) is a mechanism that allows 
cells to cope with conditions of ER stress,[490] however during sustained ER stress the 
common final pathway is apoptosis (programmed cell death). Three proximal effectors of the 
UPR exist in an inactive state under homeostatic conditions – inositol-requiring 1α (IRE1α), 
double-stranded RNA-dependent protein kinase-like ER kinase (PERK) and (activating 
transcription factor 6 (ATF6).[491] In the presence of misfolded proteins the ER chaperone 
immunoglobulin-heavy-chain-binding protein (BiP) senses these changes and releases the 
three effectors from inhibition, leading to an increase in cell-coping mechanisms.[492] The 
genes targeted by the UPR are involved in aminoacid biosynthesis and transport, the 
oxidative stress response and ER-stress-induced apoptosis.[493] The most conserved of the 
UPR pathways is IRE1α, activation of which leads to the splicing of the protein XBP1, which 
in turn leads to a myriad of cell survival processes.  
  Dysregulation in the cell’s ability to control the processing of redundant proteins efficiently 
was first realised as a possible pathway in IBD pathogenesis following the discovery that 
Xbp1-deficient intestinal epithelial cells led to a spontaneous enteritis.[488] In addition to this, 
the same paper described deep sequencing of the Xbp1 locus showing a number of rare 
alleles, two of which being nonsynonymous variants present only in IBD patients. ER stress 
is now becoming increasingly recognised as a primary mechanism in intestinal 
inflammation[488] in addition to a secondary consequence[494-496]. With regard to the generic 
inflammatory response, two ER-pathway-induced mechanisms have been proposed to lead 
to NFB activation. The PERK-EIF2α attenuation of IB and the recruitment of IB kinase by 
the IRE1α-TRAF2 complex both lead to translocation of NFB to the nucleus where it 
induces the transcription of numerous inflammatory genes.[491] Furthermore, a SNP in the 
region of ORMDL3 on 17q12 was shown to be significant in the adult CD GWAS meta-
analysis and replicated in both CD and UC in the early-onset GWAS.[13,18] Although ORMDL3 
was previously known to encode a transmembrane protein in ER,[497] a recent paper has 
shown its specific role in altering ER-mediated calcium homeostasis and the facilitation of 
the UPR[498].  
  The recent paediatric GWAS identified a susceptibility locus at 2q37.3 that yielded genome-
wide significance in UC patients from a combined analysis of the discovery and replication 
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cohorts.[18] The SNP rs4676410 lies within GPR35 in an LD block containing the genes 
CAPN10, GPR35, KIF1A and RNPEPL1. However, following the analysis of normalised 
colonic expression of each candidate gene, only CAPN10 was found to be significantly 




Box 4.4. Other candidate genes at locus 2q37. 
 
GPR35 
A G-protein coupled receptor (GPR) that has been shown to be highly expressed in the human 
stomach, small intestine and colon.[499] It is involved in the tryptophan metabolic pathway and 
has been shown to agonised by kynurenic acid [500] with dendritic cells expressing indoleamine 
2,3-dioxygenase (IDO) shown to be involved in immune tolerance through tryptophan 
catabolism[501]. GPR35 has been implicated in various conditions such as 
pseudopseudohypoparathyroidism[502] and gastric cancer[503] with other members of the GPR 
family already implicated in intestinal inflammation[504,505] 
KIF1A 
Encodes one of the kinesin superfamily proteins which is a motor protein involved in the 
transport of organelles and macromolecules along microtubules.[506] 
RNPEPL1 
RNPEPL1 is a member of the M1 family of zinc metallopeptidases with ubiquitous tissue 
distribution;[507] a SNP at the same locus has been implicated in bipolar disorder[508]. 
 
 
  The gene CAPN10 encodes calpain-10, a member of a superfamily of cytoplasmic cysteine 
proteases with several known isoforms in the form of splice variants.[509,510] Calpain-10 is a 
672 aminoacid protein which is expressed ubiquitously[511,512] and hydrolyses substrates 
important in calcium-regulated signalling pathways[513]. With regard to complex polygenic 
disease pathophysiology, CAPN10 was the first gene to be identified to confer susceptibility 
to type 2 diabetes mellitus by positional cloning.[510] Dysregulation in CAPN10 has also been 
implicated in polycystic ovary syndrome,[514] in determining serum cholesterol levels[515] and 
more recently the risk of colorectal carcinoma[516]. Although the calpains have been 
implicated in various cellular processes, including cell differentiation and proliferation,[517,518] 
the most interesting pathway with regard to inflammatory bowel disease is endoplasmic 
reticulum stress.  
  Calpain-10 is key in the regulation (via proteolysis) of ORP150 (Grp170)[519] which is 
another ER chaperone known to be upregulated during the UPR, overexpression of which 
has been shown to reduce ER stress[520]. ORP150 has been shown to act as a nucleotide 
exchange factor for BiP, hydrolysing ATP to release energy for conformational changes 
within the BiP protein.[521] (Figure 4.3) Of particular interest with regard to CD pathogenesis 
95 
 
was the finding that cigarette smoke extract induced ER stress (albeit in bronchial 
epithelium) with this effect ameliorated by the overexpression of ORP150.[522] With previous 
work on the role of XBP1 in intestinal inflammation, the replication of ORMDL3 and the 
finding of genetic polymorphisms in the CAPN10 gene in childhood IBD, the argument for a 
dysregulated ER stress response in IBD has certainly been strengthened.  
 
 
Figure 4.3.  The role of calpain-10 in endoplasmic reticulum stress. Calpain-10 is involved in 
the regulation of ORP150 via proteolysis, with ORP150 acting as a nucleotide exchange factor for BiP. 
During homeostatic conditions BiP acts to inhibit activation of the three proximal effectors IRE1α, 
PERK and ATF6 (left panel). During the unfolded protein response BiP preferentially binds to 
unfolded proteins within the ER lumen releasing the proximal effectors from their inhibition (right 
panel). Homodimerisation and trans-phosphorylation of PERK leads to cytosolic phosphorylation of 
EIF2α leading to the translation of ATF4. Autophosphorylation of IRE1α directs the splicing of XBP1 
mRNA leading to an activated form of XBP1. Once released from BiP, ATF6 translocates to the Golgi 
where it is cleaved by SP1 and SP2 producing an active fragment (ATF6 p50). These three active 
components (ATF4, active XBP1 and ATF6 p50) migrate to the nucleus where they activate the 
transcription of the UPR target genes. ORMDL3 has also been shown to positively regulate the 
phosphorylation of EIF2α. (Molecules implicated in intestinal inflammation/IBD are indicated by a *) 
4.4  The future  
 
  Although there are clear differences in the phenotypic characteristics of early-onset and 
adult-onset,[141] the influence of genetic factors on these variations is likely to be small. With 
clear similarities in the genetic risk of both phenotypes, and parallel dysregulated pathways 
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implicated, the aim of future research should undoubtedly focus on the confirmation of the 
shared associated mutations. The functional implications of these mutations will then not 
only lead to a greater understanding of IBD pathogenesis, but also allow the generation of 

































5.  The role of ICOSLG in inflammatory bowel disease - 
genetic susceptibility and mucosal mRNA expression 
 
5.1  Introduction 
 
  As discussed in Chapter 4, recent progress in determining the genes (or more often the 
loci) involved in the susceptibility to IBD has been especially notable. Meta-analyses of 
genome-wide association studies have now significantly increased the number of novel risk 
variants to over one hundred,[523,524] with the International IBD genetics consortium 
Immunochip project having already increased this number further in recent months[525,526]. 
One of these loci, identified in both adult and paediatric populations, is situated on 
chromosome 21q22 in the region of the gene encoding inducible T cell co-stimulator ligand 
(ICOSLG),[13,18] a protein expressed on antigen presenting cells and intimately involved in T 
cell differentiation. 
  The dysregulation of mucosal[527] and peripheral[528] T cells is likely to play a key role in the 
pathogenesis of IBD, resulting in secretion of pro-inflammatory mediators, accumulation of 
activated inflammatory cells and tissue damage[529]. However, the stimuli responsible for the 
initiation and maintenance of signal-mediated lymphocyte activation in IBD remain 
somewhat elusive. The ‘two-signal’ model of lymphocyte activation was first proposed by 
Bretscher and Cohn in 1970[530] and has since been widely explored providing a clearer 
understanding of the initial stages of T cell differentiation[531,532]. The two-signal model has 
now been refined and superseded by a three-signal process with antigen-specific activation 
of T cell receptors (TcR) (signal one), interaction of co-stimulatory molecules on antigen-
presenting cells (APC) with ligands on T cells (signal two) and cytokine interaction (signal 
three).[33] It has also been shown that in the absence of signal two (i.e. co-stimulation), 
lymphocytes fail to respond effectively and are rendered anergic.[533] Co-stimulation is 
therefore of pathogenic and therapeutic interest as the manipulation of co-stimulatory signals 
may provide a means to either enhance or terminate immune responses.[534,535] 
  Much research has been carried out over the last 25 years to identify the molecules 
responsible for this co-stimulatory signal. To date, cluster of differentiation (CD) 28 remains 
the best-characterised co-stimulatory molecule and is constitutively expressed on the 
surface of T cells.[33] The natural ligands for CD28 have been identified as B7 molecules and 
are present or inducible on the surface of antigen-presenting cells.[536-538] CD28-B7 
interaction results in an enhanced T cell proliferation, cytokine production, and resistance to 
apoptosis. Recent investigation has further delineated a role of CD28-B27 interactions in 
98 
 
promoting peripheral T cell tolerance.[539,540] Previous studies have also demonstrated that 
CD28-B7 interactions play an important role in several immune-mediated diseases, with 
over-expression of B7 molecules found in affected clinical material from patients with 
multiple sclerosis, rheumatoid arthritis and psoriasis.[541] There have also been reports of 
increased expression of B7 molecules in the mucosa of IBD patients.[542,543] 
  In 1999 Hutloff et al. described another member of this family of co-stimulator molecules, 
namely inducible T-cell co-stimulator (ICOS).[544] This disulphide-linked dimer with around 
40% similarity to CD28 at the protein level is upregulated on T cells after activation.[545,546] 
The ligand for ICOS (known as ICOSLG, or CD275, ICOS-L, B7RP-1 and B7h) was 
described later the same year by two independent groups[545,547] and splice variants later 
replicated elsewhere (B7H2,[548] GL50[549]). ICOS expression is stimulated on T cells by both 
TcR and CD28 signals. Importantly however, ICOS expression is not solely dependent on 
CD28 signals, as studies blocking ICOS in CD28-deficient mice further inhibited Th1/Th2 
differentiation.[550] Although ICOS engagement was shown initially to selectively produce 
high levels of IL-10 and IL-4, in vivo studies in several different models have demonstrated 
that ICOS can stimulate production of both Th1 and Th2 cytokines during initial priming and 
during effector T cell responses.[544,551] 
 
5.2  ICOS and ICOSLG expression 
 
  ICOS is present on the T cell surface with ICOSLG present on many antigen presenting 
cells and lymphoid tissue. ICOSLG has also been found on endothelial cells and the 
coronary microvasculature,[552] as well as endothelial cells,[553] testes[554] and most recently 
thyroid follicular cells[555]. With regards to epithelial expression De Haij et al. found that 
ICOSLG was constitutively expressed on both proximal renal tubular epithelial cells and 
renal epithelial cell lines,[556] with several groups showing expression on lung epithelial 
cells[557-559]. With regard to intestinal epithelial cell expression there is currently a paucity of 
data. Nakazama et al. looked in detail at ICOS and ICOSLG expression on a intestinal 
cancer cell line (HT29) as well as a small number of surgical resection specimens from IBD 
patients (n=10) and controls (n=6).[78] This group demonstrated that ICOSLG mRNA and 
protein was constitutively expressed on epithelial cell lines and colonic epithelial cells from 
clinical samples. They also demonstrated that ICOSLG expression was moderately 





5.3  Overview of other genes at the 21q locus 
 
  The single nucleotide polymorphism (SNP) identified as varying significantly between IBD 
cases and controls through genome-wide association studies (GWAS) (rs762421) is situated 
on 21q22.3 approximately 25kb upstream from ICOSLG. Also within this region are genes 
encoding DNMT3L, AIRE, PWP2H, C21orf33 and PFKL; all genes with known protein 
products. Figure 5.1 illustrates the locus region with the position of SNP rs762421 
highlighted. Although this SNP lies in an intergenic region in close linkage disequilibrium 
(LD) with ICOSLG, other genes in the region have the potential to be influenced by germline 




Figure 5.1.  Graphical representation of 21q locus region. Image taken from Ensembl genome 
browser 68.37 (GRCh37) (http://www.ensembl.org)  
 
 
5.3.1  DNMT3L  
  The gene encoding DNA (cytosine-5-)-methyltransferase 3-like gene (DNMT3L) lies closest 
to ICOSLG on chromosome 21. This DNA methyltransferase does not contain intrinsic DNA 
methyltransferase activity but instead regulates other methyltransferases (such as DNMT3a) 
through epigenetic mechanisms.[560] Currently, DNMT3L has no defined function in IBD 
pathogenesis, however it is interesting to note that a recent genome-wide scan 
demonstrated a CD susceptibility loci in the region of DNMT3A.[523] Considerable evidence 
now exists that epigenetic alterations are of importance in regulating the integrity and 
development of both innate and acquired arms of the immune system, including Th1/2 cell 
differentiation,[561-563] and have stimulated a real interest in defining the contribution of these 
alterations in immune-mediated diseases. The importance of epigenetic changes, such as 
DNA methylation, histone acetylation, and microRNA synthesis in the pathogenesis of CD 
and UC is likely to emerge as a key area of interest over the next decade.[564-567] Recent data 
demonstrated that epigenetic alterations may contribute to concordance or discordance of 
disease phenotype in twin pairs,[568,569] thereby potentially accounting for a proportion of the 
apparently hidden heritability. Intriguingly there is now data implicating NOD2 as a regulator 
of epigenetic alterations, including microRNA synthesis.[570] Studies in other diseases, 
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notably systemic lupus erythematosus,[571] and asthma[572] have provided a further focus for 
the studies of epigenetics in immune-mediated disorders. Specifically in relation to DNMT3a, 
several papers have also alluded to its involvement in idiopathic thrombocytopenic 
purpura,[573] hepatitis B,[574] epithelial tumours[575] and endometriosis[576]. Mutations in 
DNMT3L have also been found to affect DNA methylation during egg development.[577]  
 
5.3.2  Human PWP2 and AIRE  
  The human PWP2 gene is a homologue of the yeast periodic tryptophan protein 2 (PWP2) 
gene.[578] Mapping and linkage analysis near this gene led to the possible role of this region 
in autoimmune polyglandular disease type 1.[579,580] This autosomal recessive disease results 
in failure of the parathyroid glands, adrenal cortex and pancreatic β-cells along with alopecia 
and mucocutaneous candidiasis. However, in 1997 two groups using positional cloning 
identified the underlying gene as AIRE (autoimmune regulator),[581] a transcriptional 
regulatory factor. More recent evidence has suggested a role for AIRE in T cell tolerance [582] 
and as a result there has been some interest in its possible role in IBD. Torok et al. looked at 
the correlation between mutations in two exons of AIRE and serum autoantibodies in 
IBD.[583] Evaluation of 234 IBD patients did not detect any of the three polymorphisms and 
therefore could not subsequently comment on the relationship with autoantibodies. A more 
recent study proposed that AIRE represents an early molecular switch imposing a 
suppressive mesenchymal stem cell phenotype in a model of chronic colitis.[584] 
 
5.3.3  c21orf33 (HES-1/ES-1) 
  The chromosome 21 open reading frame 33 (c21orf33) gene has two aliases HES-1 and 
ES-1. HES-1 (Hairy and Enhancer-of-split 1) has been implicated in endocrine disease and 
is also involved in Notch signalling, important in endoderm development and subsequent 
neurogenesis.[585] Murine studies have demonstrated that loss of HES-1 leads to neural tube 
defects due to premature neurogenesis.[586] Under the alias of ES-1 (esterase 1), c21orf33 
may be involved in the basic function of mitochondria with elevated levels in the foetal brains 
of children with Trisomy 21.[587] Again there is a paucity of evidence for the involvement of 
HES-1 in inflammatory bowel disease, although a possible role has been established in 
psoriasis,[588] which shares several susceptibility loci with CD[589]. 
 
5.3.4  PFKL 
  PFKL (phosphofructokinase, liver) lies downstream of AIRE and no clear role in disease 
pathogenesis has yet been determined. Studies have suggested a role in the glycolytic 
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pathway in animal models[590] with some evidence that PFKL is a susceptibility locus for 
bipolar disorder[591,592].   
 
5.4  Hypotheses and aims 
 
Hypotheses:  
1. The paediatric IBD susceptibility gene identified through genome-wide scanning at 
locus 21q22.3 is ICOSLG.[18] 
2. Expression of ICOS and ICOSLG mRNA on primary biopsy material from patients 
with IBD varies significantly from non-IBD patients. 
 
Aims: To perform a detailed family-based analysis of ICOSLG using a gene-wide haplotype-
tagging approach to determine if variations in this gene are responsible for increased 
susceptibility to IBD in the paediatric population, and if so, to delineate the region of 
strongest association to guide future deep sequencing studies. Additionally to evaluate 
differences in co-stimulatory molecule mRNA expression on mucosal biopsies using 
previously acquired data from an adult cohort of IBD and non-IBD patients. 
 
5.5  Methods 
 
5.5.1  Subjects 
  A total of 1331 individuals were initially genotyped, however 56 were immediately removed 
from the analysis as they were either not part of a case-parent trio (e.g. grandparents) or had 
been re-phenotyped and deemed not to be definite PIBD. Further individuals were also 
removed as they: (1) failed genotyping completely as a result of poor DNA quality (n=55); (2) 
demonstrated Mendelian error during genotyping (n=9); or (3) were diagnosed after their 
17th birthday (n=5). Therefore a total of 1206 individuals were included in the final analysis, 
consisting of 448 PIBD patients (i.e. diagnosed before their 17th birthday) and their parents 
(n=758). Parents not part of a complete case-parent trio were used to inform the analyses 
within the liability-threshold model as described below; genotyping of parents provided 230 
complete parent-child trios. All subjects were recruited in Scotland between October 2002 
and July 2009 as part of research carried out by Dr Richard Russell (NHS Great Glasgow, 
formerly University of Edinburgh), Dr Johan Van Limbergen (University of Edinburgh), and 
latterly through the Medical Research Council (MRC)-funded Paediatric Inflammatory Bowel 
Disease Cohort and Treatment study (PICTS) held by Prof. David C Wilson (University of 
Edinburgh), Dr Richard Russell (Royal Hospital for Sick Children, Glasgow) and Prof. Jack 
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Satsangi (University of Edinburgh) (Figure 5.1). IBD was diagnosed according to standard 
clinical, histological and radiological findings[147,236] and rigorous phenotyping carried out as 
previously described;[141] the basic demographics of the PIBD group are shown in Table 5.1. 
It should be noted that where parents had a confirmed diagnosis of IBD (22 Crohn's disease 
[CD], 14 ulcerative colitis [UC], 2 colonic IBD, type unclassified [IBDU]), disease coding was 




Figure 5.1.  Flow diagram showing process of recruitment of Scottish paediatric 
inflammatory bowel disease patients into genetic studies since 2002. 
 
 
Table 5.1.  Characteristics of paediatric inflammatory bowel disease patients analysed in 
the family-based association study to determine the role of ICOSLG as a susceptibility gene. 
 
Patient Characteristic IBD CD UC IBDU 
Number (%) 448 301 (67) 107 (24) 40 (9) 
Age at diagnosis 
(years [IQR]) 
11.5 [8.9-13.3] 11.8 [9.3-13.4] 11.0 [8.4-12.9] 10.6[8.6-12.2] 
Male sex (%) 256 (57) 179 (59) 55 (51) 22 (55) 
White European (%) 430 (96) 290 (96) 102 (95) 38 (95) 
IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; IBDU, colonic IBD, type 
unclassified; IQR, interquartile range. 
 
5.5.2  Single nucleotide polymorphism selection 
  The ICOSLG gene is located on chromosome 21 between positions 45,642,874 and 
45,660,849 (Ensembl Release 68 - ENSG00000160223; Build 37). ICOSLG tagging SNPs 
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were selected using genotypic data from the CEU study (30 trios with Northern and Western 
European ancestry, collected by the Centre d’Etude du Polymorphisme Humain [CEPH]), 
available from the HapMap project.[329] SNPs were identified using Haploview software 
version 4.2 (http://www.broad.mit.edu/mpg/haploview)[593] based on solid spine of linkage 
disequilibrium (LD) (r2 >0.8, haplotype frequency >5%, minor allele frequency >10%). This 
process identified four tagging SNPs spanning a 19kb region containing two haplotype 
blocks: rs8126734, rs2838529, rs4818890 and rs2070558 (Figure 5.2). The original SNP 
(rs762421) identified through genome-wide scanning was also genotyped. Details of all 
genotyped SNPs are presented in Table 5.2. For all cases and their parents SNPs 
conformed to the Hardy–Weinberg equilibrium (p>0.001). 
 
 






Location MAF Alleles Hardy-
Weinberg 
p value 
Call rate Detectable 
odds ratio‡ 
rs762421 45615561 Intergenic 0.400 A:G 0.0986 93.9 1.45 
rs8126734 45636432 Intergenic 0.341 A:G 0.0208 96.3 1.46 
rs2838529 45638152 5'UTR 0.194 G:C 0.4947 95.4 1.56 
rs4818890 45646256 Exon 1 0.464 C:A 0.0015 94.2 1.45 
rs2070558 45655658 Intronic 0.284 G:A 0.0821 93.5 1.49 
*Based on NCBI Human Build 135; †Ensembl Release 68 - July 2012 ; ‡based on individual minimum allele 
frequency (MAF) with an 80% power to detect an effect. UTR, untranslated region. 
 
 
5.5.3  DNA extraction and genotyping 
  DNA was extracted from venous whole blood from patients and parents by either a 
modified salting-out technique[594] or by using the Nucleon BACC2 kit (Gen-Probe Life 
Sciences, Manchester, UK) and resuspended in 1× Tris-EDTA buffer (10mM Tris, pH 7.5, 
and 1mM EDTA) at a final concentration of 100ng/μL. Genotyping was carried out on the 
Illumina platform by TaqMAN® analysis (detected on an ABI PRISM 7900HT instrument with 
genotype calling utilising SDS v2.1 software) at the Wellcome Trust Clinical Research facility 
on the Western General Hospital campus, Edinburgh. DNA extraction was performed by Dr 
Richard K Russell (Royal Hospital for Sick Children, Glasgow and formerly of University of 





Figure 5.2. View of the genomic region containing ICOSLG using Haploview 4.2 software 
generated from the CEU study available through the HapMap project. ICOSLG can be seen to 
be positioned across two haplotype blocks spanning approximately 19kb. Haplotype blocks were 
generated using solid spine of LD. Tagging SNPs are identified in the schematic as SNPs 4 
(rs8126724), 8 (rs2838529), 17 (rs4818890) and 22 (rs2070558). 
 
Edinburgh) and Sean O'Neil (Medical Research Council [MRC] Human Genetics Unit, 
University of Edinburgh) as part of previous PhD projects and latterly in conjunction with 
PICTS. All genotyping was carried out in June 2009; primer sequences are shown in Table 
5.3. Mendelian errors were identified using Haploview software for the current dataset in 
addition to errors identified during a previous genetic association study performed on this 
patient group.[242]  
 
 
Table 5.3.  Primer sequences for the five single nucleotide polymorphisms used to tag 
the ICOSLG gene on chromosome 21q. 
 
dbSNP* Position Strand Sequence 
rs762421 45615561 Rev ACATTCACACACCCACAAAAATCAA[A/G]AGAGCAGATTTTCCAAAAATAGGTG 
rs8126734 45636432 Rev TTAGGATCCTGATTTTAATGTCAGG[A/G]CTGGCCAGCTGTGCCTCAACTCTGA 
rs2838529 45638152 Rev ACTGGGGAGAAAGGAGGAAAGAAAG[C/G]CCGTGTTAAAACACAGTTCGAAGCT 
rs4818890 45646256 For GGACCGCCCCATCTGCCAGCCTTGA[A/C]TGGAGCCTCCCTGGTGGATGTTTAC 
rs2070558 45655658 For AAGCCAGTCCCAGTAGCCAGGGACC[A/G]CTGAGCCTGTCGGGCAGTGACTGGC 




5.5.4  Transmission disequilibrium test  analysis 
  Transmission disequilibrium test (TDT) analyses were carried out using Haploview version 
4.2[593] by utilising the parenTDT function[595]. Briefly, this liability-threshold-model approach 
can incorporate parental phenotypes (whether part of a complete trio or not) and is based on 
the between-within-sibship association model presented by Fulker et al.[596] For the TDT 
analysis all p values are reported as corrected following permutation analysis (n=100,000 
permutations), unless otherwise stated. Calculation of the 95% confidence intervals for odds 
ratios (OR) was achieved using the formula: 
 
                
 
           
    
 
             
   
 
In all analyses a two-sided p value of less than 0.05 was considered significant.  
 
5.5.5  Transmission disequilibrium test power calculation 
  Using QUANTO (version 1.2.4; http://hydra.usc.edu/gxe),[597] and based on the most recent 
prevalence data of Scottish PIBD presented in Chapter 3 (41.2/100,000; keeping in mind 
this is data for those less than 16 years old not 17 years old) the IBD TDT analysis had 80% 
power to detect an effect with an OR between 1.45 and 1.56 depending on the individual 
SNP (ORs for each SNP are shown in Table 5.2).  
 
5.5.6  Analysis of gene-wide susceptibility signal for ICOSLG using an international 
genome-wide association meta-analysis 
  As a member of the United Kingdom Inflammatory Bowel Disease (IBD) Genetics 
Consortium and the larger International IBD Genetics consortium (IIBDGC) it was possible to 
gain access to novel genetic data generated from large case-control studies. Although a 
meta-analysis of CD genome-wide association scans (GWAS) has previously been 
published,[598] a new improved meta-analysis of GWAS data imputed with the 1000 genomes 
reference set (first available in September 2011) was interrogated 
(http://www.1000genomes.org). To assess variants in the region of ICOSLG for association 
with CD susceptibility, SNP-specific p values generated from the analyses of seven 
individual (majority adult) CD datasets encompassing 5,956 CD patients and 14,927 healthy 
controls were obtained from data collated by Dr Stephan Ripke and held jointly by the 
Analytical and Translational Genetics Unit at Massachusett's General Hospital and the 
Broad Institute (http://www.broadinstitute.org/mpg/ricopili). p values obtained were generated 
with principal component analyses as covariates, therefore correcting the whole analysis for 
population stratification and inter-study differences. The scatterplot of results was generated 
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using the ggplot2 package[599] in R version 2.14.1 (R Foundation for Statistical Computing, 
Vienna, Austria). 
 
5.5.7  mRNA expression microarray data 
  In order to identify differences in gene expression of ICOSLG and ICOS between IBD 
patients and controls, raw data (in the form of a large Microsoft Excel 2003 spreadsheet) 
was obtained from Dr Colin Noble (NHS Lothian, formerly University of Edinburgh). These 
raw data in their entirety had been acquired, analysed and published by Dr Noble (lead 
author, in conjuction with the Gastrointestinal Unit, University of Edinburgh) as two separate 
case-control studies (one examining CD[600] and the other UC[601]), and had formed part of his 
completed PhD thesis. Precise details of how this data was obtained is outlined in each 
manuscript, however a brief summary of the methods used are given here. 
  Using the Agilent microarray platform (Agilent Technologies, Santa Clara, CA), expression 
of mRNA from pinch biopsies taken from IBD patients or controls in South East Scotland 
was assessed. Biopsies were taken from the terminal ileum, ascending colon, descending 
colon or sigmoid colon of adult patients with CD (99 biopsies from 53 patients), UC (129 
biopsies from 67 patients) or controls [i.e. non-IBD patients] (73 biopsies from 31 patients). 
Of the controls, 23 had histologically normal biopsies, while only eight had inflamed colonic 
biopsies. Biopsies were defined as inflamed or uninflamed from paired samples graded by 
experienced gastrointestinal pathologists at the Department of Pathology, Western General 
Hospital, Edinburgh; details of the IBD patients and controls are given in Table 5.4 and 
Table 5.5. Biopsies were analysed and data presented as the log2 mRNA expression 
relative to a control reference marker (Stratagene universal human reference [Agilent 
Technologies, Santa Clara, CA]). The three Agilent probes evaluated were A_23_P371215 
(ICOS), A_23_166280 (ICOSLG) and A_23_317667 (ICOSLG). 
 
 
Table 5.4.  Characteristics of adult inflammatory bowel disease patients used in the 
microarray analysis of ICOS and ICOSLG mRNA expression 
 
Characteristic Crohn’s disease Ulcerative colitis 
Number of subjects  53 67 
Male sex (%) 26 (49) 33 (49) 
Median age at diagnosis (years) 28.6 37.0 
Current smoker (%) 11 (21) 6 (9) 
Family history of IBD (%) 12 (23) 5 (7) 
5-ASA therapy (%)  21 (40) 40 (60) 
Corticosteroid therapy (%)  4 (8) 10 (15) 
Immunosuppressant therapy (%) 13 (25) 11 (16) 
IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylic acid. 
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Table 5.5.  Characteristics of adult non-inflammatory bowel disease controls used in 
the microarray analysis of ICOS and ICOSLG mRNA expression 
 
Characteristic  
Number of subjects  31 
Male sex (%) 11 (35) 
Median age at endoscopy (years) 43.0 
Normal biopsy and indications (n)  Irritable bowel syndrome (9), colon cancer 
screening (6), other (7) 
Abnormal, inflamed biopsy and histological 
findings (n)  
Microscopic colitis (2), scattered lymphoid 
aggregate (2), pseudomembranous colitis (1), 




  From these data a non-parametric t test (Mann-Whitney U) was performed to determine 
statistically significant differences in expression within the entire biopsied segment of specific 
areas of the bowel. Additionally, a non-parametric one-way ANOVA (Kruskal-Wallis test) was 
used to determine the differences in expression throughout the intestine in cases versus 
controls. Statistical analyses were performed in GraphPad Prism v4.03 (GraphPad Software, 
San Diego, USA; www.graphpad.com), with a two-tailed p value of <0.05 considered to be 
statistically significant. Advice on the statistical analyses used was obtained directly from Dr 
Alex Abbas (Department of Bioinformatics, Genentech, South San Francisco, USA), the 
bioinformatician on both of Dr Noble's original papers. An outline of the processes involved 




Figure 5.3.  Outline of processes involved in microarray analysis following total RNA 
extraction from gastrointestinal biopsy material. (Performed by Dr Colin Noble) 
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5.5.8  Ethics 
  For the case-parent TDT analyses all patients and/or their parents provided full written 
consent as part of the MRC-funded PICTS cohort which was approved by local ethics 
committees at all three participating Scottish clinical networks: South-East Scotland 
(LREC/2002/6/18), West of Scotland (YREC/P12/03) and North of Scotland 
(GREC/03/0273). For the adult microarray analyses written informed consent was previously 
obtained by Dr Colin Noble from all subjects with the Lothian Local Research Ethics 
Committee approving the study protocol (REC 04/S1103/22). 
 
5.6  Results 
 
5.6.1  TDT analyses - the single SNP rs8126734-A is overtransmitted in IBD and 
CD patients 
  Analysing the entire cohort of PIBD patients and their parents demonstrated significant 
overtransmission of the rs8126734-A SNP following correction (p=0.0467; OR 1.48 [95% CI 
1.12-1.94]) (Table 5.6) This result was strengthened in the CD TDT analysis with the same 
SNP being similarly overtransmitted (p=0.0084; OR 1.85 [95%CI 1.30-2.64]) (Table 5.6). No 
single SNP was significantly overtransmitted in the UC TDT analysis (Table 5.6).  
 
 
5.6.2  The AGGC haplotype is significantly undertransmitted in CD patients 
  Focussing the remaining analyses on CD case-parent trios only and evaluating the four-
marker haplotype spanning from the intergenic SNP rs762421 to rs4818890 (the final 
tagging SNP in the first ICOSLG haplotype block) demonstrated that only one haplotype was 
significantly undertransmitted after correction (Table 5.7). This haplotype was in keeping 
with the single SNP results and the previous GWAS (CD-associated risk allele rs762421G) 
in that the haplotype contained rs762421-A and rs8126734-G and was protective for CD 
(p=0.0069, OR 0.55 [95% CI 0.39-0.79]). The converse SNP combination (rs762421-G - 








Table 5.6.  Transmission Disequilibrium Test Analysis of individual single nucleotide 











Odds ratio (95% CI) 
Inflammatory bowel disease 
rs762421 G 132:106 0.0837 0.3222 1.25 (0.96-1.61) 
rs8126734 A 127:86 0.0100 0.0467 1.48 (1.12-1.94) 
rs2838529 C 75:71 0.8736 1.0000 1.06 (0.76-1.46) 
rs4818890 A 141:102 0.0220 0.0998 1.38 (1.07-1.78) 
rs2070558 G 102:90 0.4378 0.9142 1.13 (0.85-1.50) 
Crohn's disease 
rs762421 G 92:68 0.0673 0.2582 1.35 (0.99-1.85) 
rs8126734 A 87:47 0.0023 0.0084 1.85 (1.30-2.64) 
rs2838529 N/A 50:50 0.9223 1.0000 1.00 (0.68-1.48) 
rs4818890 A 97:62 0.0141 0.0543 1.56 (1.14-2.15) 
rs2070558 G 68:61 0.5439 0.9675 1.11 (0.79-1.58) 
Ulcerative colitis 
rs762421 G 33:30 0.4669 0.9464 1.10 (0.67-1.80) 
rs8126734 G 33:27 0.4386 0.9029 1.22 (0.73-2.03) 
rs2838529 G 19:17 0.5271 0.9707 1.12 (0.58-2.15) 
rs4818890 A 34:32 0.6326 0.9921 1.06 (0.66-1.72) 
rs2070558 G 23:21 0.8815 1.0000 1.10 (0.61-1.98) 
*Based on NCBI Human Build 135. Corrected p values were generated by permutation analysis (n=100,000) as 
described in Methods. Trans, transmitted; Untrans, untransmitted; CI, confidence interval; N/A, not applicable. 
Significant p values are highlighted in bold text. 
 
 
Table 5.7.  Crohn's disease TDT haplotype analysis of the four-marker haplotype 
spanning from rs762421 to rs4818890 in the region of ICOSLG.  
 
Markers* Haplotype Freq Trans : 
untrans 






1,2,3,4 GAGA 0.341 90.8:63.5 1.43 (1.04-1.97) 0.0407 0.1686 
 AGGC 0.276 48.0:86.9 0.55 (0.39-0.79) 0.0027 0.0069 
 AACC 0.153 39.4:36.6 1.08 (0.69-1.69) 0.9202 1.0000 
 AAGA 0.117 34.8:27.1 1.28 (0.78-2.12) 0.4778 0.9910 
 AGCC 0.038 12.0:11.6 1.03 (0.46-2.32) 0.9732 1.0000 
 GGGC 0.026 5.0:8.3 0.60 (0.20-1.83) 0.3724 0.9746 
 AAGC 0.021 7.1:2.9 2.45 (0.62-9.60) 0.1230 0.5214 
 GAGC 0.017 8.4:5.3 1.58 (0.53-4.70) 0.4044 0.9821 
*Marker numbers correspond with the SNP order shown in Table 5.2. Corrected p values were generated by 
permutation analysis (n=100,000) as described in Methods. Trans, transmitted; Untrans, untransmitted; Freq, 





5.6.3  Sliding 2-marker haplotype analysis suggests a strong CD-risk signal at the 
3-prime untranslated region of ICOSLG 
  Using a sliding 2-marker haplotype analysis to further define the extent of the CD-
association signal from the intergenic rs762421 SNP, through the 3’ untranslated region 
(UTR) to the 5’ end of the ICOSLG coding sequence (rs2070558-G/C is located in intron 3), 
it can be seen that although a signal is present across the entire gene, the strongest signal is 
evident across the two marker haplotype rs762421-A / rs8126734-G (p=0.0072, OR 0.57 




Table 5.8.  Sliding 2-marker haplotype analysis spanning from rs762421 to rs2070558 








Odds ratio  
(95% CI) 
1,2 GA 0.368 94.6:65.6 0.0273 0.0657 1.44 (1.05-1.98) 
 AG 0.317 50:88.3 0.0036 0.0072 0.57 (0.40-0.80) 
 AA 0.288 69.5:55.2 0.3009 0.6323 1.26 (0.88-1.79) 
 GG 0.028 4.6:9.5 0.1892 0.4423 0.48 (0.16-1.47) 
2,3 AG 0.490 101.8:61.9 0.0048 0.0114 1.64 (1.20-2.26) 
 GG 0.308 51.4:91.1 0.0034 0.0080 0.56 (0.40-0.79) 
 AC 0.167 41.6:40.8 0.9397 0.9998 1.02 (0.66-1.57) 
 GC 0.036 10.5:11.6 0.6990 0.9708 0.91 (0.39-2.09) 
3,4 GA 0.457 100.8:65.1 0.0139 0.0359 1.55 (1.13-2.11) 
 GC 0.340 54.1:89.8 0.0101 0.0294 0.60 (0.43-0.84) 
 CC 0.202 50:50 0.9223 1.0000 1.00 (0.68-1.48) 
4,5 AG 0.410 99.8:65.8 0.0150 0.0363 1.52 (1.11-2.07) 
 CG 0.302 49.8:76.5 0.0345 0.0883 0.65 (0.46-0.93) 
 CA 0.242 51.3:62.7 0.3429 0.7032 0.82 (0.57-1.18) 
 AA 0.046 16.8:12.8 0.5903 0.9269 1.31 (0.63-2.72) 
*Marker numbers correspond with the SNP order shown in Table 5.2. Corrected p values were generated by 
permutation analysis (n=100,000) as described in Methods. T, transmitted; U, untransmitted; Freq, frequency; 
CI, confidence interval. Significant p values are highlighted in bold text. 
 
 
5.6.4  Genome-wide imputed meta-analysis data confirms the strong signal at the 
3'UTR of ICOSLG for CD susceptibility  
  A total of 1495 SNPs in the 21q22 locus were tested from the imputed international GWAS 
data and the SNP-specific p values obtained. A total of 30 SNPs attained genome-wide 
significance (p<5x10-8), all of which lay in the intergenic region at the 3'UTR end of the 





Figure 5.4.  Results of a meta-analysis of seven CD genome-wide association studies 
imputed with the 1000 genomes reference set. Scatterplot showing -logP values in the region of 
ICOSLG for 1495 single nucleotide polymorphisms.  
 
 
5.6.5  mRNA expression of ICOS and ICOSLG differs significantly across different 
intestinal sites 
  Evaluating the results for all biopsies taken from CD patients showed no difference in 
expression of ICOS or ICOSLG (with either probe) compared to non-IBD biopsies (Table 
5.9). However, to delineate whether or not differences in either molecule were evident at 
'baseline', uninflamed biopsies were compared across all sites and at each intestinal 
location. This showed significant downregulation of ICOS expression across all sites and the 
sigmoid colon, in addition to downregulation of ICOSLG expression in the ascending colon 
and upregulation in the descending colon. Similar analyses were performed comparing UC 
patients with non-IBD patients demonstrating differences in ICOS expression in all biopsy 









Table 5.9.  Differences in ICOS and ICOSLG mRNA expression (expressed as p values) in 
biopsy material from Crohn's disease patients and non-inflammatory bowel disease 
patients. 
 











ICOS 0.4206 0.0123 0.5338 0.0648 0.7595 0.0251 
ICOSLG 
(166280) 
0.0905 0.0655 0.2343 0.0226 0.3584 0.0610 
ICOSLG 
(317667) 
0.2348 0.8018 0.2343 0.2322 0.0351 1.0000 
Significant differences between cases and non-inflammatory bowel disease patients are highlighted in bold. 
Data in this table is derived from in silico analysis of microarray data obtained by Dr Colin Noble. 
 
 
Table 5.10.  Differences in ICOS and ICOSLG mRNA expression (expressed as p values) in 
biopsy material from ulcerative colitis patients and non-inflammatory bowel disease 
patients. 
 









ICOS 0.0143 0.3369 0.5680 0.3935 0.8171 
ICOSLG 
(166280) 
0.2191 0.7707 0.3110 0.8843 0.5500 
ICOSLG 
(317667) 
0.7766 0.7556 0.5433 0.3115 0.1969 
Significant differences between cases and non-inflammatory bowel disease patients are highlighted in bold. 
Data in this table is derived from in silico analysis of microarray data obtained by Dr Colin Noble. 
 
 
5.6.6  Variation in ICOS and ICOSLG mRNA expression throughout the intestine 
differs in IBD patients 
  To assess the variation in mRNA expression throughout intestine in CD patients versus 
non-IBD controls, one-way ANOVA analyses of mRNA values from all four uninflamed sites 
(terminal ileum, ascending colon, descending colon and sigmoid colon) was performed 
showing that no significant variation in ICOS expression existed in controls (p=0.0542) but 
that variation did exist in CD patients (p=0.0414); no differences between the variation of 
both ICOSLG probes between CD cases and controls was observed (ICOSLG-166280 in 
controls [p=0.0119], CD patients [p=0.0063]; ICOSLG-317667 in controls [p=0.1524], CD 
patients [p=0.4940]). Similarly for UC, variation across three uninflamed sites (ascending 
colon, descending colon, and sigmoid colon) was different in UC patients (p=0.0143) but not 
controls (p=0.0994). However, the significant variation of ICOSLG seen in non-IBD patients 
(p=0.0331) was lost in UC (p=0.3110) (probe ICOSLG-166280); no difference in variation 
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was demonstrated in the ICOSLG-317667 probe between non-IBD (p=0.2219) or UC 
patients (p=0.1534). 
 
5.7  Discussion 
 
  In this first family-based association analysis of ICOSLG in PIBD the results indicate that 
the signal at the 21q22 locus is most likely to be due to germline variation in ICOSLG, 
making it less likely that other genes in the region (such as PWP2 or AIRE) contribute 
significantly to inherited IBD or CD susceptibility. The single SNP analysis shows that 
variations in rs8126734 provided the strongest signal, suggesting that the 3' UTR of ICOSLG 
may be the area of interest. Additionally, the more recent data from the meta-analysis of 
seven CD genome-wide association scans (GWAS) confirmed this signal. mRNA gene 
expression analysis also demonstrated that variations in ICOSLG and its ligand ICOS exist 
in uninflamed IBD biopsies compared to non-IBD controls; differences in the variation of the 
expression of these genes throughout the intestine strengthen the case for further 
investigation of these molecules in IBD pathogenesis.  
  Due to the strong record in paediatric IBD phenotyping in Scotland,[141,154] the resource of 
well-defined case-parent trios[602] and Scotland's involvement in international IBD genetics 
studies[18,603] this haplotype-tagging study has several strengths. Significant findings 
generated through TDT analysis, which are robust against population substructure, are 
generally accepted as implying both linkage and association.[604] Additionally, case-parent 
trios have a greater power to detect differences in less prevalent diseases, with TDT 
analysis avoiding false positives that arise when association is present but linkage is not. [604] 
This coupled with strict coding of parents with IBD, stringent permutation analysis and 
meticulous attention to changes in IBD phenotype over time (e.g. IBDU to CD) strengthen 
this study further. The use of data from a large meta-analysis of seven GWAS and a well 
executed microarray analysis also supports the results.  
  Despite these strengths, the study design and methodology still present difficulties with 
interpretation. Firstly, although the TDT analyses was adequately powered to detect an 
effect, the use of relatively small numbers during genetic analysis does allow the possibility 
of false positives, although less so during TDT analyses. Also, as this study used a 
haplotype-tagging approach (rather than deep-sequencing), only inferences can be made as 
to the possible regions that may contribute to IBD susceptibility. With regard to the 
microarray analysis additional problems arise. Firstly, the biopsy material analysed would 
have undoubtedly contained a myriad of cell populations, meaning that differences in 
expression of ICOS and ICOSLG on different lineages may have been masked. However, it 
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should be noted that previous work has shown that ICOS is significantly upregulated in both 
lamina propria mononuclear cells (LPMC) and enterocytes in patients with CD [605] and 
UC[606]. Secondly, many of the analyses relied on a relatively small number of biopsies from 
each location, and although median values (rather than mean values) were assessed, the 
potential for false positives still exists. Another factor which may have influenced the 
microarray results are the disease controls used. Although these patients may have in fact 
contributed to the specificity of the results for IBD, there is also the possibility that intestinal 
disease may have acted as a confounding factor. Also, without the knowledge of the 
ICOSLG genotype of the patients involved, no real conclusions can be drawn on the 
influence of genotype on gene expression. Similarly, disease activity was not taken into 
account.  
  As discussed above, the role of co-stimulatory molecules in a number of different immune 
disorders has been reported. Windhagen et al. investigated the expression of cytokines and 
co-stimulatory molecules in central nervous system specimens from multiple sclerosis (MS) 
suffers (MS is an inflammatory demyelinating disease that shares many susceptibility loci 
with IBD)[607] and controls using reverse-transcription polymerase chain reaction and 
immunocytochemistry.[608] They observed an upregulation of B7-1 and B7-2 in acute MS 
plaques, particularly from early-onset disease cases. Similarly, Verwilghen et al. analysed 
the expression and function of co-stimulatory molecules in the synovial membranes of 
patients with rheumatoid arthritis and psoriatic arthritis (again diseases that share IBD 
susceptibility genes),[607] in contrast to normal controls.[609] They found that B7 was highly 
expressed on synovial fluid T cells, and that these cells produced a five-fold increase in T 
cell proliferation when used as stimulator cells compared with paired peripheral blood T 
cells. Furthermore, studies looking specifically at the role of ICOS and ICOSLG in the 
pathogenesis of lung mucosal injury have demonstrated a key role for this co-stimulator. 
Gonzalo et al. investigated the role of ICOS and CD28 in regulating Th2-mediated mucosal 
inflammatory responses in murine lung epithelial cells.[559] They demonstrated that ICOS 
plays the predominant role in regulating Th2 effector cell activation and that ICOS-mediated 
signalling contributes to the inflammatory response through the regulation of IL-4 and 
upregulation of the chemokine receptors CCR3, CCR4 and CCR8. Stanciu et al. studied the 
role and expression of ICOSLG in lung epithelial cells on unstimulated and Respiratory 
Syncytial Virus (RSV)-infected cells by flow cytometry.[558] They found that ICOSLG was 
moderately expressed on unstimulated cells and was upregulated on bronchial and alveolar 
cells following RSV infection. In addition they showed that in RSV-infected alveolar cells had 
decreased expression of ICOSLG when treated with IFN- and IL-4. A similar study by Qian 
et al. showed that an alveolar type II cell line abundantly expressed ICOSLG with 
upregulation by both TNF-α alone and in combination with INF- and LPS.[557] Evidence also 
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suggests that the ICOS-ICOSLG interaction is likely to be involved in other (auto)immune 
diseases such as coeliac disease,[610] type I diabetes mellitus,[79] inflammatory 
neuropathies[611] and most recently allergic asthma[612]. 
  There is increasing evidence that co-stimulatory molecules may play an important role in 
inflammatory bowel disease. Rugtveit et al. showed that B7.1 was upregulated compared to 
B7.2 on mucosal macrophage subsets in IBD compared to controls.[543] Similarly, Scarpa et 
al. showed that CD86 expression was not only increased in IBD patients but correlated with 
disease activity and CRP levels.[613] With regard to other co-stimulatory molecules a review 
by Danese et al. outlined the important role of CD40(L) in IBD.[614] They presented evidence 
that CD40 and its ligand are upregulated in the intestinal mucosa of IBD patients and that 
levels of soluble CD40L are increased in the serum of those affected. With activation of the 
CD40 pathway leading to the production of proinflammatory cytokines it is clear that CD40 
may play a crucial role in the propagation of IBD. In experimental colitis models there have 
been interesting, but often conflicting, results. Grose et al. looked at the expression of B7+ T 
cells in a dextran sulphate sodium (DSS)-induced model of murine colitis.[615] Although there 
was no difference in expression in the initial stages of the disease, there was a 20-fold 
increase in both B7.1 and B7.2 expression at seven days. Similarly Eri et al. used B7.1 
blocking peptide to mediate protection against experimental colitis, felt to be due to skewing 
of the Th2 cytokine response.[616] Interestingly, however, Kim et al. induced colitis in mice 
lacking either B7.1 or B7.2 and found that the disease was greatly accelerated in both 
cases.[617] Clearly the role of co-stimulatory molecules in the gut is complex and an over-
riding hypothesis for their role in IBD pathogenesis is yet to be proposed. 
  With regard to the role of ICOS-ICOSLG pathway in inflammatory bowel disease, several 
groups have looked at the aetiology of chronic intestinal inflammation, mostly in animal 
models. Totsuka et al. used a murine colitis model to demonstrate the effect of anti-ICOS 
monoclonal antibody on chronic intestinal inflammation.[618] After injecting CD4+CD45RBhigh T 
cells intraperitoneally into severe-combined immunodeficiency (SCID) mice they then 
assessed ICOS expression and clinical effects of anti-ICOS mAb versus rat IgG. They 
showed that there was upregulation of ICOS expression on infiltrating T cells within the 
mucosa. Also mice treated with anti-ICOS mAb did not exhibit signs of colitis, with good 
weight gain and no bowel wall thickening. However, they also tested anti-B7RP-1 (i.e. 
ICOSLG) mAb with no effect on colitic involvement suggesting that the ICOS-B7RP-1 
interaction may not in itself propagate colitis. These findings suggest that the effect of 
treatment with anti-ICOS mAb may be a result of elimination of ICOS-expressing pathogenic 
T cells. Another interesting find of this study was that interferon-gamma produced by lamina 
propria CD4+ cells was decreased in the anti-monoclonal antibody mice which may 
significantly influence T cell differentiation. Similarly de Jong et al. found that ICOS was 
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markedly upregulated on T cells involved in the murine colitis model, but their data 
suggested that only blockade of CD28 and ICOS had an effect on colitic changes.[619] Work 
carried out in a rat model induced colitis through the administration of DSS to sterile rats and 
again injected anti-ICOS mAb using mouse IgG as a control.[620] Using anti-CD3 mAb the 
researchers showed that ICOS was widely expressed regardless of CD3 status. They also 
found that ICOS expression on CD4+ LPMC was markedly increased following DSS 
administration. 
  With respect to work involving human colitis, Sato et al. obtained both inflamed and 
uninflamed intestinal mucosal samples from 54 patients with CD and 46 patients with 
ulcerative colitis.[621] These were compared to normal controls (colonic cancer patients) and 
disease controls (acute colitis); disease activity was assessed using the CDAI and Truelove-
Witts criteria for CD and UC respectively.[622,623] Again monoclonal antibody to anti-human 
ICOS, B7h, CD3 and CD28 were used to assess expression. They found that ICOS 
expression on LPMC was markedly increased in those with CD and UC compared with 
normal controls. Of clinical importance they also found that ICOS expression on CD4+ LPMC 
cells was related to disease activity. There were significantly higher proportions of CD4+ 
ICOS+ LPMC in inflamed areas of mucosa in CD and UC patients, similarly for CD4+ B7h+ 
LPMC.  
  One of the most interesting recent developments in the investigation of ICOS/ICOSLG in 
inflammatory disease (and especially IBD) is the recognition that these co-stimulatory 
molecules are crucial for the development of Th17 cells[624] and suppressive T regulatory cell 
function[625]. As discussed in detail in Chapter 4.3.2 the role of Th17 cells in IBD 
pathogenesis has gained much attention in recent years.[626,627] Much of the current evidence 
does not pertain directly to IBD, rather most research has focussed on the role of these 
molecules in allergic disease.[628,629] However, one study does describe ICOS and IL-17 
producing cells during colonic inflammation.[630] This work demonstrated a direct correlation 
between ICOS expression and IL-17 production in colonic intra-epithelial cells (cIELs) from 
interleukin-10 (IL-10) deficient mice (conventionally-housed IL-10 deficient mice 
spontaneously developed enterocolitis[98]). ICOS was expressed only on cIELs from IL-10 
deficient mice with IL-17-producing cells consisting of CD4+ and CD8+ cIELs; however, 
CD4+ cells were the predominant IL-17-producing cell population. ICOSLG was also shown 
to be up-regulated on colonic epithelial cells and on a population of large granular 
leukocytes during inflammation. Culture of cIELs with ICOSLG+ dendritic cells enhanced IL-
17A production from normal cIELs but failed to do so using cIELs from ICOS deficient mice. 
Significantly, in vivo treatment of IL-10 deficient mice with antibody to ICOS resulted in a 
significant reduction in colonic pathology. These findings implicate ICOS as an activational 
signal of Th17 cells during chronic intestinal inflammation, and suggest that under some 
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conditions, control of ICOS expression may help to suppress chronic intestinal inflammation. 
With regard to regulatory T cells a very recent paper has identified ICOS as a pivotal effector 
molecule in the early decision between tolerance and immunity.[631] This study showed that 
ICOS did not act like most other co-stimulatory molecules in that it was induced during the 
immune response, but not by T cells activated under tolerogenic conditions. When 
expressed, ICOS selectively caused a massive (21:1) expansion of the T effector population 
of CD4+ cells, leaving the regulatory T cell compartment almost untouched, thus markedly 
affecting the balance between effector and regulatory T cells during inflammation.  
 
5.8  Conclusion 
 
  Through robust, adequately powered TDT analysis in a well-phenotyped cohort of PIBD 
patients, the susceptibility signal at 21q22 has been shown to be likely due to variations in 
the 3'UTR of ICOSLG; this result was also confirmed using GWAS data from mainly adult 
studies. Also, using mRNA microarray analysis it has been demonstrated that ICOS and 
ICOSLG gene expression varies across different intestinal sites in uninflamed biopsies in 
IBD cases versus controls. The molecules involved in co-stimulation and the subsequent 
differentiation of T cells are clearly intricately involved in many inflammatory disease 
processes, including IBD. Although not required to initiate the response to antigen, their 
presence plays a vital role in the propagation of the inflammatory response. Given the 
genetic association with molecules such as ICOSLG in diseases such as IBD and coeliac 
disease, the work outlined above demonstrates that these molecules and other co-
stimulatory signals are likely to be important therapeutic targets for chronic immune diseases 










































6.  An exploration of C-reactive protein in paediatric 
inflammatory bowel disease 
 
6.1  Introduction 
 
  C-reactive protein (CRP) is an acute phase reactant produced predominantly in response 
to pro-inflammatory cytokines.[632,633] First identified in the plasma of patients with 
Streptococcus pneumoniae infection, it was named following the observation that it 
possessed the ability to precipitate the somatic C-fraction of the pneumococcal cell wall.[634] 
During the acute-phase response to infection or inflammation, basal CRP levels (<10mg/L) 
can rise rapidly following induction by interleukin-6 (IL-6), interleukin-1-beta (IL-1β) and 
tumour necrosis factor-alpha (TNF-α).[635,636] Primarily produced in hepatocytes, it is here that 
CRP monomers are assembled into a cyclic homopentameric structure inside the 
endoplasmic reticulum prior to secretion into the plasma, via the transcription factors 
CCAAT/enhancer-binding protein beta (C/EBPβ) and the p50 subunit of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFB).[637] Initial work indicated that binding 
of p50 to the nonconsensus kappaB site enhanced and stabilised the binding of C/EBPβ to 
the CRP promoter, with the binding of both these proteins to their overlapping cognate sites 
required for the efficient induction of CRP by IL-6.[638] This study was later expanded to show 
that the binding of these proteins displaces a complex containing CCAAT/enhancer-binding 
protein zeta (C/EBP) and recombination signal binding protein for immunoglobulin kappa J 
region (RBP-J).[639] It has now been shown that the CRP promoter has a low level of 
occupancy of these and other transcription factors (such as STAT3, cRel, Oct1, HNF-1 and 
HNF-3), with C/EBPβ the most important factor in the presence of a cytokine signal.[640-642]  
  With regard to the immunological function of CRP, the highly conserved amino acid 
sequence (with no known human variants) suggests a critical and non-redundant role.[643] 
CRP has been shown to interact with many molecules,[644] including C1q (activating the 
classical complement cascade[645]), factor H (regulating the alternative complement 
pathway[646]), FcRI and FcRII (leading to phagocytosis[647,648]), and FcαRI (promoting the 
further surface expression of FcαRI, phagocytosis and TNF-α secretion[649]), in addition to its 
primary ligand, phosphocholine, which is exposed on damaged biological membranes, 
including bacterial cell walls[650,651]. Additionally a significant role for CRP in the clearance of 
apoptotic cells and bacteria has also been postulated.[652,653] An outline of the pathways 





Figure 6.1.  Outline of the pathways involved in CRP induction, formation and function in 
response to infection and/or inflammation. Following an infectious or inflammatory stimulus, 
the production of IL-1β and IL-6 leads to CRP synthesis in the liver. A complex arrangement of 
transcription factors are modified at the CRP gene promoter, with the displacement of the C/EBP-
RBP-J complex by the C/EBPβ-p50 complex the most critical step. Following the synthesis of the 
pentameric molecule, serum CRP binds to various ligands in order to interact with immune 
modulation and apoptosis. 
 
 
  Clinically, the rise in serum CRP levels allows its routine use as a marker of disease 
presence,[654] disease activity[655] and to subsequently determine the effect of therapeutic 
intervention[656]. However, it is commonly accepted that the absence of a rise in serum CRP 
does not always indicate lack of infection or inflammation.[654] Additionally, an individual 
patient's serum CRP response to the initial infection may be 'inappropriately' low given the 
clinical history,[657] with the response to treatment also varying widely[658]. The reasons for 
these person-to-person variations are not yet clear. 
  Variations in the gene encoding CRP have previously been shown to influence baseline 
serum CRP levels in healthy individuals,[659] leading to further work demonstrating that CRP 
genotype may affect the susceptibility to conditions with an inflammatory component such as 
acute myocardial infarction[660] and systemic lupus erythematosus (SLE)[661]. The recent 
genome-wide association study (GWAS) in paediatric inflammatory bowel disease (PIBD)[18] 
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demonstrated similar susceptibility loci as adult studies,[13] implicating pathways such as 
innate immunity, the adaptive T cell response and autophagy in disease pathogenesis. 
Although CRP was not a clear positional candidate in these case-control studies (CRP is a 
relatively small gene, which has not been tagged robustly on the genotyping platforms used 
to date) there is now increasing interest in the concept that the CRP protein itself may play 
an active role in inflammatory disease pathogenesis through the mechanisms outlined 
above. 
  With regard to IBD in clinical practice, serum CRP has been shown to have some limited 
utility at diagnosis in cases suspected of having IBD and to correlate to a degree with 
disease activity in those with known disease.[657,662] Of greater interest is the finding that 
adult patients with a high serum CRP level show a superior response to biological 
therapies,[662,663] in addition to a possible correlation of CRP levels with Crohn's disease 
phenotype[664].  
 
6.2  Hypotheses and Aims 
 
Hypotheses: 
1. Variations in the CRP gene contribute to PIBD susceptibility in a robustly phenotyped 
cohort of Scottish PIBD patients. 
2. Variations in the CRP gene influence PIBD phenotype, including age at onset, 
disease location and disease behaviour. 
3. Serum CRP levels at PIBD diagnosis are influenced by CRP genotype. 
4. CRP genotype and serum CRP levels are association with the ability of patients to 
respond to anti-tumour necrosis alpha (TNF-α) therapy. 
  
Aims: To use a family-based, haplotype-tagging approach in cohort of PIBD patients and 
their parents, in addition to meta-analysis data from seven GWAS in adult CD patients, to 
determine if CRP is a candidate susceptibility gene for PIBD. Additionally, following strict 
phenotyping of patients, the influence of CRP genotype on disease phenotype, the influence 
of serum CRP levels and CRP genotype on CRP levels at diagnosis and the ability to attain 







6.3  Methods 
 
  It should be noted that the methodologies used for this study were similar to those used in 
Chapter 5, therefore only the details of relevant differences or similarities in the approaches 
used in the current chapter are highlighted below.  
 
6.3.1  Subjects 
  A total of 1331 individuals consisting of 466 early-onset IBD patients (i.e. diagnosed before 
their 17th birthday) and their parents (n=865) were included. Genotyping of parents provided 
242 complete parent-child trios. PIBD was diagnosed according to standard clinical, 
histological and radiological findings[147,236] and rigorous phenotyping carried out as 
previously described;[141] the basic demographics of the PIBD group are shown in Table 6.1. 
It should be noted that 37 parents also had a confirmed diagnosis of IBD (22 Crohn's 
disease, 13 ulcerative colitis and 2 colonic IBD-unclassified [IBDU]) and therefore disease 
coding was altered appropriately during each analysis.  
 
 
Table 6.1.  Characteristics of paediatric inflammatory bowel disease patients analysed in 
the family-based association study to determine the role of CRP as a susceptibility gene. 
  
 IBD CD UC IBDU 
Number [%] 466 [100.0] 311 [66.7] 113 [24.3] 42 [9.0] 
Median age at diagnosis 
(Years [IQR]) 
11.5 [9.0-13.2] 11.7 [9.2-13.4] 11.0 [8.9-12.9] 10.3 [8.5-12.4] 
Male sex (n, [%]) 266 [57.1] 184 [59.2] 59 [52.2] 23 [54.8] 
White European (n, [%]) 450 [96.5] 301 [96.7] 108 [95.6] 41 [97.6] 
IQR, interquartile range; IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; IBDU, 
colonic IBD, type unclassified. 
 
 
6.3.2  Single nucleotide polymorphism selection 
  The CRP gene is located on chromosome 1 between positions 159,682,079 and 
159,684,379 (Ensembl Release 68 - ENSG00000132693; Build 37) flanked by two genes, 
APCS and DUSP23, which are 124kb and 68kb downstream and upstream of CRP 
respectively. CRP tagging single nucleotide polymorphisms (SNPs) were selected using 
genotypic data from the CEU study available from the HapMap project[329] and identified 
using Haploview software version 4.2[593] based on solid spine of linkage disequilibrium (LD) 
(r2 >0.8, haplotype frequency >5%, minor allele frequency >10%) (Figure 6.2a). This process 
identified five tagging SNPs spanning a 46kb region: rs1935193, rs1130864, rs1205, 
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rs1417938 and rs11265263 (Figure 6.2b). It is important to note that three of these SNPs 
(rs1130864, rs1205, rs1417938) were specifically chosen as tagging SNPs as they had 
previously been demonstrated to influence basal CRP levels.[665-667] An additional SNP 
previously shown to influence serum CRP levels, rs1800947,[665] was also genotyped. 
Details of all genotyped SNPs are presented in Table 6.2. For all patients and their parents 
SNPs conformed to the Hardy–Weinberg equilibrium. 
 
 




dbSNP Name* Chromosomal 
position† 
Location MAF Alleles Detectable 
odds ratio‡ 
1 rs1935193 159664090 Upstream 0.301 A:T 1.48 
2 rs1205 159682233 3' flanking 0.329 C:T 1.47 
3 rs1130864 159683091 3' flanking 0.299 G:A 1.48 
4 rs1800947 159683438 Exon 2 0.063 C:G 1.94 
5 rs1417938 159684186 Intronic 0.298 T:A 1.48 
6 rs11265263 159710517 Downstream 0.072 C:A 1.88 
*Based on NCBI Human Build 135; †Ensembl Release 68 - July 2012; ‡based on individual minimum 
allele frequency (MAF) with an 80% power to detect an effect. 
 
 
Figure 6.2.  Genomic region and single nucleotide polymorphisms tagging CRP. (a) view of 
region generated from the CEU study available through the HapMap project data using Haploview 





  In order to assess the contribution of genes encoding various CRP transcription factors, the 
GWAS data described below was examined to determine if the regions containing SNPs 
tagging these genes had been genotyped. Using the "tag SNP picker" function on the 
HapMap project website (http://hapmap.ncbi.nlm.nih.gov/), eight SNPs tagging three genes 
(CEBPZ [C/EBP], HNF1A [HNF-1] and POU2F1 [Oct-1]) were identified. It was then 
ensured that these SNPs, or a suitable proxy (i.e. D'=1, r2=1.0), was present on the 
HumanHap 550 BeadChip (Illumina, San Diego) and therefore had full results available 
within the GWAS data. Suitable proxies were determined using SNAP 
(http://www.broadinstitute.org/mpg/snap/index.php)[668]; brief details of all eight SNPs are 
shown in Table 6.3. 
 
 
Table 6.3.  Summary of eight SNPs tagging three genes encoding transcription factors 
known to reside at the CRP promoter.  
 
Gene tagged dbSNP* Chromosome Location† 
CEBPZ rs10206380 2 37454286 
 rs2041840 2 37467264 
HNF1A rs735396 12 121438844 
 rs7310409 12 121424861 
POU2F1 rs7532692 1 167250080 
 rs4656538 1 167259755 
 rs7355118 1 167319763 
 rs7522390 1 167348685 
*Based on NCBI Human Build 135; †Ensembl Release 68 - July 2012. 
 
 
6.3.3  DNA extraction and genotyping 
  Primer sequences of the six SNPs tagging CRP are shown in Table 6.4; all genotyping was 
carried out in August 2009. The mean genotyping call rate for all SNPs in all patients/parents 
was 98.6%. Mendelian errors were identified using Haploview software for the current 
dataset in addition to the errors identified during a previous genetic association study 
performed on this patient group.[242] Additional genotyping data was also obtained from a 
previous genome-wide scan carried out on a nested cohort of the Scottish paediatric IBD 
patients. This genotyping was performed using the Illumina Infinium™ II HumanHap550 
BeadChip technology (Illumina, San Diego), at the Center for Applied Genomics at the 
Children's Hospital of Philadelphia. This data was previously used in the first early-onset 
GWAS and published by Imielinski et al. in 2009.[18] This data was obtained in the form of a 
BeadStudio (Illumina, San Diego) file from Dr Johan Van Limbergen (University of 
Edinburgh) and converted to the updated GenomeStudio (Illumina, San Diego) format. The 
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data contained genotyping results on a representative sample of 330 of the patients 




Table 6.4.  Primer sequences for the five single nucleotide polymorphisms used to tag the 
CRP gene on chromosome 1. 
 
dbSNP* Position† Strand Sequence 
rs1935193 159664090 Rev CAAGATACATTTTTAGAGAAATGCC[A/T]ATGATTTTTTAAACTACCTGTGATC 
rs1205 159682233 For ACTTCCAGTTTGGCTTCTGTCCTCA[C/T]AGTCTCTCTCCATGTGGCAAACAAG 
rs1130864 159683091 For CCTCAAATTCTGATTCTTTTGGACC[A/G]TTTCCCAGCATAGTTAACGAGCTCC 
rs1800947 159683438 For AGATGGTGTTAATCTCATCTGGTGA[C/G]AGCACAAAGTCCCACATGTTCACAT 
rs1417938 159684186 Rev CCCCACCCCCATACCTCAGATCAAA[A/T]CTCTCCCATAGCCTGGGGTGGCCCT 
rs11265263 159710517 Rev AGCTCTAGAGGCTGGGAAGGAAGTA[A/C]AAGATCAAGGTGGCAGAAGGTTTAG 
*Based on NCBI Human Build 135. †Ensembl Release 68 - July 2012. 
 
 
6.3.4  Replication using international case-control data 
  To assess variants in CRP for association with CD susceptibility SNP-specific p values, 
odds ratios (OR) and standard errors, generated from the analyzes of seven individual CD 
datasets imputed with the 1000 genomes reference set, encompassing 5,956 CD patients 
and 14,927 healthy controls (http://www.broadinstitute.org/mpg/ricopili/) were obtained. p 
values were generated with principal component analysis as covariates, therefore correcting 
the whole analysis for population stratification and inter-study differences. Data obtained 
through the HapMap project (CEU study)[329] and Haploview software were then used to 
visualise the haplotype structure (using solid spine of linkage disequilibrium) surrounding 
CRP to determine the areas of strongest signal. 
 
6.3.5  Serum CRP level at diagnosis 
  As part of the standard phenotyping study protocol, serum CRP levels are recorded in the 
PICTS database (held and maintained by Mrs Hazel Drummond, Database Manager, 
Gastrointestinal Unit, University of Edinburgh) at the time of diagnosis (i.e. during the initial 
workup of symptoms suggestive of PIBD and closest to the primary diagnostic endoscopy). 
As CRP reference ranges have differed marginally both geographically and with time 
throughout Scotland, in addition to minor variations in biochemical assay, results are simply 
recorded as 'raised' or 'normal' (i.e. above normal range or not) at diagnosis. The highest 
normal cut-off value in use at any time was 10mg/L. For children with no results available 




6.3.6  Response to anti-TNF-α monoclonal antibody 
  Physician global assessment was used to assess initial remission of patients naϊve to anti-
TNF-α monoclonal antibody during induction, regardless of whether or not remission was 
then sustained (as worsening disease and other factors may contribute to loss of response). 
Remission was recorded at 10-12 weeks after commencement of the induction course of 
infliximab (three infusions at weeks 0, 2 and 6 - unless infusions discontinued for severe 
infusion reaction) or adalimumab (six fortnightly doses at weeks 0-10 unless treatment 
discontinued for severe adverse effects or absolute lack of response; UK paediatric clinical 
experience has been that many children and young people need longer than four weeks to 
judge induction response with adalimumab[669]). In some cases, the paediatric CD activity 
index[670] or paediatric UC activity index[671] score for CD and UC/IBDU respectively were 
also used to define remission; a senior clinician with experience of providing the routine care 
of all these patients (Prof. David C Wilson, University of Edinburgh) made the final decision 
on whether remission was achieved. All six SNPs were tested in a multivariate model to 
determine any effect of CRP genotype on response, with all analyses corrected for IBD type 
(categorical) and age at diagnosis (quantitative) if appropriate. Serum CRP results taken at 
the time of the first anti-TNF-α induction dose were also obtained retrospectively from patient 
notes and local laboratory databases throughout the three regional paediatric 
gastroenterology networks in Scotland. 
 
6.3.7  Statistical analysis 
  Transmission disequilibrium test (TDT) analyses were carried out using Haploview v4.2[593] 
by utilising the parenTDT function.[595] Additional analyses were carried out using 
SNPStats[672] and R version 2.14.1 (R Foundation for Statistical Computing, Vienna, Austria). 
For the TDT analysis all p values are reported as corrected following permutation analysis 
(n=100,000 permutations), unless otherwise stated. The meta-analysis of the TDT and 
international GWAS data, and quantitative trait single SNP analysis was carried out using 
PLINK (http://pngu.mgh.harvard.edu/purcell/plink).[673] Chi-squared, Fisher's exact and 
Mann-Whitney U tests were carried out using R version 2.14.1 where appropriate. A two-
sided p value of 0.05 was considered significant. R was used to generate the GWAS SNP 
scatterplot using the ggplot2 package.[599] 
 
6.3.8  Power calculation 
  Using QUANTO (version 1.2.4; http://hydra.usc.edu/gxe),[597] and based on the most recent 
prevalence data of Scottish paediatric IBD presented in Chapter 3 (41.2/100,000 of the 
population less than 16 years old[674]) the IBD TDT analysis had 80% power to detect an 
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effect with an odds ratio (OR) between 1.47 and 1.94 depending on the individual SNP (ORs 
for each SNP are shown in Table 6.3).  
 
6.3.9  Ethics 
  All patients and/or their parents provided full written consent as part of the MRC-funded 
PICTS cohort which was approved by local ethics committees at all three participating 
clinical networks: South-East Scotland (LREC/2002/6/18), West of Scotland (YREC/P12/03) 
and North of Scotland (GREC/03/0273).  
 
6.4  Results 
 
6.4.1  Variations in CRP genotype increase the susceptibility to paediatric IBD 
  TDT analyses of all case-parent trios demonstrated that the A allele of two SNPs showed 
significant over-transmission to affected IBD patients after correction (rs1417938, p=0.006, 
OR 1.67 [95% confidence interval (CI) 1.22-2.29] and rs1130864, p=0.015, OR 1.56 [95% CI 
1.16-2.08]) (Table 6.5). Over-transmission of the A allele of SNP rs1935193 was nominally 
significant (uncorrected, p=0.015). Haplotype analysis across the entire gene demonstrated 
that the six-marker haplotype (ACACAC) showed significant distortion of transmission to 
affected individuals (p=8x10-4, OR 1.75 [95% CI 1.30-2.36]) (Table 6.6a). Two-marker sliding 
haplotype analysis revealed the strongest signal across a small 750 base region spanning 
the intron and exon 2 which incorporated rs1800947-C and rs1417938-A (p=0.001, OR 1.64 
[95% CI 1.22-2.21]) with the substitution of rs1417938-A with rs1417938-T across the same 
two marker haplotype conferring significant protection (p=0.017, OR 0.69 [95% CI 0.52-
0.91]) (Table 6.6b).  
 
6.4.2  Variations in CRP genotype increase the susceptibility to paediatric CD  
  TDT analysis in paediatric CD produced similar results to the PIBD group. The A allele of 
the three SNPs detailed above (i.e. rs1417938, rs1130864 and rs1935193) showed 
significant distortion of transmission (Table 6.5). Similarly, the 6-marker haplotype ACACAC 
and the two-marker haplotype rs1800947C - rs1417938A produced the strongest signal. A 
similar TDT analysis was carried out in the cohort of UC patients (n=113) and their parents, 





6.4.3  Replication of the CRP locus association in international case-control data 
  A total of 905 SNPs in the haplotype block containing CRP and the two flanking blocks, 
spanning 169kb across the three blocks, were first assessed using imputed meta-analysis 
data available from the International IBD Genetics Consortium Crohn's disease data. A total 
of 52 SNPs across the entire region attained a nominal p value of <0.05, 25 of which lay in 
the haplotype block containing CRP; 16 SNPs in the haplotype block containing CRP 
achieved a nominal p value of <0.005. A plot of the SNPs in the region is presented in 
Figure 6.3.  
 
 
Table 6.5.  Transmission Disequilibrium Test analysis of individual single nucleotide 








Odds ratio  
(95% CI) 
Inflammatory Bowel Disease 
rs1935193 A 0.0153 0.0686 1.42 (1.05-1.90) 
rs1205 C 0.2098 0.5899 1.20 (0.91-1.58) 
rs1130864 A 0.0032 0.0149 1.56 (1.16-2.08) 
rs1800947 C 0.2413 0.6808 1.36 (0.81-2.27) 
rs1417938 A 0.0015 0.0066 1.67 (1.22-2.29) 
rs11265263 C 0.2113 0.6406 1.37 (0.83-2.25) 
Crohn's Disease 
rs1935193 A 0.0089 0.0444 1.60 (1.11-2.30) 
rs1205 C 0.2191 0.6503 1.24 (0.90-1.72) 
rs1130864 A 0.0056 0.0321 1.70 (1.18-2.44) 
rs1800947 C 0.1011 0.4025 1.65 (0.90-3.01) 
rs1417938 A 0.0025 0.0145 1.89 (1.26-2.83) 
rs11265263 C 0.1489 0.5310 1.53 (0.86-2.72) 
Ulcerative colitis 
rs1935193 A 0.8864 1.0000 1.00 (0.29-3.45) 
rs1205 C 0.2743 0.7517 1.45 (0.82-2.56) 
rs1130864 A 0.1985 0.6030 1.41 (0.76-2.63) 
rs1800947 G 0.7389 1.0000 1.59 (0.87-2.91) 
rs1417938 A 0.1317 0.4807 1.25 (0.34-4.66) 
rs11265263 N/A 1.0000 1.0000 1.04 (0.59-1.82) 
*Based on NCBI Human Build 135. Corrected P values were generated by permutation analysis (n=100,000) as 









Table 6.6.  Complete haplotype and 2-marker sliding haplotype analysis from the 
transmission disequilibrium test analysis of all PIBD case-parent trios 
 
(a) Complete haplotype 
   







ACACAC 121:69 1.75 (1.30-2.36) 0.0002 0.0008 
TCGCTC 79.2:103.8 0.76 (0.57-1.02) 0.0591 0.2598 
ATGCTC 82:94.8 0.86 (0.64-1.16) 0.3795 0.8916 
ACGCTC 30:29.6 1.01 (0.61-1.68) 0.8580 1.0000 
ATGGTA 24:34 0.71 (0.42-1.19) 0.1892 0.7119 
(b) Two-marker sliding haplotype 
   







AC 136.9:87.7 1.56 (1.19-2.04) 0.0010 0.0031 
AT 96:114.5 0.83 (0.63-1.09) 0.2296 0.0547 
TC 78.6:109.3 0.71 (0.53-0.96) 0.0209 0.4677 
2,3 
CG 89.5:113.5 0.78 (0.59-1.04) 0.0917 0.2224 
TG 96:115 0.83 (0.63-1.09) 0.2172 0.4500 
CA 118:75 1.57 (1.17-2.10) 0.0026 0.0087 
3,4 
GC 87.1:121 0.71 (0.54-0.94) 0.0229 0.0461 
AC 118:75 1.57 (1.17-2.10) 0.0026 0.0042 
GG 25:34.1 0.73 (0.43-1.22) 0.2368 0.4204 
4,5 
CT 83.9:120.9 0.69 (0.52-0.91) 0.0120 0.0170 
CA 117.2:71.1 1.64 (1.22-2.21) 0.0010 0.0011 
GT 25:34.1 0.73 (0.43-1.22) 0.2368 0.4248 
5,6 
TC 84.9:121.8 0.69 (0.52-0.91) 0.0127 0.0219 
AC 115.8:70 1.65 (1.22-2.22) 0.0010 0.0013 
TA 28.6:37.5 0.76 (0.47-1.24) 0.2731 0.4918 
*Marker numbers correspond with those given in Table 6.2. Corrected p values were generated by 
permutation analysis (n=100,000) as described in Methods. Trans, transmitted; untrans, untransmitted; CI, 
confidence interval. Significant p values are highlighted in bold. 
 
 
  The two significant SNPs identified in the TDT analysis described above (rs1417938 and 
rs1130864) both attained p values of 0.004. (Notably, the triallelic SNP rs3091244, which 
has previously been associated with serum CRP levels,[675] was also significant [p=0.004]). 
Using the CD TDT analysis (discovery cohort) and the international GWAS data (replication 
cohort), combined p values and ORs were calculated using PLINK. This demonstrated that 
the risk alleles of all six SNPs provided an association signal in the same direction, with two 





Figure 6.3.  Results of a meta-analysis of seven CD genome-wide association studies 
imputed with the 1000 genomes reference set. Scatterplot showing -logP values in the region of 
CRP for 905 single nucleotide polymorphisms. Vertical dotted lines represent the boundaries of the 
CRP gene and solid lines the limits of each haplotype block. The logP value corresponding to p<0.05 
is represented by the horizontal (red) dotted line. 
 
 
Table 6.7.  Meta-analysis of Scottish transmission disequilibrium test (discovery) and 






















































































*Based on NCBI Human Build 135. CD, Crohn's disease; TDT, transmission disequilibrium test; IIBDGC, 
international inflammatory bowel disease genetics consortium; OR, odds ratio; CI, confidence interval. Results 





6.4.4  The influence of CRP genotype on CRP levels at diagnosis 
  Although four of the SNPs genotyped have previously been associated with variations in 
basal CRP levels, the influence of CRP genotype on the presence of an elevated CRP 
response at diagnosis was assessed. To achieve this, potential confounders identified in the 
PIBD cohort (i.e. IBD type and age at diagnosis) were used as covariates in a multivariate 
model. Using raised/normal serum CRP at diagnosis as a binary outcome, a representative 
sample of 342 IBD patients (229 CD [67%], 84 UC [25%] and 29 IBDU [8%]) had full data 
available. In this analysis rs1205, rs1130864 and rs1417938 showed nominal association 
with CRP levels (in a dominant model); however none of these SNPs remained significant 
after Bonferroni correction (Table 6.8). It should be noted that the presence of the risk alleles 
(rs1417938-A and rs1130864-A) identified in the TDT and GWAS data were associated with 
a raised serum CRP at diagnosis. 
 
 
Table 6.8.  Results of single nucleotide polymorphisms that demonstrated nominal 
significance in a dominant model when assessed for influence on normal/raised serum CRP 











T/T 49.5 38.4 
1.67 (1.01-2.77) 0.045 
A/T - A/A 50.6 61.6 
rs1130864 
G/G 50.6 38.9 
1.73 (1.06-2.83) 0.029 
A/G - A/A 49.4 61.1 
rs1205 
C/C 43.0 51.3 
0.57 (0.34-0.94) 0.025 
C/T - T/T 57.0 48.7 
*Based on NCBI Human Build 135. CD, OR, odds ratio; CI, confidence interval.  
 
 
6.4.5  Patients with paediatric CD and UC differ with regard to CRP genotype and 
serum CRP at diagnosis  
  Although CD and UC have been shown to share many susceptibility loci there are also 
clear differences in the candidate genes and postulated pathogenic pathways involved in 
these IBD types.[607] Evaluating the genotypic differences between CD and UC patients only 
(i.e. excluding all patients with IBDU) there was an increased frequency of the T allele of 
rs1205 in CD patients (34.2% and 22.6% in CD and UC respectively; Table 6.9). Haplotype 
analysis of these two disease groups also demonstrated significant differences in haplotype 
structure, with the strongest difference seen in the six-marker haplotype ATGCTC (Table 6.9 
and Figure 6.4). Additionally, serum CRP results were available for 229 CD patients and 84 
UC patients at diagnosis as detailed above. These results showed that a greater proportion 
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of CD patients compared to UC patients had an elevated CRP level at diagnosis (62.8% 
versus 23.8%, p<0.0001).  
 
 
Table 6.9.  Analysis of the differences in paediatric Crohn's disease and ulcerative colitis 




Allele freq  
in CD (%) 
Allele freq  





rs1935193 A 74.2 65.4 0.0156 0.0656 
rs1205 T 34.2 22.6 0.0020 0.0085 
rs1130864 G 67.4 63.3 0.2903 0.7331 
rs1800947 G 6.2 5.7 0.7991 0.7990 
rs1417938 T 67.2 63.1 0.2959 0.7404 




in CD (%) 
Haplotype freq 





ACACAC 33.6 32.6 36.2 0.3512 0.8409 
TCGCTC 28.1 25.8 34.2 0.0214 0.0819 
ATGCTC 24.3 27.5 15.6 6x10-4 0.0024 
ACGCTC 7.0 7.3 5.9 0.4938 0.9346 
ATGGTA 6.0 6.1 5.7 0.8245 1.0000 
*Based on NCBI Human Build 135. †Based on the SNP order above. Significant results are highlighted in bold. 
 
 
  To further elucidate the possible reasons for the clear differences in serum CRP at 
diagnosis between CD and UC patients, tagging SNPs of three genes encoding CRP 
transcription factors (POU2F1 [OCT1], CEBPZ [C/EBP] and HNF1A [HNF-1] were also 
evaluated. This demonstrated that none of the eight individual SNPs was over-represented 
in either CD or UC. Similarly, none of the haplotype analyses demonstrated differences 





Figure 6.4.  A linkage disequilibrium map showing the D' and r2 values for paediatric 
Crohn's disease patients and paediatric ulcerative colitis patients. (a,b) Crohn's disease; (c,d) 
Ulcerative colitis. For figures 2a and 2c, bright red squares equate to D'=1 and LOD≥2 and blue 
squares to D'<1 and LOD<2 .  
 
 
6.4.6  CRP genotype may influence age at diagnosis in early-onset IBD 
  Recent consensus guidelines have suggested that PIBD phenotype differs between those 
diagnosed aged 0-9 years of age (Paris A1a) and between 10-16 years (Paris A1b), in 
addition to work presented in Chapter 3.[154] The genotypic differences between those 
diagnosed in these two age brackets was therefore assessed. Using greater than or equal to 
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10 years or less than 10 years at diagnosis as binary outcomes, the analyses revealed that, 
correcting for IBD type (CD, UC and IBDU), SNP rs1205 was nominally significant in an 
additive model (T/T>C/T>C/C) (uncorrected, p=0.022). Interestingly the haplotype ATGCTC, 
which differed significantly between those children with CD and UC, was also associated 
with age at diagnosis less than 10 years in CD patients, with a nominal p value of 0.040. 
There were no significant SNPs when either age at symptom onset or age at diagnosis was 
evaluated as a quantitative trait across for either the IBD or CD group. 
 
6.4.7  CRP genotype does not influence CD location or behaviour  
  Due to the strong TDT results for CD the effect of CRP genotype on major CD phenotypes 
was evaluated. To achieve this clinical parameters from the PICTS database in a nested 
cohort of CD patients with full location and behaviour data available at diagnosis (n=286), 
and a second cohort who had at least 4 years of follow-up data available since diagnosis 
(n=189) was obtained; details of these sub-groups are shown in Table 6.10. There were no 
significant differences in CRP genotype (either individual SNPs or haplotypes) in CD patients 
with or without ileal disease (i.e. +/- Montreal L1 or L3), upper GI disease (i.e. +/- Montreal 
L4) or pure colonic disease (i.e. +/- Montreal L2) either at diagnosis, or at last follow up. 
Similarly CD patients with stricturing or penetrating disease behaviour (Montreal B2 or B3) 
did not differ with respect to CRP genotype compared to those with inflammatory disease 
only (i.e. Montreal B1) after at least 4 years follow up. A total of 229 CD patients had a 
'normal/raised' CRP result available at diagnosis. The three phenotypes analysed above (i.e. 
with or without ileal, upper or pure colonic disease) did not differ with respect to 
normal/raised CRP levels at diagnosis (p=0.113, p=0.504, p=0.264, respectively). 
 
 
Table 6.10.  Characteristics of Crohn's disease subgroups used to determine the influence of 
CRP genotype on disease location or behaviour. 
 
 At diagnosis At last follow up 
Number 286 189 
Male sex (n, [%]) 169 [59] 112 [59] 
Median age at diagnosis (Years [IQR])  11.7 [9.1-13.4] 11.1 [8.4-12.9] 
White European (n, [%]) 277 [97] 183 [97] 
Ileal disease (i.e. L1 or L3) (n, [%]) 163 [57] 129 [68] 
Upper GI disease (i.e. L4) (n, [%]) 138 [48] 119 [63] 
Pure colonic disease (i.e. L2) (n, [%]) 64 [22] 28 [15] 
Median follow up duration (Years [IQR]) N/A 6.1 [4.0-8.1] 
Stricturing/penetrating behaviour*  
at last follow up (n, [%]) 
N/A 50 [26] 
*B2 and/or B3. IQR, interquartile range; GI, gastrointestinal; N/A, not applicable 
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6.4.8  The influence of CRP genotype and serum CRP level on anti-TNF-α response 
  Clinical data was available regarding initial remission achieved during anti-TNF-α therapy in 
83 anti-TNF-α naϊve early-onset IBD patients (71 CD, 9 UC, 3 IBD-U; 81 received infliximab, 
2 received adalimumab). Of the 83 patients, 52 (63%) patients achieved initial remission as 
defined in the methods above. Using a multivariate model incorporating IBD type and age at 
diagnosis, only rs1205 genotype was found to have a significant effect on remission rates in 
an over-dominant model (p=0.020, OR 4.62 [95% CI 1.55-13.74]) (Figure 6.5). Those 
patients who were heterozygous for the rs1205 SNP showed a remission rate of 79% 
compared to 51% in those homozygous for the C or T allele (p=0.021). Fisher's exact testing 
across all three rs1205 genotypes (CC:CT:TT) was also significant (p=0.032). No haplotypes 
were identified that significantly differed between those achieving or not achieving remission. 
  Additionally, serum CRP levels taken in the seven days prior to the first dose of anti-TNF-α 
agent (n=73) demonstrated that, comparable to a previously published adult study,[662] 
patients gaining clinical remission had similar median serum CRP levels than those who did 
not (16mg/L versus 12mg/L respectively, p=0.999). However, patients with an elevated 
serum CRP level at anti-TNF-α induction (i.e. >10mg/L) had higher remission rates than 





Figure 6.5.  Graph showing the number of children with each rs1205 genotype achieving 




























6.5  Discussion 
 
  Using family-based TDT analyses it has been shown that CRP is a susceptibility gene for 
IBD and CD in the Scottish paediatric population, with replication in CD using data from a 
large international case-control meta-analysis. It has also been demonstrated that CRP 
genotype has potential effects on age at diagnosis, but no discernible effect on major 
disease phenotypes in a sub-group of CD patients. Additionally CRP genotype (especially 
haplotype structure) and serum CRP at diagnosis differ between CD and UC patients in the 
same Scottish PIBD population, with CRP genotype influencing the ability of these patients 
to gain initial disease remission during their first course of anti-TNF-α therapy.   
  With regard to the design of the genetic susceptibility analysis, there are research benefits 
resulting from the utilisation of family-based studies such as improved recruitment, better 
recall and documentation of possible environmental influences, accurate population 
stratification and a reduction in population heterogeneity, although a degree of inherent bias 
still occurs.[676] The ability to rigorously phenotype a distinct population of paediatric IBD 
patients, and to follow their progress over long periods has also enabled detailed analysis of 
IBD sub-groups, in addition to the collection of laboratory parameters[159] and response to 
therapies[177]. 
  The use of nonparametric linkage analysis and newer GWAS techniques [677] have now led 
to the identification of over 100 IBD susceptibility loci[526] with candidate genes involved in 
the innate immune response, autophagy and the interleukin-12/interleukin-23 
pathways.[523,524] The impetus for carrying out a candidate susceptibility gene analysis on 
CRP in this Scottish PIBD population were four-fold. Firstly, several studies in inflammatory 
conditions have identified CRP as a susceptibility gene[667,678]. Secondly, we have observed, 
along with others,[657] that children across all IBD types differ significantly in their ability to 
produce a serum CRP response, even in the presence of overt clinical disease. Interestingly, 
recent evidence has shown that mesenteric fat (hyperplasia of mesenteric fat is 
characteristic of CD) is an important source of CRP, with CRP production by mesenteric 
adipocytes triggered by bacterial and inflammatory stimuli such as E.coli and IL-6.[633] 
Thirdly, with regards to cardiovascular risk and SLE, studies have suggested that failure to 
respond appropriately to inflammation with a rise in serum CRP may be a factor in disease 
pathogenesis.[637,679] This may be especially important in light of the fact that paediatric CD 
and UC patients differ significantly with regard to CRP genotype and serum CRP response 
at diagnosis. Finally, recent evidence has suggested that adult IBD patients with a high 
baseline CRP level at induction demonstrate a better primary response to biological 
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therapies, with early normalisation of CRP levels correlating with sustained long-term 
response.[662,680]  
  It is important to note that although the results of this paediatric study demonstrate a 
positive TDT outcome with replication in a mainly adult meta-analysis, recent 
correspondence with members of the IIBDGC have revealed that the CRP locus did not 
show a susceptibility signal in the recent IBD ImmunoChip experiment.[525] This study of 
approximately 14000 CD cases and 16000 controls demonstrated a p value of 0.83 for the 
rs1130864 SNP (Dr Jeffrey Barrett, Wellcome Trust Sanger Institute, personal 
communication), therefore the risk of a false positive result in this smaller family-based 
cohort may be significant. However, although the region containing CRP may not have been 
a proven susceptibility locus in these adult studies, it is possible that the signal may be 
specific to the paediatric population (e.g. MTMR3[18]) or be as a result of geographical 
variation in risk loci or allele frequencies. It is of interest to note that in the original Wellcome 
Trust case control study in CD, a number of risk alleles showed significant variation across 
the United kingdom,[508] with previous work in Scotland showing that the contribution of the 
three common NOD2 mutations to disease susceptibility in the Scottish paediatric population 
is modest, with a population attributable risk lower than in most other populations studied[242].  
  With respect to the role of CRP genotype and inflammatory disease pathogenesis the 
evidence is substantial but often contradictory. The first stimulus to dissect the effect of CRP 
genotype with basal CRP levels came following the observation of a strong correlation 
between CRP levels and cardiovascular disease risk.[681] Although recent evidence has 
suggested that no causal link is likely to exist between CRP genotype, plasma CRP and 
cardiovascular disease,[682] extensive efforts to examine this link have provided a detailed 
insight into how inherited CRP variants influence basal CRP levels.[637] The role of CRP in 
inflammatory bowel disease in particular has been mostly detailed from a clinical 
perspective, however two studies have evaluated the contribution of CRP genotype to 
disease phenotype and treatment response. Thalmaier et al. evaluated the role of the 
rs1800847 (+1059G/C) polymorphism in CD susceptibility and disease phenotype in 241 
adult patients with CD and 199 healthy controls.[664] They reported that C allele 
homozygosity was associated with ileal disease involvement at diagnosis, with no effect on 
disease susceptibility; this study was limited by evaluating only one SNP without replication. 
The second study evaluated the role of three SNPs in CRP (rs2794521, rs1130864 and 
rs1205) with regard to response to infliximab in 189 anti-TNF naive adult patients.[683] They 
concluded that none of these polymorphisms had a significant effect on either biological (as 
defined as a decrease in serum CRP) or clinical response to infliximab or indeed any effect 
on CRP levels prior to commencing treatment.  
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  With regard to the clinical use of serum CRP in patients with inflammatory bowel disease, 
studies have looked at its utility at diagnosis, during the assessment of disease activity,[156] 
response to biological therapies[684] and association with disease outcomes such as 
surgery[685]. Although this study was unable to replicate adult studies in which patients with 
an elevated CRP responded better to biological therapies,[684] this may reflect the smaller 
numbers presented, the extensive disease phenotype of early-onset patients,[141] or differing 
response rates to biological therapies in children[686]. 
  With respect to study limitations, although the TDT analysis had sufficient power to detect 
associations within case-parent trios, the sub-phenotypic analyses may have been 
underpowered; this is especially true with regard to certain SNPs with small MAF within the 
anti-TNF-α response data. Additionally, the biological plausibility of the increased response 
in those heterozygous for rs1205 is difficult to justify, although positive molecular heterosis 
(i.e. when subjects heterozygous for a specific genetic polymorphism show a significantly 
greater effect for a trait than subjects homozygous for either allele) may be involved.[687] 
 
6.6  Conclusions 
 
  This study has demonstrated that CRP is a candidate susceptibility gene for PIBD and 
paediatric CD, with clear differences in CD and UC CRP genotype and potential effects on 
age at onset and response to anti-TNF-α agents. Further functional work is now required to 
assess the role of CRP in IBD, likely mimicking the previous work undertaken with regard to 
cardiovascular disease risk. It has already been shown that CRP genotype influences basal 
serum CRP levels, however the complex relationship between CRP genotype, CRP level 
and IBD phenotype should now be explored using 'Mendelian Randomisation', as this is 
more likely to reveal the true influence of CRP to IBD pathogenesis;[682] further insights into 
the role of transcription factors and the serum CRP response may prove fruitful with this 
respect. The evidence that CRP bridges both innate and adaptive immune pathways is 
intriguing in the context of our current knowledge of disease pathogenesis, and with CRP 
already widely used in the clinical setting, there is great potential to optimise the utilisation of 









7.  The diagnostic accuracy of faecal calprotectin during the 
investigation of suspected paediatric inflammatory bowel 
disease 
 
7.1  Introduction 
 
  Work presented in Chapter 2 and Chapter 3 has clearly shown that both the incidence and 
prevalence of paediatric inflammatory bowel disease (PIBD) has risen significantly in recent 
years, with similar trends in incidence also evident worldwide.[223] These epidemiological 
changes not only raise questions regarding disease pathogenesis, but also have implications 
for the provision of PIBD services in paediatric gastroenterology, especially during the 
process of diagnostic workup for suspected disease.  
  In routine clinical practice, the initial investigation of children with suspected bowel 
inflammation commonly includes haematological and biochemical biomarkers to identify 
those patients warranting further evaluation. However, to date sparse evidence exists to 
support their diagnostic accuracy and therefore their overall value is not entirely clear. 
Beattie et al. looked at referrals for colonoscopy over an 18 month period to assess the 
usefulness of routine blood parameters in determining the presence of organic disease.[688] 
In a group of 91 patients referred, 26 had confirmed Crohn's disease (CD) and 13 patients 
were diagnosed with ulcerative colitis (UC). None of the CD patients and one of the UC 
patients had a full set of normal blood results (which included haemoglobin [Hb], erythrocyte 
sedimentation rate [ESR], albumin, platelet count and C-reactive protein [CRP]). A similar 
study by Cabrera-Abreu et al. looked at 153 children less than 18 years referred to a tertiary 
centre with symptoms suggestive of PIBD.[689] They demonstrated a sensitivity of 90.8% 
(95% CI 83.3 - 95.7) and a specificity of 80.0% (95% CI 65.7 to 89.8%) for a combination of 
low haemoglobin or raised platelet count (i.e. one of two abnormal), demonstrating poor 
diagnostic utility of the other commonly measured parameters. A systematic evaluation of 
CRP and ESR in a large cohort of UC patients demonstrated that these parameters had 
some correlation with disease activity, but that normal values were evident in a large 
proportion of patients with mild to moderate disease activity.[657] A Scottish study 
(incorporating a South-East Scotland PIBD cohort) evaluating a similar panel of blood tests, 
but with the addition of the faecal marker calprotectin, also showed that all 48 of the IBD 
patients studied had one abnormal blood test and/or calprotectin, but the absence of a 




7.2  Background of faecal calprotectin 
 
  Faecal calprotectin (FC) is a calcium-binding protein found in neutrophilic granulocytes,[690] 
monocytes,[691] macrophages,[692] and epithelium[693]. A 24 kilodalton heterodimer composed 
of two calcium-binding proteins belonging to the S100 group of proteins (S100A8 and 
S100A9),[694] it constitutes between 40-60% of the cytosolic protein in human 
neutrophils.[690,695] FC has demonstrated bacteriostatic actions against a number of bacteria 
including Listeria monocytogenes,[696] Borrelia burgdorferi,[697] Staphlococcus aureus,[698] and 
Escherichia coli[699]. Additionally, FC has been shown to be fungicidal against several 
species.[699-701] The main mechanism of action for this microbial inhibition is the chelation of 
zinc and manganese leading to 'starvation' these organisms.[698,702] Although some bacteria 
such as Salmonella typhimurium can overcome this metal binding leading to symptomatic 
gut inflammation,[703] the efficient chelation of zinc and/or manganese (via histidine-rich 
regions of the calprotectin molecule[704]) and the enhancing the sensitivity of bacteria to 
superoxides can often produce an effective anti-inflammatory response[702].  
  FC has previously been shown to be markedly raised in children and adults with IBD, [705,706] 
with its stability for seven days at room temperature allowing the convenient collection of this 
non-invasive marker in both inpatient and outpatient settings.[695] In PIBD FC has been 
shown to correlate with endoscopic severity at colonscopy,[707] disease activity in UC[708] and 
has also demonstrated usefulness in predicting disease relapse.[709] There are currently only 
a small number of published studies that have evaluated FC during the initial investigation of 
paediatric bowel inflammation (i.e. prior to endoscopic confirmation of IBD).[161,247,705,710-712] 
These studies have often included small numbers of IBD patients or have not provided a 
detailed analysis of sub-phenotypic characteristics in a truly representative group of potential 
PIBD patients.[161,712] A recent meta-analysis evaluating the role of FC during the initial 
investigation of suspected IBD concluded that FC was a useful screening tool to identify 
patients requiring endoscopic assessment,[162] though the discriminative power to safely 
exclude IBD was significantly better in adults than in children.  
 
7.3  Hypothesis and Aims 
 
Hypotheses:  
1. The diagnostic accuracy of FC in suspected PIBD is equivalent to endoscopy and 
superior to six commonly used blood parameters. 
2. FC does not vary significantly between patients in each PIBD type. 
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3. The location of disease at diagnosis (e.g. upper intestinal disease) does not influence 
FC levels. 
 
Aims: To describe the differences in FC levels at diagnosis between the three IBD types 
(CD, UC and colonic IBD, type unclassified [IBDU]) and a group of non-IBD disease patients 
who were initially and contemporaneously referred to paediatric gastroenterology services 
for suspected bowel inflammation. Additionally, to evaluate six commonly used blood 
parameters in the same cohort to assess their utility at diagnosis compared to FC. 
 
7.4  Methods 
 
7.4.1  Setting   
  The paediatric gastroenterology department based at the Royal Hospital for Sick Children 
in Edinburgh (RHSCE) (as described in detail in Chapter 3) provides a regional service for a 
population of approximately 228,000 children in South-East Scotland (SES). This tertiary 
hospital acts as a referral centre for the three district general hospitals with paediatric 
services, in addition to two adult academic gastroenterology services in Edinburgh and all 
adult gastroenterology departments within the district general hospitals. Children presenting 
or referred with suspected bowel inflammation currently have all their primary investigations 
and initial follow up carried out at RHSCE by four experienced paediatric gastroenterologists. 
The biochemistry department based at the Western General Hospital (WGH) in Edinburgh 
has routinely processed all FC samples in the SE Scotland region since October 2004 
(under the supervision of Dr Kathleen Kingstone), with access to all tests carried out in 
primary care and all hospital-based services.  
 
7.4.2  Faecal calprotectin measurements 
  All FC measurements carried out between 1st January 2005 and 31st December 2010 in 
patients born after the 1st January 1987 (to ensure the inclusion of all patients potentially 
undergoing endoscopy before 18 years of age) in SES were obtained retrospectively from 
the biochemistry department laboratory records (through correspondence with Dr Kathleen 
Kingstone, Biochemist) as a large Microsoft Excel 2003 database (Microsoft Corporation, 
Redmond, WA). These data included patient demographics (name and date of birth), the 
unique patient identifier and unique specimen number, the location code which specifies the 
sample origin (e.g. general practice, outpatient department), the sample date and FC 
concentration in micrograms per gram (µg/g) of stool for all patients. The data also specified 
if samples were taken but were insufficient for processing (marked as 'Insuff' on the 
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database). Faecal calprotectin was measured by the PhiCal Test (Calpro AS, Lysaker, 
Norway) according to the manufacturer’s instructions in the biochemistry laboratory at the 
WGH; the local assay analytical range is currently 20 to 2500 µg/g. A normal FC value was 
taken to be <50 µg/g stool with the biochemistry laboratory routinely reporting FC results as 
“possible gastrointestinal (GI) inflammation” if between 51-100 µg/g, “GI inflammation” if 
between 101-200 µg/g and “active GI inflammation” if >200 µg/g. In order to aid analysis of 
FC levels, samples reported as <20 µg/g and >2500 µg/g were converted to 20 µg/g and 
2500 µg/g respectively. 
 
7.4.3  IBD patients   
  All incident cases of PIBD diagnosed by standard clinical, histological and radiological 
findings[147,236] since August 1997 have been collected prospectively by Prof. David C Wilson 
(Consultant Paediatric Gastroenterologist) and Ms Pam Rogers (IBD and Liver Nurse 
Specialist) and recorded on a departmental database using Microsoft Access 2003 
(Microsoft Corporation, Redmond, WA, USA) - see Chapter 3. From this database patients 
who had a FC measured as part of their initial diagnostic work-up during the 6 year period of 
FC data from 2005-2010 were identified (hereafter referred to as the IBD group). Detailed 
phenotypic characteristics[141] for these patients were also available through the Scotland-
wide Medical Research Council funded Paediatric Inflammatory Bowel Disease Cohort and 
Treatment Study (PICTS) database, details of which can be found in Chapter 3 and 
Chapter 5.6.1.  
 
7.4.4  Non-IBD (control) patients 
  Through the electronic departmental clinical records containing the details of over 5,600 
children referred to paediatric gastroenterology services since 2001, a computerised search 
using the remaining FC sample list determined those patients who had previously had 
contact with the service. This was achieved using a Microsoft Word macro (Microsoft 
Corporation, Redmond, WA, USA) developed by Dr Nick Kennedy (Clinical Fellow, 
University of Edinburgh) that interrogated the local RHSCE shared folder (known locally as 
GISecs - referring to the gastroenterology secretarial records) to pull out the name and date 
of birth of each child seen by the service. These hospital records and departmental 
endoscopy lists (generated once or twice weekly by the departmental secretaries) were used 
to identify all patients undergoing both upper and lower endoscopy due to the clinical 
suspicion of bowel inflammation, but where PIBD was subsequently excluded based on 




7.4.5  Exclusion criteria 
  Exclusion criteria for both the IBD and control groups were: (1) insufficient stool sample 
provided (usually less than 1 gram of stool, although the laboratory often attempted to 
provide FC levels in samples of between 0.5-1.0 grams); (2) aged less than one year or 
greater than 18 years of age on the endoscopy date (children less than six year old have 
previously been shown to have elevated FC levels[713-715]); (3) greater than a six month delay 
between the FC sample and the endoscopy date; (4) FC sample taken after endoscopy; (5) 
any previously known, hospital-diagnosed, GI disease; (6) previous upper or lower GI 
endoscopy for any indication.  
 
7.4.6  Blood parameters 
  Blood results (taken within six months of endoscopy and closest to the date of the FC 
sample) were also obtained to compare the diagnostic utility of FC with commonly used 
blood parameters, namely: Hb, platelet count, total white cell count (WCC), ESR, serum 
albumin and CRP. The regional paediatric biochemistry-haematology laboratory normal 
values by age and sex range are shown in Table 7.1. Within one referral centre (Victoria 
Hospital, Kirkcaldy), plasma viscosity (PV) is routinely used as an alternative to ESR, 
therefore in six patients within the control group PV results were used as a proxy for ESR 
with a reference range of 1.50-1.72 mPa/s. 
 
Table 7.1.  South-East Scotland regional paediatric biochemistry-haematology laboratory 
normal values by age and sex for the six tests evaluated  
 
Parameter 1-2yrs 2-6yrs 6-12yrs 12-18yrs 
Haemoglobin (g/L) 113-141 115-135 113-155 Male 130-160 
Female 120-160 
Total white cell count (x109/L) 6.0-17.5 5.0-17.0 4.5-14.5 4.5-13.0 
Platelets (x109/L) 150-450 
Erythrocyte sedimentation rate (mm/hr) <20 
Albumin (g/L) 33-50 




7.4.7  Data recording and statistics   
  Demographic information, details of endoscopic assessment, FC and blood results, 
phenotypic information, prescribed medications at the time of the FC sample and final 
diagnosis were recorded electronically using Microsoft Access 2007 (Microsoft Corporation, 
Redmond, WA, USA) following thorough case-note review. Statistical analysis was 
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performed using R version 2.14.1 (R Foundation for Statistical Computing, Vienna, Austria) 
and GraphPad Prism version 4.03 (GraphPad Software, CA, USA). Pearsons’s chi-square, 
Kruskal-Wallis and Mann Whitney U tests were used where appropriate; multivariate 
analysis was achieved using multiple logistic regression. The R packages epiR [716] and 
pROC[717] were used for further analysis (carried out by Dr Nick Kennedy, University of 
Edinburgh). Hb and total WCC were standardised to the reference range used for 12-18 year 
olds for the purpose of ROC curve generation. Youden Index was calculated as sensitivity + 
(specificity -1).[718] Statistical testing between ROC curves was performed using the 
DeLong[719] and bootstrap[720] methods. Statistical significance was taken to be a two-tailed p 
value of less than 0.05. 
 
7.4.8  Ethics 
  Ethics approval was sought but deemed unnecessary as this was an anonymous, 
observational study of patients already under the care of PIBD services and under the 
umbrella of the Paediatric-onset IBD Scottish Audit (PISA). 
 
7.5  Results 
 
7.5.1  Group characteristics 
  A flow diagram outlining the patient selection process is shown in Figure 7.1. In total 91 
IBD patients and 99 non-IBD controls met the inclusion criteria; the baseline characteristics 
of both groups are outlined in Table 7.2. Using univariate analysis the IBD group 
demonstrated an older age at endoscopy, a shorter time between their FC sample and 
endoscopy and higher terminal ileum (TI) intubation rates. However, only age at endoscopy 
and time between FC sample and endoscopy remained significant on multivariate analysis 
suggesting that differences in TI intubation rates between the groups was possibly a result of 
a higher age at endoscopy in the IBD group (with endoscopy being less technically 
demanding in older children). Additionally, the TI intubation rate was not significantly 






Figure 7.1.  Flow diagram showing the retrospective selection of study participants. FC, 
faecal calprotectin; GI, gastrointestinal; Yr, year; IBD, inflammatory bowel disease. 
 
 
Table 7.2.  Characteristics of the inflammatory bowel disease and control groups 
 




Number of cases 91 99  
Male sex [n (%)] 56 (62) 55 (56) 0.403 
Median age at endoscopy  
[years (IQR)] 
12.6 (9.5-14.0) 9.3 (5.2-12.7) <0.001 
Terminal ileal biopsy obtained [n (%)] 57 (63) 46 (46) 0.037 
Median time from FC result to 
endoscopy [days (IQR)] 
18 (7-44) 48 (29-87) <0.001 
Median time from FC result to blood 
result [days (IQR)] 
3 (0-9) 9 (3-30) N/A 
Median time from blood result to 
endoscopy [days (IQR)] 
13 (2-37) 56 (29-93) N/A 
*p values as determined with Chi squared or Mann Whitney U tests. IQR, interquartile range; GI, 





  The IBD group consisted of 62 CD, 21 UC and 8 IBDU patients. In IBD patients without a TI 
biopsy obtained (n=34), 88% had small bowel imaging carried out within a median time of 46 
days (interquartile range [IQR] 22-71 days) from endoscopy. All but one of the IBD group 
(99%) are currently recruited to the PICTS cohort; the remaining patient died prior to 
approach for possible consent. 
  The diagnostic categories of the control group are shown in Table 7.3 and reflect their 
definitive diagnosis after follow up of at least 12 months from the date of endoscopy (median 
follow up 41 months [IQR 24-53 months]). All children presented with one or more symptoms 
suggestive of bowel inflammation (Table 7.4); 37% had two recorded symptoms and 23% 
had three or more. All controls were followed up to at least definitive diagnosis or to 
discharge from paediatric services. Of those with no pathology identified (n=11), all have 
been discharged from further follow up on no medications. To our knowledge none of the 
control group have subsequently been diagnosed with PIBD by the end of October 2012. 
Unless now in adult services or moved away from SE Scotland, all potential PIBD diagnoses 
will have been re-referred to our service.  
 
Table 7.3.  Non-IBD (control) diagnostic categories and median faecal calprotectin values 
 
Diagnostic category Number Median FC (IQR) 
Irritable bowel syndrome 32 48 (21-123) 
Non-specific colitis 12 68 (25-258) 
No pathology identified 11 20 (20-275) 
Post-infectious enteropathy 11 45 (20-440) 
Cow's milk/wheat intolerance 8 67 (41-115) 
Threadworms 7 110 (29-275) 
Allergic enteropathy 5 80 (50-1508) 
Coeliac disease 3 350 (N/A) 
Miscellaneous 10 177 (61-292) 
Total 99  
FC, faecal calprotectin; IQR, interquartile range. 
 
Table 7.4.  Symptoms and signs in control patients suggestive of bowel 
inflammation/inflammatory bowel disease 
 
Symptom/Sign Percentage 
Altered bowel habit  76 
Abdominal pain  55 
Rectal bleeding  48 
Growth distortion  10 
Vomiting 10 
Recurrent mouth ulcers  3 
Iron deficient anaemia  2 
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7.5.2  Children with IBD have a significantly elevated FC at diagnosis compared to 
controls undergoing endoscopy 
  The median FC at diagnosis for the IBD group was 1265 µg/g (IQR 734-2024 µg/g, range 
26-2500 µg/g), which was higher (p<0.001) than the control group with a median FC of 65 
µg/g (IQR 20-235 µg/g, range 20-2500 µg/g). Within the IBD group only two patients had a 
FC <50 µg/g recorded at initial presentation, an 11-year-old girl with colonic CD (Montreal L2 
at diagnosis) who has since required immunomodulators and adalimumab, and a 4-year-old 
boy with pancolitic IBDU who is currently stable on a maintenance 5-ASA preparation. Only 
one child in the control group had a FC >2500 µg/g, a 2-year-old girl with allergic 
enteropathy who settled on dietary restrictions and who continues to have no evidence of 
PIBD during ongoing review.  
  The diagnostic accuracy for FC at different cut-off levels is shown in Table 7.5. Using the 
manufacturer’s normal cut-off of >50 µg/g gives an excellent sensitivity (0.98), but a poor 
specificity (0.44) for IBD. This specificity increases steadily with increasing FC levels until the 
“pay-off” between sensitivity and specificity (calculated by the Youden Index) plateaus at 
around 200-300 µg/g. As discussed above it can be seen that the IBD group had a higher 
rate of TI biopsy, therefore to ensure that this was not confounding the results regarding 
diagnostic accuracy, children with an available TI biopsy (n=103) were analysed separately. 
This demonstrated that using a cut-off of >50 µg/g gave almost identical results as when the 
entire cohort was evaluated (i.e. sensitivity 0.98 [95% CI 0.91-0.99]; specificity 0.46 [95% CI 
0.31-0.61]; negative predictive value 0.95 [95% CI 0.77-0.99]; positive predictive value 0.69 
[95% CI 0.58-0.79]). It is important also to note that 34% (n=63) of FC results returned after 
the endoscopic assessment was performed, and secondly that 14% (n=27) of FC results 
were not known in the preceding two weeks prior to endoscopic assessment. Given the 
minimum two week delay in RHSCE to elective GI endoscopy over the full six year period, 
these 48% (n=90) of FC results could not have influenced the decision making with regards 
to performance of endoscopy, nor the occurrence of TI intubation in 34% of patients. 
Furthermore, even for the 52% of patients where FC results were known in the two weeks 
prior to the endoscopic assessment, none were cancelled after confirmation of procedure 
based on FC result, nor had procedures expedited based on FC result - this occurred only 







Table 7.5  Measures of diagnostic accuracy for increasing levels of faecal calprotectin and 
commonly measured blood parameters in children with suspected inflammatory bowel 
disease 
 













































































































































































*Youden Index = Sensitivity + (Specificity-1); Sens, sensitivity; Spec, specificity; NPV, negative 
predictive value; PPV, positive predictive value; CI, confidence interval; LR+ve, positive likelihood 
ratio; WCC, white cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
 
  Additional analysis within the complete cohort (n=190) showed that the pre-test probability 
of IBD was 0.48 (i.e. 91/190) and that utilising a positive result of >200 µg/g provided a post-
test probability of 0.77 (111 patients had a FC >200 µg/g with 85 having IBD), an increase of 
60%.   
 
7.5.3  FC levels in children with IBD are not influenced by sex, age, IBD type or 
disease location 
  Including all 91 children with IBD and categorising the entire IBD group by sex showed no 
difference between median FC levels in males (1265 µg/g [IQR 658-1864 µg/g]) and females 
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(1250 µg/g [IQR 890-2070 µg/g]) (p=0.695). There were also no differences between the 
sexes when the CD (p=0.508), UC (p=0.859) and IBDU (p=0.999) groups were analysed 
separately. Although comparing age with FC level for the entire IBD group demonstrated a 
significant correlation (p=0.037, Spearman's rho=0.245), this was lost when analysed in a 
multivariate model which included ESR, CRP and albumin (p=0.375), likely reflecting the fact 
that disease severity was a confounder  
  To determine if disease type or location influenced FC levels, detailed phenotypic 
information was collected from the PICTS database; their Montreal[2] classification for 
location at diagnosis is shown in Table 7.6.  
 
 
Table 7.6.  Montreal classification of disease location at diagnosis for all IBD patients 
(n=91). 
 
IBD type Number 
Crohn's Disease (n=62)  
     L1 1 
     L1+L4 2 
     L2 8 
     L2+L4 8 
     L3  12 
     L3+L4 29 
     (Oral/perianal disease only)* (2) 
Ulcerative colitis (n=21)  
     E1 2 
     E2 1 
     E3 18 
IBDU (n=8)  
     Pancolitis 7 
     Limited distal colitis 1 
* Oral and/or perianal disease alone without luminal GI involvement is not recognised as a location 
phenotype in the Montreal Classification[2] but represents 5% of Scottish paediatric CD patients at 
diagnosis[141]. IBDU, colonic IBD, type unclassified 
 
 
  There was no difference (p=0.710) between CD, UC and IBDU patients, with these three 
types having median FC levels of 1258 µg/g (IQR 710-1671 µg/g), 1250 µg/g (IQR 925-2200 
µg/g) and 1463 µg/g (IQR 898-2125 µg/g) respectively. There was no difference in median 
FC levels between those with upper intestinal CD location (1440 µg/g [IQR 885-2034 µg/g]) 
and those without (1220 µg/g [IQR 400-1340 µg/g]) as defined as the presence or absence 
of Montreal L4 disease (p=0.077), nor any difference observed when comparing median FC 
levels in CD patients with any ileal (L1 ± L4 or L3 ± L4) disease (1266 µg/g [IQR 875-1757 
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µg/g]) and those without (1295 µg/g [IQR 494-1832 µg/g]) (p=0.694). To allow meaningful 
numeric comparison of UC and IBDU disease location both groups were combined and each 
patient re-classified according to the newly described Paris classification of PIBD.[154] This 
demonstrated no difference (p=0.536) between those with extensive pancolonic disease 
(Paris E4, disease proximal to the hepatic flexure) and those with more limited disease 
(Paris E1-E3, all with disease of varying extent from the rectum yet distal to the hepatic 
flexure) who had median FC levels of 1480 µg/g (IQR 978-2135 µg/g) and 963 µg/g (IQR 
691-2135 µg/g) respectively. Similarly, to evaluate all colonic IBD, CD patients with isolated 
colonic or ileo-colonic disease (L2 or L3 only) had a similar median FC level of 1230 µg/g 
(IQR 408-1421 µg/g) compared to those with UC and IBDU combined (1300 µg/g [IQR 925-
2200 µg/g]) (p=0.324).  
 
7.5.4  FC does not vary significantly between the diagnostic categories within the 
control group 
  The median (IQR) for each of the control group diagnostic categories is shown in Table 
7.3. The miscellaneous group comprised children with functional abdominal pain (n=2), 
colonic polyps (n=2), gastritis (n=2), Meckel’s diverticulum (n=1), pancreatic insufficiency 
(n=1), perianal abscess (n=1) and an as yet undiagnosed growth restriction syndrome (n=1). 
There was no difference in median FC values between the diagnostic categories (p=0.575) 
with all median values < 200 µg/g (except for the coeliac disease group which only had 3 
members). The high third quartile within the allergic enteropathy group was as a result of the 
high FC level obtained in the 2-year-old girl mentioned above. As bleeding per rectum (PR) 
often leads to a differential diagnosis of PIBD the median FC in controls presenting with 
(n=48) and without (n=51) a history of PR blood was assessed, revealing no difference in 
median FC values of 60 µg/g (IQR 20-218 µg/g) and 65 µg/g (IQR 25-275) respectively 
(p=0.512). Additionally, no difference was demonstrated when correlating age with FC levels 
across all control group diagnostic categories (p=0.051, Spearman's rho=-0.197). 
 
7.5.5  Medications do not seem to influence FC levels 
  Within each group 24% of PIBD cases and 33% of controls were on any oral medication at 
the time of FC sampling (p=0.219). Combining all patients, there was no difference 
(p=0.519) in median FC between those currently prescribed (275 µg/g [IQR 40-1265]) or not 
prescribed (385 µg/g [IQR 60-1275 µg/g]) any medication. Within the control group the 
median FC level of patients prescribed proton pump inhibitors (PPIs) (n=10) was 108 µg/g 
(IQR 20-240 µg/g) which was similar to those not on PPIs (n=89) (60 µg/g [IQR 21-240 
µg/g]) (p=0.906).  
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7.5.6  FC performs better than commonly used blood parameters as a diagnostic 
biomarker during the evaluation of children with suspected IBD 
  To compare the performance of FC with six commonly used blood parameters, blood 
results taken at a similar time as the FC measurement were analysed (median time 
difference 6 days [IQR 1-28 days]; see Table 7.2). The availability of each blood parameter 
for each group is shown in Table 7.7.  
 
 
Table 7.7.  Availability of blood parameters measured in the IBD and control groups 
 
  IBD group Control group 
Availability of individual tests [n (%)]   
Haemoglobin 89 (98) 91 (92) 
Total white cell count 89 (98) 91 (92) 
Erythrocyte sedimentation rate 87 (96) 83 (84) 
Platelets 85 (93) 90 (91) 
Albumin 89 (98) 83 (84) 
C-reactive protein 87 (96) 85 (86) 
All six blood parameters available 84 (92) 71 (72) 
IBD, inflammatory bowel disease 
 
 
  The diagnostic accuracy of each blood parameter in comparison to FC is outlined in Table 
7.5. Figure 7.2 demonstrates that the area under the curve (AUC) for FC was greater than 
all six blood parameters at 0.93 (95% CI 0.89-0.97), and significantly higher than ESR 
(p=0.011), CRP (p=0.006), total WCC (p<0.001), Hb (p<0.001) and platelet count (p<0.001), 
but was not significantly greater than albumin (p=0.374). Further analysis of albumin as a 
predictor for IBD revealed that the optimum threshold was in fact 41g/L (within the normal 
paediatric reference range of 33-50 g/L), with the relevant diagnostic specificity using our 
normal lower limit of normal being far inferior (Table 7.5). However, by combining FC and 
serum albumin (using an optimised formula of [60 + FC/100 μg/g] - [serum albumin in g/L]) it 
can be seen that the AUC is improved at 0.96 (95% CI 0.93-0.99); however this was not 
significantly different to FC alone (p=0.227). Using the above formula and utilising a cut-off 
of 20 produced the following diagnostic accuracy indicators: sensitivity 0.97 (95% CI 0.90-
0.99), specificity 0.81 (95% CI 0.71-0.89), negative predictive value 0.96 (95% CI 0.88-0.99) 




Figure 7.2.  Receiver operating characteristic (ROC) curves and corresponding area under 
the curve (AUC) for faecal calprotectin and commonly measured blood parameters in 
paediatric patients with suspected IBD. AUC, area under the curve; CI, confidence interval; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein; Hb, haemoglobin; WCC, white cell count.   
 
 
7.6  Discussion 
 
  The results of this study demonstrate that FC is a highly useful biomarker during the initial 
investigation of suspected PIBD. Using only children presenting with suspected bowel 
inflammation, without any known GI diagnosis, and subsequently undergoing their first full 
endoscopic investigation, it has clearly been shown that FC is markedly raised in those with 
IBD, with no influence of IBD type or location. The study has also provided evidence that FC 




  Although some would possibly argue that FC is not needed in a classical presentation of 
CD or UC, this data shows the utility of FC across the whole clinical spectrum of all types of 
IBD (e.g. those without luminal CD or with mainly extraintestinal symptoms) and, even more 
importantly, shows the potential utility of FC in deciding which children and teenagers 
presenting with possible gut inflammation may not need endoscopic assessment. 
  The extensive clinical use of FC as a biomarker in GI-related disease for over seven years 
within RHSCE leads to this study having several strengths in relation to study design and the 
analyses performed. Firstly, the regional IBD cohort is representative of the larger Scottish 
nationwide cohort with regard to demographic composition and disease location at 
diagnosis.[141] Previous studies often excluded younger children,[708,721] those with a high 
suspicion of IBD[711] and those on medications,[161] potentially skewing subsequent analyses. 
This is reflected in the modest pre-test probability in this study of 0.48 which is lower than 
reported in two recently published relevant papers on FC usage.[161,247] Additionally, previous 
groups often used a control group of patients with no known GI symptoms or signs to 
generate sensitivity and specificity,[708,712] which is certainly not applicable in a real world 
clinical setting of a paediatric GI service. In fact within this study a selection bias does occur 
from the entire cohort assessed using FC levels, but this bias works against the test as only 
sicker children with increased FC levels are likely to be referred to specialist GI services and 
undergo endoscopy. Secondly, only including those undergoing full endoscopy, and the 
reporting of small bowel imaging within the IBD group, has ensured robust phenotyping of all 
patients; many studies include only patients undergoing colonoscopy[705] or provide no 
details of endoscopic investigation[712]. Thirdly, the large study group presented here (n=190) 
has allowed further meaningful examination of particular sub-groups. Previous studies have 
frequently combined those with previously confirmed IBD[708] (therefore presenting a 
heterogeneous group with both de novo disease and established PIBD), or presented small 
numbers of each IBD type[161].  
  The retrospective design of this study does however produce potential limitations. Firstly, 
as the clinical utility of FC was not evaluated during the initial decision to perform endoscopic 
assessment it cannot be determined whether or not the FC level contributed to the individual 
gastroenterologist’s choice to perform endoscopy. Similarly, the influence of the various 
blood parameters on the ultimate decision to perform endoscopy could not be elucidated. 
This is an important factor when assessing the usefulness of any biomarker in this context 
as prior knowledge of the FC result may have led to the avoidance of unnecessary 
endoscopic procedures, or conversely the delay in PIBD diagnosis (which may have 
occurred in two of the patients if FC level had been used in isolation at diagnosis). Secondly, 
during the study datawas collected within a time period of 6 months prior to endoscopy with 
other prospective studies standardising the sampling time (e.g. one week prior to 
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endoscopy) to potentially eliminate a confounding effect of variable disease activity on their 
results.[707] Although useful during the initial phases of determining the diagnostic accuracy 
of a certain biomarker, the approach taken here is more comparable with current clinical 
practice, with children often attending general practice and/or a general paediatrician with 
non-specific GI symptoms prior to assessment by a paediatric gastroenterologist. Delay to 
endoscopic assessment of suspected paediatric PIBD has been a major issue in many 
countries including the United Kingdom (UK), although changes in National Health Service 
(NHS) service design in Scotland has dramatically reduced this waiting time over the period 
from 2005 to 2011. Thirdly, another potential difference from previous studies is the use of a 
relatively low upper limit of FC assay. For example Perminow et al.[247] were able to 
demonstrate a significantly higher FC level in those with CD versus UC (1181 µg/g, range 
11-6123 µg/g; 1250 µg/g, range 13-8625 µg/g respectively) due in all likelihood to their 
(undisclosed) higher reference range. Finally, two potential confounding factors in this study 
were the differing rates of TI biopsy in the IBD and control groups and the effect of oral 
medications. With regard to these aspects the analyses have shown that TI intubation rates 
were likely a result of the higher age of the IBD group, that removal of those without a TI 
biopsy did not change the main results of diagnostic accuracy and that TI intubation rates did 
not differ between those with and without a FC level available at endoscopy; it is 
acknowledged however that this study was likely not powered to look at the effects of drugs 
on FC levels. 
  Acknowledging the relative weakness of retrospective study design, there is confidence 
that (1) the robust choice of inclusions (i.e. only children presenting with suspected bowel 
inflammation, without known GI diagnosis, and subsequently undergoing their first ever 
endoscopic investigation); (2) the evaluation of all of the FC levels performed in the region 
over the six year study period; (3) the ability to review and follow up all suspected paediatric 
cases of gut inflammation in a defined geographical region (one child was initially placed in 
the "no pathology identified" control group but was very recently diagnosed as non-specific 
colitis and was re-assigned as such); and (4) the knowledge of all new regional cases of 
PIBD (within paediatric services in primary, secondary and tertiary care) to the end of 
October 2012, when taken together, add considerable confidence to the generalisability of 
these findings to all PIBD services worldwide. 
  Based on the clinical experience at RHSCE, laboratory guidance and relevant literature, [708] 
a FC cut-off of 200 µg/g has been routinely used as the threshold for the suspicion of a new 
PIBD diagnosis, accepting the need for full clinical history, examination and other blood 
tests. This has been validated by the results with the Youden index suggesting a FC level 
between 200-300 µg/g providing an optimum sensitivity/specificity. Although several newly 
described serum markers have been identified as possible markers of IBD, these are often 
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present at higher levels in certain sub-phenotypes[722] or are only available as research 
tools[723]. Commonly measured blood parameters remain the investigations of choice, with 
ESR[155] and CRP[724] currently providing the best indication of possible IBD, but have a 
relatively poor diagnostic accuracy, especially specificity. As discussed above, previous work 
by a group in SES demonstrated that the use of common blood tests could be enhanced 
significantly by the inclusion of FC in a “panel” of inflammatory markers during the 
investigation of suspected IBD.[159] This has been further enhanced with the development of 
a combined FC and serum albumin score described above, which provided a better 
(although not statistically significantly) AUC than FC alone. 
  GI endoscopic assessment is difficult for children, with the need for hospital or day-case 
admission. For the children this involves fasting, bowel preparation (if undergoing lower GI 
evaluation) and anaesthesia/sedation (admission to a day-case unit and total intravenous 
anaesthesia usage is the current design for elective procedures at RHSCE). For their 
parents, anxiety and time away from employment or dependent younger children is also a 
potential issue. It is also expensive, with a wide variation in training and resources across 
different countries.[725] By comparison FC can be obtained by providing the family with 
instructions, a sample pot, a prefilled laboratory request form and suitable packaging for 
postage to the appropriate IBD unit. It is relatively cheap in the UK; currently, the NHS 
laboratory pays £485 per kit (PhiCal Test) equating to £6.70 per sample. NHS requests are 
charged at £24 per test as this currently used test remains relatively labour intensive (Dr 
Kathleen Kingstone, personal communication). 
 
7.7  Conclusion 
 
  This study has shown that FC is significantly raised in children with IBD compared with 
non-IBD, scoped controls, and that FC provides greater diagnostic accuracy than other 
commonly used blood parameters. The characteristics of both groups and the timing of their 
investigations represent a true reflection of the investigative procedures carried out in 
children with suspected bowel inflammation and it is suggested that FC should now be used 
routinely during the initial assessment of these children. Further studies are now required to 
fully determine the effect of FC measurement on endoscopy rates, with the potential to 
reduce the number of children undergoing endoscopic assessment for suspected IBD, 
therefore reducing costs,[726] streamlining paediatric GI endoscopy services, and reducing 





8  Faecal calprotectin for the diagnosis of paediatric 
inflammatory bowel disease: a systematic review and meta-
analysis 
 
8.1  Introduction 
 
  In Chapter 7 it was demonstrated that faecal calprotectin (FC) performs better than any of 
the commonly used blood parameters (i.e. C-reactive protein, erythrocyte sedimentation 
rate, platelet count, haemoglobin, total white cell count and albumin) with regard to 
diagnostic accuracy in paediatric inflammatory bowel disease (PIBD). A previous meta-
analysis evaluating the role of FC during the initial investigation of suspected IBD concluded 
that FC was a useful screening tool to identify patients requiring endoscopic assessment, 
however the discriminative power to safely exclude IBD was significantly better in adults than 
in children.[162] Pooled sensitivity in adults was 0.93 (95% confidence interval [CI] 0.85-0.97) 
and pooled specificity 0.96 (95% CI 0.79-0.99); the corresponding values in children were 
0.92 (95% CI 0.84-0.96) and 0.76 (95% CI 0.62-0.86) respectively. In this analysis the 
included paediatric studies presented FC levels in a total of 226 IBD patients, with several of 
the included patient cohorts containing a combination of both new and established cases of 
PIBD. Since the publication of this meta-analysis, whose literature search ended in October 
2009, several studies assessing the diagnostic accuracy of FC in PIBD have been 
published, including the data described in Chapter 7.  
 
8.2  Hypothesis and Aim 
 
Hypothesis: The addition of newly identified studies of diagnostic accuracy of FC published 
since October 2009, in addition to the strict inclusion of only patients undergoing their 
primary investigation for suspected PIBD, will improve the pooled sensitivity and specificity 
of FC in PIBD diagnosis. 
 
Aim: The aim of this study was therefore to re-evaluate the diagnostic accuracy of FC for 






8.3  Methods 
 
8.3.1  Literature search 
  Inclusion criteria were retrospective or prospective case-control studies utilising FC (index 
test) during the diagnostic workup of children with suspected bowel inflammation who 
underwent at least colonoscopy. It should be noted however that for PIBD both 
ileocolonoscopy and upper endoscopy are recommended[154] and therefore during the 
assessment of methodological quality this was considered the reference standard. An 
electronic search was conducted using OVID Medline (1946 – May Week 3 2012) and 
Embase (1974 - Week 25 2012) using a detailed, comprehensive search strategy outlined in 
Table 8.1. In addition to this, relevant keywords in PubMed (www.ncbi.nlm.nih.gov/pubmed), 
Google Scholar (www.scholar.google.co.uk) and the Cochrane Library were also used to 
ensure the robust identification of articles still undergoing indexing. A hand search of articles 
was also performed, drawn from reference lists of retrieved articles, personal collections and 
meeting abstracts; only papers published in full were considered for inclusion. There was no 
English language restriction and, to ensure no relevant study was excluded, all foreign 
language papers were retrieved in full text and translated using Google Translate 
(www.translate.google.co.uk). No paediatric filters were used in the initial search. 
 
8.3.2  Study identification and data acquisition 
  Following the completion of the initial literature searches and study selection, the potentially 
relevant citations were imported into Endnote version X2.0.4 (Thomson Reuters, NY, USA) 
and the full papers obtained. Studies were then evaluated independently for eligibility by two 
reviewers (Dr Paul Henderson and Prof. David C Wilson, University of Edinburgh) with any 
discrepancy resolved by discussion. From each included study the following data was 
extracted and entered into a customised database in Microsoft Access 2007 (Microsoft 
Corporation, WA, USA): first author, year of study publication, country of origin, language, 
age range of study subjects, number of IBD cases (sub-divided into Crohn's disease [CD], 
ulcerative colitis [UC] and colonic IBD, type unclassified [IBDU]), number of non-IBD cases, 
FC assay used and FC normal cut-off value. To allow the robust inclusion of all appropriate 
studies corresponding authors were contacted via email to clarify certain parameters if 
uncertainty existed, especially in relation to the construction of diagnostic 2x2 tables. 
Following confirmation of the number of patients presenting with newly suspected bowel 




Table 8.1. Detailed Medline search strategy used to gain high sensitivity and precision for 
detecting diagnostic accuracy studies of faecal calprotectin. 
 
1 exp inflammatory bowel diseases/ 
2 ibd.mp. 
3 exp ileitis/ 
4 (ulcerative colitis or proctocolitis or proctosigmoiditis or rectocolitis or rectosigmoiditis or 
ulcerative rectocolitis or ulcerative proctocolitis or hemorrhagic ulcerative or hemorrhagic 
proctocolitis or proctitis or haemorrhagic ulcerative or haemorrhagic proctocolitis or crohn$ 
disease or ileitis or regional enteritis or granulomatous ileocolitis or ileocolitis or 
granulomatous colitis).mp. 
5 4 or 1 or 3 or 2 
6 exp Leukocyte L1 Antigen Complex/ or faecal calprotectin.mp. 
Included Entry terms: 
 Calcium-Binding Myeloid Protein P8,14 
 Calcium Binding Myeloid Protein P8,14 
 Calgranulin 
 Calprotectin 
 Migratory Inhibitory Factor-Related Protein MRP 
 Migratory Inhibitory Factor Related Protein MRP 
 Myelomonocytic Antigen L1 
 Antigen L1, Myelomonocytic 
 L1 Antigen 
 Antigen, L1 
 27E10 Antigen 
 Antigen, 27E10 
 Leukocyte L1 Protein 
 L1 Protein, Leukocyte 
7 calprotectin.mp. 
8 calgranulin.mp. 
9 6 or 7 or 8 
10 5 and 9 
 
 
8.3.3  Assessing methodological quality of included studies 
  In order to assess the methodological quality of the individual studies a modified version of 
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool was used,[727,728] 
which is recommended by the Cochrane Diagnostic Reviewers’ Handbook[729]. This modified 
version of the QUADAS tool consists of 11 items concerning methodological characteristics 
that have the potential to introduce bias. From these 11 items the most relevant 8 sections 
were coded. Also, in line with the Cochrane Collaboration recommendations,[729] three 
relevant supplementary items were added. All items were coded as ‘positive’ (i.e. no bias), 
‘negative’ (i.e. potential bias) or ‘unclear’; disagreements were resolved by consensus. No 
summary quality score was calculated in line with previous concerns regarding their 
validity.[730] Details of the included and additional items, and how each was coded, are 
shown in Box 8.1.  
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1. Representative spectrum 
Recruitment of children less than 18 years of age presenting with symptoms suggestive of bowel 
inflammation and undergoing primary investigation with no previous diagnosis of PIBD should have 
occurred. Inclusion from the right patient group above should have yielded a representative sample 
of patients who would receive the test in practice. That is, a majority of patients with Crohn's 
disease, the inclusion of patients with IBDU and a male preponderance.[141,731]  
 Yes - both the right patient group was recruited and a representative sample of patients 
yielded following recruitment 
 No - either the right patient group and/or a representative sample not present 
 Unclear - insufficient information to determine spectrum 
 
2. Reference standard 
Upper and lower endoscopy with or without terminal ileum intubation should have been performed 
(consensus reference standard being the Porto Criteria[147]). Although the Porto Criteria state that 
ileocolonoscopy is essential they recognise that this is not possible in 100% of cases and emphasise 
that ileal intubation should be 'attempted'. 
 Yes - both upper and lower endoscopy performed 
 No - only upper OR lower endoscopy performed 
 Unclear - insufficient information to determine the reference standard used 
 
3. Disease progression 
In view of the chronic nature of PIBD, the frequent delay in diagnosis[231] and diverse/non-specific 
presenting symptoms and signs, a delay of 3 months between calprotectin sampling and endoscopy 
was deemed acceptable. 
 Yes - time between index and reference tests is shorter than 3 months, or at least for an 
acceptably high proportion of patients 
 No - time between index and reference tests was longer than 3 months for an unacceptably 
high proportion of patients 
 Unclear - Information of the timing of tests is not given or no clear 
 
4. Partial verification 
The entire cohort (or random selection) of patients (that is all patients suspected of bowel 
inflammation) underwent both upper and lower endoscopy. 
 Yes - all included patients underwent upper and lower endoscopy 
 No - not all patients underwent upper and lower endoscopy 
 Unclear - not clear if all patients received reference test 
 
5. Differential verification 
Patients should have received the same reference standard (i.e. upper and lower endoscopy) 
irrespective of the index test result. 
 Yes - same reference standard used in all patients 
 No - choice of reference standard varied between individuals 







6 and 7. Test and diagnostic review  
The endoscopy results were interpreted without knowledge of the calprotectin results and the 
calprotectin results interpreted without knowledge of the endoscopy results? 
 Yes - test results were interpreted blinded to the results of the other test 
 No - clear that one set of test results was interpreted with knowledge of the other 
 Unclear - unclear whether blinding took place 
 
8. Withdrawals 
All patients initially eligible for the study (i.e. patients <18yrs with suspected bowel inflammation 
with a stool sample obtained for faecal calprotectin) were accounted for. 
 Yes - clear what happened to all patients 
 No - not all patients accounted for 
 Unclear - it is not clear how many patients entered the study and hence whether there were 
any withdrawals 
 
Additional items  
 
9. Clear definition of a positive result 
The study provided a clear definition of what was considered to be a 'positive' result?  
 Yes - clear definition of a positive result given 
 No - no clear definition of a positive result 
 Unclear - not clear what a positive result would mean in the context of the study 
 
10. Treatment withheld until index test and reference standard performed 
Treatment was withheld until both the index test (faecal calprotectin) and the reference standard 
(upper and lower endoscopy) were performed. 
 Yes - treatment withheld until both tests performed 
 No - treatment started prior to both tests being performed 
 Unclear - not clear if treatment started prior to both tests being performed 
 
11. Was the study free from commercial funding? 
Evidence that commercial funding or influence was present during the study, especially with relation 
to the calprotectin assays used. 
 Yes - no evidence of commercial funding during the study 
 No - evidence of commercial funding during the study 
 Unclear - no statement of funding given 
 
 
8.3.4  Statistical analysis 
  Following the robust construction of the diagnostic 2x2 tables, specificity, sensitivity and 
95% CI for each of the included studies was calculated using the epiR package in R v2.14.1 
(R Foundation for Statistical Computing, Vienna, Austria).[716] A hierarchical summary 
receiver operating curve (ROC) model was fitted by the HSROC package[732] in R to provide 
a summary ROC curve, and to allow derivation of pooled sensitivity and specificity 
estimates. This Bayesian model is of similar form to that proposed by Rutter and 
Gatsonis,[733] but uses a probit link rather than a logit link function and is also fitted using a 
Gibbs sampling approach. The Gibbs protocol was to collect 100,000 iterations after a 
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10,000 iteration burn-in period, and then to estimate the model’s parameters as the median 
of those obtained from sampling every hundredth realisation. Trace plots (the 1000 
realisations of each parameter returned by the Gibbs sampler) were checked to ensure that 
the Markov Chain had achieved equilibrium, and therefore that the median estimate was 
appropriate in each case. Vague priors (Uniform distributions with wide ranges) were used 
for between-study parameters. This analysis was carried out by Dr Niall Anderson (Centre 
for Population Health Sciences, University of Edinburgh). As suggested by the Cochrane 
Diagnostic Test Accuracy group (http://srdta.cochrane.org/), no analysis of study 
heterogeneity was performed, as these tests do not account for heterogeneity explained by 
phenomena such as positivity threshold effects. 
 
8.4  Results 
 
8.4.1  Study selection 
  Using the detailed search strategy outlined above, 289 abstracts were identified from the 
OVID Medline/Embase search and 381 abstracts retrieved from a detailed search of 
PubMed, Google Scholar, the Cochrane Library and the hand search of references. 
Following a thorough review of these abstracts and the exclusion of duplicates a total of 106 
papers were imported into Endnote for evaluation. The majority of these papers were 
published in English (n=96) with three in Polish,[734-736] two in French,[737,738] two in 
Spanish[739,740] and one each published in Dutch,[741] Japanese[742] and Russian[743]. After the 
identification and exclusion of papers not presenting primary data (n=7) the full text of all 99 
remaining articles were obtained through the University of Edinburgh or NHS Knowledge 
Network library resources, or by direct contact with the corresponding author(s). Following 
review of the full text articles a total of 14 studies[160,705,707,708,710,711,715,721,739,744-748] were 
considered for potential inclusion.  
  In six of the 14 potential studies it was unclear if the subjects represented only children 
undergoing their initial diagnostic work up for suspected PIBD,[707,708,715,721,745,748] therefore all 
corresponding and/or senior authors were contacted via email for clarification. Authors 
representing three studies kindly provided their complete raw study data,[707,708,745] however 
insufficient detail was present to allow the robust identification of children with de novo 
disease and these studies were therefore excluded (after agreement with their respective 
authors). Although the 2007 study by Fagerberg et al.[721] included both known and de novo 
PIBD patients (therefore considered for potential inclusion pending the availability of the raw 
data) it was deemed after discussion with the authors that this study contained an unknown 
number of patients from their earlier publication (Fagerberg et al. 2005[710]) and it was 
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therefore excluded on this basis. The authors of the remaining two studies were contacted 
and kindly responded but were unable to provide their primary data and these were therefore 




Figure 8.1.  Flow diagram showing the process of selecting paediatric studies of diagnostic 
accuracy of faecal calprotectin that included only children undergoing their primary 
investigation for suspected inflammatory bowel disease. 
 
 
8.4.2  Baseline data of included studies 
  The eight remaining studies included five of the seven studies from the previous meta-
analysis[160,710,711,746,747], one non-English language manuscript[739] and two larger studies 
published since 2009,[705,744] which included the data presented in Chapter 7. Baseline data 
was extracted from the manuscripts or obtained directly from the authors; the details of each 
study are presented in Table 8.2. (It should be noted that this data represents all the patients 
in each study, not necessarily those with FC results available; this is discussed below). All 8 
studies (containing a total of 715 cases and controls) were published in the last seven years 
in countries with developed health care services (Europe and Australia) with seven studies 
performed in large tertiary referral centres and one population-based study.[746] The median 
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number of PIBD cases in each study was 34 (range, 12-117; IQR 25-69) and the median 
number of total study participants was 55 (range, 36-197; IQR 45-123). All studies used 
either the Phical® (Calpro AS, Lysaker, Norway) or Calprest® (Eurospital, Trieste, Italy) FC 
assay with normal cut-off values of either 50μg/g or 100μg/g.  
 
 
Table 8.2.  Details of the eight faecal calprotectin diagnostic accuracy studies (715 cases 



















CD UC IBDU 
Fagerberg 
(2005) 








Spain 12 [28] 10 2 0 31 0.4 - 15.3 Calprest 50 
Sidler 
(2008) 
Australia 31 [51] 30 1 0 30 2.2 - 16.0 Phical 50 
Ashorn 
(2009) 
Finland 37 [77] 13 21 3 11 2.7 - 19.9 Phical 100 
Perminow 
(2009) 
Norway 62 [62] 39 19 4 38 0.8 - 17.9 Phical 50 
Diamante 
(2010) 
Italy 117 [59] 49 68 0 80 1.0 - 18.0 Calprest 100 
Henderson 
(2012) 
Scotland 91 [48] 62 21 8 99 1.3 - 17.7 Phical 50 
*Data obtained directly from the authors as not presented in the original manuscript. PIBD, paediatric 
inflammatory bowel disease; Prev, PIBD prevalence; CD, Crohn's disease; UC, ulcerative colitis; IBDU, colonic 
inflammatory bowel disease, unclassified; Cont, controls; FC, faecal calprotectin. 
 
 
8.4.3  Assessment of methodological quality of included studies 
  The eight studies underwent quality assessment using the QUADAS tool as discussed 
above; a summary of the results are presented in Figure 8.2. Only three studies were 
deemed to have a representative spectrum of patients, with the inclusion of a majority of CD 
patients and patients with IBDU. Similarly, three studies described upper and lower 
endoscopy in all patients (with one study presenting terminal ileum intubation rates), with 
three studies not clearly defining the type of endoscopy performed. Interestingly only two 
studies reported delay in FC sampling, and only two demonstrated blinding of both reference 
standard to index test and vice versa. All but two papers explained withdrawals (one of 
which was the population-based study) and only one had no clear definition of a positive 
164 
 
result evident in the manuscript. Of note, only one paper commented on whether FC 
samples were obtained prior to commencing treatment, which may be a major confounder in 
reports of diagnostic accuracy. There was no evidence of commercial funding in any of the 




Figure 8.2.  A summary of the methodological assessment of the eight included case-control 
studies that evaluated the diagnostic accuracy of faecal calprotectin during the 
investigation of suspected paediatric inflammatory bowel disease. +, no bias, -, potential bias, 




8.4.4  Diagnostic 2x2 tables and individual study results 
  As each of the eight studies now included only children presenting with de novo disease, 
the original manuscripts were examined to determine the number of true positives, false 
positives, true negatives and false negatives. For three of the studies exact data extraction 
was either not possible[746] or not clear[711,747] despite thorough examination of the manuscript 
and therefore the authors were contacted directly by email to clarify the number of PIBD and 
non-PIBD cases with abnormal FC levels (i.e. >50μg/g). All queries in this respect were 
answered fully with reference to their raw data by the relevant three authors and 2x2 
diagnostic tables were constructed. In one study the authors highlighted that the original 
published figure depicting their calprotectin results was in fact inaccurate and therefore 
provided the exact data for clarification.[711] It should be noted that in the population-based 
study by Perminow et al. a total of five patients did not have a FC level available (three PIBD 
patients and two non-PIBD controls) and therefore the sensitivity and specificity calculations 
for this study include only 95 of the original 100 patients in the cohort.[746] The numbers of 
children used to populate the 2x2 diagnostic tables is presented in Figure 8.3 together with 




Figure 8.3.  2x2 diagnostic accuracy table and forest plot for the eight included studies 
evaluating the diagnostic accuracy of faecal calprotectin during the investigation of 
suspected paediatric inflammatory bowel disease. TP, true positive; FP, false positive; FN, false 
negative; TN, true negative. Numbers in brackets represent 95% confidence intervals. 
 
 
8.4.5  Diagnostic accuracy meta-analysis 
   The total number of children in the final meta-analysis was 715, which included 394 PIBD 
patients and 321 non-PIBD controls. This represented a 74% increase in the number of 
included PIBD patients and a 93% increase in the total number of patients (i.e. both PIBD 
and non-PIBD controls) compared to the previous meta-analysis.[749] Pooled sensitivity and 
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specificity for the diagnostic accuracy of FC in suspected PIBD were 0.978 (95% CI 0.947-
0.996) and 0.682 (95% CI 0.502-0.863) respectively. The positive likelihood ratio was 3.074 
and negative likelihood ratio 0.0324. Figure 8.4 presents the diagnostic values of the studies 




Figure 8.4.  Hierarchical summary receiver operating characteristic graph for the eight 
included studies evaluating the diagnostic accuracy of faecal calprotectin during the 
investigation of suspected paediatric inflammatory bowel disease. Solid red dot, pooled 
sensitivity and specificity; red dotted line, 95% credible region (Bayesian equivalent of confidence 






8.5  Discussion 
 
  Through robust systematic review and appropriately performed meta-analysis it has been 
shown that FC has extremely high sensitivity (97.8%) and modest specificity (68.2%) for 
PIBD during the investigation of children with suspected bowel inflammation. With regard to 
the initial hypothesis, the inclusion of two larger studies published since October 2009 and 
the strict selection of only children undergoing their primary investigation for PIBD, has in 
fact increased the sensitivity but marginally reduced the specificity compared to the original 
meta-analysis by van Rheenen et al.[162] The assessment of methodological quality 
determined that there were deficiencies in all the studies evaluated, but especially with 
regard to important aspects such as the use of a representative spectrum of patients, an 
acceptable reference standard (upper and lower endoscopy) and the poor reporting of 
current treatment modalities in use during FC sampling. 
  With regard to improving PIBD diagnosis, biomarkers present in serum and faeces have 
attracted the most attention to date.[750] In Chapter 7 it was demonstrated that FC performed 
better than all of the commonly used blood markers; previous work in a smaller number of 
the same cohort showed that FC was also better than all the blood markers combined.[159] As 
alluded to briefly in Chapter 1, there is currently no consistent body of work on any 
biomarker during PIBD diagnosis, although small case series and markers such as ANCA, 
ASCA and lactoferrin have been intermittently trialled. Without doubt the clear advantage of 
a quality biomarker such as FC is that screening is performed in conjunction with the initial 
clinical assessment and often before invasive procedures such as endoscopy and 
radiological imaging. 
  This study has several strengths with regard to its methodology and analysis. Using a 
robust electronic search strategy in multiple databases (with the augmentation of the search 
through the use of PubMed and Google Scholar),[751] the use of free text words within these 
databases,[752,753] and the inclusion of non-English language manuscripts[754] allowed the 
identification of the appropriate studies for inclusion (i.e. high sensitivity). In addition the 
detailed email discussions with the authors of potential papers ensured that the included 
studies contained only paediatric patients with de novo disease rather than cohorts of new 
and established PIBD cases, ensuring the robustness of the final pooled data. In line with 
current practice, summary scores during the QUADAS assessment were not used and the 
statistical analysis involved in calculating pooled sensitivity and specificity also took into 
account different cut-off values for defining a positive test during the meta-analysis.[755] 
  It is also recognised that several potential limitations exist in the analysis, arising mainly 
from the variable quality of the included studies discussed above. The composition of study 
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cohorts was inconsistent, often with the inclusion of children less than one year, [715,739,746] or 
the exclusion of children with very-early onset disease (i.e. less than six years old)[710,711]. 
Also the PIBD groups contained either an overwhelming majority of one IBD type such as 
CD[747] or no patients with IBDU[705,711,739,747]. The prevalence of PIBD in each study was also 
variable (28-77%) suggesting that bias was present at study recruitment; tertiary centre 
referral bias was also likely to have influenced outcome.[756] 
  To date there have been two meta-analyses of the diagnostic accuracy of FC during the 
investigation of suspected IBD.[162,757] van Rheenen et al. performed a comprehensive meta-
analysis of FC diagnostic accuracy studies in both adults and children with a literature 
search that ended in October 2009.[162] Using a robust method of identifying relevant studies 
and sound statistical methods they identified 13 eligible studies (six adult and seven 
paediatric) published between 2000 and 2009. A thorough electronic search strategy and 
clear definitions of their QUADAS scoring were presented, however despite claims that 
authors were contacted in cases where information was missing (specifically regarding 2x2 
tables), two paediatric studies that included children with known PIBD were included in the 
final analysis.[707,745] Additionally, of the remaining five studies, anomalies in the 2x2 tables 
were also apparent (based on our detailed discussions with all authors outlined above). The 
conclusions of the paediatric meta-analysis (i.e. sensitivity 92%, specificity 76%) were 
therefore erroneous, and the reported statistical superiority of the pooled specificity of the 
adult data over the paediatric data may have therefore not existed. Prior to this analysis, von 
Roon et al. had performed a systematic review and meta-analysis of studies published to 
March 2006 that compared FC with a histological diagnosis of CD, UC or colo-rectal 
cancer.[757] Again the authors used appropriate search strategies but sensitivity and 
specificity were pooled separately; additionally studies that included a healthy control group 
(which has been shown to increase the accuracy of a diagnostic study[758]) were included in 
the final analysis. Combining all studies of diagnostic accuracy and studies that compared 
FC levels of known IBD patients from non-IBD patients they concluded that in children a FC 
cut-off of 50μg/g gave a sensitivity of 0.83 (95% CI 0.73-0.90) and specificity of 0.85 (95% CI 
0.77-0.91); comparable results for a cut-off of 100μg/g were 0.98 (95% CI 0.94-1.00) and 
0.97 (95% CI 0.92-0.99) respectively. However, in view of the limitations discussed and the 
heterogeneity of the populations studied, the accuracy of this analysis should certainly be 
questioned. 
  As discussed briefly in Chapter 7 the effect of the use of FC on endoscopy is certainly of 
interest. van Rheenen et al. calculated that the use of FC as a screening tool for IBD would 
reduce endoscopy rates by 67% in adults and 35% in children.[162] In another recently 
published study, referring clinicians were blinded to the calprotectin result in 68 children 
presenting with a clinical suspicion of PIBD.[759] Their analysis revealed that using the 'clinical 
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eye' of the paediatrician would have resulted in 38% of children undergoing IBD-negative 
ileo-colonoscopy, with this figure dropping to 32% if a FC level of 50μg/g was used, and 
reducing further still to 22% using a FC level of 50μg/g in the absence of GI infection. The 
authors however acknowledged the limitations to their study with regard to the lack of 
reference standard in all patients and the paucity of data regarding drug use in the study 
participants. Mention is also given to the difficulties surrounding false positives and false 
negatives. It has been documented that calprotectin can be elevated in other conditions such 
as cystic fibrosis[760] and enthesitis-related arthritis[761] and therefore a negative endoscopy 
for IBD does not always indicate failure of FC as a screening test. With regard to cost 
analysis, there have been no comprehensive studies to date, however limited data on actual 
or potential endoscopy reduction suggest a significant benefit.[726,759] 
  Besides the use of FC during diagnosis there is also a growing body of literature with 
regard to its use in disease activity monitoring. Although studies have shown the lack of 
correlation of FC levels with disease location (Chapter 7),[762] and clinical disease activity 
scores,[762,763] there is certainly evidence that FC does have some utility in distinguishing 
endoscopic activity and mucosal healing.[763,764] Extrapolating from this data it is likely that, 
with increasing use in the clinical setting, that a combination of symptoms and signs, serum 
markers and calprotectin will prove the most fruitful with regard to assessing ongoing 
intestinal inflammation in IBD patients. 
 
8.6  Conclusion 
 
  Following on from work presented in Chapter 7 it can be seen that, despite some 
limitations in the case-control studies to date, a robust meta-analysis of 715 patients 
undergoing their primary investigation of suspected PIBD has demonstrated that FC has a 
very high sensitivity (98%) and modest specificity (68%) for PIBD at diagnosis. With work 
from other groups already showing that FC is a useful tool for the clinician with regard to 
screening children with suspected bowel inflammation, especially in the context of other 
clinical findings, its routine addition to the investigations carried out in children with 
suspected intestinal inflammation is likely to increase. However, it has yet to be seen how 
this biomarker will perform with regard to reducing endoscopy rates and the subsequent 

































9.  The role of autophagy in Crohn's disease 
 
9.1  Introduction 
 
  Major CD susceptibility pathways uncovered through recent genome-wide association 
studies (GWAS) implicate the innate immune response (e.g. NOD2), the more specific, 
acquired T cell response (e.g. IL23R, ICOSLG) and autophagy (e.g. ATG16L1, IRGM).[598,765] 
Examination of the disease-associated microbiome has also alluded to several potentially 
contributory organisms, most notably adherent-invasive E.coli strains (AIEC), which have 
been isolated by independent investigators in both adult[766] and paediatric[767] CD patients. 
This chapter will discuss the emerging role of autophagy in CD, with particular focus on 
enteric E.coli strains with an adherent and invasive phenotype (AIEC). 
 
9.2  (Macro)-Autophagy  
 
  Two cellular processes, the ubiquitin-proteasome pathway and autophagy are involved in 
the removal of redundant, misfolded and harmful proteins.[768,769] Unlike the proteasome, 
autophagy can target large protein aggregates and also has the ability to degrade 
deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and lipids.[770] Ultimately all autophagic 
pathways converge at the lysosome, a central, acidic organelle that harbours lysosomal 
hydrolases such as peptidases and nucleases.[771] Three major types of autophagic 
mechanisms have been described in mammalian cells, namely chaperone-mediated 
autophagy (CMA), microautophagy and macroautophagy. CMA is estimated to degrade 
approximately 30% of cytosolic proteins, specifically targeting proteins bearing a motif in 
their amino acid sequence biochemically related to the pentapeptide KEFRQ.[772] This 
pathway is mediated by heat shock cognate 70 and degradation occurs following interaction 
with lysosomal-associated membrane protein 2.[773] Microautophagy refers to the direct 
engulfment of the cytoplasm by the lysosome.[774] This process has been shown to occur in 
five main stages, namely microautophagic invagination, followed by vesicle formation, 
expansion, scission and degradation.[774] Although discovered in the 1960s,[775] many of the 
mechanisms involved in microautophagy are still unclear and its role in disease is still to be 
determined. Although several other forms of autophagy are now being investigated,[774] it is 
the process of macroautophagy which has gained most attention in the field of disease 
pathogenesis.[776] Macroautophagy (hereafter referred to as autophagy) differs from CMA 
and microautophagy in that it relies on specialised double membrane vesicles called 
autophagosomes that form de novo through the assembly of protein and lipid constituents. 
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Enigmatic for many years, it is now clear that autophagosomes originate from the surface of 
membranes of various cell organelles, including the endoplasmic reticulum, mitochondria 
and the plasma membrane.[777]  
  Autophagy is upregulated in response to many stimuli including starvation, genotoxic stress 
and microbial infection,[778] and is controlled by the ATG proteins (or autophagy-related 
proteins). The process can be divided into three distinct stages: vesicle nucleation, vesicle 
elongation and fusion of the autophagosome with a lysosome (Figure 9.1). The further 
detailed and complex molecular machinery involved in autophagosome formation is 





Figure 9.1.  Schematic representation of autophagy. An expanding membrane sac (the 
phagophore) sequesters cytosolic material forming a double membrane vesicle (the 
autophagosome) enclosing proteins, organelles or pathogens to be degraded. The autophagosome 








Figure 9.2.  Molecular machinery of autophagosome formation. Two ubiquitin-like protein 
conjugation systems (the LC3/ATG8 and ATG12 systems) mediate membrane formation and 
expansion. PE, phosphatidylethanolamine; G, glycine 
 
 
9.3  Antimicrobial autophagy (xenophagy) 
 
  Autophagy is activated in response to diverse stress or stimuli, including infection and is a 
crucial part of the innate immune defence against micro-organisms.[779] Antimicrobial 
autophagy, also referred to as xenophagy can selectively target microbes, including viruses, 
protozoa and bacteria for degradation in lysosomes.[779] Host cell defence against infection is 
complex and involves the convergence of several pathways. Pathogens invading host cells 
are initially detected by pattern recognition receptors (PRR), which include Toll-like receptors 
(TLR) on the surface of cells and interior of endosomes, and cytosolic NOD-like receptors 
(NLR). PRRs detect the presence of microbes through specific microbe-associated 
molecular patterns (MAMPs) such as peptidoglycan and lipopolysaccharide which are major 
constituents of bacterial cell walls.[343] The recognition of MAMPs by PRRs triggers the 
activation of several signalling cascades, among them NFB an important regulator of 
inflammatory cytokine production, as well as antimicrobial mechanisms to clear the infection. 
Mounting evidence supports a role for autophagy as an antimicrobial mechanism 
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downstream of TLR and NLR signalling. For example, stimulation of NOD2 by 
muramyldipeptide (MDP), a constituent of peptidoglycan, induces autophagy in dendritic 
cells in a receptor-interacting serine-threonine kinase 2 (RIPK-2) dependent manner[30] 
(discussed in more detail in a latter section of this Chapter), while stimulation of TLR2, 4 and 
7 with their specific ligands has also been shown to stimulate autophagy.[780,781] In addition to 
its essential role in innate immune defence against infection, autophagy plays a role in the 
adaptive immune response. Autophagosomes can deliver pathogen protein fragments 
(peptides) to MHC class II molecules. Once the MHC class II molecule is bound to the 
pathogen fragment it is transported to the surface of the cell where it triggers an appropriate 
CD4+ T-cell response.[782] 
  Recently, cargo receptor proteins or adaptors such as p62/SQSTM, NBR1 and NPD52 that 
contain both ubiquitin-binding and LC3-binding domains have been shown to detect 
intracellular bacteria.[783] Bacteria are heavily ubiquitinated in the host cell cytosol,[784] 
therefore by simultaneously binding to ubiquitinated cargo and LC3-containing 
autophagosomes, cargo receptors can target invading microbes to lysosomes for 
degradation. For example, p62 and NPD52 have recently been shown to target the 
intracellular pathogen Salmonella typhimurium to the autophagic machinery.[785] Additionally, 
recent work has demonstrated that phosphorylation of the autophagy receptor optineurin by 
protein kinase TANK binding kinase 1 (TBK1) enhanced the LC3 binding affinity and 
autophagic clearance of ubiquitin-coated cytosolic Salmonella enterica.[786] While it is clear 
that both PRRs and cargo receptors contribute to the detection and elimination of cytosolic 
bacteria via autophagy, it remains to be determined how these factors functionally 
interconnect, and whether they constitute a general anti-microbial defence mechanism or a 
more specific defence against pathogens. 
 
9.4  Genetic variants in autophagy pathway genes and Crohn's disease 
susceptibility  
 
  Before discussing the autophagy-related proteins implicated in CD aetiopathogenesis it is 
first important to recognise the genetic research that ignited the current interest in autophagy 
within the study of IBD. The first study to link the autophagy pathway with CD pathogenesis 
was a genome-wide association study (GWAS) by Hampe et al. carried out in 2007.[26] Using 
735 CD patients and 368 controls, single nucleotide polymorphisms (SNPs) with a p value 
<0.01 were followed up in three independent cohorts. This revealed a disease association 
with SNP rs2241880 in the autophagy-related 16-like 1 (ATG16L1) gene on chromosome 
2q37.1. Resequencing of exons, splice sites and promotor regions concluded that the entire 
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association signal was likely due to this threonine to alanine substitution (Thr300Ala or 
T300A), however very recent data has suggested additional variants, independent of 
rs2241880, could implicate any of the coiled-coil domain, the WD (tryptophan-aspartic acid, 
Trp-Asp or WD40 repeat) domain and/or the 3' untranslated region, in CD susceptibility.[787] 
Almost immediately following this initial finding of association with ATG16L1, confirmation of 
this association was published by the same group in an independent cohort[788] and within 12 
months multiple research groups had replicated the discovery in a variety of cohorts both in 
Europe and further afield.[400,402,789-791] Subsequently, further individual genetic association 
studies have confirmed this finding in Caucasian populations,[792] in addition to validation by 
several meta-analyses.[13,793] However replication in Asian populations has not been 
forthcoming despite various attempts.[793-796] Interestingly several paediatric studies have 
sought to confirm the association in childhood-onset CD however results have been 
conflicting, with two smaller studies confirming the association[283,403] while two larger studies 
proved negative,[305,797] possibly reflecting the strong association with ileal Crohn's disease (a 
phenotype not as common in childhood-onset disease[141]). 
  Another gene on chromosome 5q33.1, immunity-related GTPase family, M (IRGM), was 
linked with CD susceptibility through a genome-wide association scan by the Wellcome Trust 
Case Control Consortium (WTCCC), again in 2007.[400] In a case-control study involving 
1748 CD patients and 2938 controls, SNPs achieving a p value < 10-5 (below the stringent 
threshold of their original study that incorporated several major diseases [508]) were followed 
up. Using a new panel of over a thousand Caucasian CD patients, allele frequency 
comparisons were made between CD cases and nearly six thousand non-autoimmune 
WTCCC cases (which included patients with bipolar disorder, coronary artery disease and 
hypertension) as well as independent population controls from the 1958 British Birth Cohort. 
The strongest replication adjacent to a known gene was for SNPs rs13361189 and 
rs4958847 immediately flanking the IRGM gene on chromosome 5. Resequencing of IRGM 
in 48 CD patients revealed three novel SNPs which were subsequently genotyped in an 
independent case-control cohort. This demonstrated that only the silent 313T>C variant was 
associated with CD. This SNP was in strong linkage disequilibrium with the original 
rs13361189 suggesting that the causal variant may lie in a regulatory region adjacent to 
IRGM thus affecting transcription. Since this initial finding, the association of SNPs in IRGM 
have been replicated in other adult CD populations,[13,407,798] but again not in early-onset 
cohorts[18,409]. 
  A subsequent meta-analysis of three GWAS with 3230 adult CD cases and 4829 controls 
demonstrated that the A allele of a SNP on chromosome 12q12 (rs11564258) was over-
represented in CD patients, tagging a 0.89Mb region containing both Leucine-rich repeat 
serine/threonine protein kinase 2 (LRRK2) and mucin 19, oligomeric (MUC19),[13] this was 
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later replicated in a paediatric GWAS[18]. Although the susceptibility gene at this locus has 
been shown to be most likely LRRK2 (rather than MUC19),[799] replication in subsequent 
individual studies has been inconsistent[800,801]. A further SNP (rs2412973) at locus 22q12 
has shown association with childhood-onset CD patients.[18] With regards to colonic 
expression, the only gene in this region which was shown to differ between the two major 
IBD types (CD and ulcerative colitis) and healthy controls was myotubularin-related protein 3 
(MTMR3). This gene showed significantly reduced expression in colonic biopsies in UC 
patients compared to controls and was also significantly associated with CD in the meta-
analysis of discovery and replication cohorts. To date there have been no attempts to 
replicate this finding in either adult or paediatric populations. 
  Along with the original discovery of ATG16L1 variants, SNPs in the region of protein 
tyrosine phosphatase, non-receptor type 2 (PTPN2) were also described.[400] This was again 
replicated in several populations, including paediatric cohorts.[802-804] Genetic association 
studies have also identified SNPs in unc-51-like kinase 1 (ULK1),[805,806] with conflicting 
results with regard to the association of variations in neutrophil cytosolic factor 4 
(NCF4)[789,807,808]. 
 
9.5  Autophagy proteins implicated in Crohn's disease pathogenesis  
 
9.5.1  ATG16L1 and NOD2 
  Following the initial identification and confirmation of ATG16L1 as a CD susceptibility gene 
in 2007,[26,789,790] and its relationship with an ileal disease phenotype,[788] further studies 
began to unravel the potential biological relevance to this protein in CD pathogenesis. 
ATG16L1 is a member of a large group of ATG and ATG-related proteins which are 
intimately involved in autophagosome biogenesis.[809] Along with ATG12 and ATG5, 
ATG16L1 forms a 800kDa complex in a 2:2:2 stoichiometry; and although this ATG12 
system has no deconjugating enzyme, the complex is formed constitutively irrespective of 
nutrient conditions.[809,810] During autophagosome formation the complex localises to the 
outer surface of the isolation membrane and dissociates following completion of the 
autophagosome.[811]  
  One of the first studies that began to outline the precise functional role of ATG16L1 was by 
Fujita et al.[810] Using a variety of mammalian cell culture techniques they demonstrated that 
the ATG12-ATG8-ATG16L1 complex was involved in LC3-lipidation, and interestingly that 
overexpression of ATG16L1 (specifically the coiled-coil region) disrupted the subunit 
stoichiometry leading to reduced autophagy. Also, the importance of correct localisation of 
ATG16L1 to sites of LC3-lipidation (such as the plasma membrane) was also shown to be 
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vital for appropriate autophagosome formation. The same group later described the 
interaction of the Golgi-resident GTPase Rab33B with ATG16L1, however the precise 
pathways involved during autophagy are still to be determined.[812] More relevant to CD 
pathogenesis, Saitoh et al. demonstrated that ATG16L1-deficient macrophages produced 
high amounts of the inflammatory cytokines interleukin 1-beta (IL-1β) and interleukin-18 (IL-
18) following stimulation with the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide 
(LPS).[813] They also showed that this increased IL-1β production was due to Toll/IL-1 
receptor domain-containing adaptor inducing IFN-β (TRIF)-dependent activation of caspase-
1 in ATG16L1-deficient cells. Additionally they utilised mice with ATG16L1-deficient 
haematopoetic cells to highlight their increased susceptibility to dextran sulphate sodium-
induced colitis, which was in turn alleviated by treatment with IL-1β and IL-18 antibodies. 
  Cadwell et al. extended this work by initially generating mice and murine embryonic 
fibroblasts that were hypomorphic for ATG16L1 (using gene trap-mediated disruptions of 
ATG16L1).[25] Using this method allowed the detailed investigation of the consequences of 
low-expressing ATG16L1, avoiding the lethal effect of gene deletion.[814,815] They 
demonstrated that rapamycin-induced degradation of the adaptor protein p62 and LC3-II 
was diminished in ATG16L1 hypomorphic fibroblasts, which was restored by expressing 
ATG16L1. Additionally they showed that hypomorphic mice expressed approximately 25% of 
the expected levels of ATG16L1 in their ileum which equated to an increase in LC3-I:LC3-II 
ratio and p62. However, more importantly, these mice also showed striking abnormalities in 
Paneth cell morphology (Paneth cells are felt to be a key site in CD pathogenesis[816]) 
including lack of mucal lysozyme staining, reduced and disorganised granules, degenerating 
mitochondria and absence of apical microvilli. Following this, these changes in Paneth cell 
biology were confirmed in ileocolic resection specimens from CD patients carrying the 
ATG16L1 risk allele. Overall these data provided the first indication that ATG16L1 had a 
specific role in humans and mice in regulating the specialised properties of Paneth cells. 
  In 2010 there were several publications which intriguingly brought together two of the major 
pathways implicated in CD pathogenesis, namely the innate response (through NOD2) and 
autophagy. The innate immune system is the body’s first-line, non-specific response to 
foreign antigen. Both transmembrane and intracellular pattern recognition receptors (PRRs) 
recognise conserved, microbe-specific molecules named pathogen-associated molecular 
patterns (PAMPs; also known as microbe-associated molecular patterns (MAMPs)) such as 
LPS and peptidoglycan, leading to an appropriate immune response.[343] The NLR family are 
a major group of PRRs with a characteristic domain architecture comprising a central 
nucleotide binding and oligomerisation domain (NOD), an N-terminal effector binding 
(CARD) domain and C-terminal leucine-rich repeats (LRR) through which they detect 
MAMPs.[817] A key breakthrough in both CD and complex disease pathogenesis came in 
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2001 when fine mapping of the IBD1 locus on chromosome 16 identified the LRR variants of 
the NOD2 gene as conferring susceptibility to CD.[17] Since this discovery these NOD2 
mutations have been widely replicated in both adult- and early-onset disease,[13,18] with 
functional studies beginning to unravel the role of NOD2 in CD.[818,819] Although initially 
identified as a cytosolic protein, recent studies have shown that NOD2 also resides at the 
plasma membrane.[820] This membrane localisation suggests that NOD2 may function at the 
sites of bacterial entry to directly engage with pathogens and signal an appropriate 
inflammatory and antimicrobial response.[820] Furthermore, it is proposed that NOD2 can 
recognise danger associated molecular patterns (DAMPs) which are exposed when there is 
disruption of host cell membranes.[821] Some pathogens, such as Salmonella typhimurium 
and enteropathogenic E.coli (EPEC) use type-3-secretion systems (T3SS) to inject effector 
proteins into the cytosol of host cells to mediate adhesion and invasion, and this may act as 
a DAMP recognised by NOD2. 
  The first of the seminal papers involving ATG16L1 and NOD2 demonstrated that NOD2 
stimulation by its ligand muramyl dipeptide (MDP) induced autophagy in human, monocyte-
derived dendritic cells (DCs) and also influenced bacterial handling and antigen 
presentation.[30] This was shown to be independent of TLR4 signalling and required the 
NOD2 signalling mediator RIPK-2 in addition to PI3K and the autophagy proteins ATG5, 
ATG7 and ATG16L1. Additionally, they demonstrated that DCs isolated from individuals with 
any of the three known CD-associated NOD2 or T300A ATG16L1 variants exhibited 
defective autophagy. Also cells carrying a NOD2 variant failed to localise Salmonella 
enterica and CD-associated adherent-invasive E.coli species to autophagosomes, with this 
effect reversed by artificially inducing autophagy using rapamycin. At the same time a study 
led by Dana Philpott in Toronto similarly used bone marrow-derived macrophages and 
macrophages from NOD2-deficient mice to demonstrate NOD2-dependent autophagy 
induction with MDP.[31] Interestingly this group highlighted RIPK-2 independent autophagy 
induction, with colocalisation of NOD2 and ATG16L1 at the plasma membrane, with only 
cells homozygous for the T300A mutation effecting autophagy. NOD2 and ATG16L1 were 
also found to surround invading pathogens at the entry foci with mutant NOD2 proteins 
failing to do so. Homer et al. further showed that MDP-activated autophagy and NFB 
signalling, in addition to increased Salmonella killing, was dependent on NOD2 and 
ATG16L1 expression, specifically in intestinal epithelial cells; this response was again shown 
to be altered by known CD-associated NOD2 mutations.[822] The same group has most 
recently show the dual role of RIPK-2 in NOD2-induced autophagy with a positive signal 
through activation of p38 MAPK and reduced autophagy mediated by the phosphatase 
PP2A.[823] Kuballa et al. also showed abnormal capture of internalised Salmonella within 
autophagosomes in epithelial cells carrying the T300A mutation.[824] A summary of the role of 
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ATG16L1 and NOD2 in autophagy and the defects demonstrated when CD-associated 




Figure 9.3.  Summary diagram showing the role of ATG16L1 and NOD2 in the autophagy 
pathway and the defects observed when CD-associated mutations are present. The left 
panel shows the normal autophagy response with NOD2 recruiting ATG16L1 to the plasma 
membrane, normal autophagosome and autophagolysosome formation, followed by MHC II 
antigen presentation and an appropriate adaptive immune response. The right panel demonstrates 
abnormal membrane localisation of ATG16L1 with the LRR and T300A mutations resulting in 
abnormal bacterial killing and defective antigen presentation. 
 
 
  Further work has now shown that ATG16L1 is intimately involved in autophagosome 
formation with Ravikumar et al. showing that ATG16L1 interacts with the heavy chain of 
clathrin (a protein that plays a major role in the development of coated vesicles [825]) during 
the formation of ATG16L1-positive pre-autophagosomes[826]. This was shown to occur at the 
plasma membrane, although no obvious disruption of the clathrin-ATG16L1 interaction was 
observed with the T300A mutation. The inflammatory cytokine profile of cells possessing the 
T300A mutation has also been investigated with MDP-stimulation of peripheral blood cells 
harbouring T300A showing increased IL-1β , IL-6 and IL-10,[827,828] in addition to a reduction 
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in IFN- production[829]. Lee et al. went on to show that increased IL-1β production was a 
result of increased p62 levels in ATG16L1-deficient cells.[830] The T300A mutation has also 
recently been shown to produce hyperstable interactions between DCs and T cells at the 
immune synapse, with increased T cell activation, specifically the T-helper 17 cell 
response.[831] Work highlighting the role of ATG16L1 during Helicobacter pylori infection as 
well as murine Norovirus has also been presented.[832,833] 
 
9.5.2  IRGM 
  The immunity-related GTPase (IRG) family of proteins, first described in the 1990s, can be 
separated into IRGA, IRGB, IRGC, IRGD and IRGM subfamilies based on homology across 
their GTP-binding domain, however only two IRG sequences, both transcribed, are present 
in humans, namely IRGC and IRGM.[834] IRGC is not induced by interferons (unlike IRGM) 
and seems to be very tissue-specific, having been shown to be mainly expressed in the 
testes.[834] To date, five different 3'-splicing isoforms have been identified for human IRGM 
with the protein products of these isoforms predicted to have molecular weights of between 
19-24kDa.[835] 
  Interferon-gamma (IFN-) has long been recognised as important cytokine during the 
cellular response to bacterial invasion.[836] One of the first indications that the 47-kDa 
GTPase family, including IRGM, was involved in this response was the observation that 
genes encoding these proteins were upregulated during IFN- stimulation.[837,838] Culture of 
murine macrophage and fibroblast lines in medium containing high concentrations of IFN- 
showed a significant number of cDNA fragments belonging to both the 65-kDa and 47-kDa 
GTPases, including Irgm1 (also known as LRG-47, the murine homologue of IRGM). 
Following this, work by MacMicking et al. demonstrated that Irgm1 null mice failed to control 
Mycobacterium tuberculosis replication, with defective bacterial killing of mycobacterium-
containing phagosomes in null macrophages.[839] MacMicking et al. also observed impaired 
maturation of Mycobacterium tuberculosis-containing phagosomes suggesting a critical role 
of Irgm1 in vacuolar trafficking; this work was validated in a similar study by Feng et al.[840] A 
further study investigated this role showing that there was an increase in autophagic 
vacuoles and the maturation of mycobacterial phagosomes in murine macrophages 
transfected with Irgm1, with Irgm1 partially co-localising with small LC3-positive 
organelles.[841] Singh et al. used a number of autophagic markers such as 
monodalsyncadaverine, Lyso-Tracker red and Mito-Tracker red to demonstrate early 
autophagic vacuoles, vacuole acidity and the presence of mitochondrial material in vacuoles 
respectively, induced by over-expressing Irgm1 in murine macrophages.[842] However, more 
interestingly, they also demonstrated that human IRGM participates in autophagy induced 
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conventionally (by the use of rapamycin or serum starvation) and by IFN- in human 
macrophages, and confirmed an increase in mycobacterial survival using siRNA to IRGM. 
More recent work has also shown that IRGM participates in virus-induced autophagy, with 
siRNA knockdown of IRGM decreasing the number of autophagosomes induced by measles 
virus, hepatitis C virus and HIV proteins.[843] Although many other studies have confirmed the 
importance of IRGM in cellular resistance to a number of pathogens [844,845] some conflicting 
evidence still exists[28].  
 
9.5.3  LRRK2 
  Leucine-rich repeat serine/threonine protein kinase 2 (LRRK2; also known as PARK8) is a 
multi-domain protein of 2527 amino acids.[846] This large ubiquitous protein with multiple 
functional domains, namely kinase, ROC GTPase, Cor, leucine-rich repeat, ankyrin and 
WD40[847] has been linked to CD through the association of a SNP on chromosome 
12q12[523]. LRRK2 is expressed in a large number of murine tissues, including lung, heart, 
kidney and small intestine.[848] In addition, recent work has demonstrated that full length 
LRRK2 is a common constituent of human peripheral blood mononuclear cells such as 
CD14+ monocytes, CD19+ B cells and CD8+ and CD4+ T cells.[849] 
  To date, little work has focussed on the potential functional role of LRRK2 in CD 
pathogenesis. However, due to mutations in LRRK2 having been consistently associated 
with Parkinson's disease (PD) (a neurodegenerative disease characterised by progressive 
disturbances in motor, autonomic and psychiatric functions[850]) an increasing number of 
studies are now beginning to unravel the complex functions of this protein. The best 
characterised mutation in LRRK2 (G2019S - a glycine to serine substitution at amino acid 
2019) was initially demonstrated in several familial cases of PD[851] and subsequently 
common variations in LRRK2 have been shown to contribute to the risk of sporadic 
PD[852,853]. This, coupled with the previously established importance of autophagy in a 
number of neurodegenerative diseases,[854] has focussed current research on the role of 
LRRK2 during the autophagic process.  
  LRRK2 has been shown to localise to vesicular granular structures of the late endosomal-
lysosomal pathways.[406,855,856] Several membrane microdomains such as the neck of 
caveolae, microvilli/filopodia and intraluminal vesicles of multivesicular bodies (MVBs) were 
shown to contain LRRK2, as well as cytoplasmic puncta corresponding to MVBs and 
autophagic vacuoles.[855] A recent study demonstrated that overexpression of wild-type 
LRRK2 increased autophagy through activation of a calcium-dependent protein kinase 
kinase-β (CaMKK-β)/adenosine monophosphate (AMP)-activated protein kinase (AMPK) 
pathway.[857] This effect was through nicotinic-acid adenine dinucleotide phosphate (NAADP) 
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receptors causing calcium efflux and partial alkalinisation of lysosomal store pH. Increased 
LC3 punctae were also visualised with overexpression of full-length LRRK2, but not the 
mutant protein, suggesting involvement of the kinase domain. Further work has provided 
evidence that the presence of the G2019S-mutant protein in neuronal cells leads to the 
accumulation of autophagic structures, with an impaired autophagic balance also 
demonstrated in non-neuronal and yeast cells,[857] induced pluripotent stem cells from 
patients with the G2019S mutation also show an accumulation of autophagic vacuoles[858]. 
Similarly, aged LRRK2-null mice show increased LC3-II and p62 in the kidney with a 
subsequent inflammatory response.[859] 
  More pertinent to CD pathogenesis, work by Liu et al. showed that LRRK2-deficient mice 
had significantly poorer clinical outcomes in an experimental (DSS-induced) colitis model 
compared to their wild-type counterparts, manifested as increased weight loss and 
diarrhoea.[860] A further study by Gardet et al. in human subjects used peripheral blood 
mononuclear cells and intestinal biopsies from IBD patients to further delineate the role of 
LRRK2.[861] Stimulation of macrophage-differentiated THP-1 cells with IFN- showed an 
increase in both LRRK2 mRNA and protein, with peripheral blood mononuclear cells from 
healthy controls showing a similar response in CD3+ T cells, CD19+ B cells and CD11b+ 
monocytes. LRRK2 mRNA expression was also shown to be increased six-fold in inflamed 
CD biopsies compared to paired non-inflamed biopsies, with histological specimens showing 
LRRK2-positivity in CD206 macrophages, CD103+ dendritic cells and CD20- B cells. Gardet 
et al. also showed, using luciferase-based reporters, that LRRK2 can activate NFB 
pathways dependent on the IKK complex. Particularly relevant to CD they also demonstrated 
that LRRK2 co-localised with S. typhimurium in the cytosol of RAW macrophages, with 
LRRK2 siRNA knockdown reducing reactive oxygen species after IFN- stimulation and 
increased S. typhimurium survival in a gentamicin-protection assay. Extending this work, 
Hakimi et al. showed that LRRK2 is present in a subset of circulating leucocytes with the 
expression of R1441Cmutant LRRK2 in a primary, non-neural cell model revealing an 
autophagy defect manifested as a reduction of LC3-II levels.[849] Stimulation of murine bone-
marrow derived macrophages by a variety of pattern-recognition receptor ligands (which are 
likely to be pivotal in CD pathogenesis[862]) produced up-regulation of LRRK2 mRNA with 
respect to LPS, R837 and CpG and down-regulation when stimulated with Pam3CSK4. 
 
9.5.4  MTMR3 
  MTMR3 encodes a protein of the tyrosine phosphatase superfamily.[863] The MTMR 
proteins are involved in the regulation of phosphatidylinositol (PtdIns) and its derivatives, 
accounting for around 10% of the total lipid in eukaryotic membranes.[864] This family of 
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proteins (a subgroup of the PtdIns(3)P phosphatases) has 15 members, only nine of which 
(including MTMR3) possess the active phosphatase domain that specifically 
dephosphorylates PtdIns(3)P.[865] PtdIns(3)P is highly enriched as a component of the 
elongating isolation membrane and autophagosome membranes in yeast,[866] with MTMR3 
ubiquitously expressed and shown to hydrolyse PtdIns(3)P to its derivative PtdIns[867]. Roles 
in autophagosome size and constitutive autophagy initiation in epithelial cells,[868] coupled 
with hVps34 (a class III PI 3-kinase) being intimately involved in autophagy and the 
suppression of autophagy by the PI 3-kinase inhibitor Wortmannin, makes this group of 
proteins of particular interest[869,870]. PtdIns(3)P has specifically been shown to bind to the 
autophagy protein ATG18[871-873] and this ATG18-PtdIns(3)P interaction has now been 
recognised as an essential component for the efficient progression of both selective and 
non-selective autophagy[874]. It is likely that the ATG18-PtdIns(3)P complex exerts this role 
through the interaction of the ATG18-ATG2 complex with ATG9 which is the only known 
integral membrane ATG protein.[875] Further work has now extended the role of MTMR3 
specifically in autophagy. Work in alveolar basal epithelium (A549 cells) by Taguchi-Atarashi 
et al. showed that overexpression of mutant MTMR3 (MTMR3C413S) produced an increase in 
GFP-LC3 and GFP-ATG5 which was not seen with wild-type overexpression.[869] Also, this 
increase in autophagy was dependent on PtdIns(3)P, with siRNA knockdown of MTMR3 
producing a similar response, suggesting MTMR3 as a negative regulator of autophagy. The 
22q12 locus harbouring MTMR3 has now also been associated with lung cancer,[876] with 
specific MTMR3 mutations discovered in gastric and colorectal cancer,[877] all of which may 
be important in the context of the emerging role of autophagy in cancer biology[878]. 
 
9.5.5  PTPN2 
  The PTPN2 gene is located on chromosome 18p11 and codes T cell protein tyrosine 
phosphatase (TC-PTP, also known simply as PTPN2), one of over 100 PTP proteins 
capable of removing phosphate moieties from tyrosine residues of protein substrates.[879] 
First cloned in 1989,[880] this ubiquitous protein exists as two splice variants, one localised to 
the nucleus and the other to the endoplasmic reticulum[879]. Much of the functional work 
surrounding this protein has been through investigation of PTPN2 knockout mice that 
demonstrate a progressive systemic inflammation and abnormal cytokine environment.[881] 
TC-PTP has also been shown to be involved in haematopoiesis and autoimmune 
disease.[879] 
  Much of the work specifically relating to the role of PTPN2 and CD has been performed by 
Scharl et al. The first of these papers studied the role of PTPN2 in intestinal barrier function. 
They demonstrated that PTPN2 was over-expressed in biopsies from CD patients, and that 
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stimulation of an intestinal epithelial cell (IEC) line with IFN- increased PTPN2 levels.[882] 
Also, PTPN2 knockdown increased STAT1 and STAT3 phosphorylation after IFN- 
stimulation and increased epithelial permeability as determined by FITC-Dextran flux across 
IEC monolayers. Similar increases in IL-6 and macrophage chemoattractant protein 1 (MCP-
1) were seen with PTPN2 knockdown in a monocyte cell line in a subsequent study.[883] 
Other work showed comparable results when IECs were stimulated with TNF-α.[884] Very 
recent research has now shown a role for PTPN2 in autophagy with siRNA knockdown in 
IECs reducing autophagosome formation as well as autophagy induction as determined by 
persisting Listeria infection; this was replicated in colonic lamina propria fibroblasts from 
patients with CD carrying the PTPN2 variant.[885] Additionally a novel variant in PTPN2 
(rs1893217) was also shown to impair autophagosome formation, as well as elevating IFN- 
levels in response to MDP.[886] 
 
9.5.6  NCF4 and ULK1 
  One of the first GWAS to identify the association of autophagy genes with CD susceptibility 
postulated NCF4 as a candidate gene.[789] Although this finding was replicated soon 
afterwards,[807] several studies have also proved negative[808,887]. NCF4 (also known as 
p40phox) is a member of the cytoplasmic SH3-domain proteins involved in the activation of 
gp91phox during phagocytosis.[888] Along with other phox proteins (e.g. p67phox) NCF4 is 
involved in the generation of reactive oxygen species (ROS) by the reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase complex, which is critical in the 
antimicrobial functions of phagocytic cells.[889] In addition to NCF4-deficient mice showing 
defective killing of S.aureus,[889] ROS have also been shown to be important during 
autophagy induction[890]. A limited number of studies have demonstrated an association with 
an ileal[807,891] or perianal[892] phenotype with one functional study showing a reduction in 
reduced ROS in GM-CSF-primed granulocytes from CD patients harbouring the NCF4 
mutation[893].  
  To date only two studies have evaluated the role of the well-characterised autophagy 
protein ULK1 in CD pathogenesis. The first of these demonstrated that the SNP rs12303764 
near ULK1 was significantly associated with CD in a case-control study, replicated in a 
transmission disequilibrium test in 335 case-parent trios.[805] This association with ULK1 
variants was then recently replicated in an independent case-control study in New 
Zealand.[806] Although the association with rs12303764 was not present in their population, 
several other SNPs in the region of ULK1 showed positive association, however the 
replication for these SNPs in larger GWAS meta-analysis data was variable. The ULK1 
gene, consisting of 28 exons, with a transcript length of 5211 basepairs and a translation 
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length of 1050 residues, is localised on chromosome 12q24. The two known mammalian 
orthologs of yeast Atg1, ULK1 and ULK2, form a stable complex with ATG13, FIP200, 
ATG101 and mTORC1. Although this complex is intimately involved in autophagy induction, 
in view of its currently weak association with CD a detailed discussion of the role of ULK1 in 
autophagy is outwith the scope of this chapter, however several excellent reviews of its 
biological function are available.[894,895] 
  It has yet to be seen what direct role CD-association variants in NCF4 and ULK1 will play, if 
any, in CD pathogenesis. However future research will undoubtedly endeavour to illicit any 
further association given the vital role of ULK1 in the mTORC1 complex and the intriguing 
importance of ROS in bacterial handling. A summary of the postulated autophagy-related 





Figure 9.4.  Postulated autophagy-related pathways influenced by CD susceptibility 






9.6  Adherent invasive E.coli 
 
  E.coli is normally a harmless commensal micro-organism that can become a highly-
adapted pathogen through the acquisition of specific virulence factors. To date eight 
pathovars have been extensively studied and implicated in a wide range of diseases, of 
which enteropathogenic E.coli (EPEC), enterohaemorrhagic E.coli (EHEC), 
enterotoxinogenic E.coli (ETEC) and diffusely adherent E.coli (DAEC) cause gastroenteritis 
in humans.[896] In addition there are several recently described E.coli pathovars, of which 
AIEC are the most relevant to CD. The association of AIEC with CD was first reported by 
Darfeuille-Michaud and colleagues in the late nineties,[897,898] and since then AIEC have been 
isolated from independent studies involving adult and paediatric CD patients [766,767,899]. The 
high prevalence of AIEC strains observed in the ileal mucosa of CD patients has been 
attributed to their ability to adhere to the glycosylated carcinoembryonic antigen-related cell 
adhesion molecule 6 (CEACAM6), which is overexpressed on the surface of epithelial cells 
in patients with CD.[109] In addition the ER-stress response chaperone Gp96 is highly 
expressed in epithelial cells of patients with CD and has been demonstrated to act as a host 
cell receptor for AIEC.[108] Recently, complete genome sequencing of the reference strain of 
CD-associated AIEC LF82 has shown that this strain contains several virulence factors 
including the lpf operon, which encodes long polar fimbriae (LPF).[900] AIEC have also been 
shown to interact with Peyer's patches, specialised cells of the intestinal epithelium via LPF, 
and the prevalence of AIEC strains containing the lpf operon was shown to be markedly 
higher in CD-patients compared to controls.[901] 
  Following adhesion AIEC can invade the intestinal epithelium, breaching the epithelial 
barrier and are subsequently found in the lamina propria of patients with ileal CD. A recent 
study investigated the role of autophagy in the replication and survival of E.coli in epithelial 
cells.[27] Specifically, the authors investigated whether cells deficient in the CD-associated 
autophagy proteins IRGM and ATG16L1 affected intracellular replication and survival of 
AIEC strains. This study demonstrated that the AIEC strain LF82 have enhanced replication 
and survival in both IRGM and ATG16L1 deficient cells. Remarkably, autophagy deficiency 
did not interfere with the replication and survival ability of other E.coli strains tested, 
including non-pathogenic, environmental, commensal, or pathogenic strains involved in 
gastroenteritis, suggesting a specific role for autophagy in restraining AIEC. AIEC can 
translocate the epithelium into the lamina propria where they can replicate and survive within 
macrophages. In a subsequent study the same group investigated whether defects in 
autophagy affected the replication and survival of AIEC in macrophages.[902] AIEC were 
shown to recruit the autophagy machinery to sites of entry into host cells and autophagy 
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limited intramacrophagic replication. Impaired IRGM or ATG16L1 expression resulted in 
increased AIEC in macrophages and significantly this was accompanied by increased 
secretion of the pro-inflammatory cytokines IL-6 and TNF-. Further studies demonstrated 
that a family of micro-RNA (miRNAs) miR-196 that are expressed in the intestinal epithelium 
of individuals with CD down regulate the expression of IRGM in those with the protective 
variant (c.313C).[903] The resulting impairment of the autophagy response resulted in 
increased intracellular replication and survival of AIEC. Taken altogether these studies 
suggest that stimulation of autophagy, perhaps using small molecule inhibitors of mTORC1, 
would be a therapeutic strategy to restrain AIEC replication and dampen the exacerbated 
inflammatory response that leads to chronic inflammation and granuloma formation 
observed in patients with CD. 
 
9.7  Autophagy pathway-phenotype correlations in Crohn's disease   
 
  A number of studies have now endeavoured to correlate CD phenotypes with autophagy 
gene risk variants in an attempt to translate knowledge of the autophagy pathway to clinical 
application. The most replicated finding in this respect is the positive association of 
ATG16L1 and IRGM variants with ileal disease phenotype. Along with Prescott et al. who 
initially reported this finding for ATG16L1 in a cohort from the United Kingdom,[788] groups in 
Australia[404] and Portugal[801] have recognised this relationship, with the Portuguese group 
also showing this association for IRGM. Similarly carriage of the ATG16L1 risk variant has 
been shown to correlate with a reduction in extra-intestinal manifestations, however the 
study was likely unpowered to detect an effect.[904] Another reported positive association was 
with IRGM variants and the need for ileocolectomy, however the number of patients in the 
study again make this difficult to interpret.[905] Several recent studies have attempted to 
define the association of autophagy gene risk variants with the presence of granulomas on 
intestinal biopsy samples, with conflicting results. (A granuloma is an inflammatory lesion 
containing epithelioid cells, macrophages, and lymphocytes, and is considered one of the 
pathological hallmarks of CD, however detection at endoscopy is variable [906]). Wolfkamp et 
al. in a cohort of approximately 200 patients demonstrated no association of granulomas 
with CD-risk variants in ATG16L1 or IRGM.[907] SNPs in NCF4 and ATG4A have also shown 
negative correlation with the presence of granulomas in an Israeli cohort.[908] A larger study 
from Belgium, which included 464 patients, did find both a positive and negative association 
of variations in four autophagy-related genes (ATG2A, ATG4A, ATG4D and FNBP1L ); to 
date these genes have not been shown to confer a susceptibility risk to, or altered protein 
expression in, CD.[909] 
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  The role of the microbiome in the pathogenesis of CD has become more prominent in 
recent years,[910] with a small number of studies aiming to determine the relationship 
between autophagy risk-variants and microbial components. Murdoch et al. looked at the 
presence of four antimicrobial antibodies stratified by CD-associated variants.[911] They 
showed that in a cohort of over 600 CD patients, that increased seropositivity for anti-
Saccharomyces cerevisiae antibody (ASCA) was associated with carriage of the ATG16L1 
variant and that the IRGM CD-risk variant was associated with increased anti-flagellin 
seropositivity. Frank et al. looked at DNA extracted from intestinal specimens from 35 CD 
patients to determine the microbial composition and its relationship with genotype.[912] 16S 
rRNA sequence analysis revealed that patients with the NOD2 or ATG16L1 variants had 
significantly altered microbiota, although the authors did acknowledge that the study was 
underpowered to determine any genera-specific effects.  
 
9.8  Conclusions 
 
  It can be seen that following the emergence of autophagy as a pathogenic mechanism in 
CD that some progress has been made to unravel the functional aspects of these complex 
pathways. To date much of the research surrounding this topic has been focussed on 
genetic susceptibility and despite the field of autophagy progressing at a rapid pace, much is 
still unknown regarding the precise molecular abnormalities that may underlie the disease 
process. It is likely that further knowledge of the autophagy proteins involved specifically in 
CD and a deeper insight into the role of xenophagy (especially in the context of AIEC and 
the ileal disease phenotype) will be required before effective intervention can be 
implemented to alter the disease course. Functional work is now required to determine the 
potential therapeutic modulation of both the autophagy pathway itself, in addition to targeting 
specific bacterial subgroups such as AIEC, although these therapies will most likely only be 












10.  Laboratory Methods 
 
  In order to fully assess the NOD2 stable cell lines and to evaluate autophagy induction and 
MTOR activation outlined in Chapter 11 and Chapter 12, the following laboratory methods 
were employed. 
 
10.1  Cell lines and tissue culture 
 
  Human Embryonic Kidney 293 (HEK293) cells (American Type Culture Collection, ATCC) 
and HEK293 cells stably expressing green-fluorescent protein (GFP)-labelled light chain 3 
(LC3) (a kind gift from Dr Craig Stevens, University of Edinburgh and Napier University) 
were grown in high glucose (4.5g/L) Dulbecco's Modified Eagle Medium (DMEM) (Gibco). 
HCT116 cells (a colorectal carcinoma cell line; ATCC) and HCT116 stably expressing GFP-
LC3 (also a kind gift from Dr Craig Stevens, University of Edinburgh and Napier University) 
were grown in McCoy's 5A medium (Gibco). SW480 cells and HT29 cells (ATCC) were 
grown in Leibovitz and DMEM media respectively. All media were supplemented with L-
Glutamine, 10% FCS (Invitrogen) and Penicillin-Streptomycin (Gibco). Cells were incubated 
at 37ºC in high relative humidity (95%) and controlled CO2 level (5%), except SW480 cells 
that were grown at 37ºC in sealed flasks. Cells were maintained in 75cm2 culture flasks 
(Costar®), passaged twice-weekly using trypsin (Gibco) and cells checked monthly for 
mycoplasma infection at the Institute for Molecular Medicine, University of Edinburgh using 
the MycoAlert mycoplasma detection kit (Lonza). Cells from two confluent 75cm2 flasks of 
each cell line were also frozen after suspension in 12 x 1ml aliquots of freezing mix (1.8ml 
dimethyl sulfoxide [DMSO], 10.2ml FCS), placed in a Nalgene "Mr Frosty" freezing container 
(Thermo Scientific) and immediately stored at -80ºC; cells were then transferred to liquid 
nitrogen storage within 48hrs. Fresh aliquots of cells were thawed and re-seeded 
approximately every 8-12 weeks to ensure the culture of robust, healthy cell populations; cell 
viability was routinely assessed by trypan blue (Gibco) exclusion. 
 
10.2  Western blot procedure 
 
  Cells were grown on 6-, 12- or 24-well culture plates (Greiner Bio One; all culture plates 
were purchased from this manufacturer unless otherwise stated). Following the appropriate 
treatments, culture media was removed and cells scraped into 1ml of phosphate-buffered 
saline (PBS), placed in a 1.5ml eppendorf tube and centrifuged at 1200rpm for five minutes; 
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supernatants were then carefully removed. Pellets were then incubated for 30 minutes on ice 
in the presence 30-50μl of protein lysis buffer (see Table 10.1) and supplemented with 10μl 
of phosphatase inhibitor cocktail 1 and 2 (Sigma-Aldrich) per 1ml of lysis buffer. Lysates 
were centrifuged in standard 1.5ml eppendorfs at 13,000rpm for 15 minutes, and protein 
quantification for each sample was determined using the Qubit fluorometer (Invitrogen) as 
per the manufacturer's instructions.  
 
 
Table 10.1.  Buffers and solutions used during laboratory experiments 
 
Buffer or Solution (volume) Components 
Tris pH 6.8/8.0/8.8 (1000ml) 
 121.14g Trizma base (Sigma-Aldrich) 
 1000ml ddH2O 
(pH adjusted accordingly using HCl and verified 
using a standard digital pH meter) 
Protein lysis buffer (40ml) 
 
 6ml of 150mM sodium chloride solution  
 2ml of 50mM tris(hydroxymethyl)aminomethane 
(Tris) solution (pH 8.0) 
 200μl of 0.5% Tergitol-type nonyl 
phenoxypolyethoxylethanol (NP-40) (Sigma-Aldrich)  
 One tablet of EDTA-free complete protease 
inhibitor cocktail (Roche) 
 31.8ml ddH2O 
10x transfer buffer (1000ml) 
 144g Glycine (Promega) 
 30g Trizma base (Sigma-Aldrich) 
 1000ml ddH2O 
10% SDS solution (1000ml) 
 100g SDS (Sigma-Aldrich) 
 1000ml ddH2O 
10x SDS buffer (1000ml) 
 900ml 10x transfer buffer 
 100ml 10% SDS solution 
Phosphate-buffered saline/Tween® 
0.1% solution (400ml) 
 400ml phosphate-buffered saline 
 400μl Tween® 20 (Sigma-Aldrich) 
 
Milk powder solution 5% or 10% 
(10ml) 
 0.5g or 1g Marvel dried milk powder (Premier 
Foods) 
 10ml 0.1% PBS/Tween® solution (Sigma-Aldrich) 
ddH2O, double distilled water; SDS, sodium dodecyl sulphate 
 
  Samples were placed in a heat block at 95ºC for approximately 10 minutes after the 
addition of 10μl of 3x SDS to each sample. Cell lysates were separated by sodium dodecyl 
sulphate (SDS) gel electrophoresis on 6-15% gels dependent on the size of the protein(s) 
being investigated. The volumes of double distilled H2O (ddH2O), Tris (pH 8.8), Protogel 












6% 7% 8% 10% 12% 15% 
ddH2O (ml) 3.87 3.8 3.6 2.84 2.17 1.17 
Tris pH 8.8 (ml) 3.73 3.73 3.73 3.73 3.73 3.73 
Protogel 40% (ml) 2.0 2.3 2.7 3.3 4.0 5.0 
10% SDS (ml) 100 100 100 100 100 100 
 ddH2O, double distilled water 
 
 
  In addition, 40μl of 25% ammonia persulphate and 10μl of Tetramethylethylenediamine 
(TEMED; Sigma-Aldrich) were added to polymerise the gel solutions. The gel solution was 
then poured between two glass plates, left to set for approximately 10 minutes and a stacker 
with similar components (with the exception of the substitution of Tris pH 8.8 for Tris pH 6.8) 
poured on top. Cell lysates were resolved using gel electrophoresis (Mini-PROTEAN Tetra, 
Bio-Rad) with running buffer (100ml 10x SDS buffer and 900ml deionised water - Table 
10.1) and run for approximately 2hrs at 120V/400mA depending on protein size. To allow the 
accurate assessment of protein size during blotting, 5μl of protein standard (PageRuler Plus, 
Fermentas) was placed in at least one lane of each gel. Proteins were then transferred to 
mixed ester nitrocellulose membrane (Hybond-C Extra, GE Healthcare) in transfer buffer 
(120ml 10x transfer buffer, 130ml methanol, 900ml deionised water) for between 90-120 
minutes at 400mA. 
  Following transfer, membranes were placed in trays and stained with Ponceau S (Sigma-
Aldrich) for several minutes to confirm successful protein transfer. Following ponceau 
staining, membranes were de-stained with PBS. To minimise non-specific binding of 
antibody, membranes were placed in trays on a roller in 10% milk powder solution for 30 
minutes prior to incubation with antibody. Primary antibody at a concentration of between 
1:500-1:4000 (depending on the experimental protocol) was then added to 5% milk powder 
solution and incubated overnight in a tray at 4ºC on a rocker. 
  Following incubation with primary antibody, membranes were washed for five minutes (x3) 
in 0.1% PBS/Tween®. Secondary antibodies (10μl anti-rabbit IgG-HRP or 2.5μl anti-mouse 
IgG-HRP [Dako]) were placed in 5% milk powder solution and incubated with membranes for 
approximately 90 minutes at room temperature. Before developing, membranes were again 
washed for five minutes (x3) in 0.1% PBS/Tween®. Each membrane was then placed face-
down on Saran wrap (Dow Chemical Company) with between 100-2000μl of ECL Western 
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Blot Analysis fluid (GE Healthcare) which was prepared as per manufacturer's instructions. 
Membranes were bathed in analysis fluid for approximately 5 minutes, the excess fluid 
removed, and then placed on a generic acetate transparency sheet, covered in Saran wrap 
(ensuring all bubbles expelled) and secured in autoradiography cassettes (Research 
Products International). For development, appropriately cut BioMax® XAR film (Kodak) was 
placed in the cassettes for between 10 seconds and 30 minutes (as required for each 
antibody) and inserted into a standard film developer (Agfa Curix 60, Agfa-Gevaert N.V, 
Mortsel, Belgium). 
 
10.3  Immunofluorescent microscopy 
 
  Cells were seeded on 19-mm borosilicate glass coverslips (Fisher Scientific) in 6- or 12-
well plates at a density of approximately 2x104 cells. After 24 hours, if required, cells were 
transfected with the appropriate constructs for a further 16 hours. Cells were washed in PBS, 
placed on a custom-made chamber (with coverslips placed on a moist sponge to avoid 
desiccation) then fixed with 200μl of 4% paraformaldehyde for 15 minutes. Cells were then 
washed in PBS and permeabilised with 200μl of PBS/0.2% Triton X-100 (Dow Chemical 
Company) for 10 minutes before being blocked for 30 minutes with 200μl of PBS containing 
10% foetal calf serum (FCS) (Gibco). For protein detection, 1-5μl of primary antibody was 
added to 10ml of PBS containing 1% FCS and incubated overnight at 4ºC. The following day 
cells were incubated for 1 hour at room temperature with fluorescein isothiocyanate (FITC) 
or tetramethyl rhodamine isothiocyanate (TRITC) conjugated anti-mouse or anti-rabbit 
secondary antibodies (Invitrogen). Cells were then fixed to standard microscope slides with 
adhesive containing 4’,6’-diamidino-2-phenylindole (DAPI) (VECTASHIELD®, Vector 
Laboratories) to allow the easy identification of cell nuclei. Images were captured using an 
Axioskop 2 fluorescent microscope (Carl Zeiss) and, if required, analysed using Image J 
software (National Institutes of Health). 
 
10.4  Lipofectamine transfection  
 
  Cells were seeded in a standard 12-well culture plate for at least 16 hours, or until 
approximately 70% confluent. For each well to be transfected, 250μl of Opti-MEM® reduced 
serum medium (Gibco) was placed in two 1.5ml eppendorfs. In one eppendorf, the 
appropriate amount of DNA was placed (usually between 0.5-2.0μg); in the other, 2µl of 
Lipofectamine 2000 (Invitrogen) was used for every 1µg of DNA. These two solutions were 
left at room temperature for 5 minutes then mixed thoroughly. Following another 25 minute 
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period at room temperature, this solution was added dropwise onto the cell culture 
monolayer and placed at 37ºC in high relative humidity (95%) and controlled CO2 level (5%). 
Transfected cells were harvested (or treated with the appropriate substance) after 16-18 
hours, then lysed and processed for either western blot or immunofluoroescent microscopy 
as detailed above.  
 
10.5  Transformation and details of vectors 
 
  For the transformation of constructs, Escherichia coli DH5α bacteria were used (a kind gift 
from Dr Craig Stevens).[913] These bacteria and the vector to be transformed were first 
placed on ice in suitable containers. 20mls of agar was then liquefied in a standard 
microwave oven for approximately two minutes and the agar left to cool slightly before the 
addition of Ampicillin (Gibco) at a 1:1000 concentration; two Petri dishes were then filled with 
10ml of agar. Two 1.5ml eppendorfs were filled with 100μl of bacteria suspension and 
approximately 50ng of construct DNA was then placed in the second eppendorf, leaving the 
first eppendorf as a (blank) control; these solutions were then left on ice. After 30 minutes 
the solutions were placed at 42oC for two minutes then back on ice for two minutes. 300μl of 
Lysogeny Broth (LB) was then added to each sample and incubated for 1-2 hours at 37oC. 
Each solution was added to one agar plate and evenly spread using sterile glass beads. 
Plates were then placed inverted into a standard tissue culture incubator overnight at 37oC. 
The following day, 200ml of LB was placed in a large canted neck flask. After 
supplementation with 1:1000 Ampicillin (from 100mg/ml stock), a sterile pipette tip was used 
to pick a single colony of bacteria for inoculation of the LB solution, and then cultured 
overnight at 37oC with gentle agitation. (As an intermediate step, to make glycerol stock to 
thus avoid the need for further transformations of the same vector, 600μl of LB bacteria 
solution was placed in a CryoTube [Thermo Scientific] before the addition of 600μl glycerol 
and stored at -80oC.) DNA was then extracted using the QIAGEN Plasmid Midi Kit 
(QIAGEN) as per the manufacturer's instructions. DNA concentration and purity were then 
assessed using a Nanodrop spectrophotometer (Thermo Scientific). A ratio of absorbance 
above 1.8 at 260nm and 280nm was deemed acceptable.[914]   
  The generation of haemagglutinin-tagged (HA) wild type NOD2, HA-NOD2 (1-693) lacking 
the C-terminal LRR domain and HA-NOD2 (1-247) comprising only the two N-terminal 
CARD domains were created using site directed mutagenesis (Stratagene); further details of 
their generation have previously been published.[915] The 1-693 and 1-247 mutants were 
produced by the introduction of a stop codon at amino acids 694 or 248. These variants had 
previously been generated in the laboratory of Professor Jack Satsangi (Gastrointestinal 
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Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh) and were a kind 
gift from Dr Elaine Nimmo and Dr Craig Stevens. In addition to the NOD2 vectors, GFP-LC3 
and HA-tagged S6K were also previously generated and available in the laboratory of Prof. 
Satsangi at the start of the project. 
 
10.6  Immunofluorescent microscopy and western blot analysis 
 
  For immunofluorescent microscopy analysis, especially in relation to the assessment of 
cells undergoing autophagy, captured raw images were first loaded in Image J (National 
Institutes of Health), which was downloaded from http://rsbweb.nih.gov/ij/download.html. In 
order to accentuate the presence of autophagosomes (depicted by bright punctate green 
foci) the Process>Shadows>North function was used. Following this, the 
Plugins>Analyze>Cell counter function was utilised to count the cells of interest. These 
values were recorded in a custom-made Excel 2007 (Microsoft) spreadsheet that 
automatically calculated overall percentages. In all immunofluorescent microscopy analysis 
of autophagy induction, at least 100 cells were evaluated taken from five random fields of 
view at 40x magnification.  
 
 
Figure 10.1.  Examples depicting the use of ImageJ and Microsoft Excel 2007 to analyse 
captured microscopy pictures and western blot gels. (a) Raw microscope capture of cells 
undergoing autophagy. (b) 'North' shadowing effect used in ImageJ to accentuate the LC3 punctae. 
(c) Cell counter tool used to manually count punctae in cells. (d) Microsoft Excel 2007 spreadsheet 
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used to automatically calculate percentage of cells counted compared to total cell number. (e) 
Progression of analysis of raw western blots using the gel analysis function following inversion.  
  For densitometry analysis of western blots, films containing the blots were first scanned as 
TIFF images using an Epson Perfection 1660 Photo flat-bed scanner (Epson). These TIFF 
images were then loaded in Image J and after inverting the image (to achieve a "positive" 
value), the Analyze>Gels function was used to outline each lane with the scale set to 'pixels'. 
After each lane was plotted, the 'magic wand' tool was used to outline the graphical 
representation of each blot and the area analysed using the Analyze>Measure function. 
Each lane was analysed in turn and, if applicable, β-actin blot densitometry also performed 
to adjust for any discrepancies in protein loading. The numbers corresponding to each blot 
density were then copied into Excel 2007 (Microsoft) and the protein:actin ratio calculated 
using simple formulae. An outline of these methods are depicted in Figure 10.1.  
 
10.7  Antibodies 
 
  All antibodies were kept at -20ºC or 4ºC as per the manufacturer's instructions. Several 
antibodies were frozen in aliquots to avoid repeated freeze-thaw cycles. In addition, 
antibody-milk powder solutions were often frozen and used up to three times in order to 
avoid repeated purchases. Details of each antibody used during all the experiments are 
given in Table 10.3.  
 
 
Table 10.3.  Details of antibodies used during laboratory experiments 
 
Antibody Name/description Manufacturer (ID) Host Dilution 
Atg7 Cell Signaling (#2631) Rabbit 1:1000 
β-Actin Santa Cruz (sc-69879) Mouse 1:4000 
FLAG M2 Sigma-Aldrich (F3165) Mouse 1:4000 
Green fluorescent protein Abcam (ad290) Rabbit 1:1000 
HA.11 (16B12) Covance (MMS-101P) Mouse 1:4000 
LC3B Abcam (ab48394) Rabbit 1:1000 
NOD2 (2D9) Santa Cruz (sc-56168) Mouse 1:1000 
NOD2 Polyclonal (28-301) Cayman (160777) Rabbit 1:1000 
NOD2 Polyclonal (28-301) ABR (MA1-16611) Mouse 1:1000 
PARP Cell Signaling (#9542) Rabbit 1:1000 
p62 BD Biosciences (610833) Mouse 1:1000 
Phospho-S6 Ribosomal Protein  
(Ser 235/236) (2F9) 
Cell Signaling (#4856) Rabbit 1:1000 
Phospho-p70 S6 Kinase (Thr389) (1A5) Cell Signaling (#9206) Mouse 1:1000 
p70 S6 Kinase Cell Signaling (#9202) Rabbit 1:1000 
S6 Ribosomal Protein (54D2) Cell Signaling (#2317) Mouse 1:1000 




10.8  Drug treatments 
 
  A list of drug and substances used during all the laboratory experiments, including their 
stock solution, working concentrations and manufacturers are shown in Table 10.4. 
 
 
Table 10.4.  Details of drugs and substances used during all laboratory experiments. 
 
Drug/substance Stock solution Working conc. Manufacturer/Supplier 
Azathioprine 100mM 30-90μM Tocris Bioscience 
Bafilomycin A1 100μM 10μM Invivogen 
CFDA-SE 5mM 500μM eBioscience 
Chloroquine 100mM 100μM InvivoGen 
Cycloheximide 10mg/ml 10μg/ml Supleco 
Dimethyl sulphoxide Neat Equivalent volume Sigma-Aldrich 
FITC-MDP 10mg/ml 1μg/ml InvivoGen 
Geneticin 50mg/ml 0-1500mg/ml Invitrogen 
Infliximab 100mg/ml 3-30μg/ml Centocor 
L18-MDP 10mg/ml 1-75μg/ml InvivoGen 
6-thioguanine 300mM 30-90μM Tocris Bioscience 
Methotrexate 100mM 33-99μM Tocris Bioscience 
3-methyladenine 1mg/ml 10μl/ml Sigma-Aldrich 
MG132 20mg/ml 10μM Calbiochem 
Rapamycin 10mM 10μM InvivoGen 
U0126 100mM 10μM Cell Signaling 
Withaferin-A 10mg/ml 2-10M Sigma-Aldrich 
 
 
10.9  Flow cytometry 
 
  For flow cytometry, cells were labelled with 5-(and -6) – carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) (eBioscience). The stable incorporation of CFDA-SE into cells 
allows for tracking of cell proliferation (up to eight cell divisions) as its intracellular 
concentration is sequentially halved. To achieve this labelling, 179.4μl of DMSO was added 
to CFDA-SE stock giving a 5mM solution. This was converted to a 1:10 dilution (500μM) and 
10μl of solution added per ml of cells (i.e. ~1x106 cells in 1ml). The cell suspension was then 
placed at 37oC in the dark for approximately 8 minutes and then 3-4 volumes of ice cold 
complete medium (DMEM) added; cells were then plated as per the experiemental protocol. 
Following the completion of the experiment, cells were washed three times via 5 minute 
centrifugation at 1200prm with ice cold complete medium. The final cell pellet was then 
resuspended in 4% paraformaldehyde for 15 minutes to fix then washed (3x at 1200rpm) 
prior to resuspension in FACS wash 1% FCS solution. Cell suspensions were analysed by 
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Dr Elizabeth Freyer (Institute of Genetics and Molecular Medicine) using an Aria II flow 
cytometer (Becton Dickinson), with the results analysed using FACSDiVa (BD Bioscience). 
 
10.10  Polymerase chain reaction 
 
  RNA was extracted from HEK293 and HCT116 cells using RNeasy® kits (Qiagen). RNA (1 
µg) was then transcribed to cDNA using the SuperScriptIII® Reverse Transcriptase cDNA kit 
(Invitrogen) with a 1:1 mixture of oligo-dT20 and random hexamers as primers. To produce 
standards, firstly NOD2 plasmid was diluted serially from 1M to 1:1000M and GAPDH 
(derived from SW480 cells) similarly diluted from 1:50 to 1:5000. PCRs for NOD2 and 
GAPDH were carried out on the Rotorgene®6000 (Qiagen). The PCR mix was: EXPRESS 
SYBR® GreenER qPCR Supermix (Invitrogen) with premixed ROX containing 1µM of each 
primer and template cDNA, with RNA-negative and water controls. NOD2 primers had 
previously been generated in the laboratory of Prof. Satsangi and were a kind gift from Dr 
Elaine Nimmo. Primers were selected using Primer3 and crossed exons. The qPCR cycle 
was as follows: 95°C for 2 minutes, then 40 cycles of 95°C for 10 seconds and 60°C for 
30seconds.  
 
10.11  Generation of NOD2 stable cell lines 
 
  Wild-type (WT) NOD2 and the frameshift mutant NOD2 (NOD2-L1007fs) had previously 
been sub-cloned into the p3XFLAG-myc-CMV-26 expression vector (Sigma-Aldrich) (Figure 
10.2) in the laboratory of Prof. Satsangi by Dr Elaine Nimmo (Institute of Genetic and 
Molecular Medicine, University of Edinburgh). Once stably integrated into the host cell 
genome through Geneticin selection, this vector allows the expression of a dual tagged 






Figure 10.2. Details of the p3XFLAG-myc-CMV-26 expression vector. 
 
 
  HEK293 cells have previously been shown to express low levels of NOD2, with the 
HCT116 cell line showing intermediate expression and a known wild-type genotype.[916,917] 
Prior to deriving stable cell lines expressing the NOD2 and NOD2-L1007fs proteins an rtPCR 
was performed as outlined above. This was performed to compare NOD2 expression in the 
HCT116 and HEK293 cells. This demonstrated very low expression of NOD2 in the HEK293 
cell line compared to the HCT116 cells (Figure 10.3). In addition, to confirm the well-
recognised difficulties with detecting endogenous NOD2 protein, and to determine the best 
antibody for detecting over-expressed NOD2, an antibody 'screen' of the NOD2 antibodies 
currently held in the laboratory of Prof. Satsangi was also performed using western blot 
analysis. The HA-tagged NOD2 construct was used as a positive control. This demonstrated 
that the NOD2 polyclonal antibody purchased from Cayman Chemical was the only antibody 
to readily detected over-expressed NOD2 protein, with the ABR and Santa-Cruz antibodies 






Figure 10.3. rtPCR experiment showing relatively low expression of NOD2 mRNA in the 




Figure 10.4. Results of a 'screen' of NOD2 antibodies performed on wild-type and HA-tagged 
HEK293 cells, in addition to three other gastrointestinal cell lines. (a) Wild type and HA-
tagged HEK293 cells probed with HA antibody demonstrating expression of the over-expressed 
NOD2 protein. (b) Panel of three commercially available antibodies to NOD2 used to detect 
endogenous NOD2 and over-expressed NOD2 in HEK293 cells and three other gastrointestinal cells 
lines, HCT116, SW480 and HT29. 
 
 
  For stable NOD2-expressing cell line generation, parental HEK293 and HCT116 cells were 
first subjected to increasing concentrations of Geneticin antibiotic (Gibco). From this 
treatment it was determined that a concentration of 800μg/ml of Geneticin was sufficient to 
eliminate non-resistant cells from culture. Evidence of the effect of increasing Geneticin 
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concentrations on confluent HEK293 cell culture is shown in Figure 10.5; identical results  




Figure 10.5. Geneticin 'kill curve' for the HEK293 cell line. Images from top to bottom, left to 
right show increasing concentrations of Geneticin antibiotic (μl/ml) added to culture medium for 5-7 




  Multiple 10cm2 culture plates of HEK293 and HCT116 cells were therefore transfected with 
the empty vector, NOD2 or NOD2-L1007fs vectors using Lipofectamine (Invitrogen) as 
described above. A control plate of each cell line was left untransfected to allow the 
determination of resistant colonies. Fourty-eight hours following transfection, all cultures 
were grown in DMEM or McCoy's complete medium supplemented with 800µg/ml Geneticin 
until the control plate for each cell line was void of all cells and there was clear expansion of 
resistant colonies (Figure 10.6). Approximately 14 days after Geneticin selection resistant 
colonies expressing empty vector, NOD2 and NOD2-L1007fs were lysed with trypsin and 






Figure 10.6.  Example of HCT116 cells non-transfected and transfected with Geneticin-
resistant wild-type NOD2 vector. Control plate (left panel) shows killing of non-resistant cells at 
800μl/ml of Geneticin with expanding resistant colonies evident (right panel). 
 
 
10.12  Analysis of gene-wide susceptibility signal for Vim using an 
international genome-wide association meta-analysis 
 
  As with Chapter 5 and Chapter 6, an improved meta-analysis of GWAS data imputed with 
the 1000 genomes reference set (http://www.1000genomes.org) was interrogated. To 
assess variants in Vim (the gene encoding vimentin on chromosome 10 between positions 
17,270,258 - 17,279,592 [Ensembl Release 65 - ENSG00000026025]; Build 37) for 
association with CD susceptibility SNP-specific p values generated from these analyses of 
seven individual CD datasets encompassing 5,956 CD patients and 14,927 healthy controls 
(http://www.broadinstitute.org/mpg/ricopili/) were obtained. Haploview software version 4.2 
(http://www.broad.mit.edu/mpg/haploview)[593] was used to visualise the haplotype structure 



































11.  Characterisation of cells stably expressing wild-type 
NOD2 or the Crohn's disease-associated NOD2 frameshift 
mutation. 
 
11.1  Introduction 
 
  As previously discussed, the innate immune system is the body’s first-line, non-specific 
response to foreign antigen.[33] Both transmembrane and intracellular pattern recognition 
receptors (PRRs) recognise conserved, microbe-specific molecules named microbe-
associated molecular patterns (MAMPs), leading to an appropriate immune response.[343] 
The nucleotide binding and oligomerisation domain (NOD)-like receptor (NLR) family are a 
major group of PRRs with a characteristic architecture comprising a central NACHT (or 
NOD) domain, an N-terminal effector binding domain and C-terminal leucine-rich repeats 




Figure 11.1.  Schematic showing the three main domains of the NOD2 protein with 
corresponding residues. Additionally, the location of the three well-characterised Crohn's disease-
associated mutations are shown. CARD, caspase activation recruitment domain; NACHT, NAIP, CIITA, 
HET-E, TP1; LRR, leucine-rich repeat. 
 
 
  As discussed in detail in Chapter 4 and Chapter 9, although NOD2 was the first Crohn's 
disease (CD) susceptibility gene to be described, polymorphisms in this gene on 
chromosome 16 remain the strongest risk signal to date.[15] Polymorphisms in NOD2 have 
also been associated with an increased risk of graft versus host disease in allogeneic stem 
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cell and bone marrow transplantation, Blau's syndrome (a granulomatous disease affecting 
the eyes, skin and joints), allergic inflammation as well as other conditions.[607,918-922] There 
are currently three well-defined NOD2 polymorphisms which confer a high degree of disease 
susceptibility for CD (Figure 11.1),[923] with additional rarer variants recently described[603]. In 
one meta-analysis, those carrying two risk alleles had a 17.1-fold (95% CI 10.7–27.2) 
increased risk of CD;[924] to date the NOD2 frameshift (L1007fs) variant has consistently 
been shown to confer the highest individual risk of developing CD[923,924]. 
 
11.2  NOD2 pathway signalling 
 
  NOD2 has been shown to have cellular expression in antigen presenting cells such as 
dendritic cells and macrophages,[925] as well epithelial and Paneth cells[19,926]. Within these 
cell types it has been shown to interact with an array of different proteins,[927] however the 
exact mechanisms involved in the pathway from NOD2 to (1) NFB and pro-inflammatory 
cytokine release; (2) antigen presentation through the major histocompatibility complex class 
II system; and (3) type I interferon release, remain ill-defined[23,928]. In addition, the precise 
pathways coordinating the autophagy response to muramyl dipeptide (MDP) sensing 
(described in Chapter 9) are still poorly understood.  
  Initial studies of NOD2 function demonstrated that MDP-stimulation through the LRR 
domain led to NFB activation.[929] This process is initiated through a conformational change 
in NOD2 structure, leading to unfolding of the molecule to expose the CARD domain. 
Following this change, binding to the downstream adaptor protein RIPK-2 (or RICK) occurs, 
most likely at the plasma membrane.[930,931] The association of NOD2 and RIPK-2 leads to 
polyubiquination of RIPK-2 at lysine 209 which in turn requires the presence of an E3 ligase 
(most likely cIAP1/cIAP2), with other proteins such as ITCH also involved.[932-934] Other 
NOD2-interacting proteins include negative regulators such as Erbin,[935] Centaurin beta 
1,[936] and angio-associated migratory cell protein,[937] in addition to Rac1 GTPase[938]. A 
number of NOD2 regulatory factors such as GRIM-19, CARD9 and Bid have also been 
described.[939-941] 
  The well-characterised CD-associated NOD2-L1007fs variant has been shown to truncate 
the terminal 33 amino acids of the protein, resulting in a marked loss in the capacity to 
activate NFκB.[925] This MDP recognition abnormality in CD is in contrast to the Blau's 
syndrome mutation where mutations in the NACHT/NOD region affect the activation of 
NOD2, rather than MDP recognition. Despite a significant volume of research evaluating the 
clinical aspects of carriage of the CD-associated NOD2 variants, little is known about the 
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effect of NOD2 expression on cell morphology, proliferation, apoptotic response or protein 
stability. 
  With regard to cellular morphology, there are few studies to date evaluating the direct effect 
of NOD2 expression on cell size. Although researchers have directly imaged Paneth cells of 
patients with and without NOD2 polymorphisms,[942] in addition to murine work assessing the 
morphology of Peyer's patches in NOD2-deficient mice,[943] little data exists demonstrating 
any direct effect of NOD2 expression (wild-type or variant) on cell (or nuclear) size. In work 
carried out by Cruickshank et al., NOD2 mRNA levels in primary colonic epithelial cells 
(CEC) from C57BL/6 mice were measured.[944] This demonstrated that cells stained for the 
proliferation marker Ki67 contained significantly higher levels of NOD2 mRNA than cells 
stained for differentiation (with alkaline phosphatase). Also, crypt length was assessed in 
NOD2+/+ and NOD2 -/- mice, showing that NOD2-/- mice had shorter colonic crypt length 
(both pre- and post-infection with Salmonella) compared to their wild-type counterparts, 
although again this did not directly assess the cellular size, rather a proxy for cell 
proliferation. Further experiments in vitro showed that primary cultures of NOD2-/- CEC 
contained significantly higher numbers of apoptotic cells (as assessed by caspase 3 activity) 
and that cell numbers did not increase after 24 hour and 48 hour in culture, compared with 
NOD2+/+ CECs, although the data for these cultures at baseline was absent. Additionally, 
shRNA knockdown of NOD2 in colonic carcinoma cells lines (HT29 and SW480) 
demonstrated that reduced NOD2 protein expression led to a decline in cell survival, 
explained by decreased viability and increased apoptosis. Other studies evaluating the role 
of NOD2 in apoptosis have shown that MDP stimulated (FOXP3+) regulatory T cells were 
protected from death receptor Fas-mediated apoptosis.[22] However, despite evidence that 
NOD1 and other CARD-containing proteins are intimately involved in apoptosis through the 
caspases,[945,946] the over-riding mechanisms controlling apoptosis through NOD2 specifically 
remain elusive[947,948]. 
 
11.3  Hypotheses and aims 
 
Hypotheses:  
1. The stable over-expression of NOD2, but not the CD-associated NOD2-L1007fs 
variant influences basic cell morphology, early cell proliferation and baseline 
apoptosis. 
2. NOD2 protein stability and half-life are regulated through the ubiquitin-
proteasome pathway.  
3. The NOD2-L1007fs variant has altered stability and half-life in mammalian cells.  
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Aims: to characterise and compare HEK293 cells stably expressing wild-type NOD2 
(hereafter referred to as NOD2) or the CD-associated NOD2-L1007fs variant. More 
specifically to assess whether NOD2 affects cell morphology, proliferation, and baseline 
apoptosis. The regulation of protein stability and half-life of NOD2 and NOD2-L007fs variant 
through the proteasome and lysosome degradation pathways will be evaluated. 
 
11.4  Results 
 
11.4.1  HEK293 stably express both NOD2 and NOD2-L1007fs proteins with 
failure of the NOD2-L1007fs protein to interact with muramyl dipeptide 
  In order to assess the expression level of NOD2 and NOD2-L1007fs proteins in the derived 
HEK293 cell lines (see Chapter 10.11), western blot analysis was performed. Figure 11.1 
shows that the cell lines stably express proteins of the expected size (NOD2 ~130kDa), with 
the NOD2-L1007fs variant demonstrating a marginally smaller protein size in keeping with a 




Figure 11.1.  HEK293 cells showing the 
stable expression of NOD2 and NOD2-
L1007fs proteins. HEK293 cells stably 
expressing empty vector act as a control. The 
upper panel was probed with FLAG antibody 
demonstrating expression of NOD2 protein at 
130kDa and a marginally smaller protein in-
keeping with a truncated LRR domain on the 
NOD2-L1007fs protein. Emp, empty vector; WT, 
wild-type; F/S, NOD2-L1007fs. 
 
 
  To confirm that the expressed proteins were NOD2, immunofluorescent microscopy was 
performed using the NOD2 (Cayman) primary antibody identified in the initial antibody 
screen (Figure 10.4). In addition, cells derived from pooled clones and single clones were 
evaluated for uniform NOD2 expression, to determine the appropriate cell lines to use in 
subsequent experiments (Figure 11.2). It can be seen that both the pooled clones of the 
NOD2 and NOD2-L1007fs cells expressed similar levels of NOD2 protein, with empty vector 
used as a negative control. (Figure 11.2a). Similarly, three separate NOD2 single clone cell 
lines also expressed similar levels of NOD2 protein for both the NOD2 and NOD2-L1007fs 
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(Figure 11.2b). It was therefore decided that the pooled clones would be used in 
subsequent experiments as clonal selected cells may have integrated the plasmid at an 
inappropriate location (therefore disrupting a gene important for the pathway being studied). 
Pooled clones would hopefully mask any unwanted phenotype in addition to avoiding the 




Figure 11.2.  Immunofluorescent 
microscopy confirming stable 
expression of both wild-type NOD2 
and NOD2 frameshift proteins in 
pooled and single clones. (a) pooled 
clones and (b,c) three separate single 
clones in the HEK293 NOD2 and 
NOD2-L1007FS cell lines. Cells were 
probed with NOD2 primary antibody 
(Cayman) followed by incubation with 
(TRITC) conjugated anti-rabbit 
antibody. Nuclei are stained (blue) and 




  To assess the basic interaction of both the NOD2 and the NOD2-L1007fs proteins with 
MDP, cell lines were incubated for either 2 or 24 hours with FITC-labelled MDP. Figure 11.3 
shows that at 2 hours the MDP had penetrated the cell membrane and colocalised with the 
NOD2 protein (Figure 11.3a). This was more evident at 24 hours post MDP treatment 
(Figure 11.3b). In contrast, no colocalisation of MDP with NOD2-L1007fs was observed at 






Figure 11.3.  Failure of MDP to 
colocalise with the NOD2-L1007fs 
protein. (a, b) Cells treated with 1μg/ml 
of FITC-labelled MDP (green) for either 2 
or 24 hours show colocalisation (yellow) 
of MDP and NOD2 protein (red). (c, d) At 
both time points there is no clear 
colocalisation with the NOD2-L1007fs 




11.4.2  Overexpression of wild-type NOD2 or NOD2-L1007fs does not affect 
nuclear or cellular size 
  To assess the effect of overexpression of NOD2 and NOD2-L1007fs on nuclear size in the 
HEK293 stable cells, the three lines (empty vector, NOD2 and NOD2-L1007fs) were cultured 
for 24 hours on cover slips, fixed, permeabilised and stained with DAPI. Immunofluorescent 
microscopy was then used to produce five random images (at 40x magnification) of each cell 
line, with ImageJ used to measure the area of 100 randomly selected cells from each line. 
Figure 11.4a shows that no clear difference in nuclear size was evident on visual inspection; 




Figure 11.4.  Effect of 
overexpressed WT NOD2 and 
NOD2-L1007fs on nuclear size. 
Cells stably transfected with empty 
vector, NOD2 and NOD2-L1007fs 
were cultured for 24 hours in 
DMEM, fixed, permeabilised and 
stained with DAPI. 
Immunofluorescent microscopy was 
used to capture 5 random images 
(for each cell line) and nuclear size 
determined using ImageJ software. 
(a) Examples of images captured for 
each cell line. (b) Graph showing no 
statistical difference in nuclear size 
by Mann Whitney U testing. NS, not 




  A similar process was carried out to assess any differences in cell size. The three HEK293 
cell lines were cultured for 24 hours in standard 6 well plates. Following this, cells were 
placed under a standard light microscope and five random images taken of each cell line (at 
40x magnification). Cell size was determined using ImageJ by measuring the area of 50 
representative cells. Figure 11.5 shows that no difference in cell size was evident. 
 
 
Figure 11.5.  Effect of overexpressed 
WT NOD2 and NOD2-L1007fs on 
total cell size. Cells stably transfected 
with empty vector, NOD2 and NOD2-
L1007fs were cultured for 24 hours in 
DMEM. Normal white light microscopy 
was used to capture 5 random images 
(for each cell line) and mean cell size 
determined using ImageJ software. (a) 
Examples of images captured for each 
cell line. (b) Graph showing no statistical 
difference in nuclear size by Mann 
Whitney U testing. NS, not significant. 
WT, wild-type; F/S, NOD2-L1007fs. 
 
 
11.4.3  Presence of over-expressed NOD2 protein influences cell proliferation 
independent of wild-type or frameshift status 
  It had been observed during routine cell passaging that both the HEK293 NOD2 and 
NOD2-L1007fs cultures were proliferating at a faster rate than the empty vector stables. To 
assess if this was correct, and to assess if any difference in proliferation could be quantified, 
the three HEK293 stable cell lines were labelled with CFDA-SE. Cells were cultured for 72 
hours, with a control (i.e. non-proliferating) CFDA-SE-labelled cell suspension analysed at 
time 0 for comparison for each cell line. It can be seen in Figure 11.6 that even after 24 
hours in culture both the NOD2 stable cell lines had already shown an increased rate of 
proliferation compared to the empty vector. This was further accentuated by 36 hours, when 
the geometric mean CFDA-SE level for the empty vector cell line had only dropped to 5% of 





Figure 11.6.  Results of CFDA-SE 
proliferation studies to determine 
differing proliferation rates of stable 
cell lines. Empty vector, NOD2 and NOD2-
L1007fs HEK293 cells were cultured for 72 
hours following labelling with CFDA-SE. (a) 
Flow cytometry plots showing continued 
accelerated proliferation at Days 2 and 3 
for both the NOD2 and NOD2-L1007fs cell 
lines. (b) Graph showing relative 
percentage reduction in geometric mean 
CFDA-SE level from baseline (Day 0) 
confirming the visual assessment of flow 
plots. WT, wild-type; FS, NOD2-L1007fs. 
 
 
11.4.4  The effect of stable NOD2 expression on apoptosis 
  To assess the baseline level of apoptosis, the three HEK293 stable cell lines were cultured 
in DMEM in standard 6-well culture plates for 24 hours. Following this period cell pellets 



































































were collected and lysates probed with Poly ADP ribose polymerase (PARP) antibody 
looking for differences in cleaved PARP (a measure of apoptotic activity[948]). Figure 11.7 
shows that the basal level of PARP cleavage was similar in all three cell lines. To assess 
whether NOD2 influences the apoptotic response in response to stress (specifically serum-
starvation and MDP treatment) cell lines were cultured in standard DMEM, Dulbecco’s 
balanced salt solution (serum-starved) or treated with 5μg/ml of L18-MDP, all for 24 hours. 
Figure 11.8 shows that both the NOD2 and NOD2-L1007fs cell lines had an increased 
apoptotic response to serum starvation at the 24 hour time point compared to the empty 
vector, with a stronger response seen in the wild-type NOD2-expressing cells. No clear 




Figure 11.7.  Assessment of baseline 
apoptosis in cell lines stably 
expressing NOD2 and NOD2-L1007fs. 
Three HEK293 cell lines stably expressing 
empty vector, NOD2 and NOD2-L1007fs 
were cultured for 24 hours in DMEM with 
lysates probed for PARP. Empty, empty 
vector; WT, wild-type; F/S, NOD2-L1007fs.  
 
 
Figure 11.8.  Assessment of the effect of stress on apoptosis in cell lines stably expressing 
NOD2 and NOD2-L1007fs. Three HEK293 cell lines stably expressing empty vector, NOD2 and 
NOD2-L1007fs were cultured for 24 hours in either DMEM, Dulbecco's balanced salt solution (serum-
starved) or in DMEM with 5ìg/ml of L18-MDP. After 24 hours of culture lysates were probed with 




11.4.5  The NOD2 frameshift protein has a shorter  half-life than wild-type NOD2 
and is mainly degraded in a proteasome dependent manner, possibly through the 
CARD domain 
  To compare the half-lives of the NOD2 and NOD2-L1007fs proteins, cells from each stable 
line were cultured in 6-well culture plates and treated with cycloheximide (a well-
characterised inhibitor of protein synthesis[949]) for 24 hours; cells were collected at 0, 8, 16 
and 24 hours post treatment and lysates assessed for NOD2 protein levels by western blot 
using FLAG antibody. Figure 11.9 shows that the NOD2-L1007fs protein has a shorter half-




Figure 11.9.  Treatment of HEK293 NOD2 and NOD2-L1007fs cells with cycloheximide 
demonstrates that the NOD2-L1007fs protein has a shorter half-life than NOD2. Stable cell 
lines were treated with cycloheximide at 10ug/ml for 24 hours, with cell pellets obtained at 0, 8, 16 
and 24 hour time points. Lysates were probed with FLAG antibody and relative NOD2 protein level 
compared to β-actin. Empty, empty vector; WT, wild-type; F/S, NOD2-L1007fs; Chx, cycloheximide. 
 
 
  To further assess the mechanism by which the NOD2 protein is degraded, two well 
characterised inhibitors of the ubiquitin proteasome or lysosome degradation pathways were 
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utilised. MG132 (carbobenzoxyl-L-leucyl-L-leucyl-L-leucinal) is a natural peptide-aldehyde 
proteasome inhibitor derived from a Chinese medicinal plant.[950] This compound binds to the 
beta subunit of the 20S proteasome and therefore blocks the proteolytic action of the 26S 
proteasome complex.[951] MG132 therefore effectively inhibits the degradation of proteins 
disassembled by the ubiquitin-proteasome pathway. Conversely, chloroquine, a 4-
aminoquinoline drug used mainly in the treatment of malaria, has been shown to inhibit the 
lysosome, thus reducing the degradation of proteins broken down via this pathway.[952] 
Chloroquine enters the acidic lysosome where deprotonation leads to trapping of the 
compound in the lysosomal compartment, leading to an increase in pH and reduced 
lysosomal pathway activity.[953] HEK293 cells were transiently transfected with HA-tagged 
NOD2 or NOD2-L1007fs DNA then treated with MG132 for 6 hours and with chloroquine for 
16 hours in standard medium (DMEM) to assess the potential accumulation of each protein. 
Figure 11.10 shows that both the NOD2 and NOD2-L1007fs proteins accumulated with 
MG132 treatment, with a characteristic high molecular weight polyubiquination 'smear' 
evident on the western blot.[954] Chloroquine treatment had no observable effect on NOD2 




Figure 11.10.  Use of MG132 and chloroquine to determine the main pathway utilised to 
degrade the NOD2 and NOD2-L1007fs proteins. HEK293 cells were transfected with HA-tagged 
NOD2 and NOD2-L1007fs DNA for 16 hours prior to a 6 hour treatment with MG132 (10μM) or 16 
hour treatment with chloroquine (100μM). Cells were then harvested and lysates probed with HA 
antibody. Unstim, unstimulated; chloro, chloroquine; WT, wild-type; F/S, NOD2-L1007fs.  
 
 
  Having determined that the NOD2 protein is likely degraded through a proteasome-
dependant pathway, the HA-tagged full-length NOD2 protein in addition to the NOD2 
mutants with a truncated LRR domain (NOD2 [1-693]), or truncated LRR and NACHT 
domains (NOD2 [1-247]) (Figure 11.11) were subjected to a similar treatment with MG132 to 
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assess the accumulation of NOD2 protein. Figure 11.12 shows that a ubiquitin smear was 
present with a sustained accumulation of protein evident with only the minimal CARD 
domain. This suggests that the amino acid residue(s) required for ubiquitination and 
subsequent targeting of NOD2 for proteasomal degradation may be situated in the first 247 




Figure 11.11. Schematic representation of the full length NOD2 protein and mutant NOD2 
proteins used to evaluate the ubiquination site on the NOD2 protein. Site-directed 
mutagenesis was used to produce two NOD2 mutants with either the LRR, NOD2 (1-693), or the LRR 




Figure 11.12. Use of NOD2 
truncated mutant proteins to 
determine the site of possible 
ubiquination for proteasome 
degradation. HA-tagged NOD2 
protein, in addition to NOD2 (1-693) 
and NOD2 (1-247) were treated with 
MG132 (10μM) for 6 hours and cell 
lysates probed with HA antibody. 
 
 
11.5  Discussion 
 
  In HEK293 cells (that express low levels of NOD2), overexpression of NOD2 and NOD2-
L1007fs proteins can be easily detected by western blot and immunoflourescence. This 
overexpression has been shown not to influence cell or nuclear size, but does seem to effect 
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cellular proliferation, independent of polymorphism status. Additionally, although no evidence 
of differences in baseline apoptosis were apparent, cells overexpressing NOD2 or NOD2-
L1007fs had an accentuated apoptotic response to serum starvation, but not treatment with 
MDP, with the direct interaction of NOD2 with MDP impaired with the frameshift protein. 
Finally, using proteosome and lysosome inhibitors it has been determined that NOD2 protein 
stability is regulated through the ubiquitin-proteasome degradation pathway. Transient 
expression of truncated mutant NOD2 proteins revealed that stability is likely regulated  
through lysine amino acid residues present at least in the CARD domain. 
  With respect to cellular size there was no clear difference in cells expressing NOD2 or 
NOD2-L1007fs by simple light microscopy. Although this did not take into account cell 
volume per se (which would require layered imaging by confocal microscopy), it was clear 
visually that no discrepancy was evident. The processes controlling cell size are complex 
with nucleotides, amino acids, sugars and fatty acids making up the majority of structural cell 
mass.[955] Cell growth is tightly regulated by growth factors which control cell expansion 
through the phosphorylation of initiation factors, with nutrient availability and growth factors 
critical in maintaining steady growth, and the mammalian target of rapamycin (see Chapter 
12) acting as the main intracellular regulator of biosynthesis.[956] The balance between 
cellular degradation (through processes such as autophagy) and cell expansion are tightly 
controlled,[957] and the lack of evidence relating to difference in size at baseline between the 
empty vector and NOD2 cell lines, suggests that unstimulated NOD2 does not have direct 
effects on growth signalling or specifically mTOR activity. With regard to the mechanisms 
determining nuclear size, there is as yet no consensus on the factors involved. Two current 
observations which may explain differences in size are the karyoplasmic ratio (i.e. nuclear 
size is directly proportional to cytoplasmic volume)[958] and the nucleoskeletal theory which 
states that the larger the genome, the larger the cell. The latter theory has been dissected 
over recent years but has come up against resistance due to the observations that nuclear 
size differs within the same organism,[959] in addition to a 16-fold increase in ploidy having no 
effect on nuclear size[960]. There are currently no direct reasons why over-expression of 
NOD2 (either wild-type or L1007fs) would have influenced nuclear size, however with the 
endoplasmic reticulum (specifically endoplasmic reticulum stress) gaining more interest in 
CD pathogenesis (Chapter 4.3.6), and it's intimate role in the development of the nuclear 
envelope, further links between the NLRs and nuclear volume may become apparent.[492] 
  As discussed in the introduction, there is currently little direct evidence that NOD2 effects 
cellular proliferation, as crypt length has most often been used as a proxy.[944] Although 
Cruickshank et al. determined BrdU incorporation in NOD2+/+ and NOD2-/- murine colonic 
crypts, the marginal difference in the number of BrdU+ cells in the wild-type and null mice 
prior to infection with Salmonella may not have been clinically relevant, with no clear growth 
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in the null mice evident after infection suggesting only lack of growth during MDP stimulation. 
In the proliferation experiment outlined above, over the course of a 72 hour experiment, the 
HEK293 cells expressing either NOD2 or NOD2-L1007fs progressed through more cellular 
proliferation that the empty vector alone. Direct links between NOD2 and proliferation have 
not been forth-coming, however it is intriguing that the interaction between NOD2, RIPK-2 
and cIAP1/cIAP2 (as outlined in the introduction) may play a part. Conceivably, the 
overexpression of NOD2 in the absence of MDP-sensing could affect the balance of 
cIAP1/cIAP2 activity leading to modulation of any number of cell mechanisms such as cell 
survival , proliferation or differentiation.[961] Additionally, other NOD2 interacting proteins such 
as GRIM-19 are closely linked to cell proliferation,[962] with binding of these proteins 
potentially reducing their cytoplasmic availability leading to a loss in the normal negative 
feedback required to control proliferation[963].  
  Previous studies assessing the role of NOD2 during apoptosis have mainly evaluated cells 
with or without NOD2 expression. In this study, the level of baseline apoptosis of cells 
overexpressing NOD2 or NOD2-L1007fs was also considered. It was evident that the 
expression of NOD2 had no effect on baseline apoptosis (as determined by the 
measurement of cleaved PARP) but that NOD2 expression did have a negative effect on 
stress induced by serum-starvation, but not MDP treatment. This single experiment does not 
offer any indication as to the dynamics of apoptosis activation in these cell lines, and the 
effect of MDP especially may have been transient, therefore evidence of apoptosis at earlier 
time-points may have been missed. However the increased degree of apoptosis with serum-
starvation is certainly of interest. Serum-starvation is a well characterised inducer of 
apoptosis,[964,965] and there was some evidence in the HEK293 cells expressing empty vector 
that serum-starvation had activated the apoptotic pathway. The increased apoptotic 
response in the NOD2 cell lines (more so in the wild-type than L1007fs line) may reflect 
simply the processes involved in protein overexpression making the cells more sensitive to 
stress, however direct effects on apoptosis should certainly be considered. A number of 
NOD proteins have been shown to be involved in the apoptotic pathway, including 
APAF1,[966] NOD1,[967] DEFCAP,[968] and IPAF[969]. It has been recognised that these proteins 
often have a dual effect, signalling to capases and NFB leading to simultaneous pro- and 
anti-apoptotic effects,[970] similar to the effect seen with toll-like receptors[971,972]. Potentially in 
the absence of MDP stimulation the imbalance of caspase activation and NFB production 
may have led to an increased apoptotic response. Specifically with regard to the apoptotic 
response during serum-starvation, recent work showing that NOD2 binds ATP,[973] and the 
close link between ATP and energy metabolism may be relevant. 
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  Several experiments carried out on the NOD2 protein demonstrated that there were 
significant differences in half-life between the NOD2 and NOD2-L1007fs proteins. 
Additionally, work also showed that the NOD2 protein is likely to be degraded through the 
ubiquitin-proteasome pathway through lysine residues on the CARD domain or other protein 
sites. Protein half-life is controlled by the balance of protein degradation and protein 
synthesis therefore the difference demonstrated between the wild-type and L1007fs proteins 
may reflect differences in either pathway. Given that subsequent experiments demonstrated 
the likely role of the ubiquitin-proteasome pathway in NOD2 degradation, with very recent 
work confirming this finding,[974] the relevance of the differing half-lives is of interest. In fact, a 
very recent study has shown that ectopically expressed NOD2 is ubiquitinated with K48-
linked ubiquitin chains on the NOD domain followed by proteasomal degradation through 
functional TRIM27, but with proteins often displaying several ubiquitination sites on multiple 
domains,[975] it has yet to be seen if specific sites on the CARD or LRR domains will be 
determined. Specifically, the differing half-lives of the NOD2 and NOD2-L1007fs proteins 
may reflect the importance of residues on the LRR domain, and with recent work 
demonstrating the potential importance of this domain in proteasomal degradation in other 
NLR proteins,[969] further work is certainly warranted to delineate this relationship further.   
 
11.6  Conclusion 
 
  It can be seen that overexpression of the NOD2 or NOD2-L1007fs variant has no influence 
on cell or nuclear size, but does seem to effect cellular proliferation, independent of 
polymorphism status. Additionally, there is an accentuated apoptotic response to serum 
starvation with NOD2 overexpression with the NOD2 protein most likely degraded through 
the proteasome-ubiquination pathway. Further work is now required to determine the precise 
mechanisms connecting NOD2 with apoptotic and proliferation pathways, and how different 
lysine residues may be responsible for ubiquitination and subsequent proteasomal 





































12.  Autophagy signalling in inflammatory bowel disease - 
mammalian target of rapamycin, vimentin and azathioprine 
 
12.1  Introduction 
   
  In Chapter 9.5.1 recent work linking NOD2 and autophagy was examined in detail, 
especially with relation to Crohn's disease (CD). These studies carried out by several 
independent groups demonstrated that muramyl dipeptide (MDP) induced autophagy 
through NOD2, that NOD2 colocalised with the major autophagy protein ATG16L1, and that 
CD-associated variants in NOD2 influenced bacterial handling and antigen presentation.[30,31] 
Although these studies were a ground-breaking insight into NOD2 signalling, the authors 
were unable to determine the precise mechanisms involved in this MDP-induced autophagy, 
however the mammalian target of rapamycin (mTOR) was suggested as a possible major 
participant in the NOD2-autophagy pathway.[30] Additionally, with a number of novel NOD2-
interacting proteins now identified (e.g. vimentin[915]) their role in this important pathway has 
yet to be elucidated. As discussed in Chapter 1.5.3, the mechanism of action of many 
therapeutic agents remains still unclear in relation to inflammatory bowel disease (IBD) 
pathogenesis, and with autophagy a potential therapeutic target in other inflammatory 
conditions,[976-978] as well as IBD,[979] the effect of these drugs on the autophagic machinery is 
of particular interest.  
  
12.1.1  Mammalian target of rapamycin 
  Genetic screening of Saccharomyces cerevisiae identified two TOR genes (TOR1 and 
TOR2), giving an early indication of the importance of TOR in the control of cell 
proliferation.[980] This discovery was facilitated by utilising rapamycin, an antifungal 
metabolite produced by the Gram-positive eubacteria Streptomyces hygroscopicus, isolated 
from a soil sample obtained on Easter Island in the early 1970s.[981] The mammalian 
orthologue mTOR is a protein encoded by the MTOR gene on chromosome 1p36.2 in 
humans;[982] this serine/threonine protein kinase with a large molecular mass (300kDa) is a 
member of the phosphatidylinositol kinase-related (PIKK) family.[983] Since its discovery, 
mTOR has been shown to be a key component in the regulation of a myriad of complex 
cellular processes including cell growth and autophagy.[984,985] Through these intricate 
processes mTOR also influences cell proliferation, cell motility, cell survival and protein 
synthesis and transcription.[986] The majority of research focusing on mTOR has been in 
relation to cancer pathogenesis and therapy,[987] however a growing volume of work is now 
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beginning to uncover important roles for mTOR in innate immunity,[988] the adaptive immune 
response (including T cell activation[989] and regulatory T cell function[990]), behaviour and 
intellect[991] and metabolic homeostasis[992]. Since its first description in 1991, mTOR has 
been shown to bind several proteins to form two distinct protein complexes, namely 




Figure 12.1.  Schematic representation of the two known mTOR complexes. mTORC1, 
mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; 
PRAS40, proline-rich AKT substrate 40kDa; GβL, G protein beta subunit-like; 4E-BP1, Eukaryotic 
translation initiation factor 4E-binding protein 1; S6K, S6 kinase; Sin1, stress-activated protein 




  Specifically related to autophagy, although the mTORC2 complex does have some 
influence on autophagy through transcription factors such as FoxO3, the current evidence 
suggests that the autophagy response is mainly controlled through mTORC1.[993,994] In 
conditions of abundant nutrients, growth factors and insulin, signalling through mTORC1 
promotes cell growth and stimulates protein translation with concomitant inhibition of 
autophagy (Figure 12.2a). However during periods of starvation this inhibition through 
mTORC1 is released leading to autophagy induction (Figure 12.2b).  
  Although the mTOR pathway is extremely complex,[956] there are certain methods that can 
be utilised to artificially induce autophagy to allow its investigation. As alluded to above, the 
withdrawal of nutrients from culture medium is a well-recognised method of inducing 
autophagy in vitro.[995] Additionally, rapamycin (also known as Sirolimus) forms a complex 
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with FKBP12 (FK506-binding protein-12), which subsequently binds to mTOR within the 
mTORC1 complex inducing autophagy,[996] most likely through direct effects on the mTORC1 
protein regulatory associated protein of mTOR (raptor).[997,998] Rapamycin has long been 
shown to possess immunosuppressive and antiproliferative properties, being used for many 
years in transplant medicine.[999] Although rapamycin has also been shown to have direct 
effects on the mTORC2 complex,[1000] these effects relate more to glucose metabolism,[1001] 
with only some evidence linking mTORC2 with autophagy[1002]. Within the autophagy 
pathway, bafilomycin A1 (a vacuolar-type H+-ATPase inhibitor that inhibits the fusion of the 
autophagosome and lysosomes and therefore the subsequent accumulation of LC3-II[1003]) 
has also been used to accentuate the conversion of LC3-I to LC3-II and thus help to 




Figure 12.2.  Basic mTORC1 signalling pathway demonstrating activity during periods with 
and without starvation and cellular stress. (a) During periods of abundant nutrients, growth 
factors and insulin, activation of mTORC1 leads to protein translation and protein synthesis. (b) 
During starvation (or cellular stress) inhibition of mTORC1 leads to autophagy induction through the 
TSC complex and class III PI3K pathways.  
 
 
  Following induction with either pharmcotherapy or other compounds, autophagy must then 
be quantified to allow meaningful studies to be performed.[1004] As there is no single, robust 
method employed to determine this quantification, recent guidelines on the measurement 
and interpretation of autophagy assays have suggested using a combination of different 
assays, primarily western blot of LC3-I and LC3-II, immunofluorescent microscopy of steady 
state green fluorescent-labelled protein LC3 (GFP-LC3), in addition to measurement of the 
phosphorylation of substrates directly downstream from mTORC1.[1005] With regard to these 
downstream substrates of mTOR, phosphorylation of S6 kinase (S6K) and ribosomal protein 
S6 kinase-1 (rpS6) are stimulated by insulin and growth factors in an mTORC1-dependent 
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manner.[994] Phosphorylation at both these sites (S6K at threonine 389 [T389] and rpS6 at 
serine 235/236 [S235/236]) are therefore well established readouts of mTORC1 activity in 




Figure 12.3.  Diagrammatic representation of the process of autophagy induction and the 
assays used to determine these changes. Starvation/stress and rapamycin have been shown to 
act on the mTORC1 complex to induce autophagy (top panel). Due to the direct effects on mTORC1, 
substrates downstream (S6K, rpS6) are dephosphorylated which can be assessed using western blot 
(bottom left panel). Also, using GFP-LC3 (see Figure 9.2 for further details on LC3 biogenesis) a 
diffuse pattern of GFP immunofluorescence can be observed, with punctate LC3 foci visible as the 
autophagosomes form. An increase in LC3-II (smaller sized band on GFP-LC3 western blot) can also 
be determined (bottom right panel). Un, unstimulated; Stim, stimulated. 
 
 
12.1.2  The intermediate filament vimentin in CD pathogenesis 
  As discussed in Chapter 11.2 only a small number of NOD2 interacting proteins have been 
identified to date,[927] and currently there is limited knowledge with regard to their functional 
effect on NOD2.[927] In a previous yeast-two-hybrid (Y2H) screen carried out in the laboratory 
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of Prof. Jack Satsangi (Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, 
University of Edinburgh), a novel interaction between NOD2 and the cytoskeletal protein 
vimentin was described.[1007] Vimentin is the major intermediate filament (IF) protein in cells 
of mesenchymal origin where it plays an important role in the maintenance of cell 
architecture.[1008] Along with actin filaments and microtubules the IF proteins constitute one of 
the three main cytoskeletal components in eukaryotic cells, with desmin, vimentin, peripherin 
and glial filament acidic protein (GFAP) making up the type III IF proteins.[1009] Analysis of IF 
protein primary structures has shown that despite enormous diversity, all these proteins 
share a common structure, namely a central alpha-helical domain flanked by a non-helical 
N-terminal and C-terminal domains.[1010]  
  Specifically, vimentin has been shown to be important for the correct positioning and 
trafficking of organelles within the cytoplasm and is emerging as an important factor linked to 
bacterial and viral pathogenicity.[1011,1012] Several recent studies have shown that vimentin is 
expressed on the surface of certain cell types, with this surface-expressed vimentin 
possessing lectin-like properties.[1013] Vimentin can bind to the monosaccharide N-
acetylglucosamine (GlcNAc), which is cross-linked together with N-acetylmuramic acid to 
form peptidoglycan, a major constituent in the bacterial cell wall (MDP is the minimal 
peptidoglycan motif common to both Gram-positive and Gram-negative bacteria).[1014,1015] 
Furthermore, vimentin has been shown to be involved in the endocytosis of GlcNAc-
conjugated liposomes suggesting that vimentin is actively involved in the internalisation of 
GlcNAc-bearing ligands on cell surfaces.[1013,1015] Cell surface-expressed vimentin has in the 
same way been identified as the binding target for several viruses such as Japanese 
encephalitis virus with vimentin structure and gene expression changing profoundly during 
infection.[1016] Most relevant to CD pathogenesis are recent reports that vimentin is 
expressed on the surface of human brain endothelial cells where it acts as a primary 
receptor for adherent-invasive E.coli strains expressing the virulence factor IbeA (see 
Chapter 9.6).[1011] Of particular significance is that the proper formation and distribution of 
autophagosomes depends on the integrity of intermediate filament networks,[1017,1018] and 
that autophagic vacuoles are found to be associated with vimentin[1019,1020]. 
 
12.1.3  The effect of inflammatory bowel disease therapeutic agents on autophagy 
  As discussed in Chapter 9, there have now been numerous studies evaluating the 
autophagy pathway-phenotype correlation in relation to IBD, especially CD. However, 
despite this keen interest, few studies have aimed to determine any potential manipulation of 
the autophagic process with currently utilised IBD therapies. Much of the current literature 
focuses solely on the genetic aspects of autophagy in IBD,[1021,1022] yet recent studies have 
alluded to the fact that increasing autophagy levels in CD patients may be of therapeutic 
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benefit[27,902]. One of the most intriguing reports of the potential of autophagy manipulation 
was published by Massey et al. in 2008. They presented the case of a 37-year-old woman 
with severe refractory colonic and perianal CD, who had lost response to second-line 
therapies. Following treatment with Sirolimus for six months there was a marked and 
sustained improvement in both her clinical symptoms and mucosal appearance at 
endoscopy. Another case report of the successful use of autophagy inducers in CD 
treatment has been published,[1023] as well as encouraging work in IL10-/- colitic mice,[1024] 
but clinical trials have yet to prove the efficacy of these drugs in large scale clinical 
practice.[1025] 
 
12.2  Hypotheses and Aims 
 
Hypotheses: 
1. MDP-induced autophagy through NOD2 involves signalling via mTORC1 and this 
interaction is dysregulated by the CD-associated NOD2 frameshift variant (NOD2-
L1007fs). 
2. The NOD2-interacting protein vimentin is involved in MDP-induced autophagy and 
the gene encoding vimentin (Vim) has an association signal for CD susceptibility. 
3. Drugs commonly used during paediatric inflammatory bowel disease (PIBD) 
management induce autophagy through an mTORC1 dependent pathway. 
 
Aims: To establish a robust system of measuring autophagy in both HEK293 and HCT116 
cell lines in addition to a reliable read-out of mTORC1 activity during autophagy induction. 
To determine if mTORC1 and/or vimentin is involved in MDP-induced autophagy induction, 
in addition to assessing the association signal of the single nucleotide polymorphisms in the 
gene encoding vimentin (Vim) with regard to the genetic susceptibility to CD. To determine 











12.3  Results 
 
12.3.1  The stable expression of green fluorescent-labelled protein LC3 is 
required for the robust identification of autophagy induction within HEK293 and 
HCT116 cell lines. 
  To first determine the potential utility of endogenous LC3 the parental HEK293 and 
HCT116 cell lines were treated with rapamycin, serum-starvation (using Dulbecco’s 
balanced salt solution [DBSS]) or bafilomycin A1 (hereafter referred to as bafilomycin) for 4 
hours and assessed for LC3 foci formation by immunofluorescent microscopy or for LC3 
lipidation by western blot. Figure 12.4 shows that although there was some formation of 
punctate LC3 foci in the rapamycin-treated HEK293 cells and rapamycin- and bafilomycin-
treated HCT116 cells, this did not correlate well with the western blot analysis, nor did the 
predicted autophagic response to serum-starvation produce a useful readout. 
 
 
Figure 12.4.  Use of endogenous LC3 to identify autophagy induction in HEK293 and HCT116 
cell lines. HEK293 (a) and HCT116 (b) cell lines were left unstimulated or treated with rapamycin 
(100nM), serum-starvation (with DBSS) or bafilomycin (100nM) for 4 hours and the conversion of 
LC3-I to LC3-II assessed by western blot or the presence of punctate LC3 foci assessed by 
immunofluorescent microscopy (with secondary TRITC-labelled rabbit secondary). Un, unstimulated; 





  As this method of identifying autophagy induction was not robust, the HEK293 and HCT116 
cell lines stably expressing GFP-LC3 were evaluated to determine if a more rigorous system 
could be established. It first needed to be established, as suggested by the recent 
guidelines,[1005] as to what constituted a 'positive' autophagy response in the current 
experimental system. To achieve this, HEK293 GFP-LC3 cells were treated with either 
rapamycin or DBSS for 2 hours. Figure 12.5 shows that although four different methods 
used to evaluate autophagy induction exhibited some degree of measureable response, the 
use of greater than five autophagosomes (i.e. punctate LC3 foci) per cell allowed for basal 
levels of autophagy, while exhibiting significant increases in foci formation in response to 




Figure 12.5.  Evaluation of four separate methods of identifying autophagy induction in 
HEK293 GFP-LC3 cells. HEK293 GFP-LC3 cells were plated on glass coverslips and either left 
untreated or treated with rapamycin (100nM) or serum-starvation (DBSS). Cells were then fixed and 
visualised with immunofluorescent microscopy. The total number of autophagosomes (i.e. LC3 foci) 
per 40x field (a), the percentage of GFP-LC3 positive cells with greater than five autophagosomes (b), 




  With a clear method of assessing autophagy by immunofluorescent microscopy 
established, the two GFP-LC3 stable cell lines were compared for their response to 
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treatment with rapamycin, serum-starvation (with DBSS) or bafilomycin for varying lengths of 
time. Cells were then visualised directly using immunofluorescent microscopy. Figure 12.6 
shows that both the HEK293 and HCT116 GFP-LC3 cells responded well to treatment with 
rapamycin and serum-starvation, with the HCT116 cell line showing a higher basal 
autophagy level. 
  To correlate the results of the immunofluorescent microscopy with the western blot analysis 
in the GFP-LC3 stable cell lines, a more limited set of treatments were applied to cultures of 
each cell line, with cell lysates immunoblotted with both LC3 antibody (therefore detecting 
LC3 bound to GFP), in addition to GFP antibody ('free' GFP is produced following expulsion 
of the LC3 complexes from the autophagosome[1026]). Figure 12.7 demonstrates that 
detection of GFP-LC3 showed a clear increase in LC3-II response to bafilomycin treatment 
in both cell lines, and that the liberation of free GFP showed a consistent response (Figure 
12.6) in the HEK293 cells. However, the free GFP response did not correlate well in the 
HCT116 cell line and overall the GFP-LC3 response was variable and confirmed that various 






Figure 12.6.  Evaluation of autophagy response in HEK293 and HCT116 cells stably 
expressing GFP-LC3. HEK293 GFP-LC3 (a) and HCT116 GFP-LC3 (b) cell lines were treated with 
rapamycin (100nM), serum-starvation (with DBSS), bafilomycin (100nM), or left unstimulated. Figure 
shows representative immunofluorescent microscopy pictures and full results (graphs). Unstim, 
unstimulated; Rapa, rapamycin; Bafilo, bafilomycin. *=p<0.05, **=p<0.01, ***=p<0.001; NS, not 
significant by Mann-Whitney U. 
 
Figure 12.7.  Assessment of GFP-LC3 and free GFP in HEK293 GFP-LC3 and HCT116 GFP-LC3 
cell lines. Both cell lines were treated with rapamycin (100nM), serum-starvation (with DBSS) or 
bafilomycin (100nM) for 2 hours, or left untreated. Lysates were immunoblotted with LC3 antibody 




12.3.2  A reduction in phospho-S6K and phospho-rpS6 provide a robust readout 
of mTORC1 activity and autophagy induction in HEK293 and HCT116 cell lines. 
  In order to determine if a reduction in phosphorylated S6K (T389) and rpS6 (ser 235/236) 
provide a robust readout of mTORC1 activity (and therefore an indirect measurement of 
autophagy induction[1005]), HEK293 and HCT116 cells lines were treated with rapamycin, 
serum-starvation (with DBSS) or bafilomycin. Cell lysates were then immunoblotted with 
phospho-S6K and phospho-rpS6 antibodies by western blot. Figure 12.8 shows that both 
cell lines responded appropriately to rapamycin treatment and serum-starvation, with the 
level of detectable phosphorylation of S6K and especially rps6 showing a significant 
reduction at all time points. 
  While there was a clear decrease in the level of endogenous phospho-S6K observed, it 
was less clear than the decrease observed in phospho-rpS6. To overcome this, an HA-
tagged S6K construct (a kind gift from Dr Craig Stevens, University of Edinburgh and Napier 
University) was transiently transfected into both parental cell lines and a shortened 
experiment repeated. Figure 12.9 shows that exogenous HA-S6K provides a much more 
robust reduction in phosphorylation at T389 than endogenous S6K. 
 
 
Figure 12.8.  Use of phospho-S6K and phospho-rpS6 as readouts of mTORC1 activity (and indirect 
autophagy induction). HEK293 (a) and HCT116 (b) cells were plated for 24 hours before treatment 
with rapamycin (100nM), serum-starvation (with DBSS) or bafilomycin (100nM) for varying lengths 
of time. Cell lysates were then immunoblotted with the appropriate antibody by western blot. 




Figure 12.9.  Use of transiently transfected HA-tagged S6K to more robustly assess the 
reduction of phospho-S6K during autophagy. HEK293 cells (left panel) and HCT116 cells (right 
panel) were plated in 6-well plates and after 24 hours of culture transiently transfected with 2μg of 
HA-S6K DNA for 16 hours. Following this, cells were treated with rapamycin (100nM), serum-
starvation (with DBSS) or bafilomycin (100nM) for 2 hours. Cell lysates were immunoblotted with 
phospho-S6K (T389) and HA antibody by western blot. NT, not transfected; Un, unstimulated; Rap, 
rapamycin; SS, serum-starved; Baf, bafilomycin. 
 
 
  Finally, to determine if the previously established methods of autophagy induction (Figure 
12.6) and mTORC1 readout (Figure 12.8 and Figure 12.9) corresponded to true autophagy, 
two different methods were employed. Firstly, the autophagy inhibitor 3-methyadenine (3-
MA) was used in HEK293 parental cells to reduce the level of autophagy to almost basal 
levels (Figure 12.10). 3-MA is a well-recognised, non-specific inhibitor of autophagy which 
works by impeding autophagy at the sequestration step by inhibiting class III PI3 kinase 
activity, without markedly affecting protein synthesis.[1027] It can be seen that the use of 3-MA 
does not restore mTORC1 activity, as although 3-MA is thought to act upstream of mTOR, it 






Figure 12.10.  Use of 3-methyladenine to demonstrate true autophagy induction in the 
current experimental system. HEK293 cells were plated on either coverslips or 6-well plates for 24 
hours before transient transfection with HA-S6K. Cells were then left for 16 hours before being 
treated with serum-starvation (with DBSS) or serum-starvation in the presence of 3-MA (10μl/ml) for 
6 hours. Cell lysates were then immunoblotted for S6K and rpS6 (with corresponding phospho-
antibodies) in addition to direct visualisation of cells by immunofluorescent microscopy. NT, not 
transfected; Un, unstimulated; SS, serum-starved; 3-MA, 3-methyladenine. 
 
  Additionally, small interfering RNA (siRNA) to the critical autophagy protein ATG7 (see 
Figure 9.2) was used to show that the autophagy response produced by serum-starvation 
was genuine and that this response could be significantly tempered with manipulation of the 
this key autophagy protein (Figure 12.11). 
 
 
Figure 12.11.  Use of ATG7 siRNA to temper the autophagy response induced by serum-
starvation. HEK293 GFP-LC3 cells were plated on coverslips and left untransfected or transfected 
with control siRNA or ATG7 siRNA as per the manufacturer's protocol. Cells were then cultured for 
16 hours in DMEM or DBSS (serum-starved), fixed and visualised by immunofluorescent microscopy. 
**=p<0.01 using Mann-Whitney U. 
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12.3.3  HEK293 cells stably expressing wild-type NOD2 and NOD2 frameshift 
proteins exhibit normal baseline autophagy and a normal response to autophagy 
induction through mTORC1 
  Before using the HEK293 NOD2 cell lines (expressing wild-type NOD2 or the CD-
associated frameshift variant [NOD2-L1007fs]) generated in Chapter 10.11 and 
characterised in Chapter 11.4.1, their baseline autophagy levels and autophagic response 
to various stimuli was assessed. In addition to the methods of detecting autophagy outlined 
above, another protein has been used to assess autophagic flux within cells, namely 
p62.[1029,1030] p62 accumulates when autophagy is inhibited and decreases when autophagy 
is induced giving another potential readout of autophagic activity,[1030] although this assay is 
possibly felt to be a more reliable read-out of autophagy inhibition than autophagy induction. 
Figure 12.12 shows that transient transfection of GFP-LC3 into the three stable cell lines 
demonstrated no difference in baseline autophagy levels assessed by immunofluorescent 




Figure 12.12.  Immunofluorescent microscopy and western blot analysis of NOD2 stable cell 
lines demonstrating no differences in baseline autophagy levels. HEK293 cells stably 
expressing empty vector, NOD2 or NOD2-L1007fs were seeded on coverslips or in standard 6-well 
plates in standard DMEM for 6 hours. Additionally, HEK293 cells and HEK293 cells stably expressing 
empty vector, NOD2 or NOD2-L1007fs were transiently transfected with GFP-LC3. Cells were then 
assessed by (a,b) immunofluorescent microscopy after fixing, or (c) cell lysates immunoblotted with 
FLAG, p62 or LC3 antibody. Un, untransfected; EM, empty; WT, wild-type NOD2; F/S, frameshift. 
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  Following the assessment of baseline autophagy levels in the NOD2 stable cell lines, 
similar experiments in these cell lines were conducted to determine the baseline mTORC1 
activity by phosphorylation of downstream substrates of mTORC1 in response to rapamycin 
and serum-starvation. Figure 12.13 demonstrates that comparable levels of S6K (T389) and 
rpS6 (S235/236) were apparent at baseline (Figure 12.13a), with both the NOD2 and 
NOD2-L1007fs cell lines demonstrating appropriate mTORC1 responses to rapamycin and 
serum-starvation (Figure 12.13b and Figure 12.13c). 
 
 
Figure 12.13.  Baseline mTOR activity and mTOR response in HEK293 cells expressing 
empty vector, NOD2 or NOD2-L1007fs. HEK293 cells stably expressing empty vector, NOD2 or 
NOD2-L1007fs were plated for 6 hours before a 2 hour treatment with rapamycin, or serum-
starvation (DBSS). Cell lysates were collected and immunoblotted with the appropriate antibody by 
western blot. Emp, empty vector; WT, wild-type NOD2; F/S, frameshift; Un, unstimulated; R2, 
rapamycin 2hrs; SS2, serum-starvation 2hrs. 
 
 
12.3.4  MDP-induced autophagy induction in HCT116 GFP-LC3 cells does not 
signal through mTORC1 
  To establish if MDP-induced autophagy signals through mTORC1, HEK293 and HCT116 
cells stably expressing GFP-LC3 were first treated with increasing concentrations of L18-
MDP (a synthetic cell-permeable MDP derivative found to have greater potency that 
naturally occurring MDP[1031]) for six hours. Figure 12.14 shows that in keeping with the 
NOD2 rtPCR results (Figure 10.3), HEK293 cells showed no response to MDP treatment, 
whereas HCT116 cells showed a dose-dependent increase in autophagy. 
  To further ascertain if this increase in autophagy was NOD2 dependent, HEK293 NOD2 
and HEK293 NOD2-L1007fs stable cells, transiently transfected to express HA-S6K were  
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treated with 70μg/ml of L18-MDP. Figure 12.15 shows that NOD2 stable cells showed 
robust autophagy induction, with no response observed in the NOD2-L1007fs cell line. 
 
 
Figure 12.14.  MDP-induced, NOD-dependent autophagy response in HEK293 and HCT116 
cells. HEK293 GFP-LC3 cells (a) and HCT116 GFP-LC3 cells (b) were subjected to increasing doses of 
L18-MDP or serum-starvation (with DBSS) for 6 hours following which cells were assessed by 
immunofluorescent microscopy. Unstim, unstimulated; S-Starved, serum-starved. NS, not significant; 
*=p<0.05; **=p<0.01 by Mann-Whitney U. 
 
 
Figure 12.15.  MDP-induced autophagy in HEK293 NOD2 and HEK293 NOD2-L1007fs cells. 
HEK293 cell lines stably expressing NOD2 or NOD2-L1007fs were treated with 70μg/ml of L18-MDP 
for 6 hours or serum-starved in DBSS. Cells were then fixed and visualised using immunofluorescent 




  To then address the question regarding mTORC1 signalling in MDP-induced autophagy, 
cell lysates from the experiment shown in Figure 12.15 were immunoblotted with S6K 
(T389) and rpS6 (S235/236) antibodies by western blot. Figure 12.16 shows that there was 
no reduction in phosphorylation of either protein with MDP treatment, in contrast to treatment 




Figure 12.16.  mTOR response in HEK293 NOD2 cells treated with L18-MDP. HEK293 cell lines 
stably expressing NOD2 were treated with 70μg/ml of L18-MDP for 6 hours or serum-starved in 
DBSS. Cell lysates were then immunoblotted with FLAG, phospho-S6K, S6K, phospho-rpS6 and rpS6. 
Un, unstimulated; MDP, L18-MDP; SS, serum-starved. 
 
 
12.3.5  Withaferin A inhibits NOD2-dependent autophagy 
  The natural product Withaferin-A (WFA), a steroidal lactone from the plant Withania 
Somnifera, binds to and inhibits vimentin.[1032]  To confirm the effects of WFA in the current 
experimental system, treatment of cells with 2µM WFA was shown to induce vimentin 
aggregation and cleavage (Figure 12.17a and Figure 12.17b) with only minimal effects on 
cell viability (Figure 12.17c). To test whether vimentin regulates the autophagic activity of 
NOD2, the effect of WFA on NOD2-dependent autophagy stimulated by L18-MDP was 
assessed. HEK293 cells stably expressing empty vector, NOD2 or NOD2-L1007fs were 
transiently transfected with GFP-LC3. L18-MDP efficiently stimulated autophagy in HEK293-
NOD2 cells and this effect was inhibited by treatment with WFA (Figure 12.18a). As a 
control, the effect of MDP in HEK293 NOD2-L1007fs cells was also determined. As 





Figure 12.17.  Effect of Withaferin-A on vimentin aggregation and cleavage. HEK293 cells 
were treated with increasing concentrations of WFA as indicated for 2 hours. Cells were then 
visualised by immunofluorescent microscopy (a) or immunoblotted (b) with vimentin antibody. The 
viability of cells treated with WFA for 2 hours at the indicated concentrations was evaluated using 




Figure 12.18.  Withaferin-A inhibits NOD2-dependent autophagy. HEK293 cells stably 
expressing NOD2 (a) or NOD2-L1007fs (b) were transiently transfected to express GFP-LC3. Cells 
were pre-treated for 30min with WFA (2µM) before treatment for 8 hours with L18-MDP (50µg/ml). 
Cells were then fixed and visualised using immunofluorescent microscopy or cell extracts 
immunoblotted for LC3. The ratio of LC3-II to LC3-I was measured by densitometry. Unstim, 




12.3.6  The haplotype block containing Vim is a susceptibility locus for CD 
  A total of 965 SNPs in the haplotype block containing Vim and the two flanking blocks, 
spanning 163kb, were tested. A total of 51 SNPs attained a p value of <0.001, with 47 of 
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these in the block containing Vim. The strongest SNP (rs1049341) is positioned in the ninth 
exon (ENSE00001906870) of the Vim gene and attained a p value of 4.67x10-5. A plot of the 
SNPs in the region is presented in Figure 12.19. 
 
 
Figure 12.19.  Results in the region of Vim of a meta-analysis of seven Crohn's disease 
genome-wide association studies imputed with the 1000 genomes reference set. Scatterplot 
showing -logP values in the 163kb region of Vim for 965 single nucleotide polymorphisms. Vertical 
dotted lines represent the boundaries of the Vim gene and solid lines the limits of each haplotype 
block. The -logP value corresponding to p<0.05 is represented by the horizontal (red) dotted line. 
 
12.3.7  A number of drugs used in inflammatory bowel disease management 
induce autophagy, with azathioprine producing robust autophagy through 
mTORC1 in an ERK-independent manner  
  To first assess the effect of commonly used drugs on autophagy induction, HEK293 GFP-
LC3 and HCT116 GFP-LC3 cells were treated with increasing doses of each drug and 
autophagic activity levels determined by immunofluorescent microscopy. To determine the 
most appropriate concentration of each drug to use, the literature was examined and either 
documented therapeutic blood levels or concentrations used in previous in vitro assays were 
used (see Table 10.4).[474,1033-1036] The four drugs that were easily accessible and chosen for 
evaluation were 6-thioguanine, azathioprine, infliximab and methotrexate; all drugs 
previously shown to influence IBD natural history.[1037] Although in practice 6-mercaptopurine 
is the thiopurine used in those intolerant to azathioprine (Chapter 3.5.5), 6-thioguanine 
measurement is now used in clinical practice to help identify inter-person variation that may 





Figure 12.20.  Effect of 6-thioguanine on autophagy induction. HEK293 GFP-LC3 cells (left 
panel) and HCT116 GFP-LC3 cells (right panel) were treated with increasing doses of 6-thioguanine 
or rapamycin (100nM) for 16 hours or left unstimulated. 6-TG, 6-thioguanine; Unstim, unstimulated; 
Rapa, rapamycin. NS, not significant; *=p<0.05; **=p<0.01 by Mann-Whitney U. 
   
 
Figure 12.21.  Effect of azathioprine on autophagy induction. HEK293 GFP-LC3 cells (left panel) 
and HCT116 GFP-LC3 cells (right panel) were treated with increasing doses of azathioprine or 
rapamycin (100nM) for 16 hours or left unstimulated. Aza, azathioprine; Unstim, unstimulated; 
Rapa, rapamycin. *=p<0.05; **=p<0.01 by Mann-Whitney U. 
 
Figures 12.20, 12.21, 12.22 and 12.23 show the results for increasing doses of 6-
thioguanine, azathioprine, infliximab and methotrexate, in HEK293 GFP-LC3 and HCT116 




Figure 12.22.  Effect of infliximab on autophagy induction. HEK293 GFP-LC3 cells (left panel) 
and HCT116 GFP-LC3 cells (right panel) were treated with increasing doses of infliximab or 
rapamycin (100nM) for 16 hours or left unstimulated. IFX, infliximab; Unstim, unstimulated; Rapa, 
rapamycin. NS, not significant; *=p<0.05; **=p<0.01 by Mann-Whitney U. 
 
 
Figure 12.23.  Effect of methotrexate on autophagy induction. HEK293 GFP-LC3 cells (left 
panel) and HCT116 GFP-LC3 cells (right panel) were treated with increasing doses of methotrexate or 
rapamycin (100nM) for 16 hours or left unstimulated. MTX, methotrexate; Unstim, unstimulated; 
Rapa, rapamycin. NS, not significant; *=p<0.05 by Mann-Whitney U. 
 
  It can be seen that treatment with all four drugs led to autophagy induction in the HCT116 
cell line, but only azathioprine induced autophagy robustly in both cell lines. To complement 
the immunofluorescent microscopy results, HCT116 cells were treated with the 
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concentration of each drug producing the greatest autophagic response, lysed and 
immunoblotted for LC3, p62, rpS6 (S235/236) and total rpS6. Cells were also treated with 
rapamycin, serum-starvation or bafilomycin as controls. Figure 12.24 shows that 6-
thioguanine, azathioprine and methotrexate showed strong LC3-I to LC3-II conversion and a 
reduction in p62, with 6-thioguanine and azathioprine also showing a clear reduction in rpS6 
(S235/236) phosphorylation suggesting that autophagy induction may be induced in 




Figure 12.24.  Effect of four drugs used in paediatric inflammatory bowel disease on 
autophagy and mTOR activity. HCT116 GFP-LC3 cells were treated with infliximab (50μg/ml), 6-
thioguanine (60μM), azathioprine (90μM), methotrexate (66μM), rapamycin (100nM), bafilomycin 
(100nM) or cultured in normal DMEM or DBSS (serum-starvation) for 16 hours. Cell lysates were 
then immunoblotted for p62, LC3, rpS6 (S235/236) or total rpS6. Un, unstimulated; IFX, infliximab; 6-




  As azathioprine was found to be a potent inducer of autophagy in both HCT116 and 
HEK293 cells a further assessment of any dose dependent effect evident by western blot 
was undertaken. Figure 12.25 shows that increasing doses of azathioprine led to a dose-
dependent reduction in p62 levels, with 1μM enough to produce a robust reduction in rpS6 
(S235/236) levels. It should be noted that trypan blue exclusion was performed on cells 






Figure 12.25.  Dose-dependent effect of azathioprine on autophagy induction and mTORC1 
activity. HCT116 GFP-LC3 cells were treated with azathioprine (1, 5 and 60μM), rapamycin (100nM), 
bafilomycin (100nM) or cultured in normal DMEM or DBSS (serum-starvation) for 16 hours. Cell 
lysates were then immunoblotted for p62, rpS6 (S235/236) or total rpS6. Un, unstimulated; Rap, 
rapamycin; SS, serum-starvation; Baf, bafilomycin.   
 
 
  To further delineate the pathways involved in azathioprine autophagy induction, cells were 
treated with the ERK inhibitor (U0126) or the non-specific autophagy inhibitor 3-MA in 
conjunction with azathioprine. Figure 12.26 shows that neither U0126 or 3-MA had any 
effect on autophagy induction or mTORC1 activity, suggesting that azathioprine may exert 




Figure 12.26.  Effect of the ERK inhibitor U0126 and autophagy inhibitor 3-methyladenine 
(3-MA) on azathioprine-induced autophagy. HCT116 GFP-LC3 cells were treated with 
azathioprine (60μM) in the presence or absence of U0126 (10μM) or 3-MA(10μg/ml), in addition to 
treatment with rapamycin (100nM) or bafilomycin (100nM). Cells were also left untreated or 
cultured in DBSS (serum-starved). Cell lysates were then immunoblotted for p62, LC3, rpS6 




12.4  Discussion 
 
  Using a robust system of autophagy induction in mammalian cells it has been shown that 
MDP-induced autophagy is unlikely to signal through mTORC1, that vimentin is intimately 
involved in the process of autophagy and that a number of drugs used in the treatment of 
inflammatory bowel disease induce autophagy, and that azathioprine may do so through a 
mechanism that involves the inhibition of mTORC1. 
  The landmark papers by Travassos et al. and Cooney et al. gave new insights into the 
NOD2-autophagy pathway, not only with regard to autophagy itself but also antigen 
presentation and bacterial handling,[30,31] with others further expanding this knowledge[822]. 
Since this work, surprisingly few studies have gone on to establish the exact mechanisms 
involved in MDP-induced autophagy. There has been some discrepancy in the previous 
literature regarding the requirement for NOD2 in MDP-induced autophagy, with Travassos et 
al. reporting the direct recruitment of the autophagic machinery to sites of bacterial 
invasion,[31] with other groups showing a NOD2-dependent pathway[30,822,1039]. Similarly the 
requirement for RIPK-2 has been conflicting, possibly reflecting the cell types and strains of 
bacteria involved in the different experimental systems.[30,31,822,1039] Recently, Homer et al. 
have published further work demonstrating that RIPK-2 tyrosine kinase activity plays an 
essential but dual-faceted role in NOD2-autophagy induction, providing both an activating 
signal through stimulation of MAPK p38 and the relief of PP2Ac-PPP2R1A-mediated 
repression of autophagy.[823] MAPK p38 has been shown to be involved in the mTORC1 
pathway using p38-activating stresses (such as anisomycin),[1040] in addition to the 
manipulation of MAPK p38 altering the localisation of the critical autophagy protein 
ATG9[1041]. However, MAPK p38 has also been shown to positively or negatively regulate 
autophagy depending on the stimulus, and the processes underlying p38-regulated 
autophagy remain poorly understood.[1042,1043] Furthermore, Homer et al. demonstrated a role 
for MEKK4 during NOD2-induced autophagy,[823] with recent work showing that the 
phosphorylation of ATG5 by the MEKK4-p38 pathway inhibits autophagy[1044]. Although the 
current study suggests that there is no clear signalling through mTORC1 during autophagy, 
the complex nature of the mTORC1 pathway,[956] especially during autophagy[1045] requires 
further examination of this pathway during MDP stimulation, although the possibility that 
mTORC1-independent pathways exist should continue to be explored. 
  The origin of autophagosomes has recently gained intense interest in the field, and it is now 
clear that these double-membrane structures can originate from the surface of various cell 
organelles, including the endoplasmic reticulum, mitochondria and the plasma 
membrane.[1046] One of the major autophagy proteins ATG16L1 interacts with the heavy 
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chain of clathrin, and the plasma membrane has been shown to contribute to the formation 
of ATG16L1-positive pre-autophagic structures via endocytosis.[826] Additionally, there is now 
mounting evidence that NOD2 (previously thought to be purely a cytosolic protein [1047]) also 
resides and functions at the plasma membrane.[31,819,1048] This membrane localisation has 
lead to the suggestion that NOD2 functions at sites of infection to directly engage with 
pathogens and signal an appropriate inflammatory and antimicrobial response.[1048] This 
hypothesis is supported by a recent study demonstrating colocalisation of NOD2 and the 
major autophagy protein ATG16L1 at the plasma membrane with NOD2 recruiting ATG16L1 
to sites of bacterial infection.[31] Further work has shown that a clathrin- and dynamin-
dependent endocytic pathway regulates MDP internalisation and NOD2 activation.[1049] 
  The work presented above has demonstrated that vimentin is intimately involved in MDP-
induced autophagy induction, as well as being a susceptibility gene for CD. This is in 
keeping with previous work (from our group) demonstrating that the ability of NOD2 to signal 
an appropriate inflammatory response, and to limit the invasion and survival of a CD-
associated strain of AIEC, is impaired by treatment with the vimentin inhibitor WFA.[819] 
These findings are likely to be in part due to the additional observations that vimentin is 
important for the correct localisation of NOD2 to the plasma membrane, since CD-
associated NOD2 variants are unable to interact with vimentin and are mislocalised to the 
cytosol.[819]  
  Manipulation of the host cell plasma membrane and associated proteins is an essential 
step for the uptake, survival and replication of pathogens.[1050] Vimentin structure changes 
profoundly during bacterial infection and up regulation of Vim gene expression has been 
observed during pathogenic H.pylori infection.[1051] Most relevant to CD pathogenesis are the 
recent reports that vimentin is expressed on the surface of human brain endothelial cells 
where it acts as a primary receptor for meningitis associated E. coli (MenPEC) strains 
expressing the virulence factor IbeA,[1011] with vimentin-mediated signalling required for 
IbeA+ E.coli invasion of these cells.[1011] The IbeA virulence factor is not restricted to 
MenPEC, and is also present in a variety of other E.coli pathovars, including 18.5% of AIEC 
strains and 17% of diarrhoeagenic E.coli.[107,1052] NOD2 activity has been shown previously 
to depend on the integrity of the actin cytoskeleton, with drugs disrupting actin having been 
shown to significantly increase the ratio of soluble to insoluble NOD2.[1053] Several bacterial 
pathogens manipulate the host cell cytoskeleton for their own intra- and inter-cellular 
motility[1054] with the invasion of epithelial cells with AIEC markedly reduced by cytochalasin 
D and colichicine indicating an important role for actin microfilaments and microtubules[107]. 
An important role for the cytoskeleton in the regulation of autophagy is also emerging.[1055] Of 
particular significance is that the proper formation and distribution of autophagosomes 
depends on the integrity of intermediate filament networks,[1017] and that autophagic vacuoles 
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are found to be tightly associated with vimentin[1019]. The results of the current study 
demonstrating that vimentin is important for NOD2-induced autophagy, together with recent 
studies linking NOD2 and the cytoskeleton with the regulation of autophagy, suggest that 
NOD2 has evolved to use the cytoskeletal network, possibly through cell surface-expressed 
vimentin, as a means to engage with pathogens. NOD2 may then use the intracellular 
cytoskeleton further to directly transport internalised pathogens via the autophagy machinery 
to lysosomes for degradation. 
  With regard to the mechanism of action of drugs used in the treatment of PIBD, there are 
still several pathways that have yet to be explored, especially with regard to autophagy. 
Work described here has shown that 6-thioguanine, azathioprine, infliximab and 
methotrexate all stimulate autophagy, however only azathioprine stimulated autophagy 
robustly in both HEK293 and HCT116 cell lines. 6-thioguanine has previously been shown to 
induce autophagy in several studies (by the same group), looking at DNA mismatch repair. 
Zeng et al. demonstrated that 6-thioguanine induced autophagy through a mTORC1-
dependent pathway, mediated by Bcl2 and adenovirus E1B Nineteen-kilodalton Interacting 
Protein (BNIP3).[1056-1058] However, it should be noted that all these experiments were carried 
out in colonic cancer (HCT116 and HT29) cell lines. In addition, the study evaluating the 
mTORC1 pathway used low concentrations of rapamycin to inhibit mTOR over several days, 
to demonstrate that 6-thioguanine-induction of autophagy was reduced.[1057] However, it is 
unclear why low doses of rapamycin alone did not induce autophagy after 24 hours in 
culture, as rapamycin has clearly been shown to be an autophagy inducer.[1005]  
  Azathioprine, first described by Gertrude Elion in 1963,[1059] is the prodrug of 6-
mercaptopurine. This commonly used purine analogue has been used widely in 
transplantation medicine and in the treatment of IBD for over 50 years.[1060,1061] Although its 
precise mechanism of action is still under investigation,[1062] it is thought that azathioprine is 
first rapidly cleaved non-enzymatically by sufhydryl-containing compounds (such as cysteine 
and glutathione[1063]) into two principal components, mercaptopurine and a imidazole 
derivative.[1062] Following this, three competing enzymes (TPMT, XO and HPRT) produce 
toxic and non-toxic metabolites. The main mechanism of action, mediated through 6-
thiopurine active metabolites, are generally accepted to be the disruption of DNA, RNA and 
protein synthesis, with an increase in T cell apoptosis of particular relevance. [1064] The 
precise mechanisms of apoptosis induction are still under investigation, but the interaction of 
6-ThioGTP with Rac1 (through Bcl-xL blockade), in a CD28-dependent manner are felt to be 
crucial steps.[197] Also, it has been shown that imidazole (a NADPH oxidase inhibitor) may 
produce reactive oxygen species, leading to cellular stress. There are therefore several 
mechanisms that may account for the autophagy induction seen in both the HEK293 and 
HCT116 cells treated with azathioprine: (1) a direct genotoxic effect from DNA disruption 6-
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thioguanine metabolites; (2) the production of reactive oxygen species and (3) direct effects 
on the mTORC1 complex. With regard to the autophagic effects of infliximab, these results 
are also of interest. To date, no studies have directly evaluated the direct consequences of 
infliximab on cellular autophagy. However, work showing a reduction in bacterial 
translocation in acute pancreatitis with infliximab is notable,[1065] with the possibility that 
besides the obvious effects of pro-inflammatory cytokine disruption, increased xenophagy at 
the intestinal epithelium may be beneficial. 
  The strengths of the current study are that attempts were made to utilise several different 
methods of autophagy induction and autophagy quantification as per the recent 
guidelines.[1005] This is very relevant given the complexities of the autophagic machinery and 
the interaction of several pathways with similar end points. It is also notable that every effort 
was made to produce robust read-outs of both autophagy induction and mTOR activity, not 
only in colonic cancer cells (HCT116) but also the HEK293 cell line. 
  Although every endeavour was made to ensure robustness of the experimental systems, 
certain difficulties arose. Although most of the experiments used similar methods, the time 
points were often different and reflected the challenging work with regard to tissue culture, 
transfection, western blot analysis and the multitude of pathways involved. Ideally, all studies 
would have been performed in triplicate, using much more variable time-frames. However, 
this was not always possible and technical issues and unexpected pitfalls were encountered 
along the way. Additionally, there were problems throughout the experiments when 
attempting to correspond immunofluorescent microscopy results with immunoblot analysis, 
especially in relation to MDP-induced autophagy. Other aspects of the experimental work 
which may have influenced the results are the doses of drugs used, the lack of cell viability 
work during each experiment and the time pressures which did not allow the full 
determination of the pathways involved in the intriguing results obtained. 
 
12.5  Conclusions 
 
  This study, using a robust system of autophagy induction in mammalian cells, has shown 
that MDP-induced autophagy is unlikely to signal through mTOR, that the intermediate 
filament vimentin is intimately involved in the process of autophagy and that a number of 
drugs used in the treatment of inflammatory bowel disease induce autophagy, with 
azathioprine doing so robustly through mTOR inhibition. 
  Further studies are now required to address the precise mechanisms involved in the MDP-
NOD2-autophagy pathway in addition to the vimentin-NOD2 interaction within the context of 
CD patients. Further determination of the effect of commonly used IBD drugs on autophagy 
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is also required, especially with relation to the bacteria-epithelial interface in the intestinal 
lumen, that may allow the manipulation of bacterial translocation and dampen the 





































13.  Conclusions and future directions 
 
13.1  Paediatric inflammatory bowel disease epidemiology 
 
  It can be seen from the data presented in Chapter 2 and Chapter 3 that the incidence and 
point prevalence of paediatric inflammatory bowel disease (PIBD) has increased in Scotland, 
with supporting evidence suggesting an increasing incidence worldwide.[223] From this new 
data, Scotland now has the highest reported incidence of PIBD (< 16 years old) in the United 
Kingdom (UK) (7.8/100,000/year), with regional South-East Scotland (SES) incidence rates 
even higher at 9.5/100,000/year. Furthermore, the data also provides the only robust PIBD 
point prevalence data to date in the UK (41.2/100,000). It is not yet clear if this rise will 
continue to be evident in both developing or developed countries, or whether this rise will be 
sustained or plateau in future decades. Although there are those that suggest that this 
increase is purely a result of 'milder' forms of the disease, or the more rigorous investigation 
of those with gastrointestinal symptoms, there is certainly no evidence to imply that this is 
the case. In fact the phenotypic data collected prospectively in SES demonstrates that 
children with PIBD continue to present with extensive disease (pan-enteric CD in 34% and 
pancolitic UC in 76%) diagnosed during upper and lower endoscopy, therefore this true rise 
is likely to be in-keeping with the increase in other immune-mediated diseases.[132,1066] The 
potential regional variation in incidence rates is also of interest and suggests that 
environmental influences may be involved, with further dissection of these possible 
variations accompanied by detailed environmental data now fully warranted.  
  The rise in prevalent cases of PIBD is particularly of interest with respect to healthcare 
provision. With the increasing numbers of children cared for in paediatric services, and the 
high burden of disease demonstrated in this population, the cost of managing these often 
complex cases will rise in parallel. Additionally, with the increased use of 
immunosuppressive agents, especially maintenance therapy with costly biologicals, this cost 
will rise further and the provision of a multidisciplinary team to cater for these changes (e.g. 
PIBD nurse specialists and dietitians) will certainly need to be high on the political 
agenda.[317] Robust and comprehensive prevalence data not only assists in healthcare 
provision but also has direct effects on translational research. For example, studies of 
diagnostic accuracy and genetic association require accurate prevalence estimates in order 
to provide robust sample size and power calculations.[1067,1068] 
  The reasons for the rise in PIBD incidence remains elusive, with diet, lifestyle and other 
environmental factors most likely interacting with the gut microbiota and effecting genetic 
and epigenetic regulation in susceptible individuals.[1069] A recent large prospective cohort 
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study of over 72,000 women aged between 40-73 years used a diet and lifestyle assessment 
of vitamin D status at study entry using a validated model.[1070] The authors concluded that 
higher predicted plasma levels of vitamin D significantly reduced the risk of incident Crohn's 
disease (CD), but non-significantly for ulcerative colitis (UC). Animal studies have supported 
these findings, with vitamin D receptor (VDR) knock-out mice highly sensitive to dextran-
sulphate-induced colitis and exogenously injected lipopolysaccharide.[1071] Additionally, 
vitamin D has been shown to ameliorate experimental murine colitis, possibly by changes in 
the T regulatory cell profile.[1072,1073] The biological plausibility in this protective effect has also 
been demonstrated, with 1,25-dihydroxyvitamin D(3) stimulating expression of NOD2 in 
addition to genes encoding antimicrobial peptides.[255] With the interest in vitamin D now 
extending to both innate and adaptive immunity,[1074] and the observation that nearly 50% of 
children newly diagnosed with CD are vitamin D deficient,[1075] suggests that additional 
research is required to identify if vitamin D deficiency is a modifiable risk factor in the general 
population. Further work on the effect of urban living on the incident rates of PIBD is also 
justified. Previous work in Scotland has demonstrated that high human density is protective 
for PIBD.[253] However, with other studies demonstrating a similar[1076] or opposite effect[1077] it 
is likely that this relationship is more complex, with movement to and from urban areas 
associated with disease.  
  With regard to dysbiosis of the gut microbiota in IBD there has been a recent explosion of 
research in this field.[1078] Work from colleagues in Scotland has recently provided a 
comprehensive examination of the mucosal microbiota in children with newly-presenting, 
untreated IBD versus normal controls.[1079] Using pyrosequencing and confirmatory real-time 
PCR they demonstrated that no significant changes at phylum level among the 
Bacteroidetes, Firmicutes, or Proteobacteria were apparent. However, there was a 
significant reduction in bacterial alpha-diversity and an increase in Faecalibacterium in 
Crohn's disease versus controls; no disease-specific clustering was evident. Additional work 
has demonstrated differences in the microbiota of children with IBD, although much of this 
work has been performed on faecal (rather than mucosal) material of children on treatment, 
potentially influencing the results.[1080,1081] There are a myriad of hypotheses that aim to 
explain differences in the bacteria within the gut in health and disease, including caesarean 
delivery, breastfeeding, perinatal stress, probiotics, and antibiotics,[1082] however to date 
none of these have been confirmed as having robust association (or importantly causation) 
with PIBD. The differences described are certainly of interest, and with the overall role of the 
gut microbiota now being examined,[1083] further investigation is now required to determine 
the precise natural history of the gut microbiome from birth to PIBD diagnosis.  
  It is likely that the increasing incidence of PIBD will be as a result of some or all of these 
factors, possibly with population-specific and inter-population effects. Prospective, 
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longitudinal studies capturing incident cases of PIBD diagnosed by endoscopy and thorough 
case-note review are now required with parallel studies evaluating changes in suspected 
environmental triggers. Additionally, work addressing the issue of the severe phenotype 
seen in PIBD at diagnoses (and the subsequent rapid disease progression) should be 
performed. As with the rise in incidence, it is likely that multifactorial aetiologies will be 
evident in these studies, with hormonal, immunological, genetic and epigenetic factors all 
involved. 
 
13.2  Inflammatory bowel disease genetics 
 
  Work presented in Chapter 5 and Chapter 6 has demonstrated that the use of case-parent 
trios in genetic association analysis is still plausible in an age of large case-control 
studies.[1084] By performing a family-based study in 230 affected offspring trios, the data 
showed that the region tagged by previous genome-wide association scans on chromosome 
21q is likely to be ICOSLG. Despite having only a relatively small number of PIBD cases, the 
use of their parents, accurate power calculations based on robust prevalence data and 
correction for multiple testing confirmed the association with the 3' untranslated region of 
ICOSLG. Additionally, mRNA expression data highlighted the dysregulation of ICOSLG and 
its ligand ICOS in IBD patients, further strengthening the results. Although deep sequencing 
of this region is now required, the much broader role of co-stimulation in immune-mediated 
disease should also be explored.[1085] Specifically, the pivotal role of the ICOS:ICOSLG 
interaction may prove vital in the drive to control T cell differentiation.[1086] With this 
interaction having now been shown to be intricately involved in regulatory T cell 
populations,[625] and its importance in the early decision between tolerance and immunity,[631] 
further studies are now required to allow the manipulation of this pathway to control T cell 
numbers, fate and the ensuing cytokine environment.[1087] 
  As well as confirming already identified regions of genetic association, the use of 
transmission disequilibrium test analysis has allowed the identification of a new candidate 
susceptibility gene for PIBD, namely CRP. Although replication in large case-control studies 
was weak or non-existent, the possibility that this is a true association remains as the results 
may be population-specific or early-onset specific. C-reactive protein (CRP) has become an 
exciting molecule in recent years, moving from a simple non-specific laboratory test for 
infection and inflammation, to a molecule able to bridge the gap between innate and 
adaptive immunity. Although no clear genotype-phenotype correlations were apparent, the 
differences in CRP haplotype structure between paediatric CD and UC patients was of 
particular interest, especially given the significant differences in serum CRP levels at 
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diagnosis. Future studies are now required to determine if this finding is population or early-
onset disease specific, in addition to studies to identify if genotype-biomarker-phenotype 
correlations exist. This method of Mendelian Randomisation has been utilised to confirm [1088] 
or refute[1089] causation of previously determined disease risk factors, and given the 
emerging importance of low-grade inflammation in immune-mediated disease,[1090] the 
assessment of CRP using this method would be of merit. 
 
13.3  Faecal calprotectin 
 
  It has been clearly shown (in Chapter 7) that faecal calprotectin (FC) is markedly raised in 
children with IBD compared to scoped controls, with no influence of IBD type or location. 
Additionally, data has also provided evidence that FC performs better than six commonly 
used blood parameters (haemoglobin, white cell count, platelet count, CRP, erythrocyte 
sedimentation rate and albumin) with an area under the curve of 0.93 (95% CI 0.89-0.97), 
especially using a normal cut-off of 200μg/g. In Chapter 8 a meta-analysis of robust data 
derived from previously published case-control studies also demonstrated the high sensitivity 
(98%) and modest specificity (68%) of this faecal marker for PIBD at diagnosis. 
  An interesting mechanistic action of FC is the chelation of zinc and manganese leading to 
the starvation of gastrointestinal pathogens. As there is some evidence to suggest that 
dysregulation of serum zinc is involved in intestinal inflammation in animal models, [1091] and 
human subjects[1092] (with some debate[1093]), it would certainly be of interest to examine this 
mechanism further in the context of IBD. Although the precise microbial composition 
apparent during IBD pathogenesis is not yet described, the value of raised calprotectin levels 
during intestinal inflammation should be determined. With further details of the complex 
relationship between FC, zinc-chelation and anti-microbial activity now being evaluated,[1094] 
and the delineation of microbial diversity in IBD under review,[1079] the utility of FC in IBD 
exacerbations (akin to the use of antibiotics such as metronidazole[1095,1096]) should be 
assessed.    
  Although the use of FC in patients suspected of bowel inflammation is becoming more 
commonplace, its effect on diagnostic delay, endoscopy rates and correlation with mucosal 
healing are still under debate. It is likely that FC will serve as a adjunct to other clinical 
findings (especially history and examination) to allow the efficient handling of the large 
volume of children who present in outpatient departments with gastrointestinal disturbance. 
Prospective studies and laboratory-based studies are now required to elicit (1) an accurate 
cost-benefit evaluation (based not only on the effect on endoscopy rates, but also the effect 
on radiological investigation, blood work-up and repeated outpatient attendances); (2) a 
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detailed analysis of the relationship between FC levels and clinical (and histological) disease 
remission; and (3) the potentially beneficial effects of FC during active inflammation and its 
anti-microbial mechanism of action. Furthermore, the reasons for false negative results in 
children with overt macroscopic disease, the inter-person variability in FC levels and the 
effects of commonly used medications should be examined further. With the National 
Institute for Health and Clinical Excellence now evaluating the role of FC in IBD 
(http://guidance.nice.org.uk/DT/12), with our research group actively involved, it is likely that 
some of these questions will be addressed in the near future.    
 
13.4  NOD2 and autophagy 
  
  During the laboratory work performed during this research (presented in Chapter 11 and 
Chapter 12), it was demonstrated that NOD2 overexpression did not influence cell or 
nuclear size, but seemed to effect early cellular proliferation, independent of CD-associated 
polymorphism status. Additionally, cells overexpressing NOD2 or NOD2-L1007fs had an 
accentuated apoptotic response to serum starvation, but not to treatment with MDP. The use 
of proteasome and lysosome inhibitors also determined that NOD2 protein stability is likely 
regulated through the ubiquitin-proteasome degradation pathway, possibly through lysine 
amino acid residues present at least in the CARD domain. 
  The effect of NOD2 on cellular proliferation may certainly be of future interest, from the 
position of Paneth cell morphology and function[1097] and their role in intestinal 
homeostasis[1098]. Experiments involving MDP stimulation should also be carried out to 
determine the effects of NOD2 ligation on cell size, nuclear size and cellular proliferation, as 
this may further identify NOD2 pathways important in Paneth cell and antigen-presenting cell 
function. With regard to the role of NOD2 in cellular apoptosis, this mechanism should also 
be fully explored, especially in relation to the cellular inhibitors of apoptosis proteins 
(cIAPs).[933] Detailed exploration is required to assess the relationship between serum-
starvation, NOD2 signalling and the apoptotic machinery, with the possibility that an 
interaction with mammalian target of rapamycin (mTOR) is apparent. With regard to NOD2 
degradation, the recent report of proteasomal degradation of NOD2 through TRIM27 is of 
great importance.[974] Despite a large volume of research focusing on NOD2 signalling, 
especially with relation to CD and MDP-ligation, the function and degradation of both wild-
type and NOD2 variants need careful attention, given the diverse range of NOD2 pathways 
implicated in various diseases.[928,1099,1100] 
  Work presented here has shown that MDP-induced autophagy is unlikely to signal through 
mTOR, with the intermediate filament vimentin intimately involved in this process. A number 
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of drugs used in the treatment of inflammatory bowel disease were also shown to induce 
autophagy, with azathioprine doing so robustly in two separate cell lines through inhibition of 
mTOR. 
  The previous findings that vimentin is a NOD2 interacting protein,[915] and that the invasion 
and survival of a CD-associated strain of adherent invasive E.coli (AIEC) is disrupted with 
Withaferin-A treatment,[819] are of particular relevance with regard to the role of vimentin 
during autophagy. The importance of the cytoskeletal components continue to be described 
in relation to autophagosome biogenesis,[1101] with intermediate filaments other than vimentin 
having also now been shown to play a role in impaired autophagy[1018]. In view of the fact that 
impaired autophagy is associated with persistence of AIEC in macrophages,[902] mechanisms 
to increase cellular autophagy in some instances may be beneficial. The finding that several 
drugs known to alter the natural history of IBD[1037] increase autophagy, with robust results in 
the case of azathioprine, are certainly of interest. As these mechanisms may be cancer cell-
specific, or be related purely to cell apoptosis, experiments clearly assessing apoptosis and 
autophagy in these cells following treatment are now required. Furthermore, the increase in 
autophagy demonstrated by the use of infliximab may be of further interest, although the 
possibility that this effect may be cell type specific within the gut (as is suggested in the case 
of apoptosis induction[1102]) may prove difficult to clarify.   
 
13.5  Future research agenda 
 
  With regard to work relating to PIBD pathogenesis, epidemiology, biomarkers and 
therapeutic management, the following future research should be considered: 
 
 Parallel prospective studies of PIBD incidence and robust environmental data 
collection, focusing strongly on prenatal, perinatal and potential triggering factors 
prior to diagnosis, in addition to gene-environmental and epigenetic interactions. 
 A more complete understanding of the genetic architecture of PIBD should be 
addressed, focusing attention on the manipulation of pathways and genotype-
phenotype correlations rather than genetic risk factors that may account for a small 
proportion of the overall pathogenetic mechanism. 
 The use of genetic and clinical data to allow tailored treatment for individuals, based 
on genetic risk, immune response, the individual's intestinal microbiota and 
therapeutic response.  
253 
 
 More investigation into the role of certain biomarkers during disease progression and 
assessment, harnessing the potentially beneficial aspects of their mechanism of 
action. 
 Dissection of the current drugs used in PIBD management with a focus on 
maximising their potential and identifying alternative mechanisms of action that may 
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